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Cystic Fibrosis (CF)  is a degenerative disease, which causes thickening of the 
airway surface liquid and reduced mucociliary clearance, which provides an ideal habitat 
for bacterial infections. Early treatment of CF in children can prevent chronic infection, 
improve quality of life, and increase life expectancy. The most predominant bacteria found 
in CF-diseased lungs is Pseudomonas aeruginosa (Pa), which can be treated with inhaled 
tobramycin. Excipient enhanced growth (EEG) powder formulations are well suited for 
administering tobramycin to children, as the EEG approach provides minimal upper 
airway loss and targeted drug delivery. This method uses an initially small aerosol for high 
extrathroacic transmission, and includes hygroscopic excipients within the formulation 
that absorb moisture from the humid airways and increase lung retention of the aerosol. 
The overarching goal of this work was to develop delivery systems and strategies for 
improving respiratory drug delivery to children with CF, which was based on insights from 
computational fluid dynamics (CFD) simulations and in vitro models. The studies 
presented in this dissertation have three distinct and sequential phases: (i) CFD methods 
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development; (ii) respiratory device design and optimization; and (iii) complete-airway 
modeling for aerosol delivery strategy development. 
The methods development phase produced meshing and solution guidelines that 
were computationally-efficient, accurate, and validated based on in vitro data. Results 
showed that the two-equation k-ω model, with near-wall corrections, was capable of 
matching experimental data across a range of Reynolds numbers and particle sizes that 
are specific to respiratory drug delivery. The guidelines also provided comparable 
accuracy to the more complex Large Eddy Simulation (LES) model, while providing 
multiple order-of-magnitude savings in computational time. The device optimization 
phase developed a highly efficient delivery system for tobramycin administration to 
pediatric CF patients. Correlations were developed, based on flow field quantities, that 
were predictive of aerosolization performance and depositional loss. Successful a priori 
validation with experimental testing highlighted the predictive capabilities of the 
correlations and CFD model accuracy. The best-case delivery system demonstrated an 
aerosol size of approximately 1.5 µm and expected lung dose of greater than 75% of 
loaded dose, which is a marked improvement compared to commercial devices. The 
delivery strategy development phase identified optimal EEG aerosol properties that better 
unify drug surface concentration. These studies present numerical models of a 
tobramycin EEG powder formulation for the first time, and provide the first instance of a 
complete-airway CFD model evaluating pediatric CF lungs. Results show that EEG 
aerosols are capable of delivering the drug above the minimum inhibitory concentration 
in all airway regions, reducing regional dose variability, and targeting the lower airways 
where infection is more predominant. In conclusion, results from this dissertation 
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demonstrate: (i) accurate and efficient CFD models of respiratory drug delivery; (ii) 
optimized designs for respiratory delivery systems; and (iii) optimal delivery strategies for 
inhaled tobramycin to pediatric patients with CF. 
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Chapter 1: Specific Aims 
Respiratory drug delivery with pharmaceutical aerosols offers a number of 
advantages compared with other delivery routes and for many medications is the most 
logical approach in the treatment of lung diseases and conditions. While potentially 
beneficial, challenges associated with respiratory drug delivery include aerosolizing the 
powder at a respirable size with limited flow energy, penetrating the extrathoracic airways, 
which are intended to filter foreign objects, and depositing the aerosol at the intended 
location within the lungs to achieve the desired biological effect. Additional challenges 
after the medication is deposited in the lungs include dissolution within the limited airway 
lining fluid, avoidance of clearance mechanisms, and absorption in the mucus and airway 
tissue. 
Of the various patient groups that may benefit from respiratory drug delivery, 
administration of pharmaceutical aerosols to infants and children is especially difficult. 
Their relatively small extrathoracic airways are an obstacle to delivering drugs to the 
lungs. Furthermore, infants and children often do not comply with receiving inhaled or 
other forms of medication. Even with good patient compliance, only approximately 1% to 
10% of the initial aerosol is typically delivered to the lungs, and inter-subject variability is 
expected to be high. Further reductions in lung delivery efficiency and increases in inter-
subject variability are expected with diseased lungs.  
To improve respiratory drug delivery for infants and children, innovations are 
needed in pharmaceutical delivery strategies, devices, and formulations. The overarching 
goal of this work is to develop and optimize strategies and devices for improving 
respiratory drug delivery to infants and children using computational fluid dynamics (CFD) 
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and in vitro models. To accomplish this goal, objectives are targeted in three key areas: 
(i) model development, (ii) device development, and (iii) delivery strategy development. 
As described in more detail below, each of these key objectives is intended to move the 
field of respiratory drug delivery forward. In particular, the primary application of this work 
is to quantitatively analyze and optimize the delivery of inhaled antibiotics to children with 
cystic fibrosis (CF). 
The validation of a CFD model is often an iterative process of defining and 
adjusting numerous meshing and solution parameters until good agreement is made with 
experimental data. The first objective of this dissertation intends to streamline the model 
development process by defining a set of meshing and solution guidelines that are 
validated for the micro-particle size range and under flow conditions that are consistent 
with respiratory airways. Naturally, each project is unique and requires its own 
considerations, but these guidelines strive to reduce the effort taken to develop a CFD 
model by providing a baseline set-up that is known to give accurate results.  
With sound numerical methods, one can apply CFD to obtain detailed physical 
insight into the performance and behavior of aerosol-delivery devices. The second 
objective of this dissertation uses CFD to provide insight into dry powder inhaler (DPI) 
and cannula device development, which improve aerosol delivery efficiency. 
Specifically, delivery systems aim to provide a relatively small particle size, for increased 
lung penetration, and a high emitted dose (ED), for reduced device losses.  
The third objective of this work applies the developed nasal and lung models (with 
validated CFD methods) and optimized aerosolization device in the development of a 
delivery strategy for the administration of inhaled antibiotics to children with CF. The 
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delivery strategies employed, and developed by our group, include enhanced excipient 
growth (EEG) and nose-to-lung (N2L) administration with correctly-sized aerosols. As a 
first step, the delivery strategy will be assessed and optimized with regional CFD 
simulations of the patient interface, nasal cavity, and upper tracheobronchial (TB) 
airways. Thereafter, complete-airway CFD simulations will be used to optimize aerosol 
delivery throughout the lungs with the goal of uniform antibiotic concentrations. There are 
numerous CFD models of particle transport through the lungs in the literature and by our 
group, but there has been little work to date specific to drug delivery in pediatric lungs as 
well as in diseased lungs. 
The objectives stated above build upon one another, and all focus on providing a 
CFD-based analysis of the treatment of pediatric CF lung infections with inhaled 
antibiotics. The most recent data from the Cystic Fibrosis Foundation Patient Registry 
(2016) states approximately 30,000 people are living with the disease, with the median 
age of diagnosis being 4 months old. CF is a debilitating disease, which greatly reduces 
quality of life, with a mean survival of 48 years (Cystic Fibrosis Foundation Patient 
Registry, 2016). The disease primarily affects lung function, but also affects the pancreas, 
liver, sweat glands, and vas deferens (Elborn, 2016). In fact, the name of the disease 
originates from the pancreatic fibrosis and cysts that were described when CF was first 
identified (Andersen, 1938). 
CF is caused by a genetic mutation in the Cystic Fibrosis transmembrane 
conductance regulator (CTFR) gene (Cheng et al., 1990), which causes poor transport of 
Na+ (increased absorption) and Cl- (reduced secretion) ions through the epithelial cells 
(Matsui et al., 1998; Tarran et al., 2001), and effectively dehydrates the lungs. This 
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dehydration leads to thicker mucus and decreased mucociliary clearance (Stoltz, 
Meyerholz, & Welsh, 2015), which causes bacterial infections to reside in the lungs for 
much of the patient’s life (Boucher, 2007). The most dominant bacterium found in CF 
lungs is Pseudomonas aeruginosa (Pa) (Elborn, 2016), which typically forms a biofilm in 
the thick mucus. Biofilms are colonies of cells encased in a sticky substance (Donlan, 
2002) that attach to the lung surfaces, which makes it difficult for the patient’s mucociliary 
clearance to remove the bacteria (Boucher, 2007). The combined effects of bacterial 
infection and thick mucus leads to the three main types of lung damage in CF: 
bronchiectasis (irreversible thickening of airway walls), mucus obstructions, and 
inflammation, which all drastically reduce lung function. Key spirometry tests to evaluate 
the extent of CF lung damage are the percent of predicted forced expiratory volume in 
one second (%FEV1) and forced vital capacity (%FVC), with percentages compared to 
the baseline given for the patient’s age. Reported functional performance for CF patients 
from 11-13 years of age are a %FEV1 and %FVC of approximately 75% and 85%, 
respectively (de Jong et al., 2004), which demonstrates how severely the lungs can be 
damaged at a young age with early disease progression. 
CF mortality rates have improved in recent years and are expected to continue to 
improve (Burgel et al., 2015), with the increased survival attributed to advances in 
treatment methods (Elborn, 2016). The low median age of CF diagnosis (4 months) is 
due to the screening of newborns in many developed countries (Mayell et al., 2009), which 
allows parents and clinicians to begin treating lung infections early in the patient’s life. 
Approximately one-third of children have signs of lung damage in computed tomography 
(CT) scans by the age of three (Elborn, 2016), so starting treatment methods early is of 
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paramount importance. The methods known to improve quality of life and survival are the 
use of techniques to aid mucus clearance in the lungs (physiotherapy, vibrating 
respiratory devices, and breathing exercises), inhaled and oral antibiotics to treat infection 
(Geller & Rubin, 2009), and improvements in nutrition (Elborn, 2016). Early treatment of 
Pa can prevent patients developing a chronic lung infection during childhood (C. R. 
Hansen, Pressler, & Hoiby, 2008; Hoiby, 2011), hence the need to improve the pediatric 
administration of antibiotics. 
Tobramycin was the first commercially available inhaled antibiotic, as it has high 
activity, low toxicity, and is easily radiolabeled (A. L. Smith, 2002). A key trial that 
demonstrated the efficacy of tobramycin for treating CF was conducted by Ramsey et al. 
(1999) who demonstrated an average 12% increase in FEV1, 26% decrease in pulmonary 
exacerbations, less hospitalization, and a 1.1 log10 CFU/g reduction in Pa infection. 
Inhaled tobramycin is available in two forms: tobramycin inhaled solution (TIS), which is 
loaded into a nebulizer, and tobramycin inhaled power (TIP), which is loaded into a DPI. 
TIP is the focus of this work as DPIs require less cleaning and sterilization than nebulizers, 
and can deliver antibiotics faster (Somayaji & Parkins, 2015). An important consideration 
when treating any bacterial infection with antibiotics is to minimize the possibility of 
resistant forms of the bacterium. If the concentration of tobramycin delivered to the airway 
surface liquid (ASL) is below the minimum inhibitory concentration (MIC), then strains of 
Pa develop that cannot be treated with the antibiotic (Dalhoff, 2014). Therefore, it is 
imperative that the respiratory delivery of inhaled tobramycin is highly efficient and 
provides consistent dosage in order to minimize the possibility of antibiotics resistance. 
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Numerous studies from our group have demonstrated that the EEG method is a 
very efficient approach for delivering pharmaceutical aerosols to the respiratory airways 
(Hindle & Longest, 2012; Longest et al., 2015; Longest & Hindle, 2009b, 2012; Longest, 
Tian, Li, Son, & Hindle, 2012; Tian, Hindle, & Longest, 2014; Tian, Longest, Li, & Hindle, 
2013). EEG utilizes a spray-dried formulation of a drug that produces an aerosol with a 
mass-median aerodynamic diameter (MMAD) of less than approximately 1.5 µm (Son, 
Longest, & Hindle, 2012; Son, Longest, Tian, & Hindle, 2013), when sufficiently 
aerosolized by a DPI. These small particles have low inertia, which leads to increased 
penetration fractions, and reduced losses in the delivery system and extrathoracic region. 
The formulation includes a hygroscopic excipient that causes particle or droplet growth, 
once inside the lungs, by absorbing moisture from the humid airways. The aerosol size 
can increase to an MMAD of 3-6 µm (Tian et al., 2014; Tian et al., 2013), which increases 
its inertia and improves lung retention once it has penetrated deep in the conducting 
airways. EEG is expected to be a viable method for delivering tobramycin to pediatric 
patients with CF and diseased airways. The high delivery efficiency of the EEG method 
offers a targeted approach of providing high dose concentrations in the ASL of the 
conducting airways. Combined with N2L administration via a streamlined nasal cannula, 
losses in the patient interface and extrathoracic region are expected to be low (Longest 
et al., 2015). Using a nasal cannula also has the expected benefit of reducing patient 
distress, especially for infants and young children, when compared to a facemask 
(Amirav, 2011; Everard, 2003). 
Previous work from our group has also demonstrated the importance of using a 
concurrent experimental and CFD approach when developing aerosol delivery systems 
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(Behara, Farkas, Hindle, & Longest, 2014; Behara, Longest, Farkas, & Hindle, 2014a, 
2014b; Hindle & Longest, 2013; Longest, Azimi, Golshahi, & Hindle, 2014; Longest, 
Azimi, & Hindle, 2014; Son, Longest, Tian, et al., 2013) and evaluating particle transport 
through the lungs, with validation against in vitro (Longest & Hindle, 2009a; Longest, 
Hindle, Das Choudhuri, & Byron, 2007; Longest, Tian, Delvadia, & Hindle, 2012; Longest, 
Tian, Walenga, & Hindle, 2012; Longest & Vinchurkar, 2007b; Tian, Longest, Su, 
Walenga, & Hindle, 2011) and in vivo (Longest et al., 2015; Walenga & Longest, 2016) 
data. CFD models provide a high degree of engineering insight, such as localized 
deposition patterns, flow field characteristics, and predictions of turbulence behavior. For 
optimization of a system, changes to design parameters can be made and quickly 
evaluated via CFD (once the baseline model is developed), without running a large 
number of experiments. However, the numerical model must be validated against 
experimental data to ensure the conclusions drawn from the CFD results are accurate. 
Therefore, much of the work for this dissertation relies on collaboration with Dr. Michael 
Hindle at the VCU School of Pharmacy, and this joint effort combines the numerical and 
experimental sides of the investigation, in order to improve device design and evaluate 
deposition in the airways. 
The expected contributions to the field of respiratory drug delivery from this 
dissertation are summarized as follows: 
• An experimental and CFD model of a 6-month-old infant for the evaluation of 
N2L delivery methods 
• A set of CFD meshing and solution guidelines, which are validated against 
suitable experimental data, and will form the basis of future numerical work 
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• An optimized DPI and nasal cannula interface, using CFD insight, which 
provides highly efficient tobramycin delivery to children 
• Three characteristic experimental and CFD models of the diseased upper 
airways from patients with CF aged from 2-3, 5-6, and 9-10 years old 
• A CFD-based proof of concept for the application of EEG formulation 
tobramycin to treat pediatric CF lung infections 
• Preliminary delivery parameter recommendations for use with EEG and N2L 
aerosol administration that maximize lung delivery of the aerosol and improved 
dose uniformity across multiple lung levels based on an initial complete-airway 
CFD model of a child with CF 
Objective 1: Accurate CFD Simulations of Aerosol Delivery in Infants and 
Children 
Rationale 
From the perspective of developing a skill set, Objective 1 provides a fundamental 
understanding and working knowledge of modeling aerosol transport through pediatric 
airways via CFD. The breathing infant lung (BIL) model has been used previously for in 
vitro evaluation of surfactant administration in a representative complete-airway model 
(Holbrook, 2015). However, questions remain related to how accurately the BIL model 
approximates deposition in infant lungs, especially in terms of regional deposition. Insight 
from CFD models can be used to investigate deposition patterns in the packed bed and 
determine how that compares with an anatomically accurate model. 
Flow and particle behavior in the nasal passage is very different compared to the 
distal airways considered in the BIL model. Airflow conditions are usually transitional or 
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turbulent, and impaction is the primary deposition mechanism in the extrathoracic 
airways. As such, CFD models require different methods and considerations. There is 
limited material available in the literature for a validated methodology for applying CFD to 
nasal passage geometries. Such guidelines are available for the aerospace, oil and gas, 
and automotive industries, but these recommendations may not be applicable to 
extrathoracic airways. Therefore, Objective 1 also aims to define a set of validated 
meshing and solution guidelines that can help guide CFD model set-up, and streamline 
the development stage of an investigation. This also develops a broad set of CFD skills 
and a foundation to aid in the completion of subsequent objectives. 
Methods 
For the BIL model evaluation, a stochastic individual path (SIP) model for infant 
airways will be developed and validated against well-defined algebraic correlations. A SIP 
model separates the airways into three distinct regions and models each of them 
individually to account for changes in flow regimes through the distal airways (Longest, 
Tian, Delvadia, et al., 2012; Tian et al., 2011). The model starts with an anatomically 
accurate geometry of the extrathoracic airways to Bifurcation 3 (B3), which was 
developed from CT scan data. In this region, flow is turbulent and highly transient, and as 
such a turbulence model and transient formulation of the transport equations are applied. 
The second region covers B4-B7 with physically realistic bifurcation geometries 
(Heistracher & Hofmann, 1995), where the flow is laminar and can be modelled with a 
steady-state formulation. The third region encompasses B8-B15, and has the same flow 
conditions as B4-B7, but a new sample of particles are introduced into the domain to 
account for possible particle convergence issues as larger particles deposit upstream. 
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The infant SIP model will be based on the original adult version, but scaled to match infant 
dimensions. The CFD model of the packed bed will be compared against various 
bifurcation regions in the infant SIP model to evaluate regional and total deposition 
characteristics. 
To develop CFD meshing and solution guidelines for the airways, an initial 
validation study of a simplified geometry will be conducted using the two-equation k-ω 
model. A CFD model will be developed and validated against the experimental data from 
Pui et al. (1987), who evaluated particle deposition in a 90° bend test geometry across a 
range of Reynolds and Stokes numbers that are consistent with microparticle deposition 
in the upper airways. Once the guidelines are validated for the representative 90° bend 
geometry, they will be applied to an anatomically accurate model of an infant nasal 
passage, and validated against in vitro data provided by the VCU School of Pharmacy. 
This requires development of experimental and numerical infant N2L models, which are 
obtained via the segmentation of CT scans. Segmentation is a process whereby one 
selects pixels in the CT images that define the airways through the nasal passage. 
Selecting pixels for each slice defines voxels, which build up the 3D model, and smoothing 
algorithms in the software package provide a realistic representation of the nasal cavity. 
The geometry can then be converted to CAD data and used to build the required 
experimental and numerical models. 
Tasks 
Task 1.1: Evaluate Deposition Realism of In Vitro Packed-Bed Breathing Infant Lung 
Model (BIL) 
• Status: Complete and published (Bass & Longest, 2018a) 
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Task 1.2: Recommendations for Simulation of Microparticle Transport and Deposition 
Using Two-Equation Turbulence Models 
• Status: Complete and published (Bass & Longest, 2018b) 
Task 1.3: Validating CFD Predictions of N2L Aerosol Delivery in a 6-Month-Old Infant 
Airway Model 
• Status: Complete and published (Bass, Boc, Hindle, Dodson, & Longest, 2019) 
Outcomes 
The work completed by Objective 1 provides a thorough evaluation of an in vitro 
method for modelling whole-lung aerosol delivery using CFD insight, a set of meshing 
and solution guidelines for the numerical modelling of microparticles in the upper airways, 
and an experimental and CFD model of a 6-month-old nasal passage. The CFD-based 
evaluation of packed bed lung models will determine whether such models are accurate 
in their predictions of total and regional deposition. The solution guidelines provide a 
foundation for future CFD work in all areas of respiratory drug delivery, and aim to 
streamline the CFD model development process. The 6-month-old nasal model will be 
used in future work by our group to assess N2L delivery methods to infants, both 
numerically and experimentally. Objective 1 also provides the fundamental knowledge 
and skill sets required to model aerosol transport, through delivery systems and the 
airways, which are required for successfully completing Objective 2 and 3. 
Objective 2: Quantitative Analysis and Design of High Efficiency Pediatric DPIs  
Rationale 
Commercial DPIs are generally inefficient due to high device and extrathoracic 
losses, which typically arise from relatively large particle diameters (>2 µm) and high 
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velocity flows used to disperse the powder. Delivery efficiency of devices can be improved 
with highly dispersible powders and improvements in aerosolization performance. 
Previous work from our group has shown how turbulence characteristics of the flow 
deaggregates the powder and reduces particle size (Longest, Son, Holbrook, & Hindle, 
2013). Recent work has also shown that non-dimensional turbulence parameters, derived 
from CFD models, correlate well with the aerosol MMAD and ED for DPIs that utilize dose 
aerosolization and containment (DAC) units (Longest & Farkas, 2018). The DAC unit 
comprises a capsule that holds the powder, with inlet and outlet capillaries that introduce 
an air jet to aerosolize the powder. These DPIs are designed to be used with a low volume 
(LV) of actuation air, and are referred to as LV-DPIs. This objective uses DAC units with 
a higher flow rate (HF), which are referred to as HF-DPIs. It is expected that numerous 
changes to the HF-DPI design parameters can be explored via CFD, and predictive 
correlations can be used to estimate device performance, with a focus on minimizing 
MMAD and maximizing ED. Once the DAC unit is optimized, improvements will be sought 
in the design of the cannula that delivers the aerosol to the nasal airways, which provides 
a thorough and complete optimization of multiple elements of the delivery system. 
Methods 
Initial work will begin by applying the same non-dimensionalization and correlation 
methods to the HF-DPIs as developed for the LV-DPIs presented by Longest and Farkas 
(2018). Initial correlations will be developed using a number of prototype devices for which 
the MMAD and ED have been experimentally determined. Other flow field and turbulence 
characteristics will be explored via the CFD model, to determine what aspects of the 
device design drives performance at high flow rates, which will lead to additional non-
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dimensional parameters and correlations. Once a predictive correlation is found, 
numerous CFD models of DAC unit designs will be evaluated in terms of aerosolization 
performance. The best designs will then be tested experimentally to verify the CFD 
predictions and ensure the predicted performance of the DAC unit is achieved. A similar 
quantitative approach to design evaluation will be applied to the nasal cannula in order to 
reduce deposition losses in the patient interface. This method demonstrates the benefits 
of leveraging the strengths of experimental and numerical models, and combining them 
to drive the optimization of the delivery system. 
Tasks 
Task 2.1: CFD Optimization of an Inline DPI for EEG Tobramycin Formulations 
• Status: Complete and published (Bass, Farkas, & Longest, 2019)  
Task 2.2: Develop DPI Patient Interfaces for Improved Aerosol Delivery to Children  
• Status: Complete and in press (Bass & Longest, 2020) 
Outcomes 
Meeting the requirements of Objective 2 provides CFD-driven optimization of a 
delivery system for administering inhaled antibiotics to pediatric CF patients. The methods 
used to determine design optimizations are also beneficial for future work that aims to 
improve device performance. Once the performance of the delivery system meets a pre-
determined level of efficiency, the transport of aerosol through the airways and deposition 
patterns will then be evaluated by Objective 3. 
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Objective 3: CFD Predictions of EEG Aerosol Antibiotic Delivery to Children with 
Cystic Fibrosis 
Rationale 
To date, few studies have developed CFD models for the diseased airways of 
patients with CF. Damage to the lungs from CF is known to affect airway morphometry 
with bronchiectasis (thickening of bronchi walls), general inflammation from infection, and 
mucus obstructions. Therefore, the geometry of an airway CFD model for CF patients 
would be very different to healthy lungs, which is expected to affect the flow field and 
particle trajectories. The first such study in this field was conducted by Awadalla et al. 
(2014) who developed a Large Eddy Simulation (LES) model of porcine lungs with CF 
that replicate human CF lungs. Results showed that reduced airway diameters lead to 
higher flow velocities, which in turn caused an increase in deposition due to impaction. 
They also concluded that submicron particles may be critical in treating disease in the 
narrow airways. The first CFD investigation into aerosol administration in human CF lungs 
was conducted by Bos et al. (2015). They developed CFD models from CT scans of 40 
adult patients and evaluated whether delivered concentrations of Aztreonam lysine (AZLI) 
were sufficient in the ASL to treat infections. Results showed that concentrations were 
adequate in the majority of cases considered, though there was a large amount of inter-
subject variability. Interestingly, they also showed that the lung lobes with the most 
amount of disease had less ventilation, and hence less aerosol delivery. Primary 
limitations to this study include a number of assumptions regarding particle size and the 
ASL thickness, and CFD results were not directly validated against in vitro or in vivo data. 
Bos et al. (2017) extended this work with a second study comparing two nebulizers and 
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their efficiency at delivering TIP. Again, the CFD deposition results from this study were 
not validated against an experimental model. Objective 3 aims to build upon these studies 
by validating and evaluating EEG N2L administration of tobramycin to pediatric lungs with 
CF lung damage. 
Methods 
Three CF diseased lung models will be developed that are representative of 
patients aged 2-3, 5-6, and 9-10 years old from CT scans. This objective requires 
collaboration with Dr. Harm Tiddens’ group at Erasmus Medical Centre (Rotterdam, 
Netherlands), as they will be providing the CT scans, and conducted the human CFD 
investigations into CF lung deposition mentioned previously (Bos et al., 2017; Bos et al., 
2015). If the CF lung scans do not include the extrathoracic region, nasal models will be 
developed from our own in-house database of CT scans and combined with the diseased 
airway model. Generating experimental and numerical models from CT data requires 
segmentation of the scans as described in Objective 1. The fidelity of the scan resolution 
limits how accurately distal regions of the lung can be extracted from the CT images, and 
models of pediatric CF lungs typically terminate when the airway diameter is 1-2 mm 
(which is approximately Bifurcation 6) (Bos et al., 2015). SIP geometries will be used to 
determine deposition in each lung lobe, with dimensions that are consistent with CF lungs. 
The SIP geometries will also be modified to account for the bronchiectasis and other 
forms of lung damage associated with CF. Deposition data from the experimental and 
numerical CF SIP lung models will be used to determine whether sufficient concentrations 




Task 3.1: Develop In Vitro Upper Airway Geometries of CF Patients in Age Ranges of 2-
3, 5-6, And 9-10 Years 
• Status: Complete and in vitro testing complete  
Task 3.2: Develop CFD Models of Upper Airway Geometries for Pediatric Patients and 
Evaluate Delivery Efficiency and Aerosol Growth with Comparisons to In Vitro 
Experiments 
• Status: Complete and manuscript in preparation 
Task 3.3: Extend and Develop CFD Lung Models to Predict Regional Lung Deposition 
and Tobramycin ASL Concentrations in Healthy and CF Complete-Airway Lung Models 
• Status: Complete and manuscript in preparation 
Outcomes 
Objective 3 provides a proof of concept for applying the EEG approach, via N2L 
administration, for the treatment of bacterial infections in CF lungs with inhaled 
tobramycin. Specifically, three upper airway geometries are developed from CT scans of 
individuals with CF in the age ranges of 2-3, 5-6, and 9-10 years old. These geometries 
enable experimental and numerical models of aerosol deposition after inhalation of 
antibiotics from the optimized delivery system. The models will also be beneficial for future 
studies, by our group and others, in the field of CF treatment. Extending the lung model 
into distal regions provides insight into regional deposition patterns, and determines 
whether tobramycin is delivered in sufficient quantities to provide an ASL concentration 
that is high enough to eradicate the bacteria. 
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Chapter 2: Evaluate Deposition Realism of In Vitro Packed-Bed 
Breathing Infant Lung Model (BIL) 
2.1 Objective 
The objective of this study was to determine whether packed bed in vitro models, 
which contain spheres as the primary repeating unit, provide a realistic representation of 
aerosol deposition in the tracheobronchial region of infant lungs based on computational 
fluid dynamics (CFD) predictions. To focus on impaction deposition in the 
tracheobronchial airways, particles in the size range of 0.5 to 10 µm are evaluated. 
Systems considered are the packed bed arrangement with an inlet jet generated by 
outlets of the upper airway model and a realistic bifurcating airway anatomy. To 
understand the deposition in each of these systems, CFD simulations are implemented. 
Numerous studies from our group have validated the accuracy of CFD models for 
predicting aerosol deposition in comparison with in vitro lung experiments (Longest & 
Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian, 
Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and in vivo data 
(Longest et al., 2015; Walenga & Longest, 2016). 
2.2 Introduction 
In vitro airway models provide a convenient and scientifically useful testing 
platform for determining aerosol delivery to and deposition within the lungs (Byron et al., 
2010; Carrigy, Ruzycki, Golshahi, & Finlay, 2014; R. Delvadia, Longest, & Byron, 2012; 
Warren H. Finlay & Martin, 2008). These models can be used to determine inhaled dose 
of airborne pollutants and bioaerosols arising from environmental exposures. In vitro 
airway models are also useful in determining the lung delivery efficiency of inhaled 
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medications and developing more efficient respiratory drug delivery systems. Specific 
advantages of in vitro airway models include the avoidance of human subject testing with 
the associated safety and ethical concerns, a reproducible and controllable platform with 
well-defined physical attributes, and the ability to instrument the system as needed. 
Disadvantages include limited establishment of in vivo-in vitro correlations (IV-IVC) and 
difficulty in reproducing the highly complex and dynamic airway system (Byron et al., 
2010). 
Considering infants, a number of studies have implemented in vitro models to 
evaluate aerosol deposition in a portion of the airways. Widely used infant nasal models 
based on a single subject scan have been reported for pre-term (Minocchieri et al., 2008) 
and 9-month-old (Janssens et al., 2001) infants. Javaheri et al. (2013) developed a 
characteristic infant nasal model based on 10 previously published geometries in the age 
range of 3-18 months. Xi et al. (2012) developed a set of pediatric nasal models across 
an age range from infant to 5-years-old. The studies of Storey-Bishoff et al. (2008) and 
Golshahi et al. (2010) provide examples of implementing in vitro infant nasal models to 
determine the lung delivery efficiency of inhaled aerosols. Carrigy et al. (2014) further 
reviews the development of infant and pediatric extrathoracic models with applications to 
determine lung delivered dose from inhaled pollutants and inhaled pharmaceutical 
aerosols. 
A hybrid-style in vitro lung model can be defined as containing a geometrically 
realistic upper airway structure and an approximation of the remaining lung anatomy. As 
reported by Carrigy et al. (2014), pediatric extrathoracic models typically connect to a filter 
or aerosol impactor to evaluate total lung delivery and particle size distributions (PSD) of 
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the lung delivered dose. More detailed hybrid-style in vitro lung models also contain some 
of the upper tracheobronchial bifurcating airways. For example, Delvadia et al. (2012) 
report small, medium, and large adult upper airway geometries through the third 
respiratory bifurcation with the airway outlets contained in a lung Plexiglas chamber with 
a filtered outlet. Pulmonary deposition was calculated as the dose deposited on the 
chamber walls and filter at the chamber exit, which assumes that no dose is exhaled due 
to the presence of a breath-hold period. A mixing inlet style system was used to reproduce 
accurate inhalation profiles. Delvadia et al. (2012; 2013) report very good agreement 
between in vitro predictions of lung deposition and in vivo studies across multiple 
inhalation waveforms and devices, and the ability of in vitro models to capture intersubject 
variability. Verbanck et al. (2016) developed an adult in vitro airway model extending to 
approximately the fifth airway generation and connected each outlet to a separate 
collection filter. Studies by Longest et al. (2015; 2012) have implemented a hybrid-style 
in vitro model and sized the lung chamber prior to an impactor to reproduce realistic lung 
aerosol residence times in order to study hygroscopic aerosol growth during a respiration 
cycle. While providing additional information about respiratory aerosol transport, these 
hybrid-style lung models have not attempted to capture the mechanisms of particle 
deposition in the lower lung and, therefore, are not capable of capturing exhaled aerosol 
dose and regional aerosol deposition.  
Packed beds, also known as glass bead media or granular beds, are a form of 
porous media composed of spheres or beads in a tightly packed arrangement (Nield & 
Bejan, 1999). Fluids can move between the spheres and the spherical surfaces providing 
a high surface-area to volume ratio. Packed beds are traditionally used for gas or liquid 
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flows with surface reactions, as with component extraction or purification applications, but 
have also been characterized for aerosol filtration. Gebhart et al. (1973) initially 
characterized diffusional and sedimentation deposition in a packed bed structure. 
Subsequent studies characterized aerosol deposition by interception (K. W. Lee & 
Gieseke, 1979) and impaction (D'Ottavio & Goren, 1982) in packed beds. 
Both packed beds and the alveolar region of the lung have a high surface-area to 
volume ratio, which in the case of a packed bed can be tuned to equal that of the lung 
(Gebhart & Heyder, 1985). As a result, several studies have used simple packed bed 
models as an approximate surrogate of the human lung for deposition in the 
sedimentation and diffusion regimes. Brand et al. (1994) used a packed bed model as a 
test case to evaluate the sensitivity of the aerosol derived airway morphometry approach. 
It was assumed that aerosol bolus dispersion was identical in the lung and packed bed 
tube filled with 0.8 mm beads. Rosenthal et al. (1992) compared aerosol dispersion in a 
packed bed tube and in human subject studies. Aerosol dispersion in the human lungs 
was largely influenced by the larynx and breath-pause period, which were not captured 
in the packed bed media. Hence, inclusion of the upper airways and laryngeal jet were 
shown to be important. Rosati et al. (2003) used a packed bed model as an “approximate 
surrogate to the human lung” to compare the difference in the deposition of polydisperse 
and monodisperse aerosols. 
Very few studies have previously generated a hybrid in vitro airway model by 
combining a realistic extrathoracic airway model with a packed bed model of the lower 
lungs. This interesting idea was originally suggested by Gebhart and Heyder (1985). As 
shown in Figure 1 of their study, they approximated the mouth-throat as a 90-degree bend 
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and reproduced the first several bronchi leading to a packed bed. Modifications to the 
packed bed length and bead size allowed the model to capture deposition by diffusion 
and sedimentation consistent with in vivo experiments. In a short conference paper by 
Saini et al. (2002), a hybrid model is reported consisting of a larynx cast and glass bead 
model in a triangular geometry containing three different glass bead sizes. This model 
could theoretically capture impaction, sedimentation and diffusion deposition 
mechanisms similar to lung airways. However, comparisons to in vivo data of lung aerosol 
deposition are not provided. 
Similar to Gebhart and Heyder (1985), an appealing approach for creating a 
complete airway in vitro model is to combine a realistic 3D printed upper airway geometry 
with a packed bed structure. Realistic upper airway geometries have been shown to 
predict delivery efficiency of aerosols to the lungs consistent with in vivo data (R. Delvadia 
et al., 2012; R. R. Delvadia, Hindle, et al., 2013; Yu Zhang, Gilbertson, & Finlay, 2007). 
Packed bed arrangements can capture correct surface area to volume ratios of the lung 
as well as correct sedimentation and diffusion properties of submicrometer particles 
(Gebhart & Heyder, 1985). However, it is not currently known if packed beds can capture 
impaction similar to airway bifurcations in the mid- and lower-level bronchi. Introducing a 
jet of airflow to a packed bed will spread through the bed in a manner that may be similar 
to a bifurcating network. Furthermore, the intersections of packed spheres form flow 
dividers that will serve as aerosol deposition points potentially similar to the branching 
airways. 
The envisioned hybrid-style complete-airway model for an infant consists of a 
realistic upper airway geometry derived from a CT scan together with a shell of the plural 
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region. The plural cavity is filled with monodisperse beads. Of interest is whether the 
packed bed region can capture correct total deposition similar to the lung airways and if 
the model can capture regional (spatial) deposition distributions. Matching both total and 
regional deposition will require correctly capturing impaction, sedimentation and diffusion 
mechanisms at the appropriate time scales and flow rates of respiration. More advanced 
complete-airway models will implement multiple bead sizes, as with Saini et al. (2002). 
However, the first challenge is to determine if a packed bed of spheres can capture 
impaction similar to the bronchi and bronchioles of the respiratory airways. 
2.3 Methods 
An overview of the systems considered in this study is shown in Figure 2.1. The 
infant complete-airway in vitro model integrates a CT-scan-based upper airway geometry 
through B3 with a packed bed structure to represent the remainder of the lungs (Figure 
2.1a). The realistic model is truncated at approximately B3 based on resolution of the CT 
scan and structural integrity of the model. The TB airways extend beyond B3 through 
bifurcation B15, which contains the terminal bronchioles and leads to the respiratory 
bronchioles containing alveoli. A stochastic individual pathway model, as developed by 
Longest et al. (Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; 
Tian et al., 2011), is shown in Figure 2.1b extended from B3 exits through B15. The 
respiratory airways contain approximately 300,000 bronchi/bronchioles (including the 
respiratory bronchioles) and 480 million alveoli (Ochs et al., 2004), which is not practical 
to reproduce with current 3D printing technologies. To represent the conducting airways, 
this study implements a packed bed (PB) model as shown in Figure 2.1c. The tube shown 
in the PB model is the transition between the outlet of B3 to the sphere array. It is expected 
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that this transition region will have an important impact on performance of the PB model. 
This study focuses on deposition comparisons between the SIP and PB models, using 
CFD simulations. These systems, as well as the complete-airway model, are described 
in more detail in the following sections. 
Infant Complete-Airway Model 
The infant complete-airway in vitro model (Holbrook, 2015) was originally 
developed to evaluate the improved compliance of the lung while administering 
surfactants to infants. The upper airways (MT-B3) of the infant complete-airway model 
were based on an adult model (Walenga, Tian, & Longest, 2013) referred to as Model D, 
and scaled to match infant morphometric data (Phalen, Oldham, Beaucage, Crocker, & 
Mortensen, 1985). The lower airways (B4 onwards) are represented by a pleural cavity 
shell, constructed from an infant computed tomography (CT) scan that was completely 
filled with 6 mm diameter spheres. The pleural cavity was scaled so that the Functional 
Residual Capacity (FRC) was 150 mL of airspace after the spheres were added. The 6 
mm spheres were initially selected for the infant complete-airway model because the 
hydraulic diameter of the triangular void between three connected spheres (0.62 mm) is 
a reasonable approximation of the number average diameter of the remaining infant 
tracheobronchial airways from B4 to B15 (0.45 mm). However, this sphere diameter may 
not be ideal, and the current study intends to determine whether alternative sphere sizes 
may be more suitable for matching deposition in the infant lung. To represent the airway 
surface liquid, 12 mL of water was added to the pleural cavity to form liquid bridges 
between the connected spheres. Administration of surfactant to the model reduced the 
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surface tension of these liquid bridges and improved lung compliance in a realistic way 
(Holbrook, 2015). 
CFD-Packed Bed (PB) Model 
A CFD model was constructed to represent the PB region of the complete-airway 
model with a focus on the junction between the B3 outlet and surrounding spheres (CFD-
PB model; Figure 2.1c). The sphere arrangement is a hexagonal close packed formation, 
which gives the maximum packing density for equal diameter spheres. To account for the 
water added to the infant complete-airway model, filleted surfaces represent the liquid 
bridges between each connected sphere. The 0.29 mm radius of these fillets (see Figure 
2.1) determines the added volume of the liquid bridges, which matches the 12 mL of water 
used in the infant complete-airway model. 
The inlet duct of the CFD-PB model is equivalent to the outlet of the upper airways 
in the infant complete-airway model. That is, the CFD-PB inlet represents the transition 
from the infant complete-airway upper airways to the pleural cavity filled with spheres. 
The results evaluate two examples of CFD-PB models: one that replicates the infant 
complete-airway model with the spheres representing the lung from B4 onwards (CFD-
PB B4+), and another where the spheres represent the lung from B7 onwards (CFD-PB 
B7+). The intention of the CFD-PB B7+ case is to determine whether the spheres should 
only model the smaller tracheobronchial airways, with inclusion of more of the bifurcating 
lung geometry upstream of the packed bed. 
The inlet duct points toward the center of what this study refers to as the first 
sphere. The distance from the inlet duct to the first sphere is the same as the length from 
the inlet to the carina for the first bifurcation that the CFD-PB model represents. For 
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example, the CFD-PB B4+ case uses a distance from the inlet to the first sphere that 
matches the carinal length of B4. Imposing this distance on the CFD-PB configuration 
aims to capture impaction on the surface of the first sphere similar to the first bifurcation 
that this sphere replaces. Other cases are evaluated that consider the packed bed after 
the inlet duct, thereby looking at a cross-section (CS) of the sphere array, which are 
referred to as CFD-PB CS models. These models do not use an inlet duct and instead 
introduce flow into the domain through the entire CFD-PB model rear inlet surface (Figure 
2.3a). 
The CFD-PB models (Figure 2.3) extend three sphere diameters laterally both 
above and below the tubular inlet, with respect to gravity, to capture spreading of the 
airflow in the packed bed. Symmetry is present along the center of the inlet duct, so the 
domain extends three sphere diameters away from this symmetry plane. In the axial 
(downstream) direction, each case has an adjusted domain length so that particles do not 
escape through the outlet during a realistic transport time. At most, the domain extends 
16 sphere diameters. 
ICEM CFD 14.5 meshing software (ANSYS, Inc., Canonsburg, PA, USA) 
generated the tetrahedral, Delaunay mesh for the domain (Figure 2.3b). There is a 
conformal mesh interface between the inlet mesh and remaining domain, with a one-to-
one match between vertices and cell faces (Figure 2.3c). This ensures there is no 
interpolation of variables across the interface when solving the flow field. The mesh 
accurately resolves the shape of the filleted surfaces between spheres with appropriately 
aligned mesh lines (Figure 2.3c). The two near-wall prism layers included in the mesh are 
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sufficient to resolve the boundary layer under low-speed, laminar flow conditions. The 
volume mesh quality has a minimum value of 0.1. 
To minimize the numerical error in the CFD results, a mesh dependency study was 
performed to identify the most efficient and accurate cell size for the models. The 
deposition profiles for a coarse (1.6 million cells), and fine (12.9 million cells) mesh for the 
CFD-PB B4+ geometry were compared to determine if results converge to the same 
solution as the cell size is decreased. The deposition fraction for the coarse and fine mesh 
had an absolute difference of 0.2% for the 5.0 µm particles. Reducing the refinement level 
lower than the course mesh made it difficult to resolve the curvature of the fillets between 
sphere contacts. As these meshes give similar results, the coarse mesh was used for all 
simulations. At most, the cell count for the largest evaluated domain (CFD-PB CS) is 
approximately four million cells. 
CFD-Stochastic Individual Path (SIP) Model 
Previous studies by our group have documented the details and development of 
the SIP approach for CFD modeling of the complete airways (Longest et al., 2015; 
Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al., 
2011). Briefly, a SIP geometry is a randomly determined individual pathway through the 
lung from B4 to B15, where at each bifurcation, one branch is continued and one is not. 
Previous work by our group has shown that following a pathway through the lower left 
lobe of the lung provides deposition characteristics that are representative of the average 
of all lobes (Longest, Tian, Delvadia, et al., 2012). CFD simulations of the SIP geometry 
begin with the B4 inlet and assume steady laminar flow. Velocity and particle profile inlet 
conditions are generated from simulations in upstream airways. While it is known that 
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turbulence is generated in the laryngeal jet and extends often past B4 based on CFD 
simulations (Xi, Longest, & Martonen, 2008) our previous results indicate that the best 
agreement with human in vivo data for pharmaceutical aerosols is achieved assuming 
turbulence occurs above B4 and laminar flow occurs below B4 (Longest et al., 2015; 
Walenga & Longest, 2016). To allow for the injection of additional particles to best resolve 
deposition, the SIP model simulations were divided into B4-B7 and B8-B15 sections. 
The bifurcations used in the previously developed adult SIP models are based on 
a physically realistic geometry (Heistracher & Hofmann, 1995) and adult morphometric 
data (Yeh & Schum, 1980), which provide anatomically accurate models. Simulating the 
lung bifurcations with the SIP method greatly reduces computational processing times, 
and studies have validated the results against experimental in vitro (Longest, Tian, 
Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al., 2011) and in vivo 
(Longest et al., 2015; Walenga & Longest, 2016) data. 
To create the infant CFD-SIP model, available morphometric data must be scaled 
to match infant dimensions. A review of the literature (Dunnill, 1962; Herring, Putney, 
Wyatt, Finkbeiner, & Hyde, 2014; Hislop, Wigglesworth, & Desai, 1986; Langston, Kida, 
Reed, & Thurlbeck, 1984; Thurlbeck, 1982) shows large variation in measurements of 
infant FRC and volume fractions of the bronchial, bronchiolar, and alveolar-interstitial 
regions, which are the morphometric data required to scale from adult to infant 
dimensions. As an alternative approach, the scale factor used to convert from adult to 
infant dimensions was taken as the ratio of the average B3 outlet diameter from the infant 
complete-airway model and the adult morphometric data (Yeh & Schum, 1980), which 
gives a value of approximately 0.29. 
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Applying this dimensional scale factor to the adult morphometric lung data (Yeh & 
Schum, 1980) results in an FRC of approximately 145 mL. This value is within the span 
of lung volumes found in the literature for infants, which range from 127 mL (Hislop et al., 
1986) to 222 mL (Herring et al., 2014), and matches well with the 150 mL FRC used in 
the infant complete-airway model. Furthermore, the World Health Organization (WHO) 
Growth Charts (WHO, 2006) indicate that the 50th percentile female and male has a height 
of 49 cm and 50 cm respectively at birth, which applied to infant airway dimension 
correlations (Phalen et al., 1985) gives a B3 outlet diameter of approximately 2.55 mm 
with a standard error of 0.37 mm. This compares favorably with the average B3 outlet 
diameter from the infant complete-airway model, which is 2.30 mm. 
Transport Equations and Numerical Methods 
The ANSYS FLUENT 14.5 software package (ANSYS, Inc., Canonsburg, PA, 
USA) was used to solve the flow field and particle trajectories through the domain. The 
model settings use the best practices developed by our group in previous projects 
(Longest et al., 2015; Longest, Tian, Walenga, et al., 2012). In brief, this includes double 
precision accuracy, use of the SIMPLEC algorithm for pressure-velocity coupling, second-
order upwind spatial discretization for flow variables, and the Runge-Kutta scheme for 
particle tracking. 
The model simulates the infant lung under mechanical ventilation, which uses a 
sinusoidal volumetric flow rate over a 0.5 s interval (further details are described below). 
Therefore, the problem is time-dependent by nature, and the model requires transient 
flow conditions with first-order implicit temporal discretization. The solver uses a relatively 
small time-step size, and runs a suitable number of iterations between these time steps. 
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For all cases, a time step size of 0.005 s is small enough that the change in inlet velocity 
between time steps is minimized and 100 iterations per time step accurately resolves the 
flow field. 
 The peak inlet velocity is 2.68 m/s for the CFD-PB B4+ case, which occurs halfway 
through the sinusoidal ventilation inhalation profile and is the highest inlet velocity 
considered. This gives an estimated maximum Reynolds number at the inlet of 
approximately 400. This is far below the critical Reynolds number value for internal flow, 
so the laminar viscous model is sufficient for the flow environment. Therefore, particles 
are not subject to turbulent conditions, such as turbulent dispersion or the effects of 
turbulent anisotropy near wall boundaries. 
As the CFD-PB model represents the lung distal to at least B4, the gravity force is 
included to capture the sedimentation deposition mechanism, which becomes more 
important as the velocity slows. In the PB geometry, the effect of gravity acting in 3 
separate orientations is considered. Because particle diameters are 0.5 µm and higher, 
effects of Brownian motion are neglected. 
Considering particle injection profiles, the CFD-PB models implement a parabolic 
particle distribution (Longest & Vinchurkar, 2007b). This particle profile captures the fact 
that particle flux into the geometry starting from a well-mixed upstream concentration is 
proportional to the local fluid velocity flux. For the CFD-PB CS case, where particles enter 
throughout the PB geometry, a random uniform concentration is assumed at each of the 
multiple inlets. 
The injected size distribution separates the particles into nine bins, with particle 
diameters between 0.5 and 10 µm. The particle injection introduces 500 particles of each 
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bin size per time step, which totals 450,000 particles tracked through the domain. 
Previous work by our group has shown that this method gives suitable particle 
convergence (Longest, Tian, Walenga, et al., 2012). 
At birth, the 50th percentile weight for girls and boys is 3.2 and 3.4 kg respectively, 
based on the WHO Child Growth Chart (WHO, 2006). The selected ventilation 
parameters for an infant in this weight range are a tidal volume (𝑉𝑡 ) of 28.4 ml and 
inspiration time (𝑡𝑖𝑛) of 0.5 s (Walsh & DiBlasi, 2010). For a sinusoidal flow profile, the 











Equation (2.3.1) is found by using an arbitrary sinusoidal volumetric flow rate curve 
(𝑄 = 𝐴 sin(𝜔𝑡)) and integrating to get the volume of air added to the lung at any given 
time (𝑉 = ∫𝑄 𝑑𝑡). The known added volumes at zero time (𝑉(0) = 0) and inspiration time 
(𝑉(𝑡𝑖𝑛) = 𝑉𝑡) are applied to determine the 𝐴 and 𝜔 parameters that defined the volumetric 
flow rate. The volumetric flow rate is then divided by the inlet area to find the transient 
inlet flow velocity. The scaling parameter (𝐶) is included to control the fraction of the tidal 
volume that enters through the inlet of the CFD-PB models, as they represent a fraction 
of the entire lung. For the CFD-PB models, the scaling parameter is the inverse of the 
number of outlets at the upstream bifurcation level, so that the flow though the CFD-PB 
model represents the fraction of the lung in question. For example, if the CFD-PB model 
represents B4-B15, the scaling parameter is one eighth, as there are eight outlets at the 
B3 level. 
For the CFD-PB models, evaluating a sub-domain of a larger packed bed imposes 
challenges when defining the boundaries between adjacent domains in a numerical 
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model. Each CFD-PB case uses wall boundaries at the left, rear, top, and bottom sides 
of the simulated domain (see Figure 2.3), and the results assume that these boundaries 
have little influence, as they are sufficiently far away from the region of interest. To verify 
this assumption, the velocity magnitude close to these wall boundaries is evaluated for 
all cases and the geometry is deemed suitable if the magnitude is small relative to the 
region of primary particle deposition. Furthermore, particle deposition on the domain 
extremes are checked, and the geometry is considered sufficiently large if very few 
(<0.1%) particles deposit on these wall boundaries. 
As the sides of the CFD-PB sub-domain that connect to adjacent domains are 
walls, the side opposite the inlet defines an outlet boundary to permit flow through the 
sphere array. An outflow defines the boundary condition at this outlet, with a weighting of 
one, such that all flow entering through the inlet leaves through this boundary. For the 
CFD-SIP model, outlets also use outflow boundary conditions, except that each outlet 
has half of the mass flow rate that enters the inlet at each bifurcation level. 
Comparison Criteria 
Deposition efficiency (DE) is the mass of particles that deposit in a pre-defined 
region, over the mass of particles that enter that region, expressed as a percentage: 
 
𝐷𝐸𝑖 =
Mass Deposited in Region i
Mass Entering Region i
× 100 (2.3.2) 
The advantage of the DE is that results can compare individual regions of interest 
directly by excluding upstream particle deposition. 
Deposition fraction (DF) is the mass of particles that deposit in the entire 
computational domain, over the mass of particles that enter the domain through the inlet, 







× 100 (2.3.3) 
The DF can be calculated from the DE by: 
 




where 𝑛 is the number of bifurcations or sphere layers in a given range. DF provides an 
estimate of total deposition in a region by considering all upstream losses. 
Residence time (𝑡𝑟𝑒𝑠) is the amount of time that a particle spends within a pre-
defined region of the domain. For the entire domain, the residence time is the difference 
between the time the particle escapes through the outlet boundary and the time the 
particle entered the domain. Similarly, for a given range of sphere layers, the residence 
time is the difference between the times that the particle crosses the first and last layer of 
spheres in the range. 
2.4 Results 
Comparison of CFD Predictions and Algebraic Correlations for Deposition 
To verify that the CFD predictions of infant aerosol deposition are reasonable, 
comparisons were made across a particle size range of 0.5 to 10 µm to established 
algebraic correlations. The CFD model included the infant mouth-throat (MT), upper 
tracheobronchial region through B3, and remaining TB region as a SIP geometry through 
B15, resulting in an Infant MT-B15 model. The algebraic correlations for comparison 
capture particle deposition due to sedimentation and impaction. Three correlation models 
were considered, which implement different approximations for deposition. Specifically, 
the Finlay model (W. H. Finlay, 2001) combines an analytical approximation for 
sedimentation (Heyder & Gebhart, 1977) and an empirical impaction probability (Chan & 
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Lippmann, 1980). The ICRP (ICRP, 1994) and Rudolf (Rudolf, Kobrich, & Stahlhofen, 
1990) models both use the same empirical expressions, but use different parameters to 
predict DE in the MT, upper tracheobronchial, and lower tracheobronchial regions. 
Figure 2.4 shows that the CFD results from the Infant MT-B15 model compare 
reasonably well with the range of established algebraic correlations. The Infant MT-B15 
model deposition data also exhibits the expected S-shape profile, where smaller particles 
with lower Stokes numbers are able to follow the flow streamlines, and larger particles 
deviate from the streamlines and deposit due to impaction. As predictions from the Infant 
MT-B15 CFD model compare well with these established algebraic correlations for 
impaction and sedimentation in the airways, it is acceptable to use it as a benchmark for 
comparison when evaluating the suitability of packed bed in vitro lung models. Hence, the 
deposition characteristics for a range of bifurcations in the CFD-SIP model can be 
compared with the CFD-PB model to determine whether the latter accurately represents 
drug deposition in an infant lung. 
Influence of CFD-PB Walls on Velocity Field 
To ensure the CFD-PB domain is sufficiently large, the velocity magnitude near 
the top, bottom, left and rear of the model is evaluated for all cases before analyzing 
particle deposition. Figure 2.5 shows an example of such a velocity field, and that applying 
wall boundaries conditions at all locations, except the inlet and outlet, does not influence 
results. The velocity field in Figure 2.5 is for the CFD-PB B4+ case at the peak of the 
sinusoidal inhalation, which gives the highest inlet velocity for all cases considered. The 
nodal value at Point A is 1.2e-5 m/s and is considerably smaller than the maximum value 
in the domain (3.8 m/s). Figure 2.5 also shows that the air entering the domain is a 
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relatively high velocity jet directed at the first sphere opposite the inlet duct, which is 
immediately diffused. The implications of this phenomenon on particle deposition are 
discussed further below. 
Effect of Inlet Style on Particle Deposition in CFD-PB Models 
The outlet from the prototyped upper airways can be located in the CFD-PB model 
in a number of different configurations, which are presented in Figure 2.6b-d. The naming 
convention for CFD-PB inlet configurations refers to the direction of the duct with respect 
to the sphere array. As randomly filling the pleural cavity makes it difficult to determine 
the sphere arrangement around the prototyped bifurcation, the sensitivity of the model to 
each inlet configuration is evaluated. 
Figure 2.6a compares the three inlet configurations and the possible gravity 
orientations for each case based on transport during the infant inhalation period. The X 
and Y inlet configurations both show very similar deposition profiles, whereas the Z inlet 
configuration resulted in less deposition than the other cases. The Z inlet requires the 
removal of one sphere from the array to include the inlet duct, which means there is a 
greater distance between the inlet and the nearest wall where particles may deposit. This 
is the likely cause of differences in results and demonstrates the importance of the inlet 
configuration. Note that the distance from the inlet to the first sphere opposite the duct 
matches the carinal length for B4 for the X, Y, and Z inlet configurations. 
Changing the gravity orientation for each inlet configuration has little influence on 
the DF for all particle sizes. As expected, there is a very small amount of deposition due 
to sedimentation in the upper tracheobronchial airways. Subsequent subsections 
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investigate the total and regional deposition characteristics of the CFD-PB model in more 
detail. 
Figure 2.6 demonstrates that the model is not sensitive to the inlet direction with 
respect to gravity, but it is sensitive to how close the spheres are to the inlet duct. To 
minimize the influence of the inlet position on deposition results, the sphere arrangement 
around the bifurcation outlet can be included in a prototyped model. Using the Z inlet 
configuration, the first sphere in the packed bed can be located at a given distance from 
the inlet duct. To ease the transition from realistic airway bifurcations to the packed bed, 
the first sphere can be located at a distance from the inlet that matches the distance to 
the carina for the next bifurcation. Therefore, subsequent cases that require an inlet duct 
use this type of inlet configuration, with carinal lengths of 3.92 mm for the CFD-PB B4+ 
case and 2.25 mm for the CFD-PB B7+ case. 
Effect of Sphere Size on Particle Deposition in CFD-PB Model 
Figure 2.7 compares the deposition profiles over inhalation for three CFD-PB B4+ 
cases that each use a different sphere diameter; as the sphere size increases, the DF 
decreases. This demonstrates that total deposition in a packed bed experimental model 
can be potentially tuned to match the behavior of an infant lung by varying the sphere 
size. However, the results show that deposition is very sensitive to small changes in 
sphere size for larger particles (>3 µm). For example, the DF for 5 µm particles drops by 
approximately 50% and 80% (relative difference) as the sphere size increases from 1.0 
mm to 1.5 mm and 2.5 mm respectively. Therefore, selecting an appropriate single sphere 
size, or even several sphere sizes, to represent the infant lung for a wide range of particle 
diameters would be difficult. 
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Comparison of Particle Deposition in CFD-SIP and CFD-PB Models 
Figure 2.8 compares deposition in the CFD-SIP results with the CFD-PB B4+ and 
B7+. In Figure 2.8a, the CFD-PB B4+ model uses 6 mm spheres and represents the infant 
lung distal and inclusive of B4, and the CFD-SIP results show DF from B4 to B15. The 
total DF compares quite well between the CFD-SIP and CFD-PB B4+ models, with the 
absolute error decreasing from 5.22% for the 0.5 µm particles to -7.55% for the 7 µm 
particles. Note that particles larger than 7 µm are neglected here as it is expected that 
most would deposit in the MT-B3 region. 
In Figure 2.8b, the CFD-PB B7+ model again uses 6 mm spheres, but this time 
uses the inlet from B7 to introduce flow into the domain. The CFD-SIP results show DF 
data from B7 to B15. In this case, the CFD-PB B7+ model matches the DF of the CFD-
SIP model better for the sub-micrometer particles than CFD-PB B4+, with absolute errors 
that are less the 1%. However, the results do not compare well for the larger (>4 µm) 
particles. 
The deposition profiles in Figure 2.8 show how the models behave with regard to 
total deposition, but do not describe the spatial deposition through the lung. Figure 2.9 
shows the particle deposition in three regions for the CFD-PB B4+ case. The three 
regions are the sphere directly opposite the inlet duct, the spheres that surround the inlet 
duct, and then the remaining spheres in the domain. The inset image shows the 3D 
particle deposition on the first sphere. From Figure 2.9, it is clear that the majority of 
deposition occurs on the first sphere that the particles encounter as they enter the packed 
bed. This goes against the intended behavior of the model, as the packed bed should 
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replicate the lung bifurcations by allowing particles to penetrate into downstream regions 
of the domain matching both total and regional deposition. 
If a packed bed model can be designed to overcome the impaction issue at the 
inlet that is apparent in Figure 2.9, it is important to evaluate how the particles travel 
through the rest of the packed bed domain. Figure 2.10 compares the deposition profile 
from a CFD-PB CS case through a number of layers with the results from B5 to B15 of 
the CFD-SIP. Up to 16 layers of spheres are included in the CFD-PB CS model, as this 
covers the maximum distance that the particles travel through the domain during the 
transient inhalation profile. Note that consistent residence time between the CFD-PB CS 
and CFD-SIP models is not considered at this stage, but is explored below. These results 
show that the total DF is much higher across all 16 sphere layers than the CFD-SIP 
model. The only way to match particle deposition between the two models is to consider 
just one layer of spheres in the CFD-PB CS model. Again, this shows that regional 
deposition in a packed bed model does not compare well with what is expected in the 
infant lung. 
Comparison of Particle Residence Time in CFD-SIP and CFD-PB Models 
Figure 2.11a and b show frequency plots of particle residence time through the B4-
B7 and B8-B15 regions of the CFD-SIP model respectively. Table 2.1 shows the mean 
and range of particle residence times for the full CFD-SIP model. The results for CFD-PB 
B4+ through two sphere layers are presented in Figure 2.11c and Table 2.2. Two sphere 
layers were selected so that the mean residence time for all particle sizes compares well 
with the CFD-SIP data (0.089 s for CFD-PB vs. 0.097 s for CFD-SIP). However, the 
standard deviation (SD) and spread of data in the plots shows that there is considerably 
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more variability in residence time in the CFD-PB model (SD = 0.080 for CFD-PB vs. 0.023 
for CFD-SIP). This is likely due to the number of different pathways that particles can take 
when they reach a sphere junction compared to a bifurcation. Similar behavior is seen 
when looking at the results for the CFD-PB CS case in Figure 2.11d and Table 2.3. Here 
the CFD-PB CS model covers nine sphere layers to match the mean residence time 
(0.099 s for CFD-PB vs. 0.097 s for CFD-SIP), but again there is more variability in the 
particle residence times (SD = 0.053 for CFD-PB vs. 0.023 for CFD-SIP). 
Comparative Dimensions of CFD-PB and CFD-SIP Models 
These results have so far focused on quantitative values for DF and the residence 
time of particles travelling through the CFD-PB domains. A qualitative comparison 
between the size of the CFD-PB and CFD-SIP models can also be made. The bounding 
box around the B4-B7 and B8-B15 sections of CFD-SIP have a diagonal length of 
approximately 18 mm and 13 mm respectively. This means roughly five sphere layers of 
the 6 mm spheres are required in the CFD-PB model to match the length of the CFD-SIP 
model. The results from Figure 2.11 show that two layers of 6 mm spheres after the inlet 
duct are required to match residence times between the CFD-PB B4+ and CFD-SIP 
models, and nine layers of 6 mm spheres are required for the CFD-PB CS case. 
Therefore, the overall dimensions of either version of the PB model that would be capable 
of representing residence time are considerably different from the SIP model. This finding 
is further complicated by the other fundamental issue highlighted by the results of this 
study, which is the majority of particles impact on the first sphere of the CFD-PB model. 
As such, regional deposition results for an optimized packed bed model, in terms of both 




This study concludes that packed bed models do not provide a realistic 
representation of aerosol deposition in an infant lung. Although total deposition compares 
well between the CFD-PB and CFD-SIP models, regional deposition via impaction 
behaves very differently in a packed bed than it does in lung bifurcations. The positive 
outcomes from this investigation are that the Infant MT-B15 model matches the deposition 
profile predicted by well-known algebraic correlations, and that the application of packed 
bed models for a complete-airway in vitro model have been more completely evaluated 
with a clear conclusion. 
The lung deposition data from the Infant MT-B15 model were benchmarked 
against three well-known algebraic correlations (W. H. Finlay, 2001; ICRP, 1994; Rudolf 
et al., 1990), but ideally this study would compare with in vivo results. Unfortunately, in 
the literature to date, little in vivo aerosol deposition data are available due to ethical 
concerns associated with studies on infants. One study (Salmon, Wilson, & Silverman, 
1990) evaluated aerosol delivery in 9 to 36 month old boys via a face mask and nebulizer 
system. However, the deposition was assessed by collecting urine samples and 
estimating lung absorption of the delivered dose, which only provides total lung deposition 
results. Several other studies (Amirav et al., 2002; Chua et al., 1994; Fok et al., 1996; 
Mallol, Rattray, Walker, Cook, & Robertson, 1996) used gamma scintigraphy to obtain 
regional deposition data, but were all performed on diseased lungs (cystic fibrosis, 
bronchiolitis, or bronchopulmonary dysplasia), which makes it difficult to compare the 
results with healthy infant lungs. 
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The geometry of the packed bed results in a flow field that is considerably different 
from airway bifurcations. This in turn gives particle deposition characteristics that are not 
comparable to the lung. The images in Figure 2.12 show the two possible ways that 
spheres may contact each other in a close-packed array, and the resulting voids available 
for airflow. Note that each of the voids shown in Figure 2.12b is connected to one of the 
orifices on the voids in Figure 2.12d, and so on in the sphere array. 
The geometry in Figure 2.12b can be described as a trifurcation with triangular 
inlets and outlets. The walls of the trifurcation are very close to any potential outlets, which 
may explain the amount of impaction deposition seen in the results. The general shape 
of the geometry also contrasts greatly with lung pathways, which are typically bifurcations 
with circular or elliptical cross sections and have longer straight sections approaching 
each bifurcation. The geometry in Figure 2.12d is further removed from observations of 
human lung anatomy. Here, multiple flow pathways converge in a relatively large cavity, 
which suggests a chaotic flow field and particle motion. In summary, the shape and 
characteristics of the voids between packed bed spheres do not resemble lung 
bifurcations, which explains why the aerosol deposition results do not compare well in this 
study. 
It is important to recall that the focus of this study was on impaction deposition in 
a packed bed that is dimensionally similar to airway bifurcations. The major finding is that 
spatial and temporal deposition of aerosols in packed beds is very different from lung 
bifurcations. Hence, the packed bed model as constructed in this study cannot be used 
to form a complete-airway deposition model for particles in all size ranges that can 
correctly capture regional particle deposition. It does appear that a correctly configured 
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PB model can capture total lung deposition from impaction provided that multiple sizes of 
spheres are used. 
These results have limited impact on previous studies that employed packed beds 
as lung models. For example, the study of Gebhart and Heyder (1985) focused on 
diffusion and sedimentation deposition of particles less than or equal to 1.5 µm in 
diameter. The study of Rosenthal et al. (1992) has already established that particles in 
PB models are dispersed differently over time than in human lungs, as we observed in 
Figure 2.11. However, this finding should not preclude the use of PB geometries as a 
uniform testing standard for comparison studies that require a model with fine scale 
structures or large surface-area to volume ratios as in the lungs. For example, the PB 
geometry remains an excellent model for evaluating the sensitivity of the Aerosol-Derived 
Airway Morphometry (ADAM) technique as with Brand et al. (1994). 
One difference between an in vitro packed bed model and the CFD implementation 
in this study is the sphere arrangement. The geometry in the CFD model uses closely 
packed spheres, whereas an experimental model would typically lead to random packing. 
However, it is expected that the conclusions would be the same with a random fill sphere 
arrangement, as the key issue with packed beds is that the geometry is very different 
from lung bifurcations. A random fill sphere arrangement would only exacerbate the 
difference between a packed bed and the human lung, and lead to more variability in the 
flow field and particle deposition. 
Based on the results of this study, we view the use of a PB in a complete-airway 
in vitro model as limited. One potential solution may be to 3D print airway bifurcations 
through the impaction zone of the TB airways and implement a PB for sedimentation and 
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diffusion deposition in the alveolar region. However, 3D printing all conducting airway 
pathways down to approximately B15 is currently not practical and may result in a very 
fragile structure. A PB alveolar region can accurately reproduce the deposition surface-
area to air-volume ratio of the lungs. However, the overall volume of the model will be 
significantly larger than in vivo conditions due to the large volume occupied by the 
spherical solids. Hence, spatial resolution of regional deposition cannot be reproduced 
for direct comparisons with gamma scintigraphy radiolabeled aerosol deposition results. 
Provided that it is not important to match spatial resolution of deposition, the hybrid-style 
model of Saini et al. (2002) may be capable of capturing regional aerosol deposition. This 
model was composed of a laryngeal structure attached to a triangular geometry 
containing multiple levels of different sizes of spheres. Based on the illustration of the 
model, there are only 2 or 3 layers of spheres on each level, consistent with CFD 
predictions that large regions of bifurcating airways can be reproduced with several layers 
of spheres. Furthermore, the triangular structure of the container will allow for different 
uniform cross-sectional velocities in different zones of the model, enabling multiple 
deposition mechanisms to be captured. Provided that the lung is viewed as a series of 
concentric shells that are opened, laid flat, and stacked, the Saini et al. model may be 
worth further exploration as a complete-airway alternative. In contrast, truly resolving 
spatial and temporal deposition with an in vitro complete-airway model, which was the 
focus of this study may require the consideration of 3D printed in vitro upper airways 






Figure 2.1: Overview of models described throughout the study: (a) In Vitro Complete 




Figure 2.2: Geometry of (a) 6 mm packed bed with fillets between connected spheres 




Figure 2.3: CFD-PB mesh and geometry showing (a) isometric view of full sphere array, 
(b) close-up view of inlet duct mesh (with length to carina included), and (c) close-up view 
of first sphere that shows the conformal interface between unit cells, aligned mesh lines 




Figure 2.4: Comparison of deposition profile for the Infant MT-B15 model predicted by 




Figure 2.5: Reduction of velocity magnitude close to the wall boundaries on the top, 




Figure 2.6: Evaluation of inlet configurations with (a) showing the deposition profile for 




Figure 2.7: Comparison of deposition profiles when varying the sphere diameter in the 
CFD-PB B7+ model. Only the 0.5 to 7 µm particles are shown as the majority of larger 




Figure 2.8: Comparison of CFD-SIP results with (a) CFD-PB B4+ and (b) CFD-PB B7+. 
Error (%) is presented as the absolute difference between the deposition fraction in the 













Figure 2.11: Particle number frequency distribution vs. residence time for (a) CFD-SIP 
B4-B7 and (b) CFD-SIP B8-B15, (c) CFD-PB B4+ through two sphere layers, and (d) 
CFD-PB CS through nine sphere layers. Number of spheres layers in each CFD-PB case 




Figure 2.12: Basic geometry showing (a) trifurcation spheres, (b) trifurcation void (fluid), 




















0.5 7073 0.102 (0.033) 0.076 0.427 
1 7024 0.100 (0.029) 0.076 0.394 
2 7228 0.098 (0.023) 0.077 0.413 
3 5355 0.093 (0.018) 0.078 0.250 
4 4225 0.095 (0.019) 0.078 0.251 
5 2151 0.093 (0.014) 0.080 0.186 
7 408 0.099 (0.014) 0.084 0.141 





















0.5 24630 0.090 (0.081) 0.011 0.489 
1 23925 0.093 (0.081) 0.011 0.482 
2 24886 0.089 (0.078) 0.010 0.471 
3 25796 0.086 (0.079) 0.011 0.494 
4 26031 0.086 (0.078) 0.012 0.477 
5 26478 0.082 (0.076) 0.011 0.485 
7 12570 0.099 (0.085) 0.012 0.490 





















0.5 26354 0.091 (0.048) 0.025 0.448 
1 23697 0.091 (0.046) 0.026 0.466 
2 23744 0.096 (0.046) 0.026 0.452 
3 22847 0.094 (0.044) 0.027 0.448 
4 16105 0.099 (0.046) 0.027 0.435 
5 6847 0.099 (0.045) 0.031 0.455 
7 126 0.124 (0.086) 0.046 0.421 




Chapter 3: Recommendations for Simulation of Microparticle 
Transport and Deposition Using Two-Equation Turbulence Models 
3.1 Objective 
The objective of this study is to determine both mesh and CFD solution parameters 
that enable the accurate simulation of microparticle deposition under flow conditions 
consistent with the upper respiratory airways including turbulent flow. To represent 
conditions similar to the upper respiratory airways, a simple 90o curved tube is selected 
as a characteristic geometry. This geometry provides a different test scenario than the 
constricted tube model that is typically used to represent turbulence in the upper airways. 
Both the nasal and MT airways contain curved tube features that are associated with high 
particle deposition. Furthermore, deposition in bifurcations is often approximated with 
correlations for deposition in curved tubes (Martonen et al., 2000). The comparison metric 
considered will be total microparticle deposition, based on the well documented 
experimental results of Pui et al. (1987) with Re = 6,000 and Re = 10,000. For 
comparison, Breuer et al. (2006) previously published LES in curved tubes with excellent 
agreement when compared with Pui et al. (1987). In addition to an evaluation of mesh 
and solution parameters, a key question to be addressed is whether the LES agreement 
with experiments (Breuer et al., 2006) can be matched with the correct use of a much 
simpler and computationally efficient two-equation turbulence approach. 
3.2 Introduction 
Laminar, transitional and fully turbulent flows are all expected to occur in the upper 
respiratory airways. Transitional and turbulent flow as well as the process of flow regime 
change from laminar to turbulent flow is notoriously difficult to predict and can be 
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influenced by upstream conditions, wall surface roughness and even environmental noise 
(Schlichting, 1987; Tennekes & Lumley, 1972; Wilcox, 1998). Transitional and turbulent 
flows are known to have a significant impact on particle deposition through the interaction 
of turbulent eddies and discrete elements, which typically increases deposition compared 
with the laminar flow case (Crowe, Troutt, & Chung, 1996). Therefore, accurate 
predictions of lung doses arising from either inhaled pollutant particulate matter or 
pharmaceutical aerosols requires reasonable approximations of both the turbulent flow 
field and the interaction of turbulent eddies with particles. 
The upper airways consist of the oral and/or nasal geometry, trachea and 
approximately the first six airway bifurcations. Jets of airflow with flow detachment and 
recirculation are formed in the nasal valve and larynx (Xi et al., 2008; J. X. Xi et al., 2012). 
As described in previous experimental and numerical results (Ahmed & Giddens, 1983a, 
1983b; Ghalichi et al., 1998), transition to turbulence in flow constrictions of 50 and 75% 
area reductions occurs at Reynolds numbers of approximately 1,100 and 400, 
respectively, which are significantly lower than the typical value of 2,300 for a straight 
cylindrical conduit. Considering a mean inhalation flow rate of 60 L/min (LPM), upper-
airway Reynolds number values for an adult range from approximately 10,620 (larynx) to 
553 (bifurcation B6). Peak inhalation flow rate with a dry powder inhaler (DPI) can reach 
160 LPM (R. R. Delvadia, Wei, Longest, Venitz, & Byron, 2016), significantly multiplying 
these Reynolds number estimates at the point in time when the largest concentration of 
an inhaled pharmaceutical aerosol is entering the lungs. Furthermore, inhalers introduce 
air jets or sprays in the mouth-throat (MT) geometry, which are frequently turbulent and 
significantly impact MT depositional loss of the aerosol (DeHaan & Finlay, 2004; Longest, 
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Hindle, Das Choudhuri, & Xi, 2008). In a previous study of the laryngeal jet, Xi et al. (2008) 
showed that the turbulent viscosity ratio maintained a value of at least 2 through 
bifurcation B6 at an inhalation flow rate of 30 LPM. The study of Lin et al. (2007) also 
showed turbulence intensity values of 20% extending from the laryngeal jet into the lungs. 
A number of studies have demonstrated the importance of turbulence on deposition 
throughout the upper airways (Ball, Uddin, & Pollard, 2008; Jayaraju, Brouns, Lacor, 
Belkassem, & Verbanck, 2008; Lambert, O'Shaughnessy, Tawhai, Hoffman, & Lin, 2011; 
Longest, Tian, Delvadia, et al., 2012; Matida, Finlay, Breuer, & Lange, 2006; Xi et al., 
2008; J. Xi & Longest, 2007; Z. Zhang & Kleinstreuer, 2011). Surprisingly, some of these 
studies have shown that turbulence can increase or decrease depositional loss (Longest 
& Vinchurkar, 2007b; Xi et al., 2008). While eddy interaction serves to increase 
depositional particle losses, the blunt turbulent velocity profiles can actually reduce 
impaction at carinal ridges. Furthermore, increased eddy viscosity can reduce secondary 
flows and associated particle impaction on bifurcation sidewalls. 
Turbulence has been captured in respiratory airway geometries with models that 
range in complexity from the one-equation Spalart-Allmaras model (Wilcox, 1998) to full 
resolution of all turbulence scales with direct numerical simulation (DNS) (C. L. Lin et al., 
2007). Specific examples include two-equation turbulence models such as the k-ε 
(Stapleton, Guentsch, Hoskinson, & Finlay, 2000) and k-ω (Xi et al., 2008; Z. Zhang & 
Kleinstreuer, 2011), detached eddy simulation (Jayaraju et al., 2008), large eddy 
simulation (LES) (Jayaraju et al., 2008; Jin, Fan, Zeng, & Cen, 2007; Matida et al., 2006) 
and DNS (C. L. Lin et al., 2007). In general, studies that compare results from multiple 
models typically find that the simpler model is inadequate compared with the more 
82 
 
complex model. This move to more complex turbulence models makes the simulation of 
large airway regions including the influence of transient inhalation over a 5 s period 
impractical due to the time and computational power that is required to run the 
simulations. Critical questions that are often overlooked in turbulence model comparison 
studies include: (i) what impact will discrepancies in velocity and turbulence parameters 
have on particle deposition, (ii) are the simpler models being properly applied, and (iii) is 
the most developed version of each simpler model being applied. For example, Ball et al. 
(2008) compared experimental results with predictions of two-equation turbulence models 
and found discrepancies in the velocity and turbulent kinetic energy (TKE) results. 
However, particle deposition was not considered and the more recent Low Reynolds 
Number (LRN) k-ω model was not included. Matida et al. (2006) compared aerosol 
deposition between LES and shear stress transport (SST) k-ω turbulence models and 
found significantly better predictions with the LES model compared to in vitro 
experiments. While these results were based on particle deposition, they did not include 
LRN k-ω predictions and neglected near-wall (NW) corrections, which were previously 
shown to be important (Matida, Finlay, & Grgic, 2004). Similar findings of superior 
performance with a LES model compared with a standard k-ω model without NW 
corrections were reported by Jayaraju et al. (2007). Furthermore, while LES has been 
found to be more accurate than two-equations models based on the predictions of 
turbulence properties, the increase in computational cost is very large. In a simple 
representative geometry of a curved pipe at Re = 10,000, Breuer et al. (2006) reported 
that grid convergent results required approximately 2.3 million control volumes. In a 
constricted pipe test geometry, Zhang and Kleinstreuer (2011) reported that LES 
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simulations required approximately 100-fold more computer power than using a two-
equation turbulence model. 
Two-equation turbulence models implement the Reynolds Averaged Navier 
Stokes (RANS) equations and simulate turbulent effects typically with a kinetic energy (k) 
and dissipation (ε or ω) term. Transport equations are formed for the two turbulence 
terms, which are then combined into a turbulent viscosity scalar that is present in the 
RANS equation and functions as an added viscosity on the flow field (Wilcox, 1998). The 
effect of turbulence on particle dispersion is then approximated through the use of an 
eddy interaction model, which implements the turbulence terms to stochastically recreate 
eddy structures and predict associated chaotic motion of particles as a random walk 
(Crowe et al., 1996). A primary shortcoming of all two-equation turbulence models is the 
assumption of isotropic (direction independent) turbulent fluctuations near wall 
boundaries (Wilcox, 1998). Matida et al. (2004) provided a NW correction for anisotropic 
turbulence effects, which has frequently been applied (Longest & Hindle, 2009a; Longest 
et al., 2007; Longest et al., 2008). Longest and Xi (2007) reported that improved NW 
interpolation of the velocity field was also needed in turbulent simulations using two-
equation models. Of the available two-equation models, the LRN k-ω model has been 
most successful in predicting transitional and turbulent flows including reasonable 
predictions of particle deposition (Kleinstreuer & Zhang, 2003; Longest & Hindle, 2009a; 
Longest et al., 2007; Longest et al., 2008; Longest, Tian, Delvadia, et al., 2012; Longest, 
Tian, Walenga, et al., 2012; Longest & Xi, 2007; Tian et al., 2011; Z. Zhang & Kleinstreuer, 
2003, 2011). Low Reynolds number refers to the fact that the model simulates the flow 
field all the way through the viscous sub-layer, i.e., the low Reynolds number region, and 
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can be successfully applied to both low and high Reynolds number flows (Wilcox, 1998). 
The primary advantage of two-equation models is high efficiency approximation of very 
complex transitional and turbulent flow phenomena. However, questions remain if these 
models can successfully be applied to predict particle deposition in the upper respiratory 
airways (Ball et al., 2008; Matida et al., 2006). 
Studies that have used the LRN k-ω model with NW anisotropic and sometimes 
velocity interpolations have reported reasonable agreement with experimental results of 
turbulence metrics and particle deposition. Zhang and Kleinstreuer (2003) compared the 
performance of two-equation turbulence models in a constricted flow geometry and 
showed that the LRN k-ω model reproduced laminar, transitional and turbulent flow 
characteristics comparable with the experimental measurements of Ahmed and Giddens 
(1983a, 1983b, 1984). Other studies also using the constricted tube geometry have 
reached similar conclusions (Ryval, Straatman, & Steinman, 2004; Varghese & Frankel, 
2003). The more recent study of Zhang and Kleinstreuer (2011) considered a series of 
two-equation turbulence models compared with LES in constricted tube and MT 
geometries. The LRN k-ω model was again shown to perform well and predictions of 
nanoparticle deposition in the MT were similar to LES. Our group has successfully applied 
the LRN k-ω model to predict particle deposition in the upper respiratory airways with 
good agreement to in vitro (Longest & Hindle, 2009a; Longest, Tian, Walenga, et al., 
2012; Longest & Vinchurkar, 2007b; Longest & Xi, 2007) and in vivo (Longest et al., 2015; 
Walenga & Longest, 2016) studies. These simulations have considered pharmaceutical 
aerosols including jet and spray effects from DPIs (Longest, Tian, Delvadia, et al., 2012; 
Longest, Tian, Walenga, et al., 2012; Tian et al., 2011), metered dose inhalers (MDI) 
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(Longest, Tian, Walenga, et al., 2012; Walenga & Longest, 2016; Walenga et al., 2013), 
and soft mist inhalers (R. R. Delvadia, Longest, Hindle, & Byron, 2013; Longest & Hindle, 
2009a; Longest, Hindle, & Das Choudhuri, 2009). For example, Longest et al. (2012) 
showed that the MT deposition predicted by the LRN k-ω model with NW corrections was 
within 10% of in vitro experimental data for complex pharmaceutical aerosols including 
the effect of polydisperse aerosol size, transient inhalation over an approximately 5 s 
period and turbulence for MDI and DPI devices. 
Based on successful applications of the LRN k-ω model with NW corrections in 
predicting aerosol deposition in upper airway geometries, it appears that this model 
provides a good compromise between accuracy and efficiency. However, in other studies 
we have shown that computational mesh structure and type can have a dramatic effect 
on solution accuracy (Longest & Vinchurkar, 2007a; Vinchurkar & Longest, 2008). 
Guidelines for the use of the LRN k-ω model and for two-equation models in general are 
not well defined for applications to the respiratory airways. The current specification of 20 
layers of computational cells through the turbulent wall region including the buffer layer 
(ANSYS, 2012) may be computational prohibitive for large complete-airway simulations 
(Longest, Tian, Delvadia, et al., 2012), and not necessary. Current recommendations may 
also be difficult to implement in complex geometries such as the nasal valve and larynx 
where flow passages are very narrow (Subramaniam, Richardson, Morgan, Kimbell, & 
Guilmette, 1998). For example, Walenga et al. (2014) reported excellent agreement with 
experimental results of particle deposition in the nose with a nasal cannula interface using 
only 5 NW cell layers. Furthermore, no recommendations are currently available for 
overall layer-to-layer (L2L) thickness of the NW mesh, or recommendations on the 
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method used to calculate gradients within control volumes, which interact with mesh type 
and resolution to influence the solution accuracy. Finally, mesh style in conjunction with 
turbulence modeling has previously not been considered in respiratory airway 
geometries. 
3.3 Methods 
Experimental Model and Results 
This numerical study aims to evaluate mesh and CFD solution parameters based 
on comparisons with the experimental data from Pui et al. (1987) in a 90° curved tube 
geometry. The Pui et al. data was collected by measuring the deposition of monodisperse 
aerosols with Stokes numbers from 0.1 to 1.4 through glass and stainless steel 90° bends 
with internal diameters (ID) of 0.93, 3.95, 5.03, and 8.51 mm and Reynolds numbers (Re) 
of 100, 1,000, 6,000, and 10,000.  
In this study, CFD-predicted aerosol deposition results are compared with the 
following Pui et al. (1987) experimental data sets: Re = 6,000 with ID = 5.03 mm; and Re 
= 10,000 with ID = 8.51 mm, which were both evaluated with stainless steel tubes. This 
covers a range of turbulent conditions and changes in the geometry by increasing the 
tube diameter. The correlation from the experimental study gives aerosol deposition 
efficiency (𝜂) as a function of particle Stokes number (St), as: 
 𝜂 = 1 − 10−0.963St (3.3.1) 
The deposition efficiency and correlation results for the selected experimental models are 
given in Table 3.1. 
87 
 
Numerical Geometry and Meshes 
The inset in Figure 3.1a shows the full computational domain that matches the 
experimental setup of the Pui et al. (1987) geometry. The straight entry and exit sections 
of the tube were included to ensure that the flow is fully developed at the 90° bend inlet 
and smoothly exits the geometry, as was the case with the experiemental model. The 
curvature ratio (bend radius over tube radius) also matches the original setup, with ratios 
of 5.7 and 5.6 for the Re = 6,000 and 10,000 cases, respectfully. 
Mesh Dependency 
Preliminary results compared five meshes to evaluate the dependency of results 
on mesh resolution. The 90° bend section for each case had approximately 1,400,000, 
672,000, 368,000, 208,000, and 83,000 hexahedral cells, inclusive of the NW layers. 
Initially, only the three finer meshes were compared, but results were almost identical, so 
the two coarser meshes were also evaluated. Consistency between deposition profiles 
(deposition fraction vs. particle diameter), velocity profiles at the inlet and outlets, and 
pressure drop across the tube were considered. Sensitivity of the turbulent flow to mesh 
resolution was also assessed by comparing u+ vs. y+ plots between the five meshes and 
to Spalding’s equation (1961). These u+ vs. y+ plots were generated from data in the 
region of fully developed flow within the turbulent buffer and sub-layer near the wall. 
The mesh dependency evaluation concluded that the coarse case (368,000 cells) 
gave the best compromise of small numerical error and reduced cell count. In several of 
the meshes that are evaluated in subsequent sections of this study, the resolution of the 
mesh in the NW region is adjusted to determine the influence on results. In all cases, the 
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core mesh (covering the bulk flow) for the grid independent case was retained, and 
different NW mesh resolution parameters are then applied. 
Near-wall Mesh Resolution 
Traditionally, there are two approaches to modelling the NW region when using 
two-equation RANS turbulence models. The wall function method uses an empirical 
formulation to model the flow in the inner and outer layer with a relatively large NW cell 
height. Wall y+ values should ideally be greater than 30, with 15 as an acceptable 
minimum. For low to medium Reynolds number flow, such as the respiratory airways, the 
ANSYS FLUENT Theory Manual (2012) advises against using the wall function approach 
as the assumptions that the method uses are not applicable to this flow regime. The other 
approach is to use the enhanced wall treatment (EWT) method where the mesh aims to 
fully resolve the NW turbulent layers. This method is considered to be y+ independent, 
but wall values of one are recommended. The main concern when using the EWT method 
is that there are an adequate number of cell layers to resolve the flow in the NW region. 
When using the k-ω turbulence model in ANSYS FLUENT, the EWT method is 
implemented by default. 
Initially four meshes are compared that each have varying degrees of NW mesh 
resolution and are suitable for the EWT method. These meshes are referred to as the 
Recommended, Intermediate, Targeted, and Poor Ratio cases, and are presented in 
Figure 3.2a. The Recommended mesh follows the NW mesh resolution guidelines in the 
ANSYS FLUENT Theory Guide (2012), with 20 cell layers that cover the region from the 
wall up to a y+ value of approximately 60 and a first layer thickness that gives a wall y+ of 
approximately one. These recommended guidelines aim to model the flow in the sub-
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layer and buffer region accurately when using the EWT option by using a high-fidelity 
mesh in the NW region. However, there are several close proximity surfaces in the nasal 
cavity, especially the meatuses, where such a high level of mesh resolution is not feasible. 
Ideally, the NW mesh in an upper airway model would be similar to the Targeted mesh, 
with five equally spaced NW cell layers and a first layer height that gives a wall y+ of 
approximately one. Here the resolution is fine enough to capture the large flow field 
gradients near the wall, but the overall cell layer height is thin enough to be included 
between close proximity surfaces. Fewer cell layers also drastically reduces the total cell 
count, so accurate results from the Targeted mesh would provide a more computationally 
efficient model. The Intermediate model uses 10 equally spaced NW cell layers with a 
wall y+ of approximately one. This provides a level of mesh resolution that falls within the 
Recommended and Target models. Finally, the Poor Ratio mesh is similar to the Targeted 
case, with the exception that the L2L ratio from Layer 1 to 2 is 1.8, and the layers are then 
equally spaced from Layer 2 to 5. This mesh is included in the evaluation to determine 
how poorly defined L2L thicknesses can influence the results. In complex geometries, the 
meshing software can stretch and shrink cell layers in order to conform to the surface. 
Therefore, it is possible to have large increases in the L2L ratio such as the Poor Ratio 
case, which may not accurately capture high gradients in the flow field. 
After evaluating the four NW mesh conditions described above, both first cell layer 
height and L2L ratio are considered. The effect of increasing the thickness of the first NW 
layer is evaluated using the meshes shown in Figure 3.2b. The definition of these Wall y+ 
meshes uses only one NW layer to neglect the influence of L2L ratio on results. 
Consistency in deposition profiles between cases will indicate that first layer thickness 
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does not influence results within the range considered. The effect of L2L ratio between 
Layer 1 and 2 is explored further with the meshes in Figure 3.2c. The Ratio meshes 
determine at what point the ratio between Layer 1 and 2 becomes excessive and begins 
to influence results. The NW layer thickness in Figure 3.2c is consistent between each of 
the Ratio meshes and gives a wall y+ of approximately one. 
The NW meshing parameters require known values of wall y+ in order to be 
defined. These values can be estimated before running the CFD simulation using the 
following equations. The skin friction (𝐶𝑓) is approximated from the Reynolds number (Re) 
by using Blasius’ equation for turbulent flow in a circular pipe (Blasius, 1913), which is 
given by 
 𝐶𝑓 ≈ 0.0791Re
−1 4⁄  (3.3.2) 
The wall shear stress (𝜏𝑤) is defined with the skin friction, fluid density (𝜌), and average 













Finally, the distance from the wall to the center of the first NW cell (Δ𝑦𝑤) is determined 
from the desired wall y+ (𝑦𝑤










Note that Equations (3.3.2) to (3.3.5) do not give exact mesh definitions, but serve as 
good estimations to get sensible NW layer thicknesses. Table 3.2 summarizes each of 
the meshes described here and includes the meshing parameters that are used to 
generate the required NW cell layers. 
Mesh Construction and Cell Types 
The meshes shown in Figure 3.2 were generated by the ICEM CFD 14.5 meshing 
package (ANSYS, Inc., Canonsburg, PA, USA). The effects of the NW cell layer 
parameters were initially explored using hexahedral cells, as shown in Figure 3.2d for the 
Targeted case. This mesh type was constructed using the block mesh approach available 
in ICEM CFD 14.5, which allows the user to create a regular, mapped, hexahedral mesh.  
Regular hexahedral meshes are ideal for CFD analysis in airway type systems, as 
they generally give the best accuracy when applied to the finite volume method 
(Vinchurkar & Longest, 2008). However, this type of mesh construction is not possible 
when developing models of nasal anatomy and potentially the MT, as the geometry is 
often too complex. Irregular tetrahedral meshes are employed in such cases, as they are 
able to conform to intricate surfaces, but numerical accuracy and robustness is sacrificed 
to some degree (Vinchurkar & Longest, 2008). Therefore, this study will compare the 
results of hexahedral and tetrahedral meshes directly to determine if there are substantial 
drawbacks associated with using tetrahedral meshes when modelling aerosol deposition. 
The mesh on the right side of Figure 3.2d is an example of the tetrahedral meshes used 
in the evaluation, specifically the Targeted NW cell layer case. These meshes were also 
generated with ICEM CFD 14.5 using the Tetra meshing capabilities. First, a CAD model 
of the 90° bend was supplied to the meshing software, and a patch-dependent, triangular 
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shell mesh was generated for each of the surfaces. A Delaunay algorithm was then 
utilized to fill the 3D volume with tetrahedral cells based on the triangular shells. Next, cell 
layers were inflated from the tube walls into the fluid volume to generate a prismatic NW 
mesh. After this inflation stage, the mesh is smoothed to ensure that the quality metric for 
all cells is greater than 0.1. Finally, the entry and exit sections of the model were extruded 
normal to the inlet and outlet of the 90° bend. This extrusion process generates prismatic 
cells that are aligned with the flow direction, which helps model the fully developed 
behavior in this region. The tetrahedral meshing method outlined here ensures good 
mesh quality, but is surprisingly more involved that hexahedral mesh construction. That 
said, tetrahedral meshing of complex geometries is much simpler than trying to apply the 
blocking method to irregular surfaces. 
Physics Model and Solver Settings 
The ANSYS FLUENT 14.5 CFD software package (ANSYS, Inc., Canonsburg, PA, 
USA) solves the transport equations that describe the flow field and particle trajectories 
through the numerical models. Initially, existing best practices developed by our group for 
modelling aerosol deposition in the extrathroacic region were applied to the 
Recommended, Intermediate, Targeted, and Poor Ratio meshes. The k-ω model solves 
the TKE and specific dissipation rate (SDR) fields, as is generally recommended for 
internal flows. The LRN correction uses a coefficient to dampen the turbulent viscosity 
that is determined when the TKE and SDR transport equations are combined. This 
coefficient is calculated from the material properties, turbulent field quantities, and model 
constants; the details of which are given by Wilcox (1998). The LRN correction should be 
applied when flow is close to the transition regime. Currently, the solver uses the 
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SIMPLEC scheme for Pressure-Velocity coupling, with Least Squares Cell Based (LSQ) 
gradient discretization, and second-order upwind schemes for flow variables. Particle 
trajectories through the domain are modeled using Lagrangian tracking with the Runge-
Kutta scheme (Longest et al., 2015; Longest & Hindle, 2009a; Longest et al., 2007; 
Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Longest & 
Vinchurkar, 2007b; Tian et al., 2011; Walenga & Longest, 2016). The particle drag, 
turbulent dispersion, and eddy interaction model are modified with NW correction user-
defined functions (UDFs), which correct for turbulent anisotropy near wall boundaries 
(Longest et al., 2008; Matida et al., 2004) and perform NW velocity interpolation (Longest 
& Xi, 2007). The NW correction may mask the behavior of the underlying physics models 
and solver settings, so they are neglected when comparing the variability between the 
four meshes. Once mesh and CFD solution parameters are defined that reduce the 
inconsistency in flow and particle deposition results, the UDFs will be applied to compare 
with the Pui et al. (1987) experimental data. 
Turbulence 
To date, LRN k-ω turbulence has been the two-equation model of choice for CFD 
particle deposition studies from our group. It has been extensively validated against in 
vitro (Longest & Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; 
Longest, Tian, Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and 
in vivo (Longest et al., 2015; Walenga & Longest, 2016) experimental data, and provided 
accurate results in these studies. Advanced models, specifically the k-ω SST and 
Reynolds Stress Model (RSM), are available that aim to model turbulence with greater 
accuracy and detail. The SST k-ω model combines the free-stream advantages of the k-
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ε model with the NW benefits of k-ω. It is the recommended RANS turbulence model in 
the ANSYS FLUENT User Guide (2012), and includes a LRN option for modeling flow 
that is close to transition. Chen et al. (2009) used the SST k-ω model for a CFD 
assessment of flow through the nasal cavity in patients with septal deviations, although 
their study did not include particle deposition. The RSM has both ε and ω formulations, 
and solves seven additional transport equations for each of the Reynolds stresses. Rygg 
and Longest (2016) applied RSM to model pharmaceutical aerosol deposition in the adult 
nasal cavity, as its formulation includes turbulence anisotropy near walls without 
additional UDFs. 
Despite the advanced formulation of SST and RSM k-ω, preliminary work for this 
study showed that these models increased processing times by approximately 30% and 
did not show substantially different results in terms of NW mesh sensitivity compared with 
the LRN k-ω model. In addition, RSM gave a very unusual velocity profile at the inlet and 
outlet of the 90° bend when compared to the other turbulence formulations. Therefore, 
the remainder of this investigation will use the LRN k-ω model, based on its previous 
successful use. Preliminary results also show that particle deposition appears to be 
dependent on the NW mesh only when the turbulent dispersion model is activated. This 
suggests that results are sensitive to resolution of the NW TKE field, as this quantity drives 
the turbulent dispersion model and its influence on particle deposition. Therefore, 
consistency in the NW TKE field between meshes is the primary initial focus of this study, 
which in turn is shown to give consistency between deposition profiles. 
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Gradient and Spatial Discretization Schemes 
The default gradient discretization scheme available in ANSYS FLUENT is the 
LSQ scheme developed by Anderson and Bonhaus (1994). This method computes the 
cell gradient by using a weighting that is based on the distance from the cell centroid to 
its adjacent cells. The two other options available for gradient discretization are the 
Green-Gauss Node-based (GGN) and Green-Gauss Cell-based (GGC) methods. 
Equation (3.3.6) describes the Green-Gauss Theorem , which defines the gradient of any 
field variable at the cell centroid (∇𝜙) by using the cell volume (𝑉), number of cell faces 









In the CFD solution, everything in Equation (3.3.6) is known except for 𝜙𝑓, which is where 
the GGN and GGC methods are applied. The GGN method approximates 𝜙𝑓 by taking it 
as the average of the face node values, as given by Equation (3.3.7): 
 
𝜙𝑓 =
𝜙0 + 𝜙1 + ⋯+ 𝜙𝑛
𝑁𝑛
 (3.3.7) 
As the GGN method requires calculation of nodal values, it is generally more 
computationally expensive than other methods. Note that, 𝑁𝑛 is eight for a hexahedral 
cell, four for a tetrahedral cell, and six for a prismatic cell. The GGC method approximates 
the field variable value at the cell face by taking it as the average of the current cell (𝜙0) 








Preliminary results showed that switching from the LSQ to GGC method had little 
influence on the flow field and deposition results. Therefore, the Results section will only 
focus on how the model behaves when the LSQ vs. GGN methods are applied. The 
disadvantage of the GGN method being more computationally expensive will be 
acceptable if it is capable of providing consistent results between the different NW 
meshes. 
It is noted that preliminary work also evaluated spatial discretization methods that 
are alternatives to second-order upwind in ANSYS FLUENT, including the third-order 
MUSCL scheme. These schemes were all excluded from further evaluation as they either 
did not apply to tetrahedral meshes, or did not have a positive effect on results at the 
Reynolds numbers considered in this study. 
Wall Roughness 
Preliminary work showed that activating the wall roughness model, with 
parameters that are consistent with the tube materials used in the Pui et al. (1987) 
experiments, had a negligible effect on the CFD deposition profiles (changed by <1%). 
This is most likely because the tubes were made from stainless steel and glass, which 
are relatively smooth materials, hence the associated wall roughness height was very 
small (<2 µm). However, the layered additive manufacturing process of common 3D 
printers often leads to rough surfaces and should be considered when evaluating regional 
and highly localized deposition (Holbrook & Longest, 2013). 
Near-wall Correction 
The NW correction UDFs developed by Longest and Xi (2007) have been used 
extensively by our group when validating numerical results against in vitro (Longest & 
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Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian, 
Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and in vivo data 
(Longest et al., 2015; Walenga & Longest, 2016). These UDFs perform two corrections: 
(i) anisotropic velocity fluctuations are introduced, and (ii) the wall-normal velocity is 
damped in the NW region, which is consistent with particle-wall hydrodynamic 
interactions. Furthermore, whenever velocity and turbulence field quantities are required 
for a calculation, they are interpolated at the particle location instead of using cell centroid 
values. Including anisotropic turbulence and damping velocity fluctuations in the NW 
region for pharmaceutical aerosols was originally implemented by our group in a study by 
Longest et al. (2008). This method built upon work reported by Matida et al. (2004), which 
in turn was based on DNS data from Wang and James (1999). The NW correction UDF 
also redefines the drag force (𝐹𝐷) for all particles as a function of the particle Reynolds 
number (Re𝑝): 
 𝐹𝐷 = 18(1 + 0.15Re𝑝
0.687) (3.3.9) 
Two control parameters are used to determine at what point each correction is 
applied to the particle. If the normal distance from the particle to the wall is less than the 
NW limit parameter, the UDFs use linear interpolation (based on the particle distance to 
the wall) to approximate the velocity and TKE values at the particle’s current location, and 
the wall-normal velocity component of the continuous phase is damped. The NW limit 
parameter is typically mesh, flow, and particle size dependent, and as such, is modified 
during the model development stage to match experimental data. 
If the non-dimensional particle y+ is below the y+ limit, the eddy lifetime is calculated 
based on the interpolated TKE value, and an anisotropic fluctuating velocity is defined 
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with the new TKE value and random numbers from a Gaussian distribution. The eddy 
lifetime and fluctuating velocity are then updated each time the particle enters a new eddy. 
Unlike the NW limit, the y+ limit parameter is not case dependent and set to a value of 60, 
as this has given good results in a numerous previous studies (Longest et al., 2015; 
Longest & Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; 
Longest, Tian, Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Matida et al., 2004; 
Tian et al., 2011; Walenga & Longest, 2016).  
In previous work, the linear method for NW interpolation that the NW correction 
UDFs use is best described by Walenga and Longest (2016). For this project, 
interpolation of the velocity and TKE fields was modified in an effort to make the NW 
correction less mesh dependent, as the objective is to improve consistency in results for 
different NW meshes. The modified approach first uses an inverse-distance weighted 
method to calculate all nodal velocity and TKE values in the domain, based on the cell 
centroid values to which each node is connected. Next, the cell in which the particle is 
currently located is identified, and the same inverse-distance weighted method is used to 
interpolate the velocity and TKE values at the particle location from the nodes that define 
the cell. In order to minimize computational effort, Shephard’s method for interpolating 
irregularly-spaced data is employed (1968), and extended for use in 3D space. 
Computation time is also reduced by storing all nodal values in memory, and retrieving 
the data as needed when interpolating to the particle location. In all, processing times for 
this modified method are negligible when compared to the time taken to reach a 
converged solution for the flow and turbulence transport equations. 
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Boundary Conditions  
Due to the simplified model geometry, the boundary conditions for this study are 
relatively straightforward. At the inlet, a uniform velocity magnitude of 17.42 m/s was 
specified for the Re = 6,000 case and 17.16 m/s was specified for Re = 10,000 (as the 
tube diameter is larger). Despite applying a uniform inlet velocity, the flow reaches a fully 
developed state before it enters the 90° bend section. Default values for Turbulence 
Intensity (5%) and Turbulent Viscosity Ratio (10) are applied, as the length of the straight 
section should minimize the effects of inlet conditions on the turbulence field in the 90° 
bend. The outlet from the domain simply uses the outflow condition, whereby all mass 
that enters though the inlet also leaves through the outlet. All walls on the straight and 
90° bend sections use a no-slip condition, and particles are trapped upon wall contact 
with the particle center of mass. 
Particle Injection 
Particles are introduced into the domain with a blunt, random spatial distribution, 
as recommended by Longest and Vinchurkar (2007b). The blunt profile defines a uniform 
proportion of particles throughout the bulk flow, and then rapidly decreases the proportion 
as the particles near the wall. This realistic distribution is used as more particles enter 
along higher flux rings of flow. For the circular tube, a center point, normal vector, and 
radius define the random inject coordinates. The center point is selected so that particles 
are injected into the tube where the straight entry section of the tube ends and the 90° 
bend starts. 
For the Re = 6,000 case, the injected particle size distribution uses seven bins with 
particle diameters that match the Pui et al. experimental data as described in Table 3.1. 
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The size distribution for the Re = 10,000 CFD case also uses seven bins, with the 4.56-
7.66 µm particles matching the sizes in the Re = 10,000 experimental data, and the 1.50-
3.80 µm selected to match the Stokes numbers in the Re = 6,000 case. No experimental 
data is available for these three smaller bin sizes, and these particles are included to 
compare against the correlation at the lower end of the size range. The CFD model injects 
5,000 particles for each bin size, as previous validation of steady-state models by our 
group have shown that tracking this number of particles per bin gives good particle 
convergence (Longest, Tian, Walenga, et al., 2012).  
Comparison Criteria 
Deposition Fraction 
The deposition fraction (DF) is defined as the ratio of the deposited particle mass 







Continuous Phase Velocity 
As mentioned previously, preliminary results showed that the differences in the 
NW mesh layers are most sensitive to the effects of the turbulent dispersion model. This 
model uses the combination of the mean (?̅?) and fluctuating (𝑢′) parts of the flow velocity, 
which is hereafter referred to as the continuous phase velocity (𝑢) where: 
 𝑢 = 𝑢 + 𝑢′ (3.3.11) 
The fluctuating velocity used by the turbulent dispersion model is defined by a random 










Application of Current Best Practices 
Figure 3.3 shows the TKE profile at 20°, 40°, 60°, and 80° around the 90° bend for 
the Recommended, Intermediate, Targeted, and Poor Ratio meshes. The plot shows a 
steep gradient near the wall, with a profile shape that is consistent with the DNS results 
from Wang and James (1999). In Figure 3.3a, the results for each mesh are all similar, 
as the flow is relatively uniform as it leaves the straight entry section of the tube. However, 
as the flow becomes more disturbed moving through the bend from Figure 3.3a to d, the 
profiles show more variability between the four meshes. Variability between each of the 
TKE profiles in Figure 3.3 can be evaluated by applying a 6th-order polynomial line of best 
fit (R2 > 0.999) and taking 30 equally-spaced sample points throughout the NW region. 
Moving from a location of 20° to 80° in the bend, the average and maximum standard 
deviation increases from 0.20 to 0.46 m2/s2 and 0.41 to 0.90 m2/s2 respectively. 
Qualitatively, both the peak TKE value near the wall and incline of the NW gradient vary 
considerably in each case. In order to achieve accurate and consistent results from the 
turbulent dispersion model, the TKE field in this NW region must be well resolved. 
The continuous phase velocity, which the particles experience near the wall in 
each of the four meshes, is shown graphically in Figure 3.4. The continuous phase 
velocity is calculated from Equations (3.3.11) and (3.3.12), with the random number 
assumed to have a value of one for the purpose of comparison between different CFD 
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models. This assumption is necessary, as the random number that the commercial code 
uses is not known. 
The values are sampled at the outlet of the 90° bend on the outer edge of the 
curved tube radius, as this location has the most variability and clearly deomonstrates the 
difference between each NW mesh. The mean velocity profiles for each case are very 
similar (not shown), but Figure 3.4 demonstrates how different the flow field can be when 
the fluctuating velocity is included. From Figure 3.4a to c, a sample particle moves through 
the NW cell layers of each mesh at a wall-normal distance of 60, 50, and 40 µm, 
respectively. The y+ values are included to indicate the non-dimensional wall distance for 
reference, with the average value for all four cases used, as the flow field varies for each 
mesh. From this figure it is clear that the particles are exposed to very different continuous 
phase velocities between each mesh. As the continuous phase velocity varies for each 
mesh, the particle trajectories through each computational domain are also different. 
The variability in the TKE field close to the wall in turn affects the particle deposition 
profile between each of the four meshes, as seen in Figure 3.5. At the smaller end of the 
microparticle size range, particles are more susceptible to turbulent dispersion (Hjelmfelt 
& Mockros, 1966; S. L. Lee & Durst, 1982; Sommerfeld, 1990) and as such, show more 
variation in DF for each mesh. As diameters move towards the nanoparticle size range, 
the particle momentum becomes too low to be influenced by dispersion or pass though 
the viscous sublayer. Between the Targeted and Poor Ratio mesh, the DF decreases by 
about 25% for 2.89 µm particles (40.32% vs. 30.10%), 50% for 2.38 µm particles (30.30% 
vs. 15.28%), and 73% for 1.10 µm particles (2.28% vs. 8.58%). Note that meshes in 
Figure 3.3 that gave lower peak TKE values and a shallower gradient also gave less 
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particle deposition. That is, lower TKE provides less turbulent dispersion, which results in 
lower DFs for particles less than 4 µm, as expected. 
Including the Green-Gauss Node-based Discretization Scheme 
Using the GGN method for gradient discretization greatly reduces the sensitivity of 
the TKE field to the NW mesh resolution, as shown in Figure 3.6. As before, the 
differences between the four meshes become more varied as the flow progresses through 
the 90° bend. However, there is less overall variability between each case. Using the 
same method as before, GGN decreases the average and maximum standard deviation 
by 40% and 45% respectively for the 20° profile (0.20 vs. 0.12 m2/s2 and 0.41 vs. 0.23 
m2/s2), 33% and 40% for the 40° profile (0.29 vs. 0.20 m2/s2 and 0.60 vs. 0.36 m2/s2), 
22% and 32% for the 60° profile (0.38 vs. 0.29 m2/s2 and 0.75 vs. 0.51 m2/s2), and 13% 
and 25% for the 80° profile (0.46 vs. 0.40 m2/s2 and 0.89 vs. 0.67 m2/s2). Furthermore, 
the peak TKE values compare closely with one another, and the incline of the gradient 
near the wall is similar for all four meshes. Removal of the Poor Ratio mesh from this 
comparison would further improve agreement in the TKE field. 
As a result of less variability in the TKE values, there is much better consistency 
in the deposition profiles for each mesh, as shown by Figure 3.7, especially for particles 
less than 4 µm in diameter. Now, between the Targeted and Poor Ratio mesh, the DF 
decreases by about 5% for 2.89 µm particles (42.46% vs. 40.06%), 18% for 2.38 µm 
particles (31.06% vs. 25.58%), and increased by 6% for 1.10 µm particles (4.30% vs. 
4.54%). Table 3.3 summarizes the mean and standard deviation for the DF across all four 
meshes and compares the LSQ and GGN methods. This confirms that less variability in 
the TKE field gives less variability in particle deposition results. More importantly, these 
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results show that application of the GGN method greatly reduces the sensitivity of the 
flow field and particle trajectories to the NW mesh resolution. 
Near-wall Mesh Resolution 
Figure 3.8a shows that increasing the L2L ratio for Layer 1 to 2 from a value of 1.0 
(i.e. the same mesh as the Targeted case) to 1.1, 1.2, and 1.5 (as shown in Figure 3.2c) 
does not appreciably influence the particle deposition profile when using the GGN 
method. This is consistent with the reduced variability between results, especially the 
Poor Ratio case, which was presented in Figure 3.7. This means the variable L2L ratio 
capabilities that are available in meshing software can be employed without negatively 
affecting the aerosol deposition results. These meshing features allow the thickness of 
NW cell layers to be reduced when the surface-to-surface proximity decreases, which 
maintains the required mesh resolution near the wall. 
Figure 3.8b demonstrates how increasing the thickness of the first NW layer from 
an approximate wall y+ of 0.5, 1.0, 2.0, and 5.0 affects the deposition profile. Note that 
these meshes use only one NW layer so the L2L ratio does not mask the sensitivity of 
results to the target wall y+. For comparison, the Targeted mesh, with a wall y+ of one and 
five equally-spaced layers, is also included in this figure. From this plot it is clear that 
increasing the thickness of the first NW cell layer, and associated wall y+ value, rapidly 
increases the DF for small (<4 µm) particles. Convergence of the deposition profiles 
occurs when using a first layer height that gives an approximate wall y+ of 1.0. 
In summary, the results show that the Targeted NW mesh, which is desirable for 
infant nasal models, is capable of producing deposition results that are comparable with 
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the Recommended NW mesh in a simplified model, when suitable best practices are 
applied. 
Tetrahedral Mesh Type 
Using a tetrahedral mesh, as depicted in Figure 3.2d, and the GGN method gives 
a very consistent deposition profile across the four NW meshes considered, as shown in 
Figure 3.9. This draws parallels to the behavior seen when activating the GGN method in 
Figure 3.7. Table 3.4 summarizes the mean and standard deviation across all four 
meshes, and shows that the variability between each case is much less than the 
hexahedral meshes (see Table 3.3). Therefore, highly mesh independent results can be 
produced with tetrahedral meshes and the GGN method, which are desirable for the 
complex surfaces. 
Figure 3.9 also includes the deposition profile for the hexahedral mesh that uses 
the Targeted NW mesh parameters from Figure 3.7. Interestingly, the DF of the 1.10 µm 
particles for the tetrahedral meshes is much greater than the hexahedral results (14.26% 
vs. 4.30%). The fact that smaller particles are more influenced by subtle changes in the 
velocity and TKE field is the likely cause of this discrepancy between results. Recall that 
the NW correction UDFs also influence DFs for the smaller particles, and have not been 
applied at this stage in the study. 
Near-Wall Correction 
Figure 3.10a and b present the effects of applying the NW correction UDFs to the 
hexahedral and tetrahedral mesh with targeted NW cell layers respectively. For reference, 
the No UDF lines in each plot are the deposition profiles for the Targeted hexahedral and 
tetrahedral meshes from Figure 3.7 and Figure 3.9 respectively. As expected, increasing 
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the NW limit parameter decreases the DF for particles less than 4 µm, as the UDF begins 
damping the wall-normal flow velocity further away from the wall. The plots also show that 
setting the NW limit to zero, effectively disabling the damping of wall-normal velocity, still 
influences the results as the particle drag force and turbulence anisotropy correction are 
applied outside of this limit. 
Adjusting the NW limit parameter allows the computational results to be tuned to 
match experimental data. The results from the tetrahedral mesh in Figure 3.10b show 
that increasing the NW limit leads to a gradual decrease in DF for small particles, which 
makes it easier to fine-tune the results. Figure 3.10a shows that the hexahedral mesh 
gives a very abrupt change in DF when adjusting the NW limit parameter beyond 2 µm. 
This is most apparent when looking at the results when changing from a NW limit of 2 to 
5 µm for the 2.38 µm particles, as the DF drops from 14.28% to 2.24%. Generally, setting 
the NW limit parameter to a value of approximately 1 to 2 µm gave consistent results 
between mesh types, and compares well with experimental data (as detailed in the 
following section). 
Comparisons with Experimental Data 
Figure 3.11a and b compares the CFD deposition profile for the 90° bend 
hexahedral and tetrahedral models, with the Re = 6,000 experimental data and correlation 
from Pui et al. (1987). From this comparison, it is clear that applying the best-case mesh 
and solver parameters, with the NW correction UDFs, gives a very good match between 
experimental and numerical results. To provide the best match to the Pui et al. data, the 
hexahedral case uses a NW limit value of 1.0 µm, and the tetrahedral case uses 2.0 µm. 
Note that the CFD results also exhibit the characteristic S-curve that is common for 
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deposition profiles in the pharmaceutical aerosol size range. This profile shape is not 
represented by the correlation, but is apparent in the experimental data points. It is noted 
that the CFD predictions match the experimental data points better than the algebraic 
correlation at a majority of the points considered. 
Figure 3.11c and d show the comparison between a hexahedral and tetrahedral 
CFD model that also adheres to the recommended guidelines developed by this study, 
and the Re = 10,000 experimental model. The experimental and numerical data also 
match well, which suggests that the CFD meshing and solver guidelines that are 
recommended by this work are applicable to a range of flow characteristics. Interestingly, 
both of these cases gave the best match to the Pui et al. data with NW limit values of 
zero; hence, the wall-normal fluctuating velocity does not need to be damp for these 
models. This may be a specific characteristic of high Reynolds number cases. Recall that 
the Re = 10,000 case uses both a larger diameter tube and higher inlet flow rate, so the 
recommended CFD guidelines are independent of model geometry and inlet conditions. 
3.5 Discussion 
This study determines a set of meshing and solver guidelines that provide 
consistent results across several different NW meshes, and have been validated against 
experiments of aerosol deposition. The selected meshes have evaluated the effects of 
the number of cell layers, wall y+, L2L ratio, and cell type (hexahedral or tetrahedral) on 
the flow field and particle trajectories, in order to determine the most efficient use of NW 
cell layers for aerosol deposition models. The investigation explored different 
discretization schemes and control parameters for anisotropic turbulence correction, with 
final results showing a reliable match with the Pui et al. data. The guidelines are applicable 
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across a range of flow Reynolds numbers and particle sizes. Table 3.5 summarizes the 
recommended guidelines at the conclusion of this study. 
As expected, the DF of particles less than 4 µm is most sensitive to the NW TKE 
field, because particles in this size range are largely influenced by eddy motion and have 
sufficient momentum to maintain an eddy dispersion velocity. Lower TKE in the NW 
region leads to less deposition of these smaller particles, and as such, one should strive 
for CFD models that give a reliable TKE field before having confidence in deposition 
results. Application of the GGN discretization scheme greatly reduced the variability of 
the TKE and particle deposition results across all the evaluated NW meshes with the 
small expense of an 11% increase in computational time (over 5,000 iterations). 
Therefore, the reasonable upper airway meshes, with five equally-spaced layers, can be 
applied to future work in contrast with the previously recommended NW mesh with 10-20 
layers. Further exploration of the NW mesh parameters with the GGN scheme showed 
that it is important to aim for a wall y+ of approximately 1.0, and that varying the L2L ratio 
did not drastically influence the variability of results between cases. This means that 
should the meshing software increase or decrease layer thickness to confirm to the model 
geometry, the results should not be significantly affected. 
Use of the NW correction UDFs allows the numerical results to be tuned to match 
experimental data. As with previous studies (Longest et al., 2015; Longest & Hindle, 
2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian, 
Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Matida et al., 2004; Tian et al., 2011; 
Walenga & Longest, 2016), a y+ limit of 60 was suitable for the anisotropic turbulence 
correction. For the Re = 6,000 case, a NW limit of 1-2 µm was required to match 
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experimental data for the hexahedral and tetrahedral cases, below which the wall-normal 
velocity is damped. For the Re = 10,000, a NW limit of zero was used, which means that 
the velocity damping correction was not required in the more turbulent case.  
Generally, CFD results tend to over-predict deposition, especially for smaller 
particle diameters. The UDFs correct this over-prediction by introducing anisotropic 
fluctuating velocity components with random numbers from a Gaussian distribution, and 
damps the wall-normal velocity component as the particle approaches the wall. The 
current study improved the UDFs by introducing an inverse-distance weighted 
interpolation method to approximate velocity and TKE values at the particle location, 
based on cell centroid values. This modification aims to make the correction less mesh 
dependent. Results show how the NW limit parameter adjusts the deposition profile for 
hexahedral and tetrahedral meshes. Based on the results of this study with the 
recommended meshing guidelines, we recommend NW limit values of 1-2 µm for 
transitional flows with Reynolds number below 10,000, and removing the NW limit 
correction when the Reynolds number exceeds 10,000. In summary, use of the 
aforementioned guidelines and anisotropic turbulence correction leads to a very good 
match between the numerical and experimental data for this 90° bend model. 
The findings from this study are consistent with previous work that has evaluated 
the LRN k-ω model in simplified models of biological internal flow. Studies by Varghese 
and Frankel (2003) and Ryval et al. (2004) both concluded that the LRN k-ω model gave 
a good match to experimental data when modeling flow through a stenosed tube, which 
is similar to constrictions in blood vessels or the respiratory airways. These models have 
similar flow conditions to the 90° bend model presented in this article, as they all 
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experience laminar, transitional, and turbulent flow. Matida et al. (2004) demonstrated 
realistic NW corrections are required in order to match deposition results from the k-ω 
model to experiments. The same conclusions are drawn from the current study, as 
application of the NW correction UDFs, which were in part (anisotropy but not NW 
interpolation) based upon the findings of Matida et al. (2004), allows the deposition profile 
to be tuned to match the Pui et al. data (1987). Specific to modelling pharmaceutical 
aerosol deposition in the lungs with LRN k-ω, Xi and Longest (2007) reported good 
comparisons between numerical models, of both realistic and simplified geometries, and 
experimental data. The meshing and solution parameter recommendations presented in 
this paper add to the research field by providing clear guidelines for using the LRN k-ω 
model. This will streamline the CFD model development process for future work that plans 
to take advantage of the efficiency and accuracy that the LRN k-ω turbulence model 
provides for microparticle deposition. 
Recently in the literature, there has been a shift towards using more complex 
turbulence models in CFD studies. The LES model resolves the turbulence field in greater 
detail than two-equation RANS models. Its formulation is also capable of overcoming 
some of the inherent NW issues with the k-ω model, which are outlined by this study, 
without the need for corrections. However, LES models demand much longer meshing 
and solver processing times, as very small cell sizes are necessary to resolve the required 
length scales, which in turn gives high cell counts. Zhang and Kleinstreuer (2011) 
compared the LRN k-ω, SST transition, and LES models for nanoparticle deposition in a 
constricted tube and idealized human airway model. They observed negligible differences 
between the three turbulence models for predicting laminar, transition and turbulent flow. 
111 
 
They also report that the more complex LES model required 100-fold more computational 
resources than the two-equation RANS model. Conversely, Jayaraju et al. (2008) 
concluded that LES/DES provided a better agreement with experimental data for a MT 
model than k-ω. However, their study used the standard implementation of the k-ω model, 
which does not include the LRN correction. It is noted that the two-equation RANS CFD 
models that are discussed here and have successfully matched experimental data (Ryval 
et al., 2004; Varghese & Frankel, 2003; J. Xi & Longest, 2007; Z. Zhang & Kleinstreuer, 
2011), including the present study, have used the k-ω model with LRN correction. 
Similar to how this study compared the LRN k-ω CFD results to the Pui et al. model 
(1987), Breuer et al. (2006) provided a comparison between LES results and the same 
experimental data set. They showed a good match between the DF from their 
computational model and the curve fitted correlation. Figure 3.12 reproduces the 
deposition profile for the Re = 10,000 model from Breuer et al. (2006), and includes the 
results from this study for the Re = 6,000 and 10,000 cases, and both hexahedral and 
tetrahedral meshes. This comparison across different Reynolds numbers is reasonable 
as the Pui et al. correlation is only a function of Stokes number, and hence is independent 
of Reynolds number. Figure 3.12 shows that the LRN k-ω models gives similar deposition 
results to the LES model across a range of particle diameters (Stokes number). 
Therefore, we believe that the LRN k-ω model, with the guidelines and NW corrections 
defined by this study, is capable of modeling aerosol deposition under conditions 
consistent with the upper respiratory airways. Advanced turbulence models are invaluable 
for modeling complex phenomena and aiding the development and validation of two-
equation RANS models. For example, the NW correction UDFs utilized by this work rely 
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on findings from the DNS data from Wang and James (1999). However, the LRN k-ω 
model provides a more computationally efficient method that can resolve the flow field in 
sufficient detail to capture microparticle deposition with the same degree of accuracy as 
LES models. 
Future work will apply these guidelines to upper airway geometries and aim to 
provide the same reliable and validated results that are presented here. This investigation 
showed that both hexahedral and tetrahedral meshes can be used with little drawbacks 
for either cell type. Using tetrahedral meshing capabilities makes the modelling of 
complex airways like the nasal cavity much easier, where using a regular hexahedral 
mesh on complex geometries is not possible. Cut-cell meshing technologies should be 
explored, where a Cartesian grid is fitted to the geometry by excluding and cutting cells 
outside of the domain. This method results in a mesh that is mostly regular and 
hexahedral in the core, with some tetrahedral, pyramid, and other polyhedra near the 
surface. The core mesh would provide the robust and computationally efficient benefits 
that are common with regular hexahedra, but it is unclear at this stage how the cut cells 
near the surface affect turbulence properties and aerosol deposition in airway CFD 
models. 
In conclusion, this study has provided a set of recommendations for mesh and 
solver settings that give consistent and validated results for a characteristic geometry. It 
is expected that application of these guidelines to more complex geometries will improve 
the model development process and provide more reliable aerosol deposition results in 





Figure 3.1: Overview of geometry and particle deposition locations on the 90-degree 
bend at deposition times of (a) 0.003 s, (b) 0.006 s, (c) 0.009 s, and (d) 0.012 s. Results 
shown are for the Re = 6,000 case that follows the CFD guidelines recommended at the 




Figure 3.2: Summary of meshes used to evaluate the sensitivity of the TKE field and 




Figure 3.3: Initial near-wall TKE profiles for each of the four meshes at angles around 




Figure 3.4: Continuous phase velocity (combined mean and fluctuating parts) to which 
the particle is exposed at wall-normal distances of (a) 60 µm, (b) 50 µm, and (c) 40 µm, 








Figure 3.6: Reduced sensitivity of TKE to the mesh when using Green-Gauss Node-
based discretization scheme at angles around the 90-degree bend of (a) 20 degrees, (b) 









Figure 3.8: Comparison of results when varying the (a) layer-to-layer ratio and (b) target 




Figure 3.9: Deposition comparison when using a mesh with a triangular surface, 
prismatic near-wall layers, and tetrahedral core. Each of the near-wall mesh resolutions 




Figure 3.10: Adjustment of near-wall UDF parameters to tune deposition results and 





Figure 3.11: Comparison to Pui et al. (1987) data when all CFD recommendations are 
applied for (a) Re = 6,000 with the hexahedral mesh, (b) Re = 6,000 with the tetrahedral 





Figure 3.12: Comparison of LRN k-ω results using the best practices from this study with 
LES data from Breuer et al. (2006). Particle diameters converted to Stokes number to be 
























6,000 5.03 0.03 1.10 6.1 6.4 
  0.13 2.38 13.4 25.0 
  0.19 2.89 29.6 34.4 
  0.36 4.01 55.0 55.0 
  0.60 5.20 76.0 73.6 
  0.72 5.70 80.6 79.7 
  1.00 6.74 88.4 89.1 
10,000 8.51 0.03 1.50 N/A 6.4 
  0.13 3.10 N/A 18.5 
  0.19 3.80 N/A 28.3 
  0.27 4.56 48.4 45.0 
  0.29 4.73 50.3 47.4 
  0.46 5.98 65.6 63.9 














Recommended 20 0.02 (≈1.0) Layers 1-8: 1.1 
Layers 8-20: 1.0 
0.70 
Intermediate 10 0.02 (≈1.0) 1.0 0.20 
Targeted 5 0.02 (≈1.0) 1.0 0.10 
Poor Ratio 5 0.02 (≈1.0) Layer 1-2: 1.8 
Layers 2-5: 1.0 
0.20 
Wall y+ ≈ 0.5 1 0.01 (≈0.5) N/A 0.01 
Wall y+ ≈ 1.0 1 0.02 (≈1.0) N/A 0.02 
Wall y+ ≈ 2.0 1 0.04 (≈2.0) N/A 0.04 
Wall y+ ≈ 5.0 1 0.10 (≈5.0) N/A 0.10 
Ratio = 1.0 5 0.02 (≈1.0) 1.0 0.10 
Ratio = 1.1 5 0.02 (≈1.0) Layer 1-2: 1.1 
Layers 2-5: 1.0 
0.12 
Ratio = 1.2 5 0.02 (≈1.0) Layer 1-2: 1.2 
Layers 2-5: 1.0 
0.15 
Ratio = 1.5 5 0.02 (≈1.0) Layer 1-2: 1.5 





Table 3.3: Mean and standard deviations of the deposition fraction for the 
Recommended, Intermediate, Targeted, and Poor Ratio meshes when using the Least 






Mean (SD) DF 
[%] 
GGN 
Mean (SD) DF 
[%] 
1.10 5.77 (2.37) 3.91 (0.59) 
2.38 24.82 (5.88) 28.12 (2.47) 
2.89 36.57 (3.94) 41.11 (0.95) 
4.01 58.58 (0.60) 60.29 (0.80) 
5.20 75.67 (0.85) 77.24 (1.77) 
5.70 82.83 (0.32) 83.81 (1.52) 




Table 3.4: Mean and standard deviations of the deposition fraction for the 
Recommended, Intermediate, Targeted, and Poor Ratio meshes when using a tetrahedral 
volume mesh, prismatic near-wall cell layers, and the Green-Gauss Node-based (GGN) 





Mean (SD) DF 
[%] 
1.10 13.35 (0.55) 
2.38 32.58 (0.50) 
2.89 42.78 (0.32) 
4.01 61.76 (0.51) 
5.20 79.38 (0.31) 
5.70 85.78 (0.34) 




Table 3.5: Summary of recommended mesh and solver parameters.
 Model/Parameter Setting/Method 
Mesh Target Wall y+ 0.5-1 
 Number of NW Layers 5 
 L2L Ratio 1.0 (may be increased with no negative effects) 
Flow Turbulence LRN k-ω 
 P-V Coupling SIMPLEC 
 Mom. & Turb. Schemes Second-order Upwind 
 Gradient Discretization Green-Gauss Node-based 
 Numerical Accuracy Double Precision 
Particles Tracking Scheme Lagrangian with Runge-Kutta 
 Turbulent Dispersion Interpolate TKE at particle location from nodes 
 Eddy Interaction Model Modified via UDF 




Chapter 4: Validating CFD Predictions of N2L Aerosol Delivery in a 6-
Month-Old Infant Airway Model 
4.1 Objective 
The primary objective of this study is to validate mesh and CFD parameters against 
experimental data for accurate modelling of microparticle deposition in an infant nasal 
airway for the assessment of N2L aerosol administration. Previously developed meshing 
and solution parameters will be applied to the CFD model, with other considerations 
specific to infant nasal models observed. Specifically, the commonly used tetrahedral and 
new polyhedral mesh types are compared, as well as laminar and turbulent flow 
conditions, and monodisperse versus polydisperse aerosol approximations. To validate 
the CFD predictions, in vitro experiments are reported in an identical nasal airway 
geometry with a nasal cannula interface. As a secondary objective, high efficiency N2L 
aerosol delivery is demonstrated in an infant airway model using both CFD and in vitro 
approaches, which is enabled by the use of micrometer-size particles as with the EEG 
strategy. 
4.2 Introduction 
The enhanced excipient growth (EEG) method of pharmaceutical aerosol delivery 
(Hindle & Longest, 2012), with nose-to-lung (N2L) administration via a streamlined nasal 
cannula, can vastly reduce deposition loses in the patient interface and extrathoracic 
airways (Longest et al., 2015) leading to high efficiency lung delivery. The EEG approach 
employs a spray-dried formulation of the drug, which when aerosolized, generally has a 
micrometer or sub-micrometer mass-median aerodynamic diameter (MMAD) (Son, 
Longest, & Hindle, 2013; Son, Longest, Tian, et al., 2013). The low inertia of these small 
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particles allows them to follow flow streamlines and penetrate deep into the conducting 
airways with little depositional loss. The aerosol formulation includes a hygroscopic 
excipient, which absorbs moisture from the humid airways, thereby causing the particles 
or droplets to grow and reach conventional sizes for respiratory aerosols (3-6 µm) as they 
reach the distal regions of the lungs. This aerosol size increase is associated with an 
increase in inertial deposition and sedimentation, which minimizes exhalation of the 
aerosol and may allow for targeted aerosol delivery. The EEG method therefore reduces 
device and extra-thoracic depositional losses, while allowing targeted delivery and greater 
retention in the conducting airways (Longest et al., 2015; Tian et al., 2014; Tian et al., 
2013). 
Using N2L aerosol administration via a streamline nasal cannula provides several 
benefits over alternative methods of aerosol delivery, which make it well suited for efficient 
aerosol administration to infants. Infants are generally nose breathers (ICRP, 1994), so 
delivery through the nasal passage can occur simultaneously while the patient is on non-
invasive ventilation. For aerosol delivery to infants, facemasks are often used instead of 
cannulas, but present several drawbacks. Two notable review papers on aerosol delivery 
to infants report that patient distress (Everard, 2003) and crying infants (Amirav, 2011) 
lead to reduced lung drug dose during aerosol administration via a facemask. Studies 
also report that an airtight seal is required between the facemask and patient face for 
optimal delivery (Amirav & Newhouse, 2001; El Taoum, Xi, Kim, & Berlinski, 2015), which 
is difficult to achieve. Furthermore, there is evidence in the literature that nasal cannula 
systems may provide improved lung delivery efficiency compared to facemasks in infants 
and children (Amirav, Borojeni, Halamish, Newhouse, & Golshahi, 2015; Reminiac et al., 
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2017). It is expected that using small diameter particles (MMAD < 2 µm) for N2L aerosol 
delivery leads to high efficiency lung doses, as the likelihood of impaction deposition is 
reduced as particles travel through the nasal cavity and nasopharynx (Storey-Bishoff et 
al., 2008; Tavernini et al., 2018). 
Multiple studies from our group have demonstrated that a concurrent experimental 
and computational fluid dynamics (CFD) approach can successfully develop and evaluate 
aerosol delivery systems, with successful validations compared with both in vitro (Longest 
& Hindle, 2009a; Longest et al., 2007; Longest, Tian, Delvadia, et al., 2012; Longest, 
Tian, Walenga, et al., 2012; Longest & Vinchurkar, 2007b; Tian et al., 2011) and in vivo 
data (Longest et al., 2015; Walenga & Longest, 2016). Deposition results from CFD 
models can provide valuable insight into the behavior of the aerosol transport through the 
delivery system and the nasal cavity, in terms of both the flow field and deposition sites. 
For example, a high concentration of deposition in a localized region of the CFD model 
may indicate the potential for design improvements, which may not be apparent in 
experimental data. However, one can only have confidence in results from a numerical 
model after it has been validated against experimental data based on the parameters of 
interest. Based on this approach, both numerical and experimental aspects of an analysis 
can be used simultaneously to facilitate improvements in a targeted drug delivery strategy 
or device. 
To achieve validation of CFD results with experimental data, it is imperative that 
sound methodology is used in the numerical model in the areas of geometry development, 
mesh generation, sub-model selection, and solution parameters. Bass and Longest 
(2018b) recently developed a set of meshing and solution guidelines for application of the 
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low-Reynolds Number (LRN) k-ω turbulence model when simulating microparticle 
deposition under conditions similar to the upper-airways. This previous study presented 
an excellent match to both experimental and Large Eddy Simulation (LES) deposition 
data across a range of particle sizes and flow conditions in a representative 90°-bend 
geometry. However, it is important to confirm the same meshing and solution guidelines 
are applicable to a more complex model of the infant nasal cavity. For example, it is 
currently an open research question if turbulence should be included in simulations of 
nasal particle deposition. This is further complicated by the presence of the nasal cannula 
interface, which forms two jets of airflow entering the nasal vestibule and progressing 
through the narrow nasal valve. 
4.3 Methods 
Nasal Model Development from Computed Tomography Scans 
Pre-existing medically necessary computed tomography (CT) scans of nasal 
airways from 3-6-month-old infants were reviewed for scan quality and completeness 
under an institutional review board (IRB) approved protocol. To develop an infant model 
with a targeted age of approximately 6 months, the selected scan was of a 68.2 cm and 
7.7 kg male that was approximately 20 weeks (5 months) old. The patient height and 
weight both fell within the 25th and 75th percentiles for a 6-month-old (6mo) infant (WHO, 
2006). Therefore, it was expected that the model was representative of the target age 
(Tavernini et al., 2018), despite being approximately one month younger. Of the available 
scans, the selected scan was chosen because the infant’s mouth was closed, it was 
complete from the nostrils through the larynx, and the slice resolution was sufficiently 
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small at 1 mm. The scan was reviewed by a pediatric otolaryngologist and found to be 
free of nasal abnormalities. 
The CT scan was segmented by the Mimics software suite (Materialise, Leuven, 
Belgium) to generate a 3D model of the infant nasal cavity from the 2D image slices. The 
process of segmentation involves selecting pixels in the CT scan, which combined with 
the slice thickness become voxels for each slice. The tools and capabilities provided by 
Mimics allow users to speed up the process by selecting threshold regions of pixels that 
fall within a greyscale range that are considered internal airways (i.e. not bone or soft 
tissue). Mimics also automatically smooths the block-shaped voxels to provide a realistic 
representation of physical anatomy. Once image segmentation is complete, the 3D model 
is transferred to 3matic (Materialise, Leuven, Belgium) where additional post-processing 
steps are performed such as wrapping, STL mesh quality improvements, and surface 
triangle reduction. Surface wrapping covers the initial surface with a second STL surface 
that removes any non-manifold faces (where three or more faces share a single edge), 
free edges (holes), or sliver faces, thereby removing any erroneous triangles from the 
surface. The STL surface is then converted to CAD data using the skin surface 
capabilities available in SpaceClaim (ANSYS, Inc., Canonsburg, PA, USA). This process 
involves manually creating polygonal patches (approximately 50) that are wrapped to 
conform to the faceted surface. Therefore, instead of the nasal cavity being defined by 
thousands of STL triangles, it is represented by approximately 50 CAD format surfaces. 
This step makes it possible to import the model into third-party CAD software. 
In SolidWorks (Dassault Systèmes, Paris, France), the nasal cavity was further 
modified to generate a suitable experimental model that can be produced with 3D printing. 
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This included supports for locating the streamlined nasal cannula and connections to an 
outlet filter to measure recovered lung dose. Design considerations were also made to 
simplify the 3D printing of the model. The model was separated into three regions that 
approximate the anterior nose, middle passage, and nasopharynx, as this makes it easier 
to clean support material from inside the nasal cavity and provides insight into the regional 
deposition within the model. The nasopharynx part of the model was also split in half to 
remove support material from around the glottis, and then sealed with locating pins and 
epoxy. 
Figure 4.1a shows the CAD surfaces of the 6mo airway experimental model with 
cannula support, outlet filter connection, and connections between the three regions. 
Figure 4.1b shows the air interface of the cannula, nasal cavity, and filter connection that 
form the CFD model surfaces. Figure 4.1b also clearly illustrates the complexity of the 
infant nasal airway, especially in the region of the turbinates and larynx. 
Experimental Set-up 
Micrometer-sized aerosols were generated using a novel mixer-heater in 
combination with a commercial nebulizer operating with reduced aerosol output. The 
mixer-heater delivery system is shown in Figure 4.2. The mixer-heater (61.6 mL internal 
volume) was designed to efficiently mix nebulized aerosol with incoming ventilation gas 
and then heat the aerosol to reduce it to micrometer or sub-micrometer size for inhalation. 
Consistent with infant high flow nasal cannula ventilation, air at a flow rate of 6 L/min was 
introduced into the mixer-heater with the heating element set to 60 °C, which resulted in 
an exit aerosol temperature from the streamlined cannula of 35 °C. Aerosol was 
generated from a 0.5% w/v albuterol sulfate solution prepared by dissolving albuterol 
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sulfate USP (Letco Medical, LLC, Decatur, AL) in water. The particle size of the emitted 
aerosol was similar to previous EEG studies, however an EEG excipient was not included, 
as hygroscopic growth in the airway model was not investigated in this study. An Aerogen 
Pro nebulizer (Aerogen, Galway, Republic of Ireland) was used in the mixer-heater, 
however the mean (SD) output of the nebulizer was reduced to 70 (7) µL/min compared 
to typical values of 300-400 µL/min when operated using the Aerogen Controller. 
Reducing the output of the nebulizer was required to ensure drying of the aerosol to 
micrometer-size at the infant gas flow rate. This was achieved by reducing the sinusoidal 
operating voltage amplitude of the controller to 14.1 Vrms compared to the normal 
operating value of 50 Vrms for the commercial nebulizer. The nebulizer was filled with 3.5 
mL of the nebulizer formulation and weighed prior to and following nebulization for each 
run (duration of 20 minutes). The mass of nebulized formulation and the concentration of 
the formulation was used to calculate the nominal dose of nebulized drug. Standard infant 
ventilator tubing with a diameter of 10 mm was used to connect the mixer-heater device 
to the streamlined infant cannula. 
Aerodynamic particle sizing experiments were performed using the Andersen 
Cascade Impactor (ACI, Copley Scientific, Nottingham, UK) placed in an environmental 
chamber (Espec, Hudsonville, MI) set to 35 °C and 99% relative humidity (RH) to minimize 
effects of evaporative size changes during measurements. The aerosol output at the exit 
of the nasal cannula was positioned at the entrance to the ACI. The ACI inlet entrained 
the aerosol exiting the nasal cannula plus additional makeup air from the environmental 
cabinet for a total ACI flow rate of 28.3 L/min. Drug was collected from the impactor stages 
and filter to determine the emitted dose, the MMAD and particle mass fraction less than 
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1 μm and less than 5 μm. MMAD and particle fractions were determined by linear 
interpolation. MMAD values were directly calculated as the size associated with a 
cumulative count of 50% based on mass percentages calculated relative to the impactor 
dose. Particle mass fractions were calculated as the cumulative mass fraction frequency 
associated with sizes of 1 μm and 5 μm, respectively. A minimum of three measurements 
were performed. 
Studies were also performed to determine the regional deposition of the mixer-
heater generated micrometer drug aerosol in the infant model as shown in Figure 4.2. 
Aerosols were continuously generated in these steady-state flow experiments as 
described above, with the outlet of the streamlined infant nasal cannula inserted into the 
nostrils of the airway model. Aerosol delivered through the infant nasal model was 
captured on a low resistance respiratory filter positioned at the exit of the trachea and 
was considered as the delivered in vitro N2L dose.  A constant flow of 7 L/min was drawn 
through the airway model. As described previously, the physical model was identical to 
the CFD model and included the nostrils, turbinates, nasopharynx, larynx and a portion 
of the trachea. The model was segmented into three portions: 1) the anterior nose, 2) the 
middle passage, and 3) the nasopharynx, larynx and trachea. Drug deposited on the 
model components and respiratory filter was recovered and analyzed using a validated 
isocratic HPLC method. AS quantification was performed with a validated HPLC method 
using a Waters 2695 separations module with a 2475 fluorescence detector (Waters Co., 
Milford, MA). Chromatography was performed using a Restek Allure PFP 150 mm × 2.1 
mm column (Bellefonte, PA). The mobile phase, consisting of methanol and ammonium 
formate buffer (20 mM, pH 3.4) in a ratio of 70:30, respectively, was eluted at a flow rate 
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of 0.4 mL/min and the detector was set to an excitation wavelength of 276 nm and 
emission at 609 nm. The column temperature was maintained at 25 °C, and the volume 
of each sample injected was 100 μL. The limit of quantification was 0.5 µg/ml (Behara, 
Longest, et al., 2014b; Son, Longest, & Hindle, 2013). The recovered emitted dose from 
the mixer heater was calculated as the mass of drug deposited on the ventilator tubing, 
cannula, nasal airway model and respiratory filter. Regional drug deposition was 
expressed as a percentage of the recovered emitted dose from the mixer heater.  
Numerical Model 
As with all CFD to experimental comparisons, the numerical model aims to 
replicate the experimental set-up as closely as possible. The following sections detail 
aspects of the CFD model set-up and the steps taken to ensure accurate and reliable 
deposition results. 
Meshing and Solution Guidelines 
Bass and Longest (2018b) recently provided a set of CFD meshing and solution 
guidelines for modelling aerosol deposition in the respiratory airways, under transitional 
and turbulent flow conditions, using the LRN k-ω turbulence model. These guidelines 
detailed near-wall (NW) mesh parameters and solver settings that provided a good match 
to experimental and LES data of micrometer (from approximately 1.0 to 7.5 µm) particle 
deposition in a characteristic 90° bend geometry. Table 4.1 summarizes the 
recommendations from that study, which will be applied to the current numerical model, 
with the intention of validating the mesh and solver settings against experimental data of 
micrometer particle deposition in an infant nasal cavity during N2L aerosol administration. 
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In addition to validating the CFD meshing and solution guidelines, this study 
explores the assumption of laminar flow versus a turbulence approximation modeled with 
the LRN k-ω turbulence model for infant nasal airways. Results evaluate the turbulent 
nature of the flow and its influence on both monodisperse and polydisperse aerosols. 
Flow through the infant nasal cavity is generally in the laminar or transitional regime when 
considering the Reynolds number at the connection tubing inlet (approximately 900). 
However, the complexity of the nasal passages and transition from the patient interface 
to nostrils may induce turbulence in the flow. Specifically, the nasal cannula interface 
creates air jets that enter the most constricted portion of the nose, i.e. the nasal valve. 
CFD models with the LRN k-ω turbulence approximation generally tend to over-
predict microparticle deposition, due to the assumption of isotropic NW turbulence. 
Longest and Xi (2007) developed a method of NW correction by utilizing FLUENT user-
defined functions (UDFs), which built upon previous work by Matida et al. (2004) and 
Wang and James (1999). The NW correction UDFs include anisotropic velocity 
fluctuations in the continuous phase and damp the wall-normal velocity in the NW region 
to represent particle-wall hydrodynamic interactions (Longest, Kleinstreuer, & Buchanan, 
2004). Further details on these corrections have been reported in previous studies from 
our group (Longest & Xi, 2007; Walenga & Longest, 2016), and recent improvements to 
interpolation methods were reported by Bass and Longest (2018b). The key control 
parameter used by the NW correction UDFs is the NW limit, as it determines the particle-
to-wall distance below which wall-normal velocity is damped. This parameter is adjusted 
to match numerical and experimental deposition data, with Bass and Longest (2018b) 
reporting values of 1-2 µm provided good comparisons in their 90° bend study. The 
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present work will compare results using the NW corrections versus the standard turbulent 
particle dispersion model, and a case that includes the LRN k-ω turbulence approximation 
of the flow field, but without the particle dispersion model activated. This investigation will 
also determine whether the NW limit control established in the simple 90° bend study can 
be applied to the highly complex infant nasal cavity model. 
Meshing Approaches 
This study compares two types of unstructured meshes for modeling aerosol 
deposition in the patient interface and nasal cavity. Ideally, numerical models use 
structured hexahedral meshes, as they generally give the best solution accuracy, stability, 
and computational efficiency. However, the complex geometry of the infant nasal cavity 
makes it prohibitively difficult to apply a structured mesh. Unstructured tetrahedral 
meshes are often used when a hexahedral mesh is not possible, as they are able to 
conform to complex surfaces and efficiently fill the domain volume with good-quality cells. 
Bass and Longest (2018b) concluded that a tetrahedral mesh with five prismatic NW cell 
layers provides similar microparticle deposition to a hexahedral mesh in a simplified 
geometry under flow conditions similar to the infant airways. However, differences in the 
deposition predictions were observed for 1 µm particles between meshes with tetrahedral 
and prismatic NW cells, which required more correction. In the current study, the 
tetrahedral and prismatic NW cell mesh is explored and applied to the infant nasal 
geometry, with mesh parameters that were established in the much simpler 90°-bend 
considered by Bass and Longest (2018b), as shown in Table 4.1. Figure 4.3a shows the 
meshing structure of the tetrahedral cells with prismatic NW cell layers at the tube inlet, 
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and Figure 4.3c shows a cut through the middle meatus that exposes the interior nasal 
mesh. 
The tetrahedral and prism mesh shown in Figure 4.3a and c was generated using 
the FLUENT meshing capabilities (ANSYS, Inc., Canonsburg, PA, USA). The process 
begins by producing a triangular surface mesh that conforms to the complex geometry. 
Curvature, proximity, and locally defined size controls are used to adjust the mesh sizing 
in order to obtain an accurate representation of the geometry surface and increase fidelity 
in regions of interest and importance. To generate the volume mesh, the software uses a 
Delaunay algorithm to fill the domain with tetrahedral cells, and the five-sided prismatic 
NW cells are added by inflating the surface mesh towards the cell interior. Definition of 
the NW cell layers follows the recommendations provided by Bass and Longest (2018b) 
of five equally spaced layers with an approximate wall y+ of one (see Table 4.1.) Once 
the meshing process is complete, the cell nodes are smoothed using the capabilities in 
FLUENT meshing to ensure that all cells have an orthogonal quality greater than 0.25, 
which provides a high-quality discretization of the domain. 
In addition to tetrahedral meshes, FLUENT meshing is capable of producing 
polyhedral meshes, which are composed of cells with any number of faces, edges, and 
vertices. Polyhedral cells generally have more faces than hexahedral or tetrahedral cells, 
which results in more cell neighbors, and hence better resolution of gradients in and out 
of the control volume (Sosnowski, Krzywanski, & Gnatowska, 2017). The various 
orientations of each cell face (see Figure 4.3d) also increases the likelihood of having 
flow aligned with a cell face, which can reduce numerical diffusion, as it does for flow-
aligned hexahedral meshes. There is much anecdotal evidence in the CFD community 
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that polyhedra provide faster convergence with lower cell counts than tetrahedra. 
However, a review of the literature shows there has been no direct evaluation of these 
two unstructured meshing approaches in the field of respiratory drug delivery research. 
The closest comparison comes from Lotfi et al. (2016) who concluded that polyhedra 
provided superior results to tetrahedra when modelling flow through a stented artery. 
However, their study did not provide details on convergence or computational efficiency. 
A study from van Ertbruggen et al. (2008) developed a CFD model representation of 
alveolar structures in the lungs, which used a polyhedral mesh, and made good 
comparisons with experimental data for laminar, very low speed flow. However, a direct 
comparison of results from tetrahedra and polyhedra was not made. Furthermore, both 
of these previous studies did not include particle transport and deposition. Peric (2004) 
provided a complete comparison of polyhedral and tetrahedral meshes for a simple 3D 
lid-driven cavity flow model under laminar conditions, and showed that polyhedra required 
50% less memory and less than 20% of the computation time. 
The advantages described here make polyhedral meshes a promising approach 
for developing computationally efficient airway models. Figure 4.3b shows the polyhedral 
mesh at the tube inlet and Figure 4.3d shows the interior mesh in the middle meatus. 
These images show that the polyhedral cell faces are generally 5- or 6-sided polygons, 
and as such, the NW cell layers have a varying number of sides. The process of 
generating a polyhedral mesh is similar to tetrahedral meshing, including the generation 
of a tetrahedral volume mesh. Once the volume mesh is complete, the software uses 
dualization and agglomeration algorithms to convert the tetrahedral cells to polyhedral. 
The details of this conversion are covered in more detail in the ANSYS User Guide (2017) 
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and other resources. As with the tetrahedral mesh, the final step is to smooth the mesh 
and ensure all cells are high quality with orthogonal quality greater than 0.25. 
In the preliminary stages of this project, other meshing approaches were 
considered. In particular, we initially evaluated the cut-cell meshing capabilities of 
FLUENT meshing. A cut-cell mesh is generated by starting with a Cartesian grid that 
encloses the geometry. Cells outside the domain are then excluded or cut to conform to 
the complex surfaces, which results in hexahedral cells in the bulk of the domain and 
irregular polyhedral cells near boundaries. This approach is appealing as it provides the 
numerical accuracy and stability of hexahedral cells with the ability to conform to complex 
geometry. However, cutting the cells near close-proximity surfaces, such as the thin-
walled cannula prongs, generated poor quality cells and an inaccurate representation of 
the geometry. This issue could be overcome by locally refining the mesh near these close-
proximity surfaces, but the cell count for the coarsest cut-cell mesh exceeded that of the 
finest tetrahedral mesh. Furthermore, the core hexahedral cells are Cartesian, but not 
flow aligned, so there may be no numerical benefit to using this mesh technology in the 
airways. Therefore, we decided not to pursue the cut-cell meshing approach further for 
respiratory aerosol simulations. 
Mesh Dependency Study 
A mesh dependency study was performed on both the tetrahedral and polyhedral 
meshes to determine the optimum grid resolution. In Figure 4.4, the volume-average 
velocity magnitude, turbulent kinetic energy (TKE), and nasal cavity deposition efficiency 
(DE) are compared for a coarse (2.76 million cells), medium (5.71 million cells), and fine 
(11.50 million cells) tetrahedral mesh, and also a coarse (0.88 million cells), medium (1.80 
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million cells), fine (3.56 million cells), and extra fine (7.42 million cells) polyhedral mesh. 
The DE is calculated from particles that are exposed to the turbulent dispersion model, 
but no NW corrections are applied. The comparison shows that the 5.71 million cell 
tetrahedral mesh and 3.56 million cell polyhedral mesh each give the best compromise 
between grid convergence and solution processing times. Between the medium and fine 
tetrahedral mesh, the volume-average velocity magnitude, TKE, and nasal cavity DE 
differ by only 0.008 m/s, 0.004 m2/s2, and 0.2% respectively. Similarly, the fine and extra 
fine polyhedral mesh differ by 0.003 m/s, 0.004 m2/s2, and 0.2%. Therefore, the remainder 
of this study uses the 5.71 million cell tetrahedral mesh and 3.56 million cell polyhedral 
mesh to compare each cell type and validate the CFD solution parameters. These cell 
counts are similar to grid convergence established in other nasal studies including the 3-
6 million cells used by Walenga et al. (2014) and the 4 million cells used by Frank-Ito et 
al. (2016). 
Boundary Conditions 
Boundary conditions in the CFD model were set to replicate the flow in and out of 
the experimental model. Mass flow inlet and outlet boundary types were applied at the 
tube inlet and filter connection outlet, with mass flow rates that gave 6 and 7 LPM 
respectively. The inlet conditions in the delivery tube, with a 10 mm inner diameter (ID), 
gave an inlet Reynolds number of approximately 900, which suggests the flow in the tube 
will be laminar. However, it is known that changes in cross-section, obstructions, and 
changes in flow path can induce transitional and turbulent flow regardless of inlet flow 
conditions (Wilcox, 1998). As mentioned previously, the effect of laminar and LRN k-ω 
models on flow and particle deposition are evaluated in the Results section. Pressure 
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inlet boundaries were applied to both the left and right nostrils in the gap between the 
cannula surface and airway walls, which were exposed to ambient pressure (gauge 
pressure of 0 Pa). The additional 1 LPM flow from the difference between the delivery 
tube inlet and filter connection outlet flow rates enters the domain through the nostrils, 
and using pressure inlets enables this inflow to vary in local velocity. 
For the LRN k-ω model cases, turbulence boundary conditions are required at 
each of the inlet boundaries, which were defined with hydraulic diameter and turbulence 
intensity. For the tube inlet, the hydraulic diameter is simply the 10 mm tube ID, as the 
cross section is circular. Turbulence intensity at the tube inlet is estimated to be 







where: 𝐼 is turbulence intensity and 𝑅𝑒𝐷 the Reynolds number using the inlet hydraulic 
diameter (ANSYS, 2017). For the nostril inlets, the hydraulic diameter is calculated by 
considering each boundary as an annulus and estimating the inner and outer diameters 
by measuring the perimeters in the CAD software, which resulted in approximately 8.1 
mm for both boundaries. As inlet velocity and Reynolds number at the nostrils is not 
known a priori, the turbulence intensity at the nostril inlets is assumed to be 1%. 
Preliminary work tested the effect of this assumption on particle deposition by changing 
turbulence intensity to 5% at the nostril inlets, and negligible influence was seen in 
deposition fractions (DFs) throughout the domain. Therefore, the turbulence intensity 
estimates made here will not largely affect the particle deposition results. 
An additional geometry extension was applied to the inlet, which was 30 mm long 
(3 times the inlet diameter), to better match the experimental conditions. Similarly, a 
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numerical extrusion was also added to the filter connection outlet, but due to recirculation 
in the filter connection, its length was increased until there was no reverse flow at the 
mass flow outlet. Particle deposition was checked on the inlet extrusion wall in the unlikely 
event there was reverse flow in this region, but this did not occur in any of the considered 
cases. Particles did deposit on the outlet extrusion wall, but these particles were not 
included in evaluations of deposition in the nasopharynx region. That is, it is assumed 
that any particles that deposit on the outlet extrusion are collected by the outlet filter. 
Solution Strategy 
As is typical for CFD simulations, the first convergence check was that the 
residuals for all transport equations fall below at least 1e-4. Flow rates through the 
pressure inlet nostrils were also checked to ensure that mass was conserved through the 
domain. Due to the difference in flow rates between the filter connection outlet and tube 
inlet, flow through both nostrils should be 1 LPM. Therefore, we were confident that mass 
through the domain was conserved if the flow rate through the pressure inlet boundaries 
is within plus or minus 0.01% of this expected value. Volume-average velocity magnitude 
and TKE were also monitored for the entire domain, and the solution was deemed 
converged when these quantities converge to a stable value with negligible fluctuation. 
During the CFD model development, we were unable to reach a converged 
solution using the steady-state formulations due to mass imbalance in a number of cells 
in the filter connection region. Further investigation of the flow field in this region showed 
an area of recirculation where the flow leaves the nasopharynx and enters the filter 
connection. Physically, this recirculating region is unstable, with the re-attachment point 
oscillating in time, making the problem fundamentally transient (time-dependent). To 
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correct this issue, we switched from the partially converged steady-state solution to a 
time-dependent formulation. This solution strategy, with an appropriately small time-step, 
allows the model to capture the physically correct oscillatory flow and reach a high degree 
of convergence, which was less than 1e-5 on all residuals. To confirm this method is valid, 
flow quantities are compared at the end of each time step to ensure there is little change 
in the flow field outside of the oscillating region. Particle DFs are also compared at the 
10th and 20th time step to make sure particle trajectories do not change with respect to 
time. For all cases considered, switching from the partially converged steady-state 
solution to transient provided excellent convergence and showed negligible change in the 
flow field and deposition characteristics. Furthermore, evaluation of the flow field revealed 
the flow recirculation was in a region outside of the infant nasal cavity and nasopharynx 
(in the filter connection), and therefore does not contribute to extrathoracic loses. 
However, the effect of flow recirculation on the in vitro deposition results is discussed in 
later sections of this study. 
Particle Injections 
In the experimental model, the tube that connects the mixer-heater device to the 
streamlined nasal cannula has a 10 mm ID, but the outlet from the mixer-heater used for 
aerosol generation is 6 mm ID. That is, the 10 mm tubing fits around the outside of the 6 
mm mixer-heater outlet, which has a 2 mm wall thickness. Therefore, particles are 
injected into the CFD model at the inlet to the tube, with a 6 mm circular diameter and a 
blunt profile distribution in space. 
Both monodisperse and polydisperse particle size distributions were evaluated in 
this study. The polydisperse size distribution used in the CFD model neglects the three 
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larger particle size bins (5.8 µm, 9.0 µm, and 10.0 µm) of the ACI analysis, as these bins 
combined account for less than 1% of the total particle mass delivered to the experimental 
model (0.28%, 0.19%, and 0.15% respectively). To ensure good particle deposition 
convergence Tian et al. (2015) recommended 10,000 particles be injected for each size 
bin, which in this case results in 60,000 total particles. To compare the total DF in each 
region of the CFD model to the experimental data, the DF for each size bin is multiplied 
by the mass of particles for that bin and divided by the total injected mass, which is then 

















where 𝑛𝑖 is the number of particles deposited for size bin 𝑖, 𝑁𝑖 is the number of particles 
that enter the CFD domain for bin 𝑖, 𝐷𝐹𝑖 is the deposition fraction for size bin 𝑖, 𝑚𝑖 is the 
mass of particles from the experimental size distribution for size bin 𝑖, 𝑀  is the total 
injected aerosol mass, and 𝜑𝑖 is the deposited mass fraction for size bin 𝑖. The region-
based DFs presented in the Results section use the above equations, with 𝑛𝑖 given as 
the number particles that deposit in a given region. 
A monodisperse aerosol is also evaluated by the CFD model to determine whether 
it gives comparable results to a polydisperse size distribution. The monodisperse particle 
size is 25% larger than the MMAD of the polydisperse aerosol, which results in 1.78 µm 
(where the measured MMAD is 1.4 µm). This approach has previously given comparable 
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results for both in vitro (Longest, Tian, Delvadia, et al., 2012) and in vivo (Longest et al., 
2015) deposition in the upper airways. Theoretically, the multiplication factor is needed 
because the particle deposition increases at a non-linear rate for an increasing particle 
diameter. For particle deposition convergence, 90,000 particles are injected into the 
domain for the monodisperse aerosol (Longest et al., 2015). The monodisperse aerosol 




The droplet size of the albuterol sulfate aerosol exiting the infant cannula was 
determined to have a mean (SD) MMAD of 1.4 (0.1) m and GSD of 1.4 (0.0) with 99.5% 
and 25.5% of the particles less than 5 m and 1 m, respectively.  
For the aerosol deposition experiments, the overall mean (SD) drug recovery was 
84.3 (3.4) % of the nominal dose. Deposition in the mixer heater was low (2.1% of the 
nominal dose) demonstrating the efficiency of the delivery system. Table 4.2 shows the 
mean (SD) experimentally determined deposition fractions expressed as a percentage of 
the recovered emitted dose from the mixer heater. Deposition on the patient interface 
(tubing and cannula) was low with only 2.23% of the dose being found in this region. 
Similarly, deposition in the infant nasal airway model was also low, with less than 5% of 
the recovered emitted dose being deposited in the combined nasal passages. For this 
micrometer-sized aerosol generated using the mixer heater, the mean drug deposition 
fraction on the respiratory filter was 92.96 %, indicating highly efficient N2L delivery under 
these steady-state inhalation flow conditions.  
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Comparison of Polyhedral and Tetrahedral Meshes 
As discussed in the Methods section, it is expected that polyhedral meshes may 
provide faster convergence than tetrahedra. Figure 4.5a and b respectively plot the 
volume-average velocity magnitude and TKE in the CFD domain against solution 
iterations for the steady-state solution of the flow field. These plots show that the 
polyhedral mesh reaches a converged solution in approximately 2,000 iterations 
compared to approximately 3,500 iterations for the tetrahedral mesh. Recall that the 
steady-state model is switched to a transient formulation, with constant boundary 
conditions, to capture flow oscillations in the filter connection and thereby enable 
convergence. Also note that the mesh-independent polyhedral case uses 3.56 million 
cells and the tetrahedral cases required 5.71 million cells. Therefore, the polyhedral mesh 
is capable of reaching a converged solution faster, and with less computational expense. 
These combined benefits of polyhedral cells result in CFD models that provide a flow field 
solution almost 3 times faster than tetrahedra, making them extremely computationally 
efficient, which is very beneficial for time-consuming transient simulations. 
In addition to improvements in processing time, polyhedral cells provide the 
benefits described in the Methods section, specifically better cell-face gradient resolution 
and reduced numerical diffusion. The accuracy of polyhedral cells is evaluated by 
comparing CFD particle deposition results with experimental data, as shown below. 
Comparison of Laminar and Turbulence Models 
A Reynolds number of approximately 900 at the 10 mm ID inlet suggests laminar 
conditions. However, changes in cross-section and flow obstructions can induce 
turbulence in the flow field, especially in regions of air jets and shear layers. Figure 4.6 
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shows iso-surfaces of turbulent viscosity ratio (TVR) in the CFD model, which is the ratio 
of turbulent viscosity to laminar viscosity. That is, a TVR of two means the turbulence in 
the flow makes the fluid twice as viscous as the laminar case. From Figure 4.6 it is clear 
that that the TVR is at least two in a large portion of the nasal cavity, and reaches a ratio 
of at least five where the flow transitions from the patient interface to nasal cavity and 
around the glottis, as it is a flow obstruction. Therefore, a turbulence model is required, in 
this case the LRN k-ω model, in order to capture the flow conditions in the CFD domain. 
The inclusion of turbulence in the model also has an influence on particle trajectories and 
deposition, as the particles interact with both the mean flow and turbulent eddies. It is 
also interesting to note that the filter connection region exhibits a large amount of turbulent 
flow, which may reduce the number of particles that reach the outlet filter and over-
estimate deposition in the nasopharynx region. 
Figure 4.7 shows the DF as a function of particle aerodynamic diameter (ρp = 1000 
kg/m3) for the laminar flow field and turbulent flow field with turbulent particle deposition, 
over a span of aerosol sizes. The MMAD of the test aerosol (1.4 µm) is labelled within 
this span. Interestingly, at this small aerodynamic diameter there is practically no 
difference between the laminar and turbulent model DFs. This is because particles less 
than approximately 1.5 µm lack sufficient inertia to remain on the random paths induced 
by turbulent fluctuations at the low level of turbulence in this flow field. They also lack 
sufficient inertia to traverse the viscous sublayer that is formed in turbulent flow. Note that 
the LRN k-ω model captures the viscous sublayer, which in this application has off-wall 
height dimension of approximately 0.25 mm, or approximately 175 times greater than the 
MMAD. In contrast, as the particle aerodynamic diameter increases beyond 1.5 µm, 
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particles are able to follow dispersion paths and reach the NW region by crossing the 
viscous sublayer. Therefore, for CFD models of aerosol deposition in the nasal airways 
to be applicable to the widest range of particle sizes, turbulence models should be 
included. In this instance, the small size of the test aerosol means that total DFs between 
laminar and turbulent models are similar. However, for an accurate and realistic 
representation of the flow field deposition across a relevant particle size distribution (i.e. 
1-7 µm), CFD models should include turbulent flow conditions and dispersion. 
Comparisons between CFD and Experimental Data 
Comparisons of the CFD monodisperse and polydisperse deposition predictions 
to experimental data are provided in Table 4.2 to Table 4.5. Table 4.2 presents the DFs 
for the laminar CFD case, Table 4.3 is the LRN k-ω case with turbulent particle dispersion 
deactivated, Table 4.4 is the LRN k-ω case with turbulent particle dispersion activated, 
and Table 4.5 is the LRN k-ω case with turbulent dispersion and NW correction UDFs. 
The difference parameter (Diff.) is defined as the absolute value of absolute difference 
between the CFD and experimental data (i.e. |DFCFD − DFExp|). All four cases show good 
agreement with the experimental data, with the highest average difference across all 
model regions being 1.75% for the polydisperse case with turbulent dispersion activated 
and without NW corrections (see Table 4.4). 
The polydisperse laminar case gives the closest match to the experimental data 
with an average difference of 0.29% across all regions and a maximum difference of 
0.68% in the anterior nose. However, from Figure 4.6 and Figure 4.7 we conclude that 
turbulence should be included in the CFD model to provide a physically realistic 
representation of flow through the domain, and be applicable to a relevant range of 
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microparticle sizes. Of the turbulent cases considered, both the monodisperse and 
polydisperse case that used NW correction UDFs gave very close matches to the 
experimental data, with average differences of 0.52% and 0.63%, respectively. It is noted 
that the NW correction UDFs used a NW limit control parameter of 2 µm on all wall 
surfaces and for both the monodisperse and polydisperse cases. This NW limit value 
corresponds well with the 1-2 µm values used by Bass and Longest (2018b) in their 
previous validation work. 
In general, the monodisperse aerosol, which has a particle size 25% larger than 
the polydisperse MMAD, under-predicts deposition in the proximal regions (nearest the 
inlet) of the nasal cavity compared to the experimental data and polydisperse deposition. 
For example, in the patient interface for the NW correction UDF case, the monodisperse 
aerosol predicts 1.21% less deposition (absolute difference) than the polydisperse case. 
In downstream regions, the monodisperse and polydisperse cases compare closely to 
one another. This is due to the larger particles in the polydisperse aerosol being filtered 
by the patient interfaces and to some extent the anterior nose, so the size distribution in 
the later stages is closer to the monodisperse aerosol. However, using a monodisperse 
aerosol with a particle aerodynamic diameter that matches the MMAD of the polydisperse 
aerosol would under-predict both regional and overall deposition in the CFD model. 
Therefore, using a representative monodisperse aerosol that is 25% larger than the 
MMAD gives a better approximation of overall deposition. 
The close comparison between each aerosol type is apparent in Table 4.2 through 
Table 4.5 and Figure 4.8, which shows particle deposition sites in the model for the 
monodisperse (Figure 4.8a) and polydisperse (Figure 4.8b) aerosols for the laminar flow 
154 
 
case. The key difference between Figure 4.8a and b is the polydisperse case highlights 
deposition hot spots that are not apparent in the monodisperse case, in particular the 
cannula bifurcation and in the nasal cavity close to the left prong. Both cases show a 
region of deposition at the rear of the nasopharynx, which is expected as this is the region 
where the bulk flow undergoes its most abrupt change in direction. Therefore, the 
polydisperse aerosol gives better physical insight, but the monodisperse aerosol gives 
good overall deposition results, and reduced computational expense. As such, there are 
benefits and drawbacks to both approaches that make them desirable for either high 
fidelity or high efficiency models. 
Figure 4.9 compares the deposition in the turbulent flow field with the standard 
dispersion model (Figure 4.9a) and with NW correction UDFs (Figure 4.9b). Figure 4.9b 
shows that applying the NW correction UDFs, with a NW limit value of 2 µm, gives a better 
overall match to the experimental DFs, and validates the CFD mesh and solution 
parameters for infant N2L aerosol administration. The standard dispersion model in 
Figure 4.9a tends to over-predict deposition in regions where there is the most change in 
flow direction, specifically the patient interface and nasopharynx. Both of these figures 
also show a large amount of deposition on the filter connection, which may suggest higher 
deposition in the in vitro nasopharynx than would occur in vivo. Based on this observation, 
future in vitro studies should consider a smaller diameter filter size to avoid unnecessary 
deposition in the filter connection and housing that would not occur in vivo. This region 
also showed a large amount of flow recirculation, which is not desirable for either a CFD 




This study demonstrates the N2L EEG approach is a viable method for aerosol 
delivery to infant lungs. The small aerodynamic diameters and low inertia allows a large 
amount of the aerosol to penetrate the nasal cavity, which results in a high lung dose with 
greater than 90% of the aerosol delivered through the connection tube. The previously 
developed CFD mesh and solution guidelines from Bass and Longest (2018b) were found 
to be appropriate for simulating microparticle deposition in the infant nasal airway based 
on good matches to experimental DFs. The best practice set-up, which includes the LRN 
k-ω turbulence model with NW corrections and follows the other recommendations in 
Table 4.1, resulted in an average absolute difference of 0.63% across all regions 
considered compared to the experimental results. The physical insight provided by the 
CFD model highlights deposition hot spots, specifically the cannula bifurcation and close 
to the prong outlets, which can be optimized in future studies to further reduce drug 
delivery loses in the patient interface and nasal cavity. The particle deposition patterns 
also show inadequacies in the in vitro model, where deposition on the filter connection 
suggests higher loses in the nasopharynx than would likely occur in a patient. 
A close match between numerical and experimental results is only possible when 
the numerical model has been appropriately developed and applied. In addition to the 
fundamental recommendations in Table 4.1, this nasal cavity simulation required 
additional key aspects to be considered. The transient nature of the flow recirculation in 
the filter connection required a time-dependent formulation and solution of the transport 
equations, despite the experimental model being run under steady-state flow conditions. 
While not surprising in hindsight, it is notable that the CFD solution would not converge 
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until the correct physics of the transient oscillatory flow were added to the solution. Correct 
prediction of particle deposition in the patient interface required an accurate spatial 
distribution for particle injection into the domain, which matched the outlet diameter of the 
mixer-heater device. In addition to previous work from our group and others (Vaish, 
Kleinstreuer, Kolanjiyil, Saini, & Pillalamarri, 2016; Y. Zhang, Finlay, & Matida, 2004) 
Table 4.3 to Table 4.5 show how the NW corrections address the over-prediction of 
microparticle deposition that is present with the standard two-equation turbulent 
dispersion model, and gives the closest match to experimental data for all turbulent cases 
considered. 
Beyond the meshing and CFD solution parameters, several other approaches to 
CFD model set-up were compared and evaluated; specifically, the mesh cell type, 
whether turbulence is required, and monodisperse and polydisperse particle size 
distributions. This study evaluated the capabilities of polyhedral cells compared to 
traditional tetrahedral cells for CFD simulations with complex geometry. The topology of 
polyhedral cells provides several numerical advantages, and results show that polyhedra 
provide a converged solution in less iterations with a lower cell count than tetrahedra, 
while also comparing well to experimental deposition data. 
With regard to flow conditions, flow and microparticle deposition in the nasal cavity 
were evaluated for both the laminar and LRN k-ω model. The laminar flow case provided 
a good match with experimental DFs, but using the LRN k-ω model gives a more 
physically realistic flow field and is suitable for a broader range of N2L applications across 
the relevant microparticle size range. Furthermore, evaluation of TVR showed regions of 
relatively high turbulence around abrupt changes in cross section and flow obstructions, 
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which must be accounted for in the CFD model. Viewed another way, running the nasal 
simulation as a laminar flow would be equivalent to conducting a physical experiment with 
a gas that had a viscosity two to five times below that of air (which does not exist), and 
assuming the fluid was air. 
The results compared both monodisperse and polydisperse aerosol deposition, 
where the monodisperse aerosol was represented with a particle size that is 25% larger 
than the MMAD of the polydisperse aerosol. The CFD model showed that the 
monodisperse aerosol can be comparable to polydisperse and experimental data for total 
and regional deposition. However, the polydisperse aerosol highlights deposition hot 
spots that are not apparent in the monodisperse case. Therefore, monodisperse aerosols 
are useful in the model development phase, as they required less computation time, but 
more accurate results require a polydisperse size distribution, which enables additional 
useful insights. 
As a secondary objective, this study demonstrates high efficiency N2L delivery 
using an aerosol with a small initial size (MMAD of 1.4 µm). The aerosol was produced 
with a mixer-heater similar to the study of Longest et al. (2013), but with a lower device 
volume and using a reduced nebulizer output. The primary advantage of this mixer heater 
system is that it employs a commercial mesh nebulizer, but uses heating elements to dry 
the droplets into smaller particles while maintaining a temperature and relative humidity 
that are safe for direct inhalation. Using this approach, lung delivery efficiencies greater 
than 90% of the aerosol that enters the connection tube were demonstrated in a 6mo 
airway model under steady state flow conditions. 
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In comparison to similar studies with infants, Lin et al. (2015) used a commercially 
available vibrating mesh nebulizer and humidifier, and evaluated delivery flow rates of 3, 
6, and 12 LPM across two different face masks for a 2-year-old nasal model. They 
reported MMADs of 2.8 µm to 3.3 µm exiting the facemask, and an inhaled mass of 2.8% 
to 6.4% (expressed as a percentage of dose loaded in the nebulizer). El Taoum et al. 
(2015) compared numerous scenarios for a 7-month-old model, including seven different 
patient interfaces, jet and vibrating mesh nebulizers, and three breathing patterns. In their 
study, lung doses (as a percent of nominal dose) range from <0.001% to 2.97%, but 
aerosol MMADs were not reported. Regarding nasal cannula systems, Sunbul et al. 
(2015) evaluated HFNC, Bubble CPAP, and SiPAP systems on a 26-week-old model 
(approximately 6 months) with different nebulizer positions, and found optimized lung 
doses (as a percent of nominal dose) of 0.79% to 1.30%. Reminiac et al. (2017) studied 
nasal high flow nebulization both in vitro and in vivo using the SAINT infant airway model 
(Janssens et al., 2001) and a non-human primate (macaque) for jet and vibrating mesh 
nebulizers, which were also placed in different locations within the system and with 
varying flow rates. They reported low aerosol MMADs at the cannula outlet, similar to the 
present study, from 1.05 µm to 1.43 µm. However, they also reported low lung doses 
ranging from 0.03% to 0.85% in vivo and 0.46% to 4.15% in vitro, due to high system 
loses in the humidifier, tubing, and cannula. 
The aerosol size considered in the current study is similar to that recommended 
by Longest et al. (2014), who demonstrated 45% to 60% lung deposition in an infant 
model of invasive mechanical ventilation. A recent correlation from Tavernini et al. (2018), 
which built upon work from Storey-Bishoff et al. (2008), estimates that for the 
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monodisperse case presented in the current study, approximately 1.23% of particles that 
enter the nostril will deposit in the cavity and nasopharynx. Furthermore, Clark et al. 
(2018) demonstrated the need for using smaller aerosol sizes to maximize lung aerosol 
delivery to pre-term infants. However, it is noted that only EEG aerosol delivery offers a 
method to retain small particles or droplets, once they are inhaled and enter the lung 
airspace. 
A primary limitation of the current study is the use of steady state inlet and outlet 
boundary conditions in both the experimental and numerical models. Infants have very 
short inhalation times. Therefore, efficient aerosol delivery will require synchronizing 
aerosol generation from the nebulizer with a portion of the inhalation period. The effective 
synchronization of the aerosol delivered to an infant was recently demonstrated by 
Dhapare et al. (2018). An additional limitation is the absence of a hygroscopic excipient 
in the test aerosol. As mentioned previously, the aerosol delivered to the experimental 
model had similar particle aerodynamic diameter to EEG aerosols, but used 0.5% w/v 
albuterol sulfate instead of an EEG formulation. Previous studies have shown that particle 
size increase has an influence on upper airway deposition (Schroeter et al., 2001; 
Walenga et al., 2014). 
This study has expanded recommendations for the accurate simulation of particle 
deposition during N2L aerosol delivery. Using these recommendations, close agreement 
between the CFD predictions and in vitro experimental results of regional drug deposition 
was attained. This study has also further demonstrated how a concurrent CFD and in vitro 
approach (Hindle & Longest, 2013; Longest & Hindle, 2009c) can lead to valuable insights 
regarding drug delivery strategies. Finally, the validated CFD model now provides a useful 
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tool to further understand and improve the N2L approach for administering 






Figure 4.1: Overview of geometry showing (a) experimental CAD model and (b) air 
interface of the CFD model. Images show the streamlined nasal cannula, three sections 





Figure 4.2: Experimental set-up schematic showing the mixer-heater aerosol 




Figure 4.3: Examples of polyhedral and tetrahedral volume meshes of the domain 
showing the (a) 5.7 million cell tetrahedral mesh, (b) 3.6 million cell polyhedral mesh at 
the inlet boundary, (c) 5.7 million cell tetrahedral mesh, and (d) 3.6 million cell polyhedral 




Figure 4.4: Summary of mesh convergence for both polyhedral and tetrahedral mesh 
types for key flow and turbulence field quantities and particle deposition characteristics; 
specifically (a) velocity magnitude, (b) turbulent kinetic energy, and (c) deposition 




Figure 4.5: Progression of volume-averaged (a) velocity magnitude and (b) turbulent 
kinetic energy during solver iterations, which shows faster convergence for the 3.6 million 




Figure 4.6: Iso-surface plots showing turbulent viscosity ratio values of 2 and 5 in (a) 
isometric, (b) side, (c) front, and (d) top views, which demonstrates large regions of the 
domain experience noticeable turbulence, especially at the interface from the cannula 
prongs to nasal cavity and around the glottis. Slices aim to show the model geometry 




Figure 4.7: Comparison of deposition profiles for laminar and turbulent with near-wall 
correction cases. Deposition fractions are similar between the two cases for small (<2µm) 
particles, but as the particle aerodynamic diameter increases (ρp = 1000 kg/m³) the 




Figure 4.8: 3D particle deposition sites, with comparisons to experimental (exp) data, 




Figure 4.9: 3D particle deposition sites, with comparisons to experimental data, for the 
polydisperse aerosol with (a) the standard turbulent dispersion model and (b) turbulent 




Table 4.1: Summary of recommended mesh and solver parameters. 
 Model/Parameter Setting/Method 
Mesh Target Wall y+ 0.5-1 
 Number of NW Layers 5 
 L2L Ratio 1.0 (may be increased with no negative effects) 
Flow Turbulence LRN k-ω 
 P-V Coupling SIMPLEC 
 Mom. & Turb. Schemes Second-order Upwind 
 Gradient Discretization Green-Gauss Node-based 
 Numerical Accuracy Double Precision 
Particles Tracking Scheme Lagrangian with Runge-Kutta 
 Turbulent Dispersion Interpolate TKE at particle location from nodes 
 Eddy Interaction Model Modified via UDF 




Table 4.2: Summary of deposition fractions for the monodisperse (Mono.) and 
polydisperse (Poly.) laminar cases. 
 Exp. Mono. Poly. 
Region Mean DF (SD) DF Diff. DF Diff. 
Patient Interface 2.23% (0.16%) 1.06% 1.17% 2.28% 0.05% 
Anterior Nose 1.11% (0.15%) 1.21% 0.10% 1.79% 0.68% 
Middle Passage 1.51% (0.26%) 1.53% 0.02% 1.50% 0.02% 
Nasopharynx 2.18% (0.87%) 1.83% 0.35% 1.79% 0.39% 
Filter 92.96% (2.93%) 94.37% 1.41% 92.64% 0.32% 
      
Average   0.61%  0.29% 
Diff. is defined as the absolute value of absolute difference between the CFD 




Table 4.3: Summary of deposition fractions for the monodisperse (Mono.) and 
polydisperse (Poly.) turbulent cases with dispersion deactivated. 
 Exp. Mono. Poly. 
Region Mean DF (SD) DF Diff. DF Diff. 
Patient Interface 2.23% (0.16%) 1.62% 0.61% 3.44% 1.21% 
Anterior Nose 1.11% (0.15%) 1.71% 0.60% 2.43% 1.32% 
Middle Passage 1.51% (0.26%) 1.43% 0.08% 1.60% 0.08% 
Nasopharynx 2.18% (0.87%) 3.07% 0.89% 2.73% 0.55% 
Filter 92.96% (2.93%) 92.17% 0.80% 89.81% 3.16% 
      
Average   0.60%  1.26% 
Diff. is defined as the absolute value of absolute difference between the CFD 




Table 4.4: Summary of deposition fractions for the monodisperse (Mono.) and 
polydisperse (Poly.) turbulent cases with dispersion activated. 
 Exp. Mono. Poly. 
Region Mean DF (SD) DF Diff. DF Diff. 
Patient Interface 2.23% (0.16%) 2.73% 0.50% 4.99% 2.76% 
Anterior Nose 1.11% (0.15%) 1.27% 0.16% 1.76% 0.65% 
Middle Passage 1.51% (0.26%) 1.42% 0.10% 1.54% 0.02% 
Nasopharynx 2.18% (0.87%) 3.00% 0.82% 3.14% 0.96% 
Filter 92.96% (2.93%) 91.58% 1.39% 88.58% 4.39% 
      
Average   0.59%  1.75% 
Diff. is defined as the absolute value of absolute difference between the CFD 




Table 4.5: Summary of deposition fractions for the monodisperse (Mono.) and 
polydisperse (Poly.) turbulent cases with near-wall correction UDFs. 
 Exp. Mono. Poly. 
Region Mean DF (SD) DF Diff. DF Diff. 
Patient Interface 2.23% (0.16%) 1.42% 0.82% 2.62% 0.39% 
Anterior Nose 1.11% (0.15%) 0.99% 0.13% 1.78% 0.67% 
Middle Passage 1.51% (0.26%) 1.15% 0.37% 1.08% 0.44% 
Nasopharynx 2.18% (0.87%) 2.42% 0.25% 2.38% 0.20% 
Filter 92.96% (2.93%) 94.03% 1.06% 91.52% 1.45% 
      
Average   0.52%  0.63% 
Diff. is defined as the absolute value of absolute difference between the CFD 
and Experimental (Exp.) data. 
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Chapter 5: CFD-based Optimization of an Inline DPI for EEG 
Tobramycin Formulations 
5.1 Objective 
The objective of this study was to implement CFD simulations to develop 
quantitative correlations that predict the aerosolization behavior of an inline air-jet DPI for 
children and then use these correlations to optimize aerosolization performance. In order 
to develop the flow-field based correlations for aerosolization performance, CFD 
simulations of four initial devices were conducted and compared with the previous 
experimentally determined aerosolization metrics reported by Farkas et al. (2019). Based 
on these findings, a second iteration of designs was developed and tested both 
experimentally and with the evolving CFD model. The complete set of ten devices was 
then used to identify the best CFD-based dispersion parameters for predicting MMAD and 
ED in the pediatric air-jet DPIs. These dispersion parameters were then used to develop 
a CFD optimized design for improved performance with increased ED and reduced 
MMAD compared with previous studies. As a final step, the best-case designs were 
produced and tested experimentally to validate the CFD predictions and optimization 
method. 
5.2 Introduction 
In the field of respiratory drug delivery, computational fluid dynamics (CFD) is 
proving to be an increasingly useful tool for the development and optimization of dry 
powder inhalers (DPIs). For example, in a series of papers, Coates et al. used CFD to 
investigate the effects of mouthpiece length and grid design (2004), capsule size (2005), 
flow rate (2005), air inlet size (2006), and mouthpiece geometry (2007) on DPI 
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performance in terms of capsule, device, and extrathoracic losses. More recently Shur et 
al. (2012) modified the air inlets of a Cyclohaler, guided by CFD analysis, to match the 
aerosolization performance of the HandiHaler.  
Our group has developed a series of high efficiency air-jet DPIs that are operated 
with 10 ml of air (via a syringe) (Farkas, Hindle, & Longest, 2018b; Longest & Farkas, 
2018; Longest, Farkas, Bass, & Hindle, 2019). These air-jet DPIs use small-gauge hollow 
capillaries that pierce a powder-containing capsule as part of loading the device, and 
serve as the air inlet and aerosol outlet. The inlet capillary supplies a high-velocity, 
compressible, turbulent jet that initially fluidizes the powder bed. It is expected that 
significant turbulence and high shear forces further break up the initially formed 
aggregates, which reduces the particle size while in the capsule chamber (Longest & 
Farkas, 2018; Longest et al., 2019). Once the size of an aerosolized aggregate is 
sufficiently reduced, it is able to escape the powder chamber through the outlet capillary 
and enter the patient interface. 
A detailed approach to modeling DPI aerosolization and transport in CFD could 
utilize Lagrangian particle tracking (Longest & Farkas, 2018; Longest et al., 2019) or 
discrete element modeling (DEM) (X. Chen, Zhong, Zhou, Jin, & Sun, 2012; Tong, Zhong, 
Yu, Chan, & Yang, 2016; Yang, Wu, & Adams, 2014) as a representation of the powder. 
However, CFD with DEM becomes computationally expensive when a complete device 
and powder dose need to be simulated in order to make design improvement predictions. 
For example, current DEM simulations that attempt to capture powder structural 
properties with particle-particle and particle-wall interactions are currently limited to one 
or two particle agglomerates (Ariane, Sommerfeld, & Alexiadis, 2018; Wong, Fletcher, 
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Traini, Chan, & Young, 2012). In contrast, an effective approach for predicting the 
aerosolization behavior of a DPI is to develop predictive correlations that relate dispersion 
parameters, which use CFD-predicted flow and turbulence quantities, to aerosolization 
performance metrics (Coates, Chan, et al., 2005; Longest & Farkas, 2018; Longest et al., 
2019; Shur et al., 2012).  
Specific to the air-jet DPI development in the current study, Longest and Farkas 
(2018) developed quantitative flow-field-based and tracer-particle-based correlations that 
related device aerosolization to flow and turbulence dispersion parameters for a very low 
volume of actuation air (i.e. 10 mL). The tracer-particle method used a relatively small 
number of Lagrangian particles, compared to modelling the entire powder bed, to sample 
turbulence and flow quantities throughout the domain. To quantify device performance, 
the aerosolization metrics of mass-median aerodynamic diameter (MMAD) and emitted 
dose (ED) (also often referred to as emitted fraction) were used. Their study showed that 
MMAD had a strong direct correlation (R2 > 0.8) with two flow-field-based dispersion 
parameters, which were a non-dimensional form of turbulent kinetic energy (k), denoted 
by 𝑘𝑓𝑖𝑒𝑙𝑑
∗ , and the product of non-dimensional k and non-dimensional specific dissipation 
rate (ω), denoted by 𝑘𝑓𝑖𝑒𝑙𝑑
∗ × 𝜔𝑓𝑖𝑒𝑙𝑑




∗ , as well as 𝑘𝑓𝑖𝑒𝑙𝑑
∗ /𝜔𝑓𝑖𝑒𝑙𝑑
∗  and wall shear stress (WSS). The predictive 
capabilities of these correlations were evaluated by Longest et al. (2019) by comparing 
the predicted MMAD and ED from CFD models to experimental results a priori, with 
results showing a low root-mean-square (RMS) error (again, for a 10 mL actuation air 
volume). The findings from these two studies demonstrated that dispersion parameters 
can be correlated to be predictive of MMAD and ED performance for air-jet DPIs. They 
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also suggested that the powder goes through a two-stage aerosolization process, where 
the first stage involves the initial dispersion from the stationary powder bed to the flow 
field, followed by secondary breakup in the high-velocity, highly-turbulent air jet. 
The present study builds upon the previous development of a high-efficiency inline 
air-jet DPI, and applies this platform to the delivery of tobramycin to children with cystic 
fibrosis (CF). A primary symptom of CF is dehydration of the airway surface liquid in the 
lungs, due to poor ion transport through epithelial cells (Matsui et al., 1998; Tarran et al., 
2001), which produces thickened mucus and poor mucociliary clearance (Stoltz et al., 
2015). Poor lung clearance and abnormal ion concentrations lead to frequent bacterial 
infections, the most predominant of which is Pseudomonas aeruginosa (Pa) (Elborn, 
2016), which can be treated by inhaled antibiotics. tobramycin was the first commercial 
inhaled antibiotic (A. L. Smith, 2002), and is available as either a solution or powder for 
nebulizers or DPIs, respectively. The efficacy of treating Pa infections with tobramycin 
was demonstrated in a clinical trial by Ramsey et al. (1999) who reported an average 
12% increase in FEV1 (forced expiratory volume over 1 second), 26% decrease in 
pulmonary exacerbations, less hospitalization, and a 1.1 log10 CFU/g reduction in Pa 
infection.  
Our group is developing a pediatric DPI for the administration of spray-dried 
excipient enhanced growth (EEG) powder formulation to children with CF as young as 2 
years old. As described by Farkas et al. (2019), the delivery system is intended to provide 
the aerosol and a full inhalation through either a sealed nasal cannula or mouthpiece 
interface. By delivering a full inhalation from a positive pressure gas source, the device 
has multiple advantages compared with typical passive DPIs including consistent 
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actuation, the flexibility of oral or nasal lung delivery, potential expansion of the upper 
airways, and resistance to exhalation through the device. The study of Farkas et al. (2019) 
previously established that improved aerosolization was achieved when all of the 
available gas flow was passed through the powder chamber. To achieve the much higher 
flow rates (~15 LPM) compared with the previous studies of Longest and Farkas (2018) 
and Longest et al. (2019) (~3 LPM), capillary diameters were increased, which alters the 
turbulence and shear stress profiles within the device. As a result, aerosolization 
characteristics and dispersion parameters are expected to be considerably different for 
the current pediatric devices compared with the previous devices that were operated with 
10 mL of actuation air.  
The proposed pediatric device for tobramycin uses an inline, positive-pressure 
actuation and air-jet aerosolization. Specifically, a standard ventilation bag is connected 
to the inlet, which provides the actuation air volume (~750 mL) and a pressure drop (~6 
kPa) across the device. The inlet capillary then supplies a high-velocity, highly-turbulent 
air jet to the capsule chamber to aerosolize the powder. Initial devices are developed for 
patients in the age ranges of 2-3, 5-6, and 9-10 years old, and aim to provide the 
inhalation volume for one breath as part of the actuation process. The present study 
focuses on the 5-6-year-old group, with a target inhalation volume of 750 mL and total 
device air flow rate of 15 LPM. 
Experimental aerosolization performance from four prototyped versions of the 
proposed pediatric air-jet DPI are presented by Farkas et al. (2019) which forms the basis 
of correlation development for the current study. The minimum device aerosolization 
performance goals of the experimental study were an ED > 85% (of loaded dose), MMAD 
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< 1.75 µm, fine particle fraction of ED < 5 µm (FPF<5µm/ED) > 90%, and FPF<1µm/ED > 20%, 
all of which were achieved by the Case 4 device (FPF<1µm/ED was 19.5%). Considering 
aerosol administration through in vitro airway models of a five-year-old child, the Case 4 
device delivered 60.7% to the tracheal filter, with 8.3% nose-throat losses, when coupled 
to the best-case nasal cannula design; and 63.8% to the tracheal filter, with 6.6% mouth-
throat losses, when coupled with the best-case mouthpiece design. This is a marked 
improvement over the typical DPI performance for aerosol administration to children that 
is reported in the literature. Specifically, for oral aerosol delivery to a 4-5 year-old in vitro 
model, Below et al. (2013) reported 5% and 22% of nominal dose deposited on the 
tracheal filter with the Novolizer and Easyhaler; and Lindert et al. (2014) reported 9% to 
11% lung delivery efficiency with the Cyclohaler, HandiHaler, and Spinhaler. For trans-
nasal aerosol delivery to children in the age ranges considered, little data is available in 
the literature. The closest available study is Laube et al. (2012) who reported <4% of 
loaded dose delivered to the tracheal filter in the 9-month-old in vitro SAINT model 
(Janssens et al., 2001). 
5.3 Methods 
The current study builds upon the initial experimental work with pediatric air-jet 
DPIs presented by Farkas et al. (2019), and the devices and results from that study are 
referred to as Experimental Iteration 1. In the current study, CFD models are developed 
for the devices in Experimental Iteration 1 and initial CFD dispersion parameters are 
calculated based on our previous work with low (~10 mL) actuation volumes (Longest & 
Farkas, 2018; Longest et al., 2019). A second round of pediatric air-jet devices is then 
prototyped and tested experimentally, which is referred to as Experimental Iteration 2. 
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New dispersion parameters, which are appropriate for the higher flow volumes of the 
pediatric air-jet DPIs (~750 mL), are then developed for both device sets (Experimental 
Iteration 1 and 2) and compared with the experimental data to determine their ability to 
predict ED and MMAD. Device optimization then begins by evaluating numerous design 
configurations with CFD and using the refined dispersion parameters to estimate 
performance. The entire experimental, CFD, and optimization approach is described in 
detail in the following sections. 
Optimization Process 
To meet the objective, the device optimization process is outlined by the block 
diagram in Figure 5.1. This process utilizes concurrent experimental and CFD models to 
provide physical insight into aerosolization performance, and iterations through the 
process aim to refine the dispersion parameters and optimize the device performance. 
The overarching aims of the process are to (i) provide an a priori validation of CFD-based 
dispersion parameter predictions of aerosolization performance and (ii) determine the 
best performing device parameters within the design space. 
The Initial Device Development stage (Figure 5.1) is largely covered by the work 
presented in our previous publications on pediatric air-jet DPI development (Farkas et al., 
2019; Longest & Farkas, 2018; Longest et al., 2019). Here the initial air-jet DPI concept 
was developed with a combination of analytical, experimental, and numerical methods. 
Fabrication of prototype air-jet DPIs uses computer aided design (CAD) models and 3D 
printing for the plastic components, with small gauge stainless steel hollow tubes used 
for the inlet and outlet capillaries. Once prototype devices are built, the Aerosolization 
Experiments stage tests the aerosolization performance (MMAD and ED) of the DPI. The 
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experimental setup uses a next-generation impactor (NGI) and high-performance liquid 
chromatography (HPLC) to determine the particle size distribution and capsule retention, 
both of which are used to establish performance metrics. In parallel to the Aerosolization 
Experiments stage, the CFD Evaluation stage uses numerical models to provide insight 
into the flow and turbulence conditions within the devices. It is expected that numerous 
CFD simulations will be conducted during the optimization process (over 100 design 
configurations), so the geometry, meshing, model set-up, and post-processing steps are 
automated as much as possible. In the Correlation Development stage, the flow and 
turbulence quantities from the CFD simulations are used to identify and develop 
dispersion parameters that are predictive of the aerosolization performance metrics. 
After predictive correlations are developed, the process loops back through the 
Aerosolization Experiments and CFD Evaluation stages to test the correlations for 
accuracy and develop insights into newly defined dispersion parameters (see Iteration 2 
in Figure 5.1). Following correlation development and testing, it is important to evaluate 
how changes to the device design influence the dispersion parameters and associated 
aerosolization performance predictions. The flow and turbulence quantities from CFD 
models of numerous design configurations are evaluated to determine trends between 
design factors and device flow characteristics. These quantities are then used in the 
dispersion parameters and correlations to provide predictions of aerosolization 
performance. Finally, the predictions of aerosolization performance from the previous 
stage are used to identify optimized device designs. The optimized device should both 
provide good aerosolization performance and be an improvement over the devices from 
Experimental Iteration 1. A priori validation of the CFD predictions was conducted by 
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producing and experimentally testing the optimized devices to determine whether the 
aerosolization performance predictions are accurate, without adjusting the models or 
correlations after the simulations are conducted. 
Experimental Materials and Powder Formulation 
Albuterol sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena, 
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France). 
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ). 
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis, 
MO). Quali-V, Hydroxypropyl methylcellulose (HPMC) capsules (size 0) were donated 
from Qualicaps (Whitsett, NC). 
Multiple batches of a spray-dried AS EEG powder formulation were produced 
based on the optimized method described by Son et al. (Son, Longest, & Hindle, 2013; 
Son, Longest, Tian, et al., 2013) using a Büchi Nano spray dryer B-90 (Büchi Laboratory-
Techniques, Flawil, Switzerland). The EEG powder formulation contained a 30:48:20:2% 
w/w ratio of AS, mannitol, L-leucine, and Poloxamer 188. 
Device Design and Experimental Methods 
The devices that were tested in Experimental Iterations 1 and 2, along with their 
inlet and outlet diameter configurations and operating conditions are summarized in Table 
5.1. The naming convention for cases in Experimental Iteration 2 gives the inlet capillary 
diameter followed by the outlet capillary diameter, as that is the primary design factor that 
was evaluated. For example, a case called 1.83/2.90 uses a 1.83 mm inlet diameter and 
a 2.90 mm outlet diameter, and all other design factors and operating conditions are the 
same as Cases 3 and 4 in Experimental Iteration 1. This includes an operating inlet 
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pressure of 6 kPa, which is easily generated with one hand operation of a pediatric size 
ventilation bag (Farkas et al., 2019). The Half Q case is the exception to this naming 
convention as it is the same device as Case 4, but implements a pressure drop of 1.5 kPa 
to reduce the flow rate through the device by a factor of two. The 1.32/2.39 case used the 
same outlet capillary diameter and pressure drop as Case 4, but included a 1.32 mm inlet 
capillary to increase flow resistance and give a similar flow rate to the Half Q case. 
Likewise, the 1.60/2.39 case used a 1.60 mm inlet capillary to give a flow rate that was 
approximately 75% of Case 4. The 2.08/2.69 case has a similar outlet to inlet diameter 
ratio (𝑑𝑜 𝑑𝑖⁄ ) as Case 4 (i.e. ~1.30). The 1.32/2.90 case has the same average capillary 
diameter (0.5 × (𝑑𝑖 + 𝑑𝑜)) as Case 4 (i.e. 2.11 mm) and tests an example where the outlet 
diameter is much larger than the inlet. Finally, the 3.00/2.08 case tests the influence of 
having a larger inlet compared to the outlet diameter, and maximizes the flow rate (and 
hence available flow energy) through the device. 
Details on the device design and experimental methods for Experimental Iteration 
1 are discussed in depth by Farkas et al. (2019). The additional experimental work carried 
out for Experimental Iteration 2 in the present study followed the same device design, 
operation, and methods as Experimental Iteration 1. In brief, a size 0 HPMC capsule was 
loaded with 10 mg of AS EEG powder formulation, and the device used hollow capillaries 
to pierce the capsule when the device was closed with a single twisting action. Actuation 
of the device passes a high velocity air jet through the inlet capillary, which aerosolizes 
the power, and the particles leave the capsule via the outlet capillary leading to the patient 
interface. In the present study, the only design factors that were manipulated were the 
inlet and outlet capillary diameters. Design factors that were kept constant included the 
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insertion length of the capillary in the capsule, capsule size, piecing angle, piercing 
location (along the long axis of the capsule), and a horizontal orientation of the device. 
Preliminary experimental work considered angling the inlet capillary relative to the outlet 
capillary, similar to Case 7 in the Longest et al. study (2019), in an effort to increase 
secondary flow, but there was little improvement in aerosolization performance. Similarly, 
preliminary work extended the outlet capillary length in an effort to expose the aerosol to 
high shear flow for a longer duration, but again there was no improvement in MMAD or 
ED compared with Experimental Iteration 1. Figure 5.2a shows a rendering of the Case 
4 device in transparent plastic, with the capsule and capillaries clearly visible. Figure 5.2b 
shows the internal flow path, which represents the computational domain for CFD models, 
and the height to which the 10 mg powder bed fills the capsule. 
All devices were actuated with a 6 kPa pressure drop via a compressed air line 
and solenoid valve. Previous results indicated very similar device performance with either 
a hand-operated ventilation bag or compressed air and solenoid valve setup (Farkas et 
al., 2019). Inlet flow rate thorough each device was recorded before loading a capsule, 
and the time of actuation (controlled by the solenoid valve) was adjusted to ensure that 
750 ml passed through the device, which is consistent with a deep inhalation volume for 
a 5-6 year old child (75% of total lung capacity) (ICRP, 1994). The aerosol 
characterization was performed using an NGI and AS drug mass was quantified using 
HPLC, with the device actuated into the NGI using a custom adaptor. After actuation, 
HPLC was used to determine recovered drug masses in the capsule and device, and the 
amount of powder that deposited on each stage of the NGI. As minimal size change is 
expected in the aerosol under ambient temperature and relative humidity (RH) conditions, 
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experiments were conducted with ambient air (T = 22°C ± 3°C and RH= 50% ± 5%) with 
the NGI at room temperature. AS quantification was performed with a validated HPLC 
method using a Waters 2695 separations module with a 2475 fluorescence detector 
(Waters Co., Milford, MA). Chromatography was performed using a Restek Allure PFP 
150 mm × 2.1 mm column (Bellefonte, PA). The mobile phase, consisting of methanol 
and ammonium formate buffer (20 mM, pH 3.4) in a ratio of 70:30, respectively, was 
eluted at a flow rate of 0.4 mL/min and the detector was set to an excitation wavelength 
of 276 nm and emission at 609 nm. The column temperature was maintained at 25 °C, 
and the volume of each sample injected was 100 μL. The limit of quantification was 0.5 
µg/ml (Behara, Longest, et al., 2014b; Son, Longest, & Hindle, 2013). The recovered dose 
from HPLC analysis for all experimental data presented in this study was greater than 
90%. 
The ED was defined as the difference between the loaded AS dose and the mass 
of AS retained in the capsule and device after one actuation, divided by the loaded dose, 
and expressed as a percentage. The MMAD was identified with linear interpolation of a 
cumulative percentage drug mass vs. cut-off diameter plot from the NGI. The cut-off 
diameters of each NGI stage were calculated using the formula specified in USP 35 
(Chapter 601, Apparatus 5) for the operating flow rate of 45 LPM. The exception in the 
present study is that the higher flow rate of some devices required the NGI to be operated 
at a flow rate of 60 LPM. To account for this when determining the MMAD for these 
devices, the cut-off diameters were recalculated using the formula from USP 35 for a flow 




The computational domains and meshes were generated according to our 
previously established best practices (Bass & Longest, 2018b; Longest & Holbrook, 2012; 
Longest & Vinchurkar, 2007a). Meshes were composed of very high quality hexahedral 
cells, with orthogonality greater than 0.25, and followed a similar construction style as our 
previous air-jet DPI studies (Longest & Farkas, 2018; Longest et al., 2019). To reduce the 
time required for CFD model development, geometry and mesh generation were 
automated as much as possible using an input file with design parameters and 
automation scripts, as it was expected that numerous design configurations would be 
explored during the optimization process. This automation reduced the time to create 
each mesh from approximately an hour of repetitive manual work to less than two 
minutes, and minimized the possibility of human error. To confirm mesh independent 
results, CFD quantities specific to flow, turbulence, and compressibility were evaluated 
for a coarse (230,208 cells), medium (496,128 cells), fine (976,000 cells), and extra fine 
(2,044,588 cells) mesh that represented the Case 4 device configuration, with mesh 
independence established between the fine and extra fine mesh. Between these two 
meshes, the volume-averaged velocity magnitude had an absolute difference of -0.05 m/s 
(-0.30% relative difference), the volume-averaged turbulence kinetic energy had an 
absolute difference of -0.02 m2/s2 (-0.19% relative difference), and the inlet and outlet 
volumetric flow rates had an absolute difference of -0.102 LPM and -0.103 LPM 
respectively (-0.54% and -0.53% respectively). This mesh resolution is also consistent 
with the cell counts used in our previous air-jet DPI CFD work (Longest & Farkas, 2018; 
Longest et al., 2019). 
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For Experimental Iteration 1, cases have inlet boundary Mach and Reynolds 
numbers ranging from 0.18-0.27 and 6,300-13,200 respectively. These cases are below 
the recommended Mach number threshold of 0.3 for compressible flow, but the ideal gas 
law for density modelling was implemented to be consistent with previous DPI studies 
(Longest & Farkas, 2018; Longest et al., 2019) and to ensure CFD models are capable 
of handling higher inlet velocity if the flow rate is increased during optimization. Based on 
inlet Reynolds numbers, some cases exhibit highly turbulent behavior, and at the very 
least flow is beyond the transitional regime. As such, the low-Reynolds number (LRN) k-
ω turbulence model was implemented, which has been extensively validated for drug 
delivery applications by our group (Bass & Longest, 2018b; Longest, Son, et al., 2013; 
Longest & Vinchurkar, 2007b), and was shown give a good compromise between 
computational accuracy and efficiency. Despite very high inlet Reynolds numbers, the 
LRN correction was applied to account for the possibility of low turbulence regions within 
the domain, particularly at locations far from the inlet capillary jet. The form of the LRN 
corrections makes the model applicable to both high and low turbulence regions, as the 
eddy viscosity damping coefficient approaches unity in regions of high turbulence and 
hence has little effect. Based on the presence of a high velocity inlet jet and compressible 
flow, shear flow corrections and compressibility effects were also implemented (Wilcox, 
1998). 
Consistent with our previous air-jet DPI CFD studies (Longest & Farkas, 2018; 
Longest et al., 2019), a steady-state approach for transport equation discretization would 
not provide a converged solution due to the presence of relatively high frequency (~1000 
Hz) flow oscillations. As such, the CFD model used a partially converged steady-state 
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solution as the initial condition, then switched to a transient approach, with a time step of 
1e-4 s that provided good convergence and accurately resolved the flow oscillations. 
Differences between volume-average flow and turbulence quantities were observed to be 
negligible after approximately 100 time-steps, suggesting that start-up effects had 
dissipated. As dispersion metrics are based on volume-average quantities, it is expected 
that this solution strategy will be capable of providing predictive correlations, as was the 
case when a similar approach was implemented by Longest and Farkas (2018). 
Both flow-based and particle-based dispersion parameters were originally 
presented by Longest and Farkas (2018), which demonstrated the predictive capabilities 
of CFD models for DPI aerosolization performance. The former used volume-averaged 
flow and turbulence quantities as the basis of the dispersion parameters, and the latter 
used tracer particles to sample flow and turbulence quantities as their trajectories moved 
from the powder bed and through the domain. As both flow-based and particle-based 
dispersion parameters performed well in previous studies, the current study will analyze 
an extended set of flow-based parameters, which reduces overall processing time. 
All flow and turbulence transport equations were solved using ANSYS Fluent 
v19.0, including the necessary sub-models and corrections described previously. CFD 
models adhered to the recommended guidelines presented by Bass and Longest (2018b), 
in particular the implementation of the Green-Gauss Node-based method for gradient 
discretization. Spatial discretization of transport equations, including k and ω, were 
second-order accurate. Convective terms used a second-order upwind scheme and 
diffusion terms used central difference. Further details on the mass, momentum, and 
turbulence transport equations are available in other publications (Longest et al., 2007; 
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Longest, Vinchurkar, & Martonen, 2006). As with the meshing stage of CFD model 
development, the setup in ANSYS Fluent that was required for each case was automated 
as much as possible by utilizing the scripting capabilities of the Fluent text user interface.  
In all experimental runs, the DPI was activated by applying a 6 kPa pressure drop 
across the device. The CFD models implement this pressure gradient with a pressure 
inlet boundary condition set to 6 kPa and a pressure outlet boundary condition set to 0 
kPa, with all pressures given as gauge pressure. The pressure difference between the 
inlet and outlet boundary drives flow through the computational model, and the device 
geometry determines flow resistance and hence the volumetric flow rate. As an initial 
validation check of both the model selection and boundary conditions, the inlet flow rate 
between CFD models and available experimental flow rate data was compared to ensure 
the numerical results were similar to the actual devices. On average, the absolute 
difference between CFD and experimental flow rate differed by approximately 1 LPM, or 
a relative difference of 6%. Generally, the CFD over-predicted flow rate compared to the 
experimental results, which can be attributed to the surface roughness of plastic 
components increasing flow resistance and minor simplifications of the geometry in the 
CFD model.  
Dispersion Parameters 
The CFD-predicted dispersion parameters used in the current study and previous 
work by our group (Longest & Farkas, 2018; Longest et al., 2019) use flow and turbulence 
quantities to characterize the conditions that drive powder aerosolization within in the 
pediatric air-jet DPI. Flow quantities are generally ubiquitous and well understood across 
all scientific fields, such as inlet flow velocity, but turbulence quantities are less common 
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in fields outside of CFD, such as turbulent kinetic energy (k) and specific dissipation rate 
(ω). In turbulence modeling, the flow velocity is typically decomposed into time-averaged 
and fluctuating components. The time-averaged component is the mean flow through the 
domain and is represented by ?̅?, ?̅?, and 𝑧̅ in the x-, y-, and z-directions, respectively. The 
fluctuating velocity component represents the random and chaotic instabilities that the 
turbulent eddies contribute to the flow, and is represented by 𝑢′, 𝑣′, and 𝑤′ in the x-, y-, 
and z-directions, respectively. The combination of mean (time-averaged) and fluctuating 
velocity components provides the instantaneous flow field velocity, i.e. 𝑢 = ?̅? + 𝑢′ . 
Turbulent kinetic energy (k) is the specific energy (per unit mass) that turbulence 





(𝑢′2̅̅ ̅̅ + 𝑣′2̅̅ ̅̅ + 𝑤′2̅̅ ̅̅ ̅) 
(5.3.1) 
with units [m2/s2]. A common analogy to describe the mean and fluctuating velocity 
components is to consider a probe that samples instantaneous velocity at a single point 
in a turbulent flow. The resultant sampling trace would show erratic oscillations in velocity 
against time. In this case, the mean velocity (?̅?, ?̅?, and 𝑧̅) would be the time-averaged 
value of the oscillations, and the fluctuating component is the difference between the 
instantaneous and mean velocity across any given time integration (White, 1991). 
The second modeling quantity used in the two-equation k-ω model is the specific 












with units [1/s], where 𝑙  is the turbulence length scale and 𝐶𝜇  is an empirical model 
constant (typically set to 0.09 as default). Physically, the specific dissipation rate 
represents the rate at which turbulent energy (per unit mass) is converted to internal flow 
energy. The presence of turbulence in the flow field contributes to the diffusive behavior 
of the fluid with an effect similar to kinematic viscosity (𝜈). To model this additional 








with units of [m2/s]. 
In the dispersion parameters, flow and turbulence quantities are calculated as 
volume-averaged values within the region of the capsule and outlet capillary. With 
turbulence kinetic energy as an example, the volume-averaged quantities within the 










where 𝑉𝑇  is the volume of the capsule and outlet capillary, 𝑘𝑖  is the turbulent kinetic 
energy in Cell 𝑖, 𝑉𝑖 is the volume of Cell 𝑖, and the summation is across all cells in the 
capsule and outlet capillary region. 
Evaluation of preliminary dispersion parameters began by identifying the 
correlation strength between experimental aerosolization metrics and the CFD-based 
parameters presented by Longest and Farkas (2018), which were developed for low-
volume devices (10 mL of actuation air) operated at higher pressures. In that study, the 
MMAD correlated well with 𝑘𝑓𝑖𝑒𝑙𝑑
∗  (ratio of volume-averaged k to inlet velocity squared) 
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giving an R2 value of 0.87, and with 𝑘𝑓𝑖𝑒𝑙𝑑
∗ × 𝜔𝑓𝑖𝑒𝑙𝑑
∗  (where 𝜔𝑓𝑖𝑒𝑙𝑑
∗  is ω non-dimensionalized 
with a characteristic time scale) giving an R2 value of 0.94. However, correlations of these 
dispersion parameters to MMAD for Experimental Iteration 1 devices in this study were 
not as strong, with R2 values less than 0.6. Other dispersion parameters from the previous 
paper were also considered for MMAD correlation, but did not achieve an R2 value greater 
than 0.8. For ED, the previous Longest and Farkas study (2018) showed that 𝑘𝑓𝑖𝑒𝑙𝑑
∗  and 
𝑘𝑓𝑖𝑒𝑙𝑑
∗ × 𝜔𝑓𝑖𝑒𝑙𝑑
∗  had a strong correlation with R2 values of 0.96 and 0.98 respectively, again 
for different low-volume high pressure devices. Though similar to MMAD in the present 
study, these dispersion parameters did not show the same correlation strength to ED with 
Experimental Iteration 1, with R2 values again below 0.6. Therefore, new dispersion 
parameters were required that were developed specifically for this pediatric air-jet DPI 
and its operating conditions. 
In parameter development for the pediatric air-jet DPI, approximately 40 dispersion 
parameters were correlated with both MMAD and ED. These dispersion parameters used 
various combinations of variables for flow quantities, turbulence characteristics, design 
parameters, and operating conditions. The strongest correlations (R2 > 0.8) from this new 
batch of dispersion parameters for Experimental Iteration 1 were identified and the 
variables used in their development were tested for accuracy and robustness in 
Experimental Iteration 2. The strength of correlation for the new dispersion parameters 
developed in the present study are given in the Results section. They are summarized 
here to discuss the variables from which they are constructed and how they aim to 
describe the device flow conditions.  
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For MMAD, the dispersion parameters that gave to the strongest correlation with 
Experimental Iterations 1 and 2 (R2 > 0.8) are summarized in Table 5.2. To improve 
correlation agreement with the MMAD experimental data, a common theme in all of the 
dispersion parameters was the inclusion of the actuation pressure, or Δ𝑃 , which 
represents the input flow energy per unit volume (J/m3). The dispersion parameter that 





where 𝑑∗  is the ratio of outlet to inlet capillary diameters and 𝑣𝑖  is the inlet capillary 
velocity. The physical basis for this dispersion parameter is the input turbulent kinetic 
energy (𝑘 in J/kg) per input flow energy (Δ𝑃 in J/m3). Division by air density can be used 
to eliminate the differing basis of the energy terms, but it is not necessary considering 
that all cases are actuated with room air. Based on trial and error experimentation, the 
correlation with MMAD was significantly improved by multiplying the dispersion parameter 
by 𝑑∗/𝑣𝑖, similar to the result of Longest et al. (2018). 
The Δ𝑃/𝑘∗𝑑∗ parameter in Table 5.2 is similar to Equation (5.3.5), but the ratio of 
k to inlet velocity is non-dimensionalized as it was by Longest and Farkas (2018). The 
numerators and denominators are also reversed as this gave a better R2 value. The 
𝑘𝜇/𝑣𝑖Δ𝑃𝑑𝑜 parameter again includes similar variables as the previous two parameters, 
but uses inspiration from the Bejan number (Bhattacharjee & Grosshandler, 1988) (Be =
Δ𝑃𝐿2/𝜇𝑣, which represents a non-dimensional pressure drop) to non-dimensionalize the 
parameter. The 𝑘∗𝜔∗𝑑∗  parameter applies the ratio of outlet to inlet diameter to the 
𝑘∗ × 𝜔∗ parameter from Longest and Farkas (2018), which had a positive influence on the 
R2 value for all cases considered. Finally, the 𝑣𝑖
′𝑑∗/𝑣𝑖Δ𝑃 parameter is again similar to the 
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first dispersion parameter discussed here, but the ratio of k to inlet velocity is non-
dimensionalized by using the fluctuating velocity component (𝑣′ = √2/3𝑘) instead of k.  
For ED, the dispersion parameters that gave to the strongest correlation with 
Experimental Iteration 1 and 2 (R2 > 0.8) are summarized in Table 5.3. In contrast to 
Longest and Farkas (2018), none of the dispersion parameters that utilize a combination 
of flow and turbulence quantities (such as 𝑣𝑖 and 𝑘) had a strong correlation with ED in 
the current study, which evaluates a pediatric air-jet DPI as opposed to a low actuation 
volume DPI. All dispersion parameters for ED presented in this study use inlet volumetric 
flow rate (𝑄𝑖) with a scale factor as a prediction of aerosolization performance. The scale 
factors that were most effective were 𝑑∗, 𝑘, and 𝑑𝑜, which all improved the correlation 
from an R2 value of 0.74 to over the threshold of 0.8 for a strong correlation in this study. 
Evaluation and Comparison Criteria 
This study uses the following metrics to quantify device performance 
improvements, compare the match between experimental and CFD results, and 
determine the accuracy of dispersion parameter predictions. 
The Relative Δ metric compares the predicted aerosolization performance of 
design configurations with Experimental Iteration 1, in order to quantify performance 
improvements over the initial designs. It is defined as the difference between the CFD-
predicted MMAD ( MMADCFD ) and the estimated MMAD ( MMADEst ), based on the 
estimated MMAD from Experimental Iteration 1, relative to the estimated MMAD: 
 





Specifically, estimated MMAD (MMADEst) is determined from the experimental data by the 
linear line of best fit between MMAD and ED for Experimental Iteration 1, which is 
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hereafter referred to as Experimental Iteration 1 Best Fit. That is, if a device configuration 
has a predicted MMAD and ED that lies on Experimental Iteration 1 Best Fit, its Relative 
Δ is zero and there is no improvement over the initial devices. If the Relative Δ is negative, 
its MMAD is smaller than would be predicted by ED alone, based on the results from 
Experimental Iteration 1, and vice versa for a positive Relative Δ. Therefore, a negative 
Relative Δ shows an improvement in aerosolization performance over Experimental 
Iteration 1 for a given ED. 
Relative difference (Rel. Diff.) is a standard statistical measure, but has different 
definitions given the application. In this instance, the difference is between the CFD-
predicted and experimental (Exp) MMAD or ED, relative to the experimental value: 
 
Rel. Diff. =  
MMADCFD − MMADExp
MMADExp





This provides a basis for comparison between the CFD-predicted and experimentally 
determined aerosolization performance. 
RMS error is also commonly used in statistical methods. It is the square-root of the 
sum-square of the difference between CFD-predicted and experimental results divided 
by the number of data points: 
 RMS Error
= √











This quantifies the error between the CFD-predicted and experimentally observed 




First and Second Experimental Iterations 
Figure 5.3 plots the MMAD against ED for Cases 1-4 from Experimental Iteration 
1, and the dashed line is Experimental Iteration 1 Best Fit (R2 = 0.98). The numerical 
annotations in the plot correspond to the markers for each device in Table 5.4. This plot 
shows that for these cases, increasing ED also increases MMAD. This is undesirable for 
DPI aerosolization performance, as we want both a small MMAD and large ED to deliver 
as much drug to the target area of the lungs as possible. Therefore, for improvement in 
aerosolization performance we intend to develop devices that perform below this dashed 
line. That is, for a given ED, the MMAD should be smaller than estimated from the linear 
fit performance of Experimental Iteration 1. 
Experimental Iteration 2 intended to test the accuracy and robustness of initial 
dispersion parameter development, identify additional dispersion parameters, and 
evaluate what aspects of device design and operation would plot MMAD and ED above 
or below the Experimental Iteration 1 Best Fit. Figure 5.4 adds the MMAD and ED data 
from Experimental Iteration 2 (Table 5.4) to Figure 5.3. The numeral annotations in the 
plot correspond to the markers for each device in Table 5.4. From this figure it is clear 
that the majority of cases exhibited similar or worse performance than Experimental 
Iteration 1, as they plot close to or above the dashed line. The exception is Case 3.00/2.08 
(VI), which has an MMAD that is approximately 0.5 µm smaller than what is expected 
from its ED and performance estimations from Experimental Iteration 1.  
The experimental results from Experimental Iteration 1 and 2, with CFD predictions 
of the flow and turbulence fields for each device, were used to develop the dispersion 
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parameters for MMAD and ED that were summarized by Table 5.2 and Table 5.3, 
respectively. The strength of MMAD and ED correlations that use these parameters is 
presented in subsequent sections. In line with the study objective, CFD-predictions of 
aerosolization performance use the dispersion parameters, and their associated 
correlations, to drive optimization of the device design. 
Flow and Turbulence Characteristics 
Before presenting details on the dispersion parameters, aerosolization 
performance, and device optimization, it is important to understand the flow field behavior 
and characteristics within the device. As mentioned in the Methods, the flow is highly 
turbulent and moderately compressible, with inlet Reynolds numbers over 10,000 and 
Mach numbers up to 0.27 for the cases in Experimental Iterations 1 and 2. Figure 5.5 
shows contours of k and velocity streamlines within the capsule of Case 4. The highest 
level of turbulence, represented with k, occurs in the shear layer where the inlet jet meets 
the relatively quiescent flow in the capsule, which propagates through the outlet capillary. 
There is also a large velocity gradient between the center of the inlet jet and the dose 
chamber. Points A (center of the jet) and B (top of powder bed) in Figure 5.5 have velocity 
magnitudes of 110.36 and 4.39 m/s respectively (or Mach numbers of 0.32 and 0.01) with 
only 1.88 mm between them. The velocity streamlines in Figure 5.5 demonstrate very 
dynamic and chaotic behavior in the secondary flow patterns within the capsule. 
As mentioned previously, preliminary experimental work tested whether angled 
inlets or a longer outlet capillary would improve aerosolization performance with 
increased secondary flow or more exposure to highly turbulent flow, respectively. It is 
reasonable to expect that increased secondary flow patterns would entrain more particles 
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from the powder bed and provide an improvement in ED. However, the preliminary work 
showed little aerosolization improvement for devices with an inlet capillary angled at 30°, 
60°, and 90° relative to the long axis of the capsule. CFD-predictions of secondary flow, 
with the stream-wise flow considered to be aligned with long axis, also did not correlate 
well with ED. It is also reasonable to expect that exposing particle agglomerates to highly 
turbulent flow for a longer duration would aid secondary breakup and reduce MMAD. 
However, extending the length of the outlet capillary from 18 mm to 30 mm and 60 mm 
also showed negligible improvement in aerosolization performance.  
This raises questions over the mechanisms within the device that are responsible 
for the most effective forms of powder aerosolization. The large velocity gradient between 
the inlet jet and remainder of the capsule region creates the correct amount of secondary 
flow in order to maintain a high ED and not fluidize the powder bed too quickly. Also, the 
maximum k to which particle agglomerates are exposed may drive secondary breakup 
and determine particle size, as opposed to time of exposure. That is, if agglomerates pass 
through the region of highest energy eddies and break up as small as that energy permits, 
additional exposure time to smaller energy eddies may not reduce the particle size further. 
This observation would explain why a longer outlet capillary length did not further reduce 
MMAD. 
Particle Size and Emitted Dose Dispersion Parameters 
Figure 5.6 plots MMAD as a function of the dispersion parameter from Table 5.2 
with the strongest correlation. For the 𝑘𝑑∗/𝑣𝑖Δ𝑃 dispersion parameter, the R
2 value is 
0.96 and standard error (SE) is 0.06 µm when correlated with MMAD. The dashed line on 
the plot is the linear line of best fit between cases considered, and represents the 
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correlation used to predict MMAD from the dispersion parameter. Considering the 95% 
interval on a normal distribution, we can assume the correlation is accurate between plus 
or minus double the SE, which is 0.12 µm and represented by the solid lines on Figure 
5.6. For context, the coefficient of variation (CoV) is defined as the ratio of SE to the mean 
MMAD, which in this case is 3.3%. 
The high R2 value, small SE, and small CoV demonstrates a very strong correlation 
between MMAD and the 𝑘𝑑∗/𝑣𝑖Δ𝑃  dispersion parameter. Beyond the statistical 
measures, the plot of data points for each case relative to the linear correlation line also 
suggests the 𝑘𝑑∗/𝑣𝑖Δ𝑃 dispersion parameter will accurately predict MMAD from CFD 
results. The correlation closely matches the full range of data points, from devices with a 
relatively small (1.6 µm) to larger (2.4 µm) MMAD, and also captures the effect of 
operating Case 4 with a lower pressure drop with the Half Q case. Furthermore, the 
correlation provides an accurate prediction for Case 1.32/2.90, with its MMAD in the 
middle ground between the 1.6-1.8 µm cases and the 2.4 µm Half Q case, which further 
demonstrates the correlation is accurate across a range of dispersion parameters and 
MMAD values. Finally, CFD results for Case 1.32/2.39 and 2.08/2.69 both show these 
devices had very similar dispersion parameter values, and the correlation is able to 
accurately predict they have the same MMAD. That is, if these cases had the same 
dispersion parameter value, but very different experimentally determined MMADs, the 
correlation would clearly be inaccurate. 
Similar to the MMAD dispersion parameters, Figure 5.7 plots ED as a function of 
the dispersion parameter from Table 5.3 with the strongest correlation. As before, the 
dashed line is the linear correlation (or line of best fit) and the solid lines represent plus 
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or minus double the SE (or the 95% interval on a normal distribution). For the 𝑄𝑑∗ 
dispersion parameter, the R2 value is 0.86, the SE is 3.0%, and CoV is 3.8% when 
correlated with ED. As mentioned previously, out of all the dispersion parameters 
considered, the device ED consistently showed the best correlations with parameters that 
used the flow rate (𝑄) through the device. Correlating ED with 𝑄 alone showed an R2 
value of 0.74, and scaling by the variables summarized in Table 5.3 improved the 
correlations.  
 Influence of Design Factors on Dispersion 
To be predictive of device aerosolization performance, it is necessary to 
understand how the CFD-predicted flow and turbulence variables in the MMAD and ED 
dispersion parameters behave in response to design factor changes. These variables are 
volume-averaged turbulent kinetic energy (𝑘) and inlet capillary velocity (𝑣𝑖) in the MMAD 
dispersion parameter, and inlet volumetric flow rate (𝑄𝑖) in the ED dispersion parameter, 
with 𝑣𝑖 directly calculated from 𝑄𝑖. Figure 5.8 is a 3D surface plot of the CFD-predicted k 
vs. inlet and outlet capillary diameters on the independent axes; and Figure 5.9 shows 
CFD-predicted Q vs. inlet and outlet capillary diameters. These data points are the result 
of running an array of 144 CFD models for every possible combination of 12 different inlet 
and outlet capillary diameters ranging from 0.41 to 3.00 mm. An effort was made to 
combine the inlet and outlet diameters into a single function that could describe the device 
behavior, with respect to the dispersion parameter variables, in a standard x-y plot. 
However, the clearest representation of how the flow and turbulence quantities vary in 
response to design factor changes is with a 3D surface plot, as both 𝑘  and 𝑄𝑖  are 
dependent on 𝑑𝑖 and 𝑑𝑜 by different relations. To estimate variable values in between the 
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CFD-predicted data points, one could define a high-order bivariate polynomial to establish 
a surface of best fit. However, in this case, the large number of CFD simulations was 
sufficient to identify design factor configurations that were possible candidates for an 
optimized device. 
Considering both Figure 5.8 and Figure 5.9 together, there is a region where 𝑑𝑖 
and 𝑑𝑜  are greater than 2.5 mm that shows k decreases (reducing MMAD) while Q 
continues to increase (improving ED). This region of high Q and decreasing k is labeled 
with ✱ in Figure 8 and Figure 9. Combining this with the MMAD and ED dispersion 
parameters (𝑘𝑑∗/Δ𝑃𝑣𝑖  and 𝑄𝑖𝑑
∗ respectively), Figure 5.8 and Figure 5.9 suggest that 
device configurations in this region would give a small MMAD and high ED, which is the 
desirable aerosolization performance. For a constant Δ𝑃  and 𝑑∗ , reducing 𝑘  and 
increasing 𝑣𝑖 would give a smaller MMAD dispersion parameter and predicts a smaller 
particle size. Likewise, for a constant 𝑑∗, increasing 𝑄𝑖 would give a larger ED dispersion 
parameter and predict less device losses. However, the predicted aerosolization 
performance from design factors is not quite as simple as what has been described here, 
as changing the inlet and outlet capillary diameters also changes the 𝑑∗ variable, which 
has an effect on both the MMAD and ED dispersion parameters. Furthermore, the Q 
through the devices in the region where 𝑑𝑖 and 𝑑𝑜 is greater than 2.5 mm is over 20 LPM, 
which for an inhalation volume of 750 mL gives an actuation time of less than 2 seconds. 
Therefore, the Q for these devices might be too high for the target age of a 5-6-year-old 
subject. That said, it is valuable insight for developing devices that may target older 
patients that inhale at higher flow rates. One final consideration regarding actuating DPIs 




𝑑𝑎 is aerodynamic particle diameter) may be higher, which would suggest the possibility 
of increased extrathoracic losses (Golshahi, Noga, Thompson, & Finlay, 2011; Javaheri 
et al., 2013; Storey-Bishoff et al., 2008; Tavernini et al., 2018). 
Aerosolization Performance and Device Optimization 
As described above, possible device design configurations from 12 inlet and outlet 
capillary diameters were considered, ranging from 0.41 to 3.00 mm, which required the 
evaluation of 144 CFD models. The majority of these models, especially those with 
relatively small capillary diameters, showed little improvement over Case 4, which has 
exhibited the best aerosolization performance from Experimental Iteration 1 and 2. Table 
5.5 summarizes the CFD-predicted aerosolization performance, from flow and turbulence 
quantities and dispersion parameter correlations, of 25 cases that had inlet and outlet 
diameters greater than 1.83 mm (as this is the inlet capillary diameter for Case 4). The 
naming convention for the markers, which are used in subsequent plots to identify each 
case, uses the first letter to identify the inlet capillary diameter and the second letter for 
the outlet, where A is 1.83 mm, B is 2.08 mm, C is 2.39 mm, D is 2.69 mm, and E is 3.00 
mm. The cases with markers highlighted in light grey are those where CFD-based 
predictions suggest that both the MMAD and ED will be better than the aerosolization 
performance of Case 4, and makers highlighted in dark grey are predicted to be worse 
than Case 4. Here, better means the CFD-predicted MMAD and ED plot below 
Experimental Iteration 1 Best Fit. What is most interesting from this data set is the CFD-
based predictions show that ED can increase as MMAD decreases (as Figure 5.8 and 
Figure 5.9 suggested), which was not apparent from Experimental Iteration 1. For 
example, for Case AD and CD, the inlet diameter changes from 1.83 mm to 2.39 mm and 
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outlet diameter is constant at 2.69 mm, with the CFD-predicted MMAD improving from 
1.92 to 1.75 µm and ED improving from 87.7% to 92.7%. Conversely, in Experimental 
Iteration 1, Case 3 and 4 had the same outlet diameter, but inlet diameters of 2.39 mm 
and 1.83 mm respectively, and they showed little difference in aerosolization, with Case 
4 having a marginally better ED. 
Figure 5.10 adds the MMAD and ED data for the cases that CFD-based predictions 
suggest are better than Case 4 (i.e. the light grey cases in Table 5.5) to Figure 5.4. The 
additional annotations in the plot correspond to the markers for each case in Table 5.5. 
As mentioned previously, cases that plot below the dashed line exhibit an improvement 
in aerosolization performance compared to Experimental Iteration 1. The Evaluation and 
Comparison Criteria section defined the Relative Δ metric that compares the estimated 
MMAD (for a given ED) with the performance of devices from Experimental Iteration 1. 
This provides a quantitative value to measure the difference between the CFD-based 
predictions and the dashed line in Figure 5.10. Table 5.6 summarizes the Relative Δ 
metric for each of the cases added to Figure 5.10, with a negative value indicating the 
performance is an improvement over Experimental Iteration 1 and the value quantifying 
the percentage improvement in aerosolization performance. From all the design 
configurations considered here, Case 2.69/2.69 and 3.00/2.69 (DD and ED) are selected 
for device optimization evaluation as they are predicted to have a smaller MMAD than 
Case 4, a negative Relative Δ, and an ED greater than 90%. These two cases are 
highlighted with the dotted ellipse in Figure 5.10. 
Figure 5.10 also provides a comparison between the CFD-based predictions and 
experimentally measured MMAD and ED for Cases 3 and 4. These data points lie within 
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the SE of the MMAD and ED correlation and the standard deviation (SD) of the 
experimental data. The accuracy of CFD-based predictions, with statistical observations, 
is discussed in greater detail in the following section. 
Experimental Validation 
Table 5.7 summarizes the comparison between CFD-based predictions and 
experimentally measured MMAD and ED for all experimentally tested devices. The 
comparison to Experimental Iteration 1 and 2 serves as the typical validation of CFD 
methods and the dispersion parameter correlations with experimental data. The 
comparison with the two optimized devices provides an a priori validation of the 
optimization process. That is, the CFD-based predictions of the MMAD and ED for those 
two design configurations were established before validating their accuracy with 
experimental testing, and no adjustments to either the CFD models or dispersion 
parameter correlations were made after obtaining the experimental data. The relative 
difference (Rel. Diff.) in Table 5.7 uses the standard definition for observed and predicted 
data. The average Rel. Diff. between CFD-based predictions and experimental 
measurements for MMAD is 2.9%, and the range of absolute error is from -0.07 to 0.13 
µm (Case 1 and Case 2.69/2.69 respectively). Similarly, for ED the average Rel. Diff. is 
3.5% and the range of absolute error is from -7.9% to 5.6% (Case 3.00/2.08 and 1.32/2.90 
respectively). The RMS Error for MMAD and ED is 0.06 µm and 3.4% respectively, which 
compares well with the SE from each of the MMAD and ED dispersion parameter 
correlations. Based on these statistical measures, the CFD flow and turbulence fields with 
𝑘𝑑∗/Δ𝑃𝑣𝑖  and 𝑄𝑑
∗  dispersion parameters provide a very good prediction of device 
aerosolization performance, verified with a priori validation. 
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Finally, the design configurations that were selected as candidates for optimized 
devices provided improved aerosolization performance compared to Case 4. The MMAD 
decreased from 1.69 µm to 1.55 µm and 1.59 µm, which is an absolute difference of 0.14 
µm and 0.10 µm, for Cases 2.69/2.69 and 2.69/3.00, respectively. Similarly, the ED 
increased from 86.0% to 90.4% and 92.3%, which is an absolute difference of 4.4% and 
6.3%. This device optimization would not be possible without the insight into the 
relationship between aerosolization performance and design factors that was possible 
with a concurrent CFD and experimental approach. 
5.5 Discussion 
This study meets the objective by establishing dispersion parameter correlations 
(𝑘𝑑∗/Δ𝑃𝑣𝑖 and 𝑄𝑑
∗) that accurately predict the aerosolization performance (MMAD and 
ED) of a pediatric air-jet DPI. Using these dispersion parameters, a full sweep of 144 CFD 
models, covering every configuration of 12 different inlet and outlet diameter capillaries, 
was evaluated for optimized predicted performance. Two candidate optimized design 
configurations were validated a priori, and found to have improved aerosolization 
performance compared to Case 4. Throughout the study, valuable insights into the flow 
and turbulence conditions within the capsule were obtained, and relationships between 
CFD flow and turbulence fields and design factors were established. 
The flow within the capsule during actuation of the DPI is surprisingly complex 
given the relatively simple geometry. Inlet Mach and Reynolds numbers suggest 
moderately compressible and highly turbulent flow, especially for cases with larger 
capillary diameters and high flow rates, and high frequency flow oscillations require a 
transient solution strategy. Analysis of the CFD velocity field shows a large velocity 
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gradient between the center of the inlet jet and quiescent capsule (from 110.4 m/s to 4.4 
m/s across a distance of 1.88 mm). The velocity gradient has an equally large negative 
pressure gradient that generates the correct amount of secondary flow to aerosolize the 
powder bed at an adequate rate. This premise is supported by the fact that ED correlated 
well with device flow rate, meaning higher flow and velocities through the device lead to 
greater entrainment of particles from the powder bed. Furthermore, Experimental Iteration 
1 showed that MMAD increased with ED, which suggests that a larger negative pressure 
gradient is capable of lifting the larger particles from the powder bed, hence the 
simultaneous increase in both aerosolization performance metrics for Experimental 
Iteration 1. 
Beyond meeting the primary objective, this study also demonstrated how the flow 
and turbulence fields, which are used in the definition of the dispersion parameters, 
behave in response to changes in design factors. 3D surface plots show that k and Q vary 
relative to inlet and outlet capillary diameters as independent variables. Results showed 
that capillary diameters larger than approximately 2.5 mm lead to a relative decrease in 
k and increase in Q, which according to the dispersion parameters gives the desired 
decrease in MMAD and increase in ED. However, given the administration of the air-jet 
DPI to children, there is a relatively low upper limit on the available flow rate through the 
device to maintain low extrathoracic depositional losses, with the target being 
approximately 15 LPM for a 5-6-year-old subject. 
The dispersion parameter correlations established in previous work by our group 
(Longest & Farkas, 2018; Longest et al., 2019) did not correlate well with Experimental 
Iteration 1 in the present study, and were further weakened when applied to Experimental 
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Iteration 2. This is because of differences in the device and operation, including a larger 
air volume, higher flow rates, and larger capillary sizes in the current study. As such, new 
dispersion parameters were established that gave strong correlations, for both MMAD 
and ED, when applied to the current data set of ten experimental runs (see Table 5.4). 
What is consistent between the dispersion parameters used in the present study and 
previous work is that the MMAD is at least partially dependent on the ratio between 
volume-averaged k and inlet flow velocity. As 𝑘 is specific turbulence kinetic energy and 
velocity is akin to specific flow kinetic energy, this ratio can be thought of as the ratio of 
turbulence to flow energy. That is, when aiming for a small particle size, one should strive 
to minimize this ratio and not necessarily minimize k alone. The addition of pressure drop 
across the device to the MMAD dispersion parameter accounts for the energy used to 
actuate the air-jet DPI. 
This study also demonstrated the strength of the CFD methods and dispersion 
parameters used in predictions of aerosolization performance with a priori validation. 
Typically, CFD models are validated against experimental data after the devices have 
been tested, and the CFD model parameters are adjusted until numerical and 
experimental results match. In a priori validation, the devices are tested after the CFD 
models are run, and results between the numerical and experimental data are compared 
and reported with no changes to the CFD model setup. The results showed that the CFD 
models and aerosolization performance predictions for the two optimized devices were 
very close to the experimentally tested MMAD and ED, with small relative, absolute, and 
RMS errors. This demonstrates that the CFD methods for air-jet DPIs established by our 
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previous work (Longest & Farkas, 2018; Longest et al., 2019) and the newly defined 
dispersion parameters are accurate predictors of device performance.  
The two candidate optimized designs decreased the experimentally measured 
MMAD by 0.10 µm and 0.14 µm (relative difference of 5.9% to 8.3%) and increased ED 
by 4.4% and 6.3% (relative difference of 5.1% to 7.4%) compared to Case 4. Therefore, 
these two devices demonstrated improved aerosolization performance compared to 
previous air-jet DPI designs. However, there is more to consider when administering 
pharmaceutical aerosols to children with air-jet DPIs than only the device aerosolization 
performance. As mentioned previously, the flow rate through the optimized devices is 
approximately 25 LPM, which, for a 750 mL inhalation volume, gives an actuation time of 
less than 2 seconds. For the target age of a 5-6-year-old child, the inhalation flow rate 
should be about 15 LPM and an actuation time of 3 seconds, meaning the optimized 
devices may increase extrathoracic losses for the age of patients selected as the focus 
of this study. That said, these devices may be suitable for older children with slightly larger 
extrathoracic airways. The impaction parameter (𝑑𝑎
2𝑄) is often used when evaluating 
extrathoracic aerosol deposition (Golshahi et al., 2011; Javaheri et al., 2013; Storey-
Bishoff et al., 2008; Tavernini et al., 2018). There is a large amount of inter-patient 
variability when using this parameter, but the general trend is that particle deposition in 
the nasal (or oral) passage typically increases as the impaction parameter increases. This 
parameter shows that if the particle size (𝑑𝑎) decreases, the extrathoracic losses may be 
the same or even increase if the flow rate (𝑄) increases. Comparing Case 2.69/2.69 and 
3.00/2.69 to Case 4, the impaction parameter increases to 59.6 µm2-LPM and 68.3 µm2-
LPM from 38.0 µm2-LPM, which indicates extrathoracic losses will be higher for the 
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optimized devices. However, the deposition vs. impaction parameter plots vary 
considerably for different age groups (and even from patient to patient within age groups) 
and typically have a non-linear S-shape profile, so the actual increase in extrathoracic 
losses may be negligible for the optimized devices. 
On the experimental side, limitations in the present study are consistent with those 
reported by Farkas et al. (2019). One additional limitation is the variability in actuating the 
device with a ventilation bag, which is the intended actuation method. Experiments used 
compressed air and a solenoid valve to actuate the devices with a pressure drop of 6 
kPa. This provided consistency from device to device and provided a clear definition of 
boundary conditions for CFD models. However, variability in the operation of a ventilation 
bag to actuate the device between caregivers could influence aerosolization performance. 
Results from the Half Q case showed that actuating Case 4 with a pressure drop of 1.5 
kPa gave an MMAD of 2.46 µm and ED of 72.0%, which was much worse than actuating 
Case 4 with 6 kPa. This is perhaps at the extreme end of a low pressure drop, but 
demonstrates the variability in device performance relative to actuation pressure. As 
such, this should be taken into consideration when establishing caregiver operation 
guidelines for actuation of the device. 
Another limitation is the large number of design options that are available for the 
air-jet DPI approach. Despite the large number of inlet and outlet capillary configurations 
that were considered, many of the design factors available for air-jet DPIs have not been 
evaluated. Preliminary work showed that angled inlet capillaries relative to the outlet and 
longer outlet capillaries did not improve aerosolization performance. However, many 
more aspects of the device design can be explored such as different size and shape 
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aerosolization chambers (instead of a size 0 capsule), capillary piercing locations and 
orientation (instead of along the long axis of the capsule), and actuating the device with 
several smaller volumes of air (instead of 750 mL in one actuation). The negative pressure 
gradient between the inlet jet and powder bed and its effect on secondary velocities within 
the capsule has been discussed previously. Changing the aerosolization chamber (or 
capsule) shape and size could leverage this phenomenon to improve ED, and would also 
need to be considered when loading the device with larger or smaller drug masses. 
Future work on improving the aerosolization performance of air-jet DPIs should 
focus on expanding the exploration of the many available design factors and their 
influence on MMAD and ED. Future iterations of air-jet DPIs design can use the physical 
insight and dispersion parameters identified in the present study to drive the design and 
optimize performance further. It would also be interesting to test how robust the newly 
defined MMAD and ED dispersion parameters are when applied to the changes in design 
that were discussed here. The secondary breakup mechanism that reduces the particle 
size, after they are entrained in the flow, is also little understood at this stage. The MMAD 
dispersion parameter shows that the ratio of k to inlet velocity should be minimized to 
reduce particle size, but the exact characteristics of the flow and turbulence field that are 
responsible for secondary breakup are unclear. The original concept used in the 
development of air-jet DPIs by our group aimed to use highly turbulent eddies to break 
up agglomerates, but this expectation has consistently been shown to be incorrect for the 
air-jet DPIs. High-resolution, high-speed imaging of the particles within the device may 
provide some experimental insight into particle break up within the flow. Similarly, utilizing 
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DEM in numerical models could provide CFD insight into break up mechanisms for air-jet 
DPIs, but such a model would be difficult to validate and very computationally expensive. 
In conclusion, newly developed dispersion parameters with CFD predictions of flow 
and turbulence quantities were capable of accurately predicting air-jet DPI aerosol 
performance in terms of MMAD and ED with a priori validation. Greater insight in to the 
flow and turbulence characteristics within the capsule was obtained, and the effect of 
design factors on these quantities was identified. Optimized devices reduced the MMAD 
by approximately 0.1 µm and increased ED by approximately 5%. However, these 
devices may be better suited to children older than 5-6 years old due to increased device 










Figure 5.2: Overview of device geometry showing (a) CAD rendering with inlet and 
outlet connections, stainless steel capillaries, size 0 capsule, and rubber O-ring, and (b) 





Figure 5.3: Plot of particle mass-median aerodynamic diameter (MMAD) against 
emitted dose (ED) for Experimental Iteration 1 (Cases 1-4). Annotations correspond with 
the Markers in Table 5.4. A small MMAD and large ED is desirable for aerosolization 
performance. The dashed line is Experimental Iteration 1 Best Fit (R2 = 0.98), where 




Figure 5.4: Addition of Experimental Iteration 2 to the MMAD vs. ED plot shown in 
Figure 5.3. Annotations correspond with the Markers in Table 5.4. Generally, these 
additional devices perform poorly compared to Cases 1-4, except Case 3.00/2.08 (VI), 





Figure 5.5: Overlay plot on the mid-plane slice of turbulent kinetic energy field and flow 
streamlines between the inlet and outlet capillaries in the capsule. Velocity magnitudes 





Figure 5.6: Particle mass-median aerodynamic diameter (MMAD) vs. dispersion 
parameter kd*/viΔP. The dashed line is the linear best fit and the solid lines show +/- 0.12 
µm, which is double the standard error (or the 95% interval on a normal distribution). Note 
that the Half Q (Δ), 1.32/2.39 (◊), 1.60/2.39 (∇), 2.08/2.69 (+), 1.32/2.90 (×), and 3.00/2.08 





Figure 5.7: Emitted dose (ED) vs. dispersion parameter Qd*. The dashed line is the 
linear best fit and the solid lines show +/- 6.17%, which is double the standard error (or 
the 95% interval on a normal distribution). Note that the Half Q (Δ), 1.32/2.39 (◊), 1.60/2.39 
(∇), 2.08/2.69 (+), 1.32/2.90 (×), and 3.00/2.08 (✱) cases are from Experimental Iteration 





Figure 5.8: 3D plot of CFD-predicted data points for turbulent kinetic energy (k) vs. inlet 
and outlet capillary diameter (di and do respectively). The MMAD dispersion parameter 
(shown in Figure 5.6) suggests smaller particles sizes are produced when k is small and 





Figure 5.9: 3D plot of CFD-predicted data points for flow rate (Q) vs. inlet and outlet 
capillary diameter (di and do respectively). The ED dispersion parameter (shown in Figure 
5.7) suggests emitted dose is improved when the flow rate is increased, but there is a 





Figure 5.10: Addition of CFD predicted aerosolization performance to the MMAD vs. ED 
plot shown in Figure 5.4. Annotations correspond with the Markers in Table 5.4 and Table 
5.6. The devices annotated with ED and DD are selected as the optimized devices as 
they have an ED prediction greater than 90%, better predicted MMAD than Case 4, and 
















Experimental Iteration 1 
Case 1a 1.52 1.52 Yes 6.0 11.4 
Bypass flow with same 
diameter inlet and outlet 
capillaries 
Case 2a 1.40 1.80 Yes 6.0 11.6 
Bypass flow with smaller 
inlet than outlet capillary 
Case 3a 2.39 2.39 No 6.0 17.4 
No bypass flow with same 
diameter inlet and outlet 
capillaries 
Case 4a 1.83 2.39 No 6.0 13.3 
No bypass flow with 
smaller inlet than outlet 
capillary, but same outlet 
as Case 3 (best performing 
case of Experimental 
Iteration 1) 
Experimental Iteration 2 
Half Q 1.83 2.39 No 1.5 6.7 
Pressure drop selected to 
give 50% of Case 4 flow 
rate 
1.32/2.39 1.32 2.39 No 6.0 5.9 
Inlet diameter selected to 
give 50% of Case 4 flow 
rate 
1.60/2.39 1.60 2.39 No 6.0 9.9 
Inlet diameter selected to 
give 75% of Case 4 flow 
rate 
2.08/2.69 2.08 2.69 No 6.0 16.9 
Similar outlet to inlet 
diameter ratio as Case 4 
1.32/2.90 1.32 2.90 No 6.0 6.8 
Same average capillary 
diameter as Case 4 
3.00/2.08 3.00 2.08 No 6.0 15.5 
Explores the effect of larger 
inlet compared to the outlet 
diameter 





Table 5.2: Summary of evaluated MMAD correlation parameters ranked in order of 
preference based on R2 value. 










𝑘: Turbulent kinetic energy 
𝑑∗: Non-dimensional length scale 
𝑣𝑖: Inlet capillary velocity 













[−]  𝜇: Fluid velocity 






] 𝑣′ = √2 3⁄ 𝑘 
𝑣′: Fluctuating velocity due to 
 turbulence 






Table 5.3: Summary of evaluated ED correlation parameters ranked in order of 
preference based on R2 value. 




















 𝑑𝑜: Outlet capillary diameter 
Note:  The R2 value for correlation between emitted dose and 𝑄𝑖 alone is 0.7427, 






Table 5.4: Summary of aerosolization performance for Experimental Iterations 1 and 











Experimental Iteration 1 
Case 1a 1.52 1.52 1.60 (0.16) 66.3 (3.1) 1 
Case 2a 1.40 1.80 1.63 (0.06) 70.2 (1.7) 2 
Case 3a 2.39 2.39 1.70 (0.18) 85.1 (8.8) 3 
Case 4a 1.83 2.39 1.69 (0.01) 86.0 (1.4) 4 
Experimental Iteration 2 
Half Q 1.83 2.39 2.46 (0.21) 72.0 (5.6) I 
1.32/2.39 1.32 2.39 1.85 (0.10) 77.9 (1.8) II 
1.60/2.39 1.60 2.39 1.71 (0.03) 83.5 (1.5) III 
2.08/2.69 2.08 2.69 1.84 (0.09) 88.7 (1.2) IV 
1.32/2.90 1.32 2.90 2.11 (0.09) 73.3 (1.2) V 
3.00/2.08 3.00 2.08 1.61 (0.08) 80.7 (5.9) VI 





Table 5.5: Summary of cases with inlet and outlet diameters greater than 1.83 mm, 
which are in the range of design configurations that are similar to Case 4. Cases shown 











1.83 1.83 1.58 72.8 AA 
 2.08 1.65 77.6 AB 
 2.39 1.77 83.4 4a 
 2.69 1.92 87.7 AD 
 3.00 2.10 91.5 AE 
2.08 1.83 1.55 71.9 BA 
 2.08 1.61 77.5 BB 
 2.39 1.71 84.9 BC 
 2.69 1.82 91.0 BD 
 3.00 2.03 96.5 BE 
2.39 1.83 1.55 70.5 CA 
 2.08 1.58 76.1 CB 
 2.39 1.64 84.6 3b 
 2.69 1.75 92.7 CD 
 3.00 1.88 100.0d CE 
2.69 1.83 1.56 69.2 DA 
 2.08 1.59 74.4 DB 
 2.39 1.62 82.9 DC 
 2.69 1.68 92.0 DDc 
 3.00 1.79 100.0d DE 
3.00 1.83 1.58 68.1 EA 
 2.08 1.62 72.7 EB 
 2.39 1.63 80.8 EC 
 2.69 1.66 89.9 EDc 
 3.00 1.72 100.0d EE 
Markers highlighted with light grey have CFD-predicted MMAD and ED 
that plot below Experimental Iteration 1 Best Fit, and vice versa for the 
dark grey markers. 
 
a:  Same inlet and outlet configuration as Case 4 
b:  Same inlet and outlet configuration as Case 3 
c:  Candidate configurations selected for optimized design 
 experimental evaluation 
d: Cases where the correlations predicted greater than 100% ED 




Table 5.6: Summary of CFD-predicted ED and MMAD compared to the estimated 
MMAD based on Experimental Iteration 1 Best Fit. Cases shown are those that the CFD 














2.69 2.39 82.9 1.62 1.68 -3.89 DD 
 2.69 92.0 1.68 1.73 -2.72a DE 
3.00 2.39 80.8 1.63 1.67 -2.65 EC 
 2.69 89.9 1.66 1.72 -3.36a ED 
 3.00 100.0 1.72 1.76 -2.51 EE 
Relative Δ is the relative difference between the CFD-predicted MMAD and the 
Estimated MMAD based on Experimental Iteration 1 Best Fit. 
 
a:  Candidate configurations selected for optimized design experimental  





Table 5.7: Summary of relative difference (RD) between the CFD-predicted (CFD) and 
experimental (Exp.) MMAD and ED. The data shows how accurately the CFD and 
dispersion parameter correlations predicted experimental aerosolization performance. 
Experimental values are given as means with standard deviations shown in parenthesis 
[n=3]. 


















Experimental Iteration 1 
Case 1 1.52 1.52 1.53 1.60 (0.16) 4.2 67.9 66.3 (3.1) 2.3 1 
Case 2 1.40 1.80 1.63 1.63 (0.06) 0.2 71.3 70.2 (1.7) 1.6 2 
Case 3 2.39 2.39 1.65 1.70 (0.18) 2.9 84.3 85.1 (8.8) 0.9 3 
Case 4 1.83 2.39 1.77 1.69 (0.01) 4.8 83.1 86.0 (1.4) 3.4 4 
Experimental Iteration 2 
Half Q 1.83 2.39 2.44 2.46 (0.21) 1.0 70.5 72.0 (5.6) 2.1 I 
1.32/2.39 1.32 2.39 1.83 1.85 (0.10) 0.9 75.7 77.9 (1.8) 2.9 II 
1.60/2.39 1.60 2.39 1.82 1.71 (0.03) 6.5 80.3 83.5 (1.5) 3.8 III 
2.08/2.69 2.08 2.69 1.84 1.84 (0.09) 0.0 90.9 88.7 (1.2) 2.5 IV 
1.32/2.90 1.32 2.90 2.08 2.11 (0.09) 1.6 78.9 73.3 (1.2) 7.7 V 
3.00/2.08 3.00 2.08 1.62 1.61 (0.08) 0.5 72.8 80.7 (5.9) 9.8 VI 
Optimized Devices 
2.69/2.69 2.69 2.69 1.68 1.55 (0.13) 8.4 92.0 90.4 (2.8) 1.8 DD 





Chapter 6: Develop Dry Powder Inhaler Patient Interfaces for 
Improved Aerosol Delivery to Children  
6.1 Objective 
The objective of this study was to explore different internal flow pathways for a 
pediatric air-jet DPI interface that minimize device and ET depositional loss using 
validated CFD methods. The design space was constrained to an internal flow pathway 
less than 75 mm in length to provide a compact and portable device, and preference was 
given to design concepts that are easy to manufacture and construct. The performance 
target was total CFD-predicted losses in the flow pathway and ET region of less than 15% 
for a pediatric subject. Combining this target with approximately 10% device loss from 
Farkas et al. (2019) results in an expected lung dose of greater than approximately 75% 
of loaded dose. Validated CFD models were used to evaluate several design iterations 
that aimed to screen candidate design concepts until the performance targets were met. 
A leading design concept explored in this study was the use of a 3D rod array, previously 
designed to maximize aerosol deaggregation (Behara, Longest, et al., 2014a, 2014b; 
Longest et al., 2015; Longest, Son, et al., 2013), to attenuate the high-velocity air jet that 
leaves the DPI and thereby reduce depositional losses in the interface and ET regions. 
6.2 Introduction 
Delivery of pharmaceutical aerosols to the lungs typically requires a nebulizer, 
metered dose inhaler (MDI), or dry powder inhaler (DPI). For the treatment of lung 
infections in pediatric patients with cystic fibrosis (CF), tobramycin inhaled powder via a 
DPI can be administered to potentially eradicate bacterial colonies. DPIs provide several 
advantages, compared with using tobramycin inhaled solution in a nebulizer, as higher 
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doses of the antibiotic can be delivered faster and the devices are easier to load and 
clean (Somayaji & Parkins, 2015). However, DPIs are associated with several 
disadvantages including poor lung delivery efficiencies, especially in children, as well as 
requiring inhalation maneuvers that may be difficult for children to achieve. For DPI use 
in children with oral inhalation, Below et al. (2013) reported 5% and 22% of nominal dose 
was deposited on a tracheal filter in in vitro experiments when testing the Novolizer and 
Easyhaler, respectively. Similarly, Lindert et al. (2014) reported 9% to 11% lung delivery 
efficiency when testing the Cyclohaler, HandiHaler, and Spinhaler with pediatric in vitro 
conditions. These devices were developed for use by adults, not the pediatric patients 
that are the focus of this study, and the poor delivery performance may be attributed to 
insufficient inhalation flow rates to correctly empty the inhaler and deaggregate the 
powder. Inhalation flow rate and other device design considerations were considered in 
two studies by Lexmond et al. (2017; 2014), who concluded that it is of paramount 
importance to design devices specifically for children when developing DPIs and pediatric 
delivery systems. 
Our group has recently published several studies related to the ongoing 
development of a pediatric DPI for the delivery of tobramycin, as a spray-dried excipient 
enhanced growth (EEG) formulation, to children with CF (Bass, Farkas, et al., 2019; Bass 
& Longest, 2018b; Farkas et al., 2019; Longest et al., 2019). The full delivery system 
includes a ventilation bag, inline air-jet DPI, and patient interface, which is described in 
detail by Farkas et al. (2019), and is designed to be as compact and portable as possible. 
The ventilation bag provides a positive pressure gas source to actuate the device with 
approximately 750 mL of air for a five-year-old child, which allows for oral or nasal 
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administration and inhibits exhalation by the patient in the reverse direction through the 
device. The air-jet DPI is composed of small diameter inlet and outlet capillaries that 
penetrate a capsule-shaped powder chamber. The inlet capillary provides a high-velocity, 
compressible, and turbulent air jet to the chamber that aerosolizes the powder and 
delivers the aerosol to the patient interface via the outlet capillary. Bass et al. (2019) 
presented an optimized inlet and outlet capillary configuration that maximized 
aerosolization performance in terms of high emitted dose (ED) and low particle size, 
which was quantified by the mass-median aerodynamic diameter (MMAD) of the aerosol. 
The present study builds upon the experimental work by Farkas et al. (2019), which 
presented an evaluation of losses in the mouthpiece (MP) and mouth-throat (MT) for oral 
administration, and nasal cannula (NC) and nose-throat (NT) for nasal administration. 
The Farkas et al. study (2019) actuated the high-efficiency pediatric air-jet DPI with a 
inhalation volume for 750 mL, for a 5-6 year old subject, and with a 6 kPa pressure drop, 
which is consistent with hand actuation of a small ventilation bag. The device was loaded 
with 10 mg of EEG albuterol sulfate (AS) as a surrogate test formulation (in place of 
tobramycin powder) and was actuated in connection with either in vitro 5-year-old MT or 
NT models to test MP or NC patient interfaces, respectively. The best-case DPI and MP 
combination for oral administration resulted in 21.8% device loss, 4.6% interface loss, 
and 6.6% MT loss, which produced an estimated lung dose of 63.8% on the tracheal filter 
(96.8% recovery). The best-case DPI and NC combination for nose-to-lung (N2L) delivery 
resulted in 21.9% device loss, 6.1% interface loss, and 8.3% NT loss, which resulted in 
an estimated lung dose of 60.7% on the tracheal filter (97.1% recovery). The current study 
aims to develop the MP and NC further to reduce interface and extrathoracic (ET) losses 
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for oral and nasal administration by utilizing computational fluid dynamics (CFD) based 
analysis of various design concepts. 
The primary disadvantage of the air-jet DPI is that the high-velocity turbulent jet 
(which efficiently aerosolizes the powder) leads to losses when it leaves the device and 
enters the patient interface and ET regions (MT or NT). The high velocity of the jet from 
the outlet capillary imparts a large amount of momentum to the particles, which in turn 
causes a large amount of impaction deposition downstream of the device. This was 
clearly apparent from the impaction of the aerosol on the back of the MT model that was 
observed by Farkas et al. (2019). The jet also tends to attach to the walls of the patient 
interface, due to the Coanda effect, which directs the aerosol towards deposition surfaces 
instead of traversing the MP or NC. As such, the flow pathway of the patient interface 
(MP or NC) should be engineered to dissipate the intensity of the jet to minimize system 
losses. Previous examples of this type of patient interface optimization include 
improvements in mouthpiece performance of a capillary aerosol generator (Hindle & 
Longest, 2013), the use of co-flow spacers with low actuation-air-volume DPIs (Farkas, 
Hindle, & Longest, 2018a; Farkas et al., 2018b), and multiple design improvements to a 
mouthpiece coupled to the Aerolizer DPI (Coates et al., 2007; Coates et al., 2004). 
6.3 Methods 
Overview and System Setup 
An overview of the flow passages for the pediatric air-jet DPI system is shown in 
Figure 6.1 for both oral and nasal aerosol administration. The air-jet DPI consists of an 
inlet orifice flow passage, aerosolization chamber, outlet orifice flow passage, and smooth 
expansion. The inlet and outlet orifice flow passages are frequently constructed with 
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hollow metal capillaries and are therefore often referred to as inlet and outlet capillaries. 
As described by Farkas et al. (2019) the air-jet DPI orients the inlet and outlet capillaries 
along the long axis of the aerosolization chamber and does not include bypass flow 
(straight through design). The air-jet DPI is connected to the ET model (MT or NT) through 
the patient interface. For pediatric aerosol delivery conditions and the straight-through air-
jet DPI design, Bass et al. (2019) previously optmized the air-jet DPI design parameters 
to maximize aerosolization performance. In the current study, the patient interface region 
is evaluated and optmized to reduce both interface and ET depositional losses. As 
desribed, a major source of this aerosol loss arises from the high-speed turbulent air jet 
that enters the patient and ET region from the air-jet DPI outlet capillary. For this reason, 
the outlet capillary and expansion region are in the pediatric interface models. The 
fundamental question of this study is then how to design the patient interface for oral or 
N2L aerosol adminstration that can attenuate a high-speed turbulent air jet while also 
reducing deposition losses. Considering the interface, potential designs are illustrated in 
Figure 6.2 based on an axial cross-section and plane of symmetry. Potential design ideas 
include internal geometry control, wall surface characteristics, and internal flow 
structures, such as the 3D rod array. Wall geoemtries are intended to either avoid 
boundray layer separation (gradual expansion) or rapidly move the wall away from the 
expanding jet (rapid expansion). A rough wall surface is included to improve boundary 
layer attachment (via boundary layer “tripping”). Internal flow structures are intended to 
quickly dissipate the turbulent jet with minimal particle depositional loss. Further details 
of each patient interface design concept are presented later in this study. 
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Farkas et al. (2019) presented the initial experimental evaluation of two MP 
designs and three different NCs, as part of the development of an air-jet DPI for pediatric 
administration of tobramycin. The regional losses for the best-case MP and NC, given as 
ratios of deposited mass to the emitted dose from the device, are given in Table 6.1. The 
present study aims to evaluate multiple MP and NC design concepts for use with the 
same air-jet DPI via CFD predictions of patient interface and ET losses. The CFD models 
were first validated against the experimental data for the best-case MP and NC from the 
Farkas et al. study (2019) to ensure the applied methods produce accurate results. The 
validated CFD models were then used to establish correlations for predicting downstream 
losses using the outlet flow conditions of the patient interface. Using CFD models and the 
deposition correlations, numerous design concepts of the MP were evaluated with a focus 
on minimizing losses in the patient interface and MT model. Best performing design 
concepts were then assessed in a full model consisting of the chosen MP design and the 
pediatric MT geometry as a final evaluation of performance improvements. Finally, the 
same lead design concepts were applied to the NC for N2L delivery, and these designs 
were also tested in full CFD models of the interface and pediatric NT geometry. 
Evaluation Process 
To achieve the study objective, the process outlined by the flow diagram in Figure 
6.3 was employed to evaluate numerous design concepts and assess the performance 
improvements of candidate patient interfaces. The primary aims of the evaluation process 
were to establish CFD-based predictive metrics for estimating the interface and ET 
depositional losses associated with each design concept and to improve device 
performance in terms of reducing these losses. 
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As with all numerical models, the computational results must be validated against 
experimental data to ensure accuracy (Figure 6.3). In the present study, the CFD models 
for oral and nasal administration were validated against the experimental data presented 
by Farkas et al. (2019) for their best case patient interfaces. Regional deposition 
efficiency (DE) in the patient interface (MP or NC) and extrathoracic regions (MT or NT) 
were compared between the CFD models and experimental data. Initially, meshing and 
solver parameters adhered to the recommendations from our previous work (Bass, Boc, 
et al., 2019; Bass & Longest, 2018b; Longest et al., 2007) and adjustments were made 
due to the specific requirements of this investigation, which are described in detail in 
subsequent sections. Validation focused on maximizing model accuracy with the MP-MT 
model, as it was used to screen the design concepts. Once model settings were 
established for the validated MP-MT model, they were not adjusted for subsequent 
models to ensure consistency between all cases considered. 
With the model validation complete, the metrics to predict losses up to the first 
impaction point from CFD flow field quantities were developed (Figure 6.3). This required 
correlation of the chosen metrics with CFD-predicted DEs in the region of interest to 
determine the strength of the metric for estimating interface performance. The intention 
of this approach is to model the patient interface flow pathway independently from the 
rest of the geometry to reduce processing times and increase the turnaround on 
screening design concepts. That is, evaluation of flow field quantities from a CFD model 
of only the MP or NC pathway can be used to predict depositional losses in the remainder 
of the geometry, which combined with CFD predictions of deposition in the patient 
interface can be used to efficiently determine performance improvements. Next, models 
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of design concepts were developed and screened using CFD predictions of interface 
losses and the aforementioned deposition metrics (Figure 6.3). Three design screen 
iterations were required to minimize system losses, with each iteration using insight from 
the last to improve performance and optimize the design (Figure 6.3). 
Finally, four MP designs from the screening stage were selected for testing in a full 
CFD model of the chosen interface coupled with the MT airway (Figure 6.3). Here the 
performance of each design is evaluated with CFD-predictions of losses in both the MP 
and MT regions. Therefore, any inaccuracies that the deposition metrics may have in 
estimating losses in the MT are removed. The selected design concepts are then applied 
to the NC, and the combined NC-NT models are tested with full CFD models to assess 
the performance improvement for nasal administration. From the final four selected 
design concepts, the best performing patient interfaces for oral and nasal administration 
were identified based on CFD predictions of patient interface and ET losses. These best-
case designs will be experimentally tested to verify the performance improvements in a 
future study. 
CFD Models 
Computational Domains and Spatial Discretization 
The MT and NT models used in the original experimental work (Farkas et al., 2019) 
were the scaled 5-6 year old VCU MT geometry (R. Delvadia et al., 2012; Wei et al., 
2018), and the realistic pediatric NT geometry from the RDD Online website 
(www.rddonline.com), respectively. These models were selected for the experimental 
study as their geometric characteristics were consistent with the 5-6-year-old age group 
(Farkas et al., 2019) considered by the device design process. The computational 
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geometry was created by importing these ET airways into SolidWorks 2018 (Dassault 
Systèmes, Paris, France), and using its 3D modelling capabilities to combine the MT or 
NT models with either the MP or NC patient interface, respectively. To maintain 
consistency between the experimental and computational models, the NC prongs were 
inserted 5 mm into the NT model and surfaces near the prong outlets were modified to 
provide an airtight seal between the NC and nostrils. As such, there is no flow through 
the nostrils around the prongs, as the device is designed to provide the full inhalation 
volume to the subject during actuation. Similarly, the MP is centrally located within the 
inlet to the MT model with an airtight seal, which is consistent with the patient’s lips 
surrounding the MP during actuation. 3D models were transferred to SpaceClaim v19.0 
(ANSYS Inc., Canonsburg, PA) where surface preparation and minor geometry 
simplifications were made to facilitate the CFD meshing process, such as the removal of 
small area faces, filleting sharp edges, and the addition of numerical extensions. 
Mesh generation (i.e. the volume discretization of the computational domain) was 
performed by using the meshing capabilities available in FLUENT v19.0 (ANSYS Inc., 
Canonsburg, PA). Due to the complexity of the geometries that include rod arrays, an 
unstructured meshing approach was taken to accurately resolve the complex model 
surfaces. Polyhedral cell topology, with prismatic near-wall (NW) cell layers, were utilized 
throughout the patient interface and ET region in all models, as we have previously shown 
that these types of cells are more computationally efficient than traditional tetrahedral 
cells and provide accurate deposition results (Bass, Boc, et al., 2019). The NW mesh 
resolution, which is critical to obtaining accurate CFD predictions of particle deposition, 
was consistent with our previously established best practices (Bass & Longest, 2018b), 
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which includes a wall y+ value of approximately one, five prismatic NW layers, and layer-
to-layer growth ratio of 1.2. Final evaluation of all meshes ensured the orthogonal quality 
metric was greater than 0.25, with cell nodes smoothed until this threshold was achieved, 
which ensures a high-quality volume discretization. 
Mesh independence was established for the MT and NT validation cases using the 
Roache method for grid refinement studies (Roache, 1994) by evaluating volume-
averaged velocity magnitude ( 𝑣𝑚𝑎𝑔 ) and turbulent kinetic energy ( 𝑘 ) between 
successively higher resolution meshes. Throughout the mesh independence study, 
solutions were checked to ensure they were within the asymptotic range of convergence 
for which the Roache method is valid. For the MT model, three meshes with approximately 
0.5-, 1.0-, and 2.0-million cells were evaluated, which gave normalized grid spacing ratios 
of 1.60, 1.32, and 1.00, respectively. Between the 2.0- and 1.0-million cell cases, the grid 
convergence index (GCI) for 𝑣𝑚𝑎𝑔  and 𝑘  was 0.07% and 1.54% respectively, which 
suggests the estimated error from the 1.0-million cell case was low and acceptable for 
use with this study. For the NT model, higher resolution meshes compared to the MT 
model were required due to the increased model complexity, with meshes using 
approximately 1.0-, 2.0-, and 4.0-million cells, which gave normalized grid spacing ratios 
of 1.58, 1.25, and 1.00, respectively. Between the 4.0- and 2.0-million cell cases, the GCI 
for 𝑣𝑚𝑎𝑔 and 𝑘 was <0.001% and 8.75%, respectively. Ideally, the GCI for 𝑘 in the NT 
model would be less than 5%, but given that 𝑣𝑚𝑎𝑔 shows a very low estimated error and 
particle trajectories in the micro-meter size range are more heavily influenced by the 
velocity field than the turbulence field, the 2.0-million cell case was deemed acceptable. 
A lower cell count is also preferred, as the transient solver was required (discussed in 
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subsequent sections), which drastically increased computational expense. As a final 
check of the selected mesh resolutions, Richardson Extrapolation (Richardson & Gaunt, 
1927) was used to estimate the exact solution of each field quantity. The absolute 
differences between the selected meshes and the estimated exact solution was negligible 
in all cases, with values of -0.01 m/s and -0.09 m2/s2 for 𝑣𝑚𝑎𝑔 and 𝑘 in the MT model, -
0.001 m/s and -0.22 m2/s2 for 𝑣𝑚𝑎𝑔 and 𝑘 in the NT model. Subsequent meshes used in 
the evaluation of new patient interface designs use similar cell sizes to these validation 
cases, as opposed to similar cell counts, to ensure the spatial resolution is consistent 
between models. 
Numerical Modeling and Solver Settings 
The Mach and Reynolds numbers at the inlet to the patient interface, given a flow 
rate of 13.3 LPM and inlet capillary diameter of 2.39 mm (Farkas et al., 2019), are 0.14 
and 5,200 respectively, which suggest incompressible and transitional-to-turbulent flow 
conditions. As such, a constant density for the fluid phase was implemented, in contrast 
to the ideal gas law in previous studies (Bass, Farkas, et al., 2019; Bass & Longest, 
2018b; Longest et al., 2019), which had a much smaller inlet jet diameter, as the Mach 
number is far below the critical value of 0.3 for compressible flow. To model the 
transitional-to-turbulent flow regime, the low-Reynolds number (LRN) k-ω turbulence 
model was used, which has been validated by our group for both the evaluation of DPI 
performance (Longest, Son, et al., 2013) and particle transport through ET airways (Bass, 
Boc, et al., 2019; Bass & Longest, 2018b; Longest et al., 2007) for adults and children. 
The formulation of the LRN correction to the k-ω model includes an eddy viscosity 
damping coefficient that scales from zero to one in regions of low or high turbulence, 
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which improves solution accuracy outside and inside the highly turbulent jet. Considering 
the inlet jet, shear flow corrections were applied to model the shear layer between the 
high-velocity jet and relatively quiescent flow in the patient interface. 
Using a steady-state solution approach, preliminary work on the validation cases 
showed the inlet jet would attach to the wall of the patient interface and move around the 
domain with erratic behavior, which prevented convergence of the transport equations. 
Therefore, a transient formulation of the transport equations was implemented to model 
the transient nature of the inlet jet development. The flow was initialized with quiescent 
conditions and the boundary conditions at the inlet caused the jet to propagate into the 
patient interface. As with the preliminary work, the jet attaches to the walls and wanders 
unpredictably in all cases considered, due to the Coanda effect. The transient solution 
approach used a time step of 1e-3 seconds, which gave good flow field convergence 
within 100 iterations per time step, and sufficiently resolved the inlet jet behavior. Also, 
during preliminary work, observation of regional DE vs. time plots showed that the total 
and regional deposition converged to a single value within 0.45 seconds, which 
determined the maximum required simulation time, as an alternative to modeling the full 
actuation time of 3 seconds. These transient solver settings and the mesh independent 
spatial discretization resulted in processing times of between 24 and 72 hours (on 10 
CPUs) depending on the cell count. This demonstrates the advantage of using the 
computationally efficient and accurate LRN k-ω model, as more detailed turbulence 
models with transient flow would drastically increase processing times. 
FLUENT v19.0 (ANSYS Inc., Canonsburg, PA) was used to obtain solutions for all 
flow and turbulence equations, including the aforementioned sub-models and corrections. 
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As with the mesh generation step, all solver settings followed our recommendations for 
modeling particle transport in DPIs and the respiratory airways (Bass, Boc, et al., 2019; 
Bass & Longest, 2018b). Specifically, the Green-Gauss Node-based method for gradient 
discretization, which combined with the NW mesh resolution requirements mentioned 
previously, provide an improvement in grid independence in the NW region, and improved 
consistency and accuracy in particle deposition data. The spatial discretization of flow 
and turbulence equations were second-order accurate, while the standard pressure 
interpolation scheme was used. Convective terms used a second-order upwind scheme 
and diffusion terms used central difference. Further details on the mass, momentum, and 
turbulence transport equations are available in other publications (Longest et al., 2007; 
Longest et al., 2006). 
A mass flow inlet condition was utilized at the inlet flow boundary to the patient 
interface, with a mass flow rate that gave a volumetric flow rate of 13.3 LPM, which is 
consistent with the volumetric flow rate through the Case 4 DPI presented by Farkas et 
al. (2019). A 10 mm length of the device outlet capillary (inlet to the patient interface) was 
included in the model to allow the flow to reach a fully-developed state before entering 
the MP or NC. A pressure outlet condition was used at the outlet of the ET airway model, 
with gauge pressure (relative to ambient pressure) set to 0 kPa. To minimize the influence 
of the pressure outlet on the flow field in the ET models, a 60 mm numerical extension 
was added to the outlet in the CFD domain. All wall boundaries in the CFD model use the 
no slip shear condition and the effects of surface roughness on the flow field and particle 
trajectories were neglected. Wall boundaries of the 3D-printed components used the trap 
discrete phase model (DPM) boundary condition such that any particle that contacts these 
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walls is assumed to deposit on the boundary. Wall boundaries of stainless-steel 
components used the reflect DPM boundary condition, with default coefficients of 
restitution, which assumes particles bounce off of these surfaces. This is a necessary 
assumption about particle behavior when the aerosol interacts with the rod array to keep 
processing times manageable, which has previously been shown to be acceptable 
(Longest et al., 2015; Longest, Son, et al., 2013). 
Particle Trajectories and Deposition Calculations 
Particle trajectories were calculated with the DPM available in FLUENT v19.0 
(ANSYS Inc., Canonsburg, PA), with the Runge-Kutta scheme used to integrate the 
particle equations of motion, which is dependent on the underlying flow and turbulence 
field quantities. Settings for the DPM follow our best practices (Bass, Boc, et al., 2019; 
Bass & Longest, 2018b; Longest & Xi, 2007; Walenga & Longest, 2016), which have been 
successfully validated against experimental deposition data. Microparticle trajectory 
calculations with the DPM and LRN k-ω turbulence approximation generally over-predict 
deposition when compared to experimental data, due to the assumption of isotropic NW 
turbulence and the associated fluctuating velocity components. As such, Longest and Xi 
(2007) proposed corrections to the NW flow and turbulence fields extending work by 
Matida et al. (2004) and Wang and James (1999), which are implemented in FLUENT via 
user-defined functions (UDFs). In summary, the NW corrections interpolate the velocity 
field from the cell centroid to the particle location, implement anisotropic fluctuating 
velocity components, and damp the wall-normal velocity to approximate particle-wall 
hydrodynamic interactions. These NW corrections use a NW limit control parameter that 
determines the wall-normal distance, below which, the wall-normal velocity is damped. 
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Previous validation work (Bass, Boc, et al., 2019; Bass & Longest, 2018b) showed that a 
NW limit of 1-2 µm was suitable for modeling microparticle deposition in the upper 
airways, with a value of 2 µm used in the present study. 
Particles were introduced into the model at the inlet to the air-jet DPI outlet capillary 
(i.e. the inlet to the CFD domain) with a blunt spatial distribution, as the inlet Reynolds 
number suggests the flow is in the transitional to turbulent regime. Initial particle velocities 
also followed a blunt profile based on each particle’s radial location relative to the circular 
boundary. A polydisperse aerosol was used in the CFD models, with the particle size 
distribution determined by next-generation impactor (NGI) characterization at the Case 4 
device outlet presented by Farkas et al. (2019). Particle deposition convergence was 
ensured by following the recommendations from Tian et al. (2015) with 100 particles per 
bin per time step, which resulted in 360,000 total particles (considering eight NGI bins 
and 450 time steps).  
Regional particle deposition in the device, interfaces, and ET models are 
compared via DE, which is the ratio of particles that deposit in a given region to number 
of particles that enter that region. To convert the DE from the CFD models (with a constant 
number of particles per bin) to a DE that is consistent with the experimentally determined 
particle size distribution, the CFD-predicted DE for each NGI bin is multiplied by the mass 



















where 𝑛𝑖 is the number of particles that deposit in the region for bin 𝑖, 𝑁𝑖 is the number of 
particles the enter the region for bin 𝑖, DE𝑖 is the DE for bin 𝑖, 𝑚𝑖 is the mass of particles 
from the NGI characterization for bin 𝑖, 𝑀 is the total aerosol mass, 𝜑𝑖 is the mass fraction 
for bin 𝑖, and DE𝑟  is the DE for a given region. To determine the mass or number of 
particles that enter the region, the mass or number of particles that deposit in upstream 
regions is subtracted from the injected aerosol conditions. Finally, the total deposition 
fraction (DF) for the entire domain, which is the ratio of particles that deposit in the domain 
to the particles that enter the domain, can be calculated from the regional DE as follows: 
 DF𝑇𝑜𝑡 = 1 − ∏(1 − 𝐷𝐹𝑟) (6.3.4) 
Deposition Metrics 
In an effort to reduce the computational cost associated with evaluating numerous 
patient interfaces, CFD-based deposition metrics that are capable of predicting deposition 
losses were sought. The intention being that only the interface flow pathway would have 
to be modeled with CFD, and the flow field at its outlet could be evaluated to predict 
downstream losses. For both the MP-MT and NC-NT models, the patient interface 
accounted for approximately 25% of the total cell count, thus reducing processing times 
by a factor of four-fold, which vastly improved the turn-around time on design candidate 
evaluations. Candidate designs that exhibit reductions in interface and ET losses with this 
approach were then fully evaluated via CFD models of the improved interface coupled to 
the ET model in the final stage of this study. That is, numerous design concepts can be 
246 
 
screened in a reduced amount of time before testing candidate interfaces via a full CFD 
model and evaluating performance improvements. 
 Figure 6.4a and b show the separation of the MP flow pathway from the MT, and 
Figure 6.4c and d show the separation of the NC flow pathway from the cannula 
bifurcation and NT. The NC was split just upstream of the bifurcation as the objective of 
the study was to evaluate interface designs that reduce the losses associated with the 
high-velocity jet from the device outlet, and preliminary work showed that losses in the 
NT region were not affected by changes to the jet intensity. That is, reducing the intensity 
of the inlet jet to the NC did not reduce ET losses, but deposition on the bifurcation was 
reduced, which suggests the potential for improvements in interface losses. Put another 
way, the inlet jet causes impaction deposition on the first surface that it encounters when 
it leaves the device outlet capillary. In the MP-MT model, this impaction surface is the 
back of the mouth-throat and the model is split between the MP and MT regions. In the 
NC-NT model, this impaction surface is the NC bifurcation and the model is split between 
these two regions. 
ET deposition metrics were evaluated by applying four different velocity profiles to 
the MT and NT models at the inlets labeled in Figure 6.4b and d, respectively. These four 
velocity profiles were named the Jet (𝑢Jet ), Turbulent (𝑢Turb ), Laminar (𝑢Lam ), and 
Intermediate (𝑢Int) profiles, and are plotted graphically in Figure 6.5a. The functions that 
define each profile are: 
 




























where 𝑢max is the peak velocity, 𝑟 is the radial location on the inlet boundary, and 𝑅 is the 
maximum radius of the inlet boundary. Using the 𝑟/𝑅 definition for the radial location on 
the inlet boundary simplified the conversion from circular to elliptical coordinates for the 
inlet to the MT model. The 𝑢Jet profile uses a Gaussian function to define the jet-type 
profile seen in Figure 6.5a, with 𝑢max determined from time-averaged peak velocity from 
the oral and nasal validation cases and 𝜎 selected to provide a volumetric flow rate of 
13.3 LPM consistent with the Case 4 DPI (Farkas et al., 2019). The 𝑢Turb profile uses the 
1/7th power law for a turbulent profile (White, 2006); the 𝑢Lam profile uses the analytical 
solution for laminar flow; and the 𝑢Int profile is simply the average of the 𝑢Jet and 𝑢Turb 
profiles. The purpose of these velocity profiles is to evaluate how the ET losses are 
affected as the jet intensity is reduced from a profile such as 𝑢Jet through an intermediate 
range (𝑢Int) to a full reduction of jet intensity with the 𝑢Turb and 𝑢Lam profiles for turbulent 
and laminar flow regimes.  
As the velocity profile changes, the spatial distribution of the particles that are 
introduced to the computational domain must reflect the inlet conditions, as higher 
velocities will carry in more particles. For example, a velocity profile such as 𝑢Jet would 
give a particle distribution that is more concentrated towards the middle of the inlet, 
whereas a profile such as 𝑢Turb  would give a more even distribution of particles. To 
determine the spatial distribution, each profile was treated as a probability density function 
(PDF) and split into 32 equally spaced rings, with particles randomly assigned to each 
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ring based on the PDF. This method of defining particle spatial distributions is similar to 
that described by Longest and Vinchurkar (2007a), but applied to the four profiles used 
to evaluate ET deposition metrics. The resulting spatial particle distribution for each MT 
of NC inlet velocity profile is shown in Figure 6.5b. 
Observations from the experimental work presented by Farkas et al. (2019) 
demonstrated a large amount of deposition on the back of the throat in the pediatric MT 
model. Therefore, initial work on predicting ET loss aimed to describe the intensity of the 
jet as it enters the MT or NT model. Specifically, these metrics were the peak velocity, 
velocity spread, and uniformity index, which were all evaluated on the plane between the 
patient interface and ET region. Peak velocity is simply the time-averaged maximum 
velocity on the sampling plane, velocity spread is the standard deviation of velocity on the 
plane, and uniformity index (UI) is given as: 
 
UI = 1 − (
∑ (|𝑢𝑖 − ?̅?| × 𝐴𝑖)
𝑁
𝑖=1
2 × ?̅? × 𝐴
) 
(6.3.9) 
where 𝑢𝑖 is the velocity on face 𝑖, ?̅? is the area-average velocity, 𝐴𝑖 is the area of face 𝑖, 
and 𝐴 is the total plane area. A UI with a value close to one describes a uniform flow 
velocity, such as the 𝑢Turb profile, whereas a value closer to zero describes non-uniform 
flow velocity, such as the 𝑢Jet profile. 
6.4 Results 
CFD Model Validation 
Deposition patterns presented in this study generally split the domain into three 
regions: the device outlet (outlet capillary and expansion), patient interface (MP or NC), 
and the ET region (MT or NT). For the purposes of model validation, regional DEs are 
compared between the CFD and experimental results in the patient interface and ET 
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regions, with DEs on the device outlet provided for completeness. Figure 6.6a shows that 
CFD predictions of aerosol DE were in close agreement with the experimental (Exp) 
results in the MP and MT regions, with a maximum absolute error in regional DE of -0.6% 
in the MT region. Total DF in the entire model also matched well between the CFD and 
experimental data with an absolute error of 0.2%. 
The validation of the NC-NT model, presented in Figure 6.6b, did not match as 
closely to the experimental data as the oral model, but was still considered acceptable. 
Maximum absolute error in regional DE was 5.1% in the NT region, and the CFD model 
over-predicted total DFs in the entire domain by 8.3%. Note that adjustment of the NW 
limit control parameter in the NW correction UDFs would reduce this over-prediction, but 
we elected to apply the same CFD model settings to all models to ensure consistency 
between cases. This lower degree of model validation relative to the MP-MT model was 
deemed acceptable as the screening iterations focused on the MP design and general 
trends in improving performance. However, the slight over-prediction of deposition in the 
NC-NT model must be taken into consideration when interpreting and evaluating results 
from those patient interfaces. 
Deposition Metrics 
Of the three deposition metrics described in the Methods section, correlating the 
time-averaged maximum velocity on the plane at the outlet of the flow pathway with MT 
(Figure 6.7a) and NC (Figure 6.7b) DE gave the best prediction of losses, with R2 values 
greater than 0.95 and standard error ranging from approximately 0.5% to 0.6%. It is noted 
that the different velocity profiles considered all had the same volumetric flow rate. 
Therefore, deposition in the MT correlates with not only volumetric flow rate, but also the 
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peak value of the velocity profile that enters the region. With such a strong correlation, 
further development of deposition metrics was not required. Figure 6.7a plots the DE in 
the MT region (Figure 6.4b) against the maximum velocity at the MT inlet for the four 
imposed velocity profiles (Figure 6.5a). Similarly, Figure 6.7b plots the DE in the NC 
bifurcation region (Figure 6.4d) against the maximum velocity at the inlet for the jet, 
turbulent, laminar, and intermediate velocity profiles. As mentioned previously, the NC-
NT model was split into the domains shown in Figure 6.4c and d as preliminary work 
showed that imposing velocity profiles at the inlets of the NT region (outlet of the NC 
prongs) had little influence on reducing ET losses. However, the deposition metrics show 
that reducing the intensity of the jet entering the NC bifurcations (as quantified by peak 
velocity) can reduce interface losses at the first impaction point, just as in the MT with 
oral aerosol delivery. 
Figure 6.8a and b show the deposition patterns in the MP-MT model when the jet 
(Figure 6.8a) and turbulent (Figure 6.8b) velocity profiles were imposed at the inlet. Figure 
6.8a shows a large amount of impaction deposition on the back of the MT, due to the high 
velocity jet entering the region, which was also observed experimentally by Farkas et al. 
(2019). In Figure 6.8b, this impaction region was minimized as the intensity of the inlet jet 
is vastly reduced with the turbulent velocity profile, which leads to a reduction in MT losses 
from 8.8% to 3.8% at the same volumetric flow rate. In the laryngeal region of the pediatric 
MT model, deposition patterns were similar between the jet and turbulent profile cases as 
inlet effects are less apparent downstream in the domain. Similarly, Figure 6.8c and d 
show the deposition patterns in the NC-NT model for the jet and turbulent velocity profiles, 
respectively. As with the MT model, minimizing the inlet jet intensity reduces the losses 
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at the first impaction point, which in the NC-NT model is the cannula bifurcation, from 
7.2% to 0.9%. However, there is little difference in NT losses when imposing different 
velocity profiles, with DEs ranging from 19.2% to 19.7%. This supports the insight from 
the preliminary work and deposition metrics that NT losses are difficult to minimize with 
changes to the design of the NC flow pathway, but NC interfaces losses can be improved. 
Design Concept Screen 1 
Diagrams that illustrate the MP design concepts in the first iteration were presented 
in Figure 6.2a. These diagrams provide an axial, mid-plane slice of the interface aligned 
with the top-down view and show the MP geometry along with any internal components. 
The first iteration implemented four design concepts, with two variations of each concept. 
The gradual expansion (GE) concept steadily increased the MP diameter from the circular 
outlet capillary to the elliptical MP outlet. The variations of the GE concept used a smooth 
(a) and an undulating (b) surface, with the intention being that the undulating surface 
would increase turbulence through tripping the boundary layer, thereby keeping the flow 
attached and preventing recirculation. The rapid expansion (RE) concept quickly 
transitions from the outlet capillary diameter to the elliptical MP cross-section with a dome 
shape that extends 6.5 mm from the capillary. The variations of the RE concept used a 
one-step (a) and two-step (b) expansion, where the two-step expansion initially 
transitioned to an elliptical cross-section that had half the radii lengths of the outlet over 
the first half of the MP length. The intent of the two-stage RE variation was to determine 
whether the MP cross-section should be increased incrementally to dissipate the intensity 
of the inlet air jet. The rod array (RA) concept used 0.5 mm diameter rods arranged in a 
3-4-3 configuration and placed in the flow pathway to break up the high-velocity inlet jet 
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and reduce its intensity. The variations of this design concept placed the rod array close 
to the outlet capillary (a) or close to the MP outlet (b) to provide insight on the optimal 
positioning of the rod array. Finally, the tear drop (TD) concept placed a streamlined 
obstacle in the flow pathway to both break up the inlet jet and minimize recirculation by 
keeping the flow attached to the outer wall of the MP. The tear drop was suspended in 
the flow pathway with six supports that were placed in a triangular arrangement and 
followed a NACA 0012 profile to reduce their influence on the flow field as much as 
possible. The variations of this design concept used a tear drop shape that extended into 
the transition region between the outlet capillary and MP, and another design that moved 
the leading edge of the tear drop away from the outlet capillary. The intent of these two 
variations was to determine the effects on impaction deposition by moving the blunt edge 
of the tear drop away from the jet source. 
Table 6.2, used in conjunction with Figure 6.2a, presents the CFD-predicted losses 
on the device outlet (DEDev) and patient interface (DEMP), and the correlation-predicted 
MT losses (DEMT) for the eight MP designs described above. The GE cases both reduced 
peak velocity at the MP outlet, which suggests an improvement in MT losses based on 
the deposition correlation. However, the interface losses for both variations of the GE 
concept were high (34.4% and 17.0%) compared to the original MP design (6.4%). It is 
interesting to note that the undulating surface (GE-b) reduced the CFD-predicted MP 
losses by approximately half compared to the smooth surface (GE-a). The RE design 
concept also reduced peak velocity and the associated MT losses, with the added benefit 
of a reduction in CFD-predicted interface losses compared to the original MP design of 
6.4% to 1.8%. The RE-a design gave the best performance improvement of all eight cases 
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considered in the first iteration, with the total domain DF reduced from 16.7% to 11.8%. 
The RA-a case gave the best reduction in peak velocity and estimated MT losses of all 
cases evaluated in the first iteration, from 8.8% to a predicted 4.9% comparing the original 
MP and RA-a respectively. The two TD cases performed well in terms of minimizing flow 
recirculation, reducing device outlet losses, and predicted MT losses, but a large amount 
of impaction deposition on the leading-edge caused very high MP losses (57.0% and 
54.7%). Based on the results from Design Screen 1, a combination of the benefits 
observed for the RE and RA type designs may be utilized to improve patient interface 
performance further. That is, the 3D rod array can be added to the RE geometry to both 
give an improved reduction in jet intensity, interface deposition loss, and predicted MT 
loss. 
Design Concept Screen 2 
The second iteration of design screening combined aspects of the RE and RA 
designs from the first iteration, and also introduced the cylindrical expansion (CE) 
geometry as an alternative to RE, as illustrated by Figure 6.2b. The RE-a+RA-a design 
combines the geometry from the one-step variation of the RE concept with the rod 
placement and configuration from the first RA variation in an attempt to leverage the 
benefits of both designs from the first design screen iteration. RE-a+RA-c is similar to RE-
a+RA-a with the rod array moved 6.5 mm downstream of the outlet capillary to gain insight 
in the placement of the rod array and its effect on losses. RE-c+RA-a uses a two-step 
expansion with a shorter first section than RE-b, and the first rod array variation, to 
evaluate the effect of keeping the flow constrained as it passes through the rods. CE+RA-
a is similar to RE-a+RA-a except it uses the cylindrical type geometry to provide a direct 
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comparison between the combined RE+RA with the CE+RA design concepts. The final 
three designs in the second screening iteration (CE+RA-d/e/f) use the cylindrical 
geometry with rod arrays that span the full width of the MP with the intention of preventing 
the jet from reaching and attaching to the walls, as well as reducing the intensity of the 
jet. The three rod arrays are located at 1.5, 10, and 20 mm from the outlet capillary to 
evaluate the deposition losses as the rod array is moved away from the source of the inlet 
jet. 
Based on the deposition results in Table 6.3, adding the RA to the RE geometry 
had the desired effect of improving MT losses by reducing the peak velocity of the inlet 
jet, which brings the total DF below the target of 15% (see bold DFTot values). However, 
the deflection of the jet due to the rod array causes higher interface losses, when 
compared to the RE-a case, as the flow is directed towards the side walls of the MP. 
Moving the RA further away from the capillary outlet in the RE-a+RA-c case leads to 
relatively high MP losses as the inlet jet flowed around the rods and attached to the walls 
instead of passing through the rod array and diffusing. Of all the design concepts 
considered in the second iteration, RE-c+RA-a had the worst performance in terms of 
flow pathway losses due to the close proximity of the interface walls to the rod array. That 
said, this case provides valuable insight as it shows that positioning the MP walls further 
away from the rod array reduces patient interface losses, which is explored further in the 
third design screen iteration. The CE+RA-a case had very similar performance to RE-
a+RA-a, which shows that the slight change in the MP geometry has little effect on 
reducing deposition losses. The final three CE design concepts with rod arrays that span 
the full width of the interface also all had a similar level of performance (13.1-14.4% total 
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DF). They show that moving the rod array away from the outlet capillary reduces the 
losses on the device outlet, but increases interface losses, so that total losses remain 
relatively constant. Despite the cases with rods spanning the full width of the interface 
having the best performance in the second design screen iteration, it is desirable to find 
design concepts that use fewer rods to simplify the construction of these patient 
interfaces. 
Design Concept Screen 3 
Using insight from the RE-c+RA-a case, the third design screening iteration 
introduces a forth RE geometry (RE-d), as illustrated by Figure 6.2c. Here, the MP walls 
are initially twice as far away from the outlet capillary (maximum width of 36 mm) and 
gradually taper towards the original elliptical cross-section. The intention of this design 
concept is to keep the patient interface walls away from the flow when it is dispersed by 
the rod array to reduce device outlet and MP losses. The RE-d+RA-a case was evaluated 
as this rod array has provided good performance in the previous iterations and for direct 
comparison with the RE-a+RA-a case. RE-d+RA-e used the best performing rod array 
from the second design screen iteration and tested whether the large number of rods was 
necessary to reduce interface losses despite the drawbacks in terms of MP construction. 
RE-d+RA-g is similar to RE-d+RA-e, but the rods span half the width of the patient, with 
this design included as an intermediate step. The RE-d+RA-a-434 case is the same as 
RE-d+RA-a with the rods placed in a 4-3-4 configuration (as opposed to 3-4-3) and was 
evaluated to determine whether this configuration provided performance improvements 
over the other design concepts. Finally, the RE-d+RA-c-EC design concept uses the rod 
array positioning seen in the RA-c case with an extended capillary (EC) that protrudes 
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6.5 mm into the patient interface. The intention of this design is to keep the inlet jet away 
from the device outlet and interface walls while forcing the flow through the rod array to 
disperse the jet and reduce its intensity. 
The results in Table 6.4 show all design concepts from the third screening iteration 
provided CFD-predicted total losses of less than 10% in the device outlet, patient 
interface, and MT regions. Widening the MP geometry had the expected effect of 
preventing the dispersed jet from depositing particles on the interface walls, which is 
clearly apparent when comparing the RE-d+RA-a case with RE-a+RA-a, as the wider 
geometry reduced total losses by 5.9% absolute difference. There was little difference in 
performance between the RE-d+RA-e and RE-d+RA-g cases, with the latter preferred as 
it required less rods and is hence easier to build. Switching the rod array configuration 
from 3-4-3 to 4-3-4 (RE-d+RA-a-434) gave a marginal improvement in reducing MP 
losses, but gave a higher peak jet velocity and therefore larger predicted MT losses, with 
total losses 0.9% higher (absolute difference) compared to the original configuration. 
Finally, extending the outlet capillary into the MP (RE-d+RA-c-EC) provided the expected 
improvement of reducing device outlet losses, and had total deposition losses that are 
comparable with the other design concepts in the third iteration. 
Figure 6.9 demonstrates how effective the 3D rod array is at diffusing the air jet in 
the patient interface. Figure 6.9a shows the highly turbulent, high-velocity jet, which is 
generated by the DPI outlet capillary, entering the RE-a MP design candidate. This jet 
extends beyond the outlet of the patient interface and imparts a large amount of 
momentum on the aerosol, which leads to increased deposition on the first impaction 
point that the jet encounters, as described previously. The jet diffusion by the 3-4-3 
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configuration rod array is clearly apparent in Figure 6.9b, with the jet almost fully 
dissipated by approximately 30 mm into the 75 mm length of the RE-d+RA-a MP design. 
The vast reduction in peak velocity of the flow leaving the patient interface is expected to 
both reduce delivery system and ET losses, based on the previously presented deposition 
correlations. The 3D rod array has the added benefit of providing a secondary breakup 
mechanism to reduce aerosol size (Behara, Longest, et al., 2014b), which may lead to 
further improvements in system performance. 
Candidate Mouthpiece Designs 
Four design concepts from the screening iterations were selected for evaluation 
with full MP and MT CFD models: RE-a, RE-d+RA-a, RE-d+RA-g, and RE-d+RA-a-EC. 
Figure 6.10 shows the CFD-predicted deposition patterns and regional DEs for the four 
candidate design concepts. Only bin sizes from 1.09 to 3.26 µm are included in Figure 
6.10 as they account for 84% of the initial particle size distribution and provide a clearer 
representation of deposition patterns in the CFD domain. Comparing losses in Figure 
6.10b-d with Figure 6.10a clearly shows that widening the MP geometry and including a 
rod array to disperse the inlet jet provides a substantial reduction in CFD-predicted patient 
interface and ET deposition losses, with an absolute difference in total DF of 10.3%. The 
best performing case of the four candidate designs was RE-d+RA-a-EC with CFD-
predicted total losses of 5.1% on the device outlet, MP, and MT region, which is a three-
fold reduction compared with the original MP (see Figure 6.6a). Comparing regional 
deposition between RE-d+RA-a-EC and the original MP, CFD-predicted losses were 
reduced from 2.4% to 0.6% on the device outlet, 6.4% to 2.2% on the MP, and 8.8% to 
2.4% in the MT region. 
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Candidate Nasal Cannula Designs 
The top four MP design concepts were applied to the NC flow pathway, which 
consists of the region between the outlet capillary and cannula bifurcation. Figure 6.11 
shows the deposition patterns and regional DEs for the four NC designs. As with the MP 
flow pathway, widening the NC geometry and including a rod array (Figure 6.11b-d) 
reduces total deposition losses compared to RE-a by a two-fold reduction (Figure 6.11a). 
Also consistent with the MP designs, the best performing NC case was the RE-d+RA-a-
EC design in Figure 6.11d. Comparing the RE-d+RA-a-EC MP and NC directly, device 
outlet losses were similar (0.6% vs. 0.8%) and interface losses were a little higher in the 
NC with an absolute difference of 1.1%. The downside to all NC designs is that losses in 
the NT region are much higher than MT losses in all cases considered, with absolute 
differences of approximately 18%, which leads to higher total DF losses. That said, recall 
that the validation cases showed that CFD models over-predicted total deposition in the 
NT model by 8.3%, so we could optimistically expect total losses to be 15-20% with 
experimental testing of these NC design concepts. 
Optimal Flow Rate for Nasal Administration 
The results in Figure 6.11 are consistent with previous findings from this study that 
changes to the flow pathway in the NC, and the subsequent changes to the flow profile 
entering the nasal cavity, has little effect on reducing NT losses. Figure 6.8c and Figure 
6.6d showed that imposing a jet or turbulent velocity profile resulted in negligible 
difference in NT losses, and similarly Figure 6.11b-d show little change in NT losses 
despite the same design concepts reducing MT losses by 6.4% (absolute difference) 
when applied to the MP interface. One method to reduce impaction deposition in the NT 
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region is to reduce the size of the aerosol that enters the nasal cavity, but exploratory 
work of this approach yielded little performance improvement as the 1.69 µm MMAD from 
the DPI as at the lower end of the characteristic S-curve deposition profile. 
The alternative approach to reduce impaction deposition is to lower the flow rate 
through the patient interface and NT to reduce particle momentum. Figure 6.12 compares 
the CFD-predicted particle deposition for the best performing NC design concept (RE-
d+RA-c-EC) at the original operating flow rate (13.3 LPM) and 75% of that inlet flow rate 
(9.9 LPM; 25% reduction). The lower flow rate reduces NT losses by 6.9% (absolute 
difference) and total losses by 7.8%. While the total system and ET losses at 9.9 LPM is 
16.3%, experimental results are expected to be even lower based on the validation case 
study. 
6.5 Discussion 
This study met its objective by presenting three MP design concepts that provide 
CFD-predicted total deposition losses of less than 15%, with the best case being the RE-
d+RA-a-EC design that showed a total DF on the device outlet, patient interface, and MT 
region of 5.1%. Combining these CFD-predicted interface and ET losses with the 
approximate 10% device loss from Farkas et al. (2019) suggests the possibility of a 
pediatric lung dose greater than 85% of the loaded dose. The NC design concepts did 
not perform as well as the MP designs with respect to increasing lung dose, as changes 
to the flow pathway had little effect on reducing NT losses. The combination of the RE-
d+RA-a-EC design concept with a reduced operating flow rate of 9.9 LPM (25% decrease) 
gave a CFD-predicted total DF of 16.3%. Previous work showed that device losses are 
strongly associated with flow rate through the pediatric air-jet DPI (Bass, Farkas, et al., 
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2019); hence operation of the delivery system at a lower flow rate, to reduce NT losses, 
may lead to increased device losses. However, experimental results of the device (Case 
1.60/2.39) that had a 25% reduction in flow rate from the Bass et al. study (2019) gave 
negligible change in MMAD (1.69 µm vs. 1.71µm) and a 2.5% increase (absolute 
difference) in device losses . Therefore, overall system losses may be improved when 
administering the aerosol via N2L delivery at a reduced flow rate. Adding this loss to the 
experimentally determined DPI loss (Farkas et al., 2019) suggests a lung dose that is 
approximately 74% of the loaded dose. This is slightly outside the performance targets 
laid out in the objective (lung dose >75%), but the validation cases showed that the CFD 
models over-predict deposition in the NC and NT, so there is a possibility that 
experimentally determined losses may be less than those suggested by these CFD-
predictions.  
The CFD-predicted patient interface and ET losses, and associated lung dose, for 
these candidate design concepts must be experimentally tested, which will be the focus 
of a future study related to the development of this system for administration of tobramycin 
to pediatric patients with CF. The candidate design concepts also met the sizing and 
construction considerations that were stated in the objective. The total length to the MP 
and NC designs is less than 75 mm and no wider than 40 mm, which allows for a compact 
and portable device. The best performing RE-d+RA-a-EC design concept also requires 
relatively few rods in the rod array, with a total of seven compared to other concepts that 
required more than 50, which allows for simplified construction of the patient interfaces. 
Considering volume, the MP and NC interfaces that employ the RE-d geometry had total 
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internal volumes of 31 and 21 cm3, respectively, which can easily be cleared with device 
actuation volumes on the order of 100s of mL. 
In addition to the primary objective, this study presents correlations that predict 
deposition in the MT and cannula bifurcation regions based on the maximum inlet velocity 
to each of these regions, with the same volumetric flow rate. The results show that 
imposing different velocity profiles with varying peak velocities can cause the CFD-
predicted deposition to range from 3.8% to 8.8% in the MT region and from 0.9% to 7.2% 
in the cannula bifurcation. Using these predictive correlations reduced the turnaround 
time for analyzing numerous design candidates as only the flow pathway for each patient 
interface was required for each CFD model. The reduction in processing time using this 
method was especially important in this study as the oscillatory nature of the high-velocity 
inlet jet required a transient solution of the transport equations.  
The deposition correlation results also show that the impaction deposition in the 
chosen region is dependent on the inlet velocity profile and not simply the inlet volumetric 
flow rate. Each of the four velocity profiles in Figure 6.5a have the same flow rate, which 
was 13.3 LPM to be consistent with the chosen DPI, but each resulted in considerably 
different particle deposition results. A common method of predicting ET losses is to utilize 
the impaction parameter (𝑑𝑎
2𝑄) where particle size (𝑑𝑎) and flow rate (𝑄) are used to 
estimate transmission through the MT or NT region (Golshahi et al., 2011; Javaheri et al., 
2013; Storey-Bishoff et al., 2008; Tavernini et al., 2018). Studies that use the impaction 
parameter typically describe a large amount of variability, with Golshahi et al. (2011), 
Storey-Bishoff et al. (2008), and Tavernini et al. (2018) providing correlations that reduce 
this variability for children, infants, and neonates, respectively. The results in Figure 6.8a 
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and b show that for a constant flow rate the deposition results increased substantially with 
respect to peak inlet velocity, which suggests that peak inlet velocity is also a significant 
indicator of ET deposition. As such, the variability in predicting ET losses with the 
impaction parameter may be reduced further if aspects of the inlet profile were taken into 
consideration. For example, operating conditions that result in a turbulent flow regime 
may have a lower peak velocity, due to the blunt turbluent velocity profile, which may 
result in lower deposition than even laminar flow if turbulent particle dipersion is low. 
Similarly, if the flow does not reach a fully-developed state before entering the 
experimental model, the inlet velocity could be very different from either a laminar 
(parabolic) or turbulent (blunt) profile, which could influence the development of 
extratoracic deposition correlations. 
As mentioned previously, particle deposition was higher in the NT models 
compared to the MT, which resulted in lower expected lung doses with nasal 
administration. This apparent disadvantage of the NC designs can be leveraged as a 
benefit for the treatment of bacterial infections in the nasal cavity. There is evidence in 
the literature that the nasal cavity and sinuses can harbor bacterial colonies that 
repeatedly lead to lung infections in patients with CF (S. K. Hansen et al., 2012; Linnane 
et al., 2015; Moller et al., 2017) despite elimination of bacteria in the lower airways. 
Therefore, treatment methods may attempt to eradicate infections by administering 
tobramycin in the nasal cavity and sinuses. This would mean that nasal administration 
with the NC designs in the current study would be a preferred method, as a portion of the 
delivered dose is deposited in the NT region. If treatment of bacterial infections in the 
nasal cavity is not deemed necessary by clinicians and a high lung dose is required, then 
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oral administration methods with the MP designs presented here would be the preferred 
method. Beyond discussions of targeting deposition in the various regions of the airways 
for uniform dosing, there are also practical aspects of oral and nasal administration that 
should be taken into consideration. The proposed system aims to deliver the lung 
inhalation volume to the subject during actuation, as well as the tobramycin dose, which 
requires an air-tight seal between the device and patient. 
Limitations of this study primarily include the assumptions and approximations 
made by the CFD models. Hygroscopic growth is known to increase particle size as the 
aerosol travels through the humid airways. This phenomenon was neglected from the 
CFD model as the increase in ET deposition from hygroscopic growth is expected to be 
small, with Walenga et al. (2014) reporting an approximate 0.1% increase in adult nasal 
airways. The same negligible impact on ET deposition in infant and pediatric airways can 
also be assumed in the present study. The rod array was added to the patient interface 
in an effort to diffuse the high-velocity inlet jet, but rod arrays have also previously been 
utilized to increase secondary particle breakup and reduce aerosol size (Behara, Longest, 
et al., 2014a, 2014b; Longest et al., 2015; Longest, Son, et al., 2013). This secondary 
breakup mechanism was not included in the CFD models due to the associated increase 
in complexity and processing times. The deaggregation from passing the aerosol through 
the rod array decreases the particle size, which would be expected to decrease interface 
and ET losses and lead to further improvements in lung dose. These potential 
improvements to the delivery system performance that were not captured by the CFD 
models will be experimentally tested in a future study. The disadvantage of including a 
rod array in the patient interface design is that placing obstacles in the flow would lead to 
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an increase in impaction deposition. However, the CFD models assumed the stainless-
steel rods did not trap any particles that contact the surface (i.e. a reflection boundary 
condition was applied). Our previous work with rod arrays has shown the losses on the 
stainless-steel cylindrical surfaces are small and matched in vitro validation data (Longest 
et al., 2015; Longest, Son, et al., 2013), but this assumption must also be tested 
experimentally. 
In conclusion, candidate MP design concepts were developed that provide total 
CFD-predicted losses of approximately 5%, and expected lung doses of approximately 
85% (when coupled with the best-case DPI from Farkas et al. (2019)). Candidate NC 
design concepts performed slightly worse than their MP counterparts, but operating the 
DPI with a 25% reduction in flow rate lead to an expected lung dose of approximately 
74%. Development of deposition correlations showed that losses were strongly related to 
peak velocity on the outlet plane of the interface flow pathway, while the flow rate through 
the device was maintained at 13.3 LPM. Findings from this study and our previous 
publications on the subject will be used in the continuing development of a tobramycin 






Figure 6.1: Overview of delivery system and extrathoracic models for (a) oral 
administration via a mouth-piece (MP) through the mouth-throat (MT), (b) nasal 
administration via a nasal cannula (NC) through the nose-throat (NT), and (c) location of 
positive-pressure air source (ventilation bag). As noted in the figure, the air-jet DPI was 




Figure 6.2: Overview of patient interface design concepts for (a) Screening Iteration 1, 




Figure 6.3: Process flow chart to evaluate design concepts with the objective of 




Figure 6.4: Overview of model geometry showing (a) mouthpiece flow pathway, (b) 
mouth-throat only model (c) nasal cannula flow pathway, and (d) nose-throat and cannula 




Figure 6.5: Boundary conditions used to establish extrathoracic deposition metrics in 
the mouth-throat models showing (a) velocity profiles applied at the inlet boundary and 





Figure 6.6: Validation of CFD-predicted deposition with experimental data for (a) the 




Figure 6.7: Plots showing the correlation between time-average peak velocity at the 
patient interface outlet (umax) and the deposition efficiency (DE) up to the first impaction 
point, which is (a) the back of the throat for the mouthpiece and mouth-throat model, and 




Figure 6.8: Particle deposition patterns in the (a) mouth-throat (MT) region with the jet 
inlet velocity profile, (b) MT region with the turbulent inlet velocity profile, (c) nose-throat 
(NT) and bifurcation (Bif) region with the jet inlet velocity profile, and (d) NT and Bif region 




Figure 6.9: Example of jet diffusion by 3D rod array in the RE-d+RA-a mouth-piece 
compared to the high velocity inlet jet in the RE-a design. Contours depict nodal values 





Figure 6.10: Deposition patterns in full mouthpiece & mouth-throat model for the (a) RE-
a, (b) RE-d+RA-a, (c) RE-d+RA-g, and (d) RE-d+RA-c-EC design concepts (see Figure 




Figure 6.11: Deposition patterns in full nasal cannula & nose-throat model for the (a) RE-
a, (b) RE-d+RA-a, (c) RE-d+RA-g, and (d) RE-d+RA-c-EC design concepts (see Figure 




Figure 6.12: Comparison of CFD-predicted deposition for the RE-d+RA-c-EC nasal 




Table 6.1: Summary of experimentally determined patient interface and extrathoracic 
deposition efficiencies and fractions (based on air-jet DPI emitted dose) from Farkas et 
al. (2019) for the best-case mouthpiece and nasal cannula devices. Experimental values 





Interface DE 6.1 (0.7) 7.1 (1.7) 
ET DE 9.4 (1.6) 11.4 (3.5) 
Total DF 14.9 (2.1) 17.8 (4.9) 
DE: Deposition efficiency 






Table 6.2: Comparison of peak velocity (Peak Vel.), predicted regional deposition 
efficiencies (DE) in the device (Dev), mouthpiece (MP), and mouth-throat (MT), and 
predicted total deposition fraction (DFTot) between the original mouthpiece and Design 
Screen 1. 










Original MP 10.5 2.4 6.4 8.8a 16.7 
Design Screen 1 
GE-a 4.1 NAb 34.4 5.6 38.1 
GE-b 4.7 NAb 17.0 6.0 21.9 
RE-ac 5.0 4.4 1.8 6.1 11.8 
RE-b 3.9 14.0 15.9 5.5 31.7 
RA-ad 2.7 27.7 7.7 4.9 36.5 
RA-b 19.3 50.5 1.0 13.6 57.6 
TD-a 3.7 0.8 57.0 5.4 59.7 
TD-b 2.6 0.6 54.7 4.8 57.1 
a:  Deposition efficiency for the Original MP case is from CFD-predicted particle 
 trajectories, whereas deposition efficiency for all other designs is predicted 
 from peak velocity at the mouthpiece outlet 
b:  The gradual expansion cases go straight from the device outlet capillary to the 
 mouthpiece, hence there is no device loss 
c: The RE-a case gave the best reduction in device and MP losses from Design 
 Screen 1 
d: The RA-a case gave the best reduction in MT losses from Design Screen 1 
 
GE: Gradual Expansion 
RE: Rapid Expansion 
RA: Rod Array 





Table 6.3: Comparison of peak velocity (Peak Vel.), predicted regional deposition 
efficiencies (DE) in the device (Dev), mouthpiece (MP), and mouth-throat (MT), and 
predicted total deposition fraction (DFTot) among the original mouthpiece, the best cases 
from Design Screen 1, and Design Screen 2. 










Original MP 10.5 2.4 6.4 8.8 16.7 
Design Screen 1 Best Cases 
RE-a 5.0 4.4 1.8 6.1 11.8 
RA-a 2.7 27.7 7.7 4.9 36.5 
Design Screen 2 
RE-a+RA-aa 2.1 6.0 4.9 4.6 14.6 
RE-a+RA-c 2.6 1.9 13.2 4.9 19.0 
RE-c+RA-a 3.9 22.5 10.6 5.5 34.5 
CE+RA-aa 2.0 6.8 4.4 4.5 14.9 
CE+RA-d 3.3 6.6 3.3 5.2 14.4 
CE+RA-ea 1.8 1.9 7.4 4.4 13.1 
CE+RA-f 1.7 0.8 9.5 4.4 14.1 
a:  These cases demonstrated a marked improvement in predicted total deposition 
 fraction over the rod array cases from Design Screen 1, when combined with 
 the rapid expansion or cylindrical geometry, but further improvements are 
 possible 
 
RE: Rapid Expansion 
RA: Rod Array 





Table 6.4: Comparison of peak velocity (Peak Vel.), predicted regional deposition 
efficiencies (DE) in the device (Dev), mouthpiece (MP), and mouth-throat (MT), and 
predicted total deposition fraction (DFTot) among the original mouthpiece, the best cases 
from Design Screens 1 and 2, and Design Screen 3. 










Original MP 10.5 2.4 6.4 8.8 16.7 
Design Screen 1 and 2 Best Cases 
RE-ab 5.0 4.4 1.8 6.1 11.8 
RE-a+RA-a 2.1 6.0 4.9 4.6 14.6 
CE+RA-a 3.3 6.6 3.3 5.2 14.4 
CE+RA-e 1.8 1.9 7.4 4.4 13.1 
Design Screen 3 
RE-d+RA-aa,b 2.3 2.1 2.2 4.7 8.7 
RE-d+RA-ea 2.4 0.6 2.0 4.8 7.2 
RE-d+RA-ga,b 2.7 0.9 1.7 4.9 7.4 
RE-d+RA-a-434 3.9 2.9 1.4 5.5 9.6 
RE-d+RA-c-ECa,b 2.7 0.7 3.0 4.9 8.4 
a:  These cases demonstrate a dramatic improvement in predicted total deposition 
 fraction (<9% combined MP and MT losses) compared to previous design 
 screens 
b: Candidate design concepts selected for evaluation with full mouthpiece and 
 mouth-throat CFD model 
 
RE: Rapid Expansion 
RA: Rod Array 
CE: Cylindrical Expansion 
434: 4-3-4 rod array configuration (as opposed to 3-4-3) 





Chapter 7: Develop CFD Models of Upper Airway Geometries for 
Pediatric Patients and Evaluate Delivery Efficiency and Aerosol 
Growth with Comparisons to In Vitro Experiments 
7.1 Objective 
The objective of this study was to develop experimentally validated computational 
fluid dynamics (CFD) models of the upper airways and growth chambers for 2-3-, 5-6-, 
and 9-10-year-old patients with Cystic Fibrosis (CF), with a focus on using a nasal cannula 
for nose-to-lung (N2L) administration. The 5-6-year-old model was experimentally tested 
and provided in vitro data for validation of the CFD model. Results aim to establish 
whether the hygroscopic properties of the powder formulation and expected residence 
times through the model are capable of targeting the lower airways beyond Bifurcation 4 
(B4+) and maximizing lung retention of the delivered dose. 
7.2 Introduction 
The primary symptom of CF in the respiratory airways is the dehydration and 
thickening of mucus due to poor ion transport (Matsui et al., 1998; Tarran et al., 2001). 
Due to poor mucociliary clearance of this thick mucus (Stoltz et al., 2015), it persists in 
the patient’s airways and provides an ideal habitat for bacterial infections (Boucher, 
2007). The most predominant bacteria found in the airways of CF patients is 
Pseudomonas aeruginosa (Pa) (Elborn, 2016), which can be treated with inhalation of the 
antibiotic tobramycin (Ramsey et al., 1999; A. L. Smith, 2002). The bacterial infections 
cause various forms of damage to the respiratory airways and surfaces, such as 
inflammation (narrowing of the airways), bronchiectasis (widening of the airways), and 
mucus plugging (obstructions in the airways) (de Jong et al., 2004). Signs of such damage 
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are apparent in computed tomography (CT) scans of patients diagnosed with CF at very 
early stages in their life (Tiddens, Donaldson, Rosenfeld, & Pare, 2010), hence the need 
for treatment of bacterial infections in pediatric subjects. Our group has recently 
developed an optimized delivery system for oral and nasal administration of tobramycin 
to pediatric patients, which consists of a ventilation bag to provide inhalation air, an inline 
air-jet DPI for efficient aerosolization of the powder, and patient interface (mouthpiece or 
nasal cannula) for high-efficiency extrathoracic (ET) transmission to the lungs (Bass, 
Farkas, et al., 2019; Bass & Longest, 2020; Farkas, Bonasera, Bass, Hindle, & Longest, 
2020; Farkas et al., 2019). 
As a next step in the device development process, the current study explores 
particle transport through the diseased airways to establish whether the pediatric air-jet 
DPI system provides effective delivery of the pharmaceutical aerosol through the nose to 
the lungs. The treatment of all infections with antibiotics requires eradication of the 
bacterial colonies, otherwise mutated strains of the bacteria may develop that are drug 
resistant. To ensure eradication of Pa with tobramycin, the amount of antibiotic delivered 
to the airway surface liquid (ASL) must be above the minimum inhibitory concentration 
(MIC) of 512 mg/L (Bos et al., 2017). Our proposed approach to tobramycin administration 
in CF-diseased airways is to utilize excipient enhanced growth (EEG) powder 
formulations to provide uniform dosing and maximize lung retention. EEG aerosols have 
a small particle size when dry, which is characterized by mass-median aerodynamic 
diameter (MMAD), that provides highly-efficient penetration into the lower airways. 
Therefore, the advantage of using EEG aerosols for tobramycin administration is the 
ability to target deposition in the lower airways where bacterial infection is more 
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predominant (Tiddens et al., 2010). The hygroscopic excipient in the powder formulation 
absorbs moisture from the humid respiratory airways, and the dry particles grow to form 
larger droplets. The larger aerosol size in the lower airways improves lung delivery via an 
increase in impaction during inhalation and exhalation, as well as increased 
sedimentation during a breath hold. 
The concept of an upper airway and growth chamber model to evaluate EEG 
aerosol deposition and growth has previously been reported for oral (Longest, Tian, Li, et 
al., 2012) and nasal (Longest et al., 2015) aerosol administration in adults. An 
anatomically accurate model of the upper airways, from the ET region to Bifurcation 3 
(B3), is used to model aerosol transmission to the lower airways. Thereafter, a cylindrical 
growth chamber is used to model the aerosol growth as a representation of the humid 
respiratory airways, with its dimensions selected to give a droplet residence time 
consistent with the lungs. Previous studies using growth chamber models have shown 
that they are an effective method for evaluating EEG aerosol growth via a concurrent 
numerical and experimental approach, with good validation between CFD and in vitro 
deposition and particle size data (Longest et al., 2015; Longest, Tian, Li, et al., 2012). 
The present study developed new growth chamber models, which included the nose-
throat (NT) region through the upper airways (up to B3), to evaluate EEG aerosol 
deposition and growth in CF-diseased airways of patients aged 2-3, 5-6, and 9-10 years 
old. 
7.3 Methods 
Three models were developed to evaluate aerosol transport and growth in a 2-3-, 
5-6-, and 9-10-year-old patient. An in vitro growth chamber model for a 5-6-year-old 
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patient (see Figure 7.1) was prototyped and tested with the best-case DPI and nasal 
cannula from Farkas et al. (2020) (see Figure 7.2) to provide experimental data for CFD 
model validation. Thereafter, numerical models for all three age groups were developed 
to evaluate particle deposition and growth in the representative geometries. The 
geometries used in the in vitro and numerical models consists of an upper airway (NT to 
B3) extracted from CT scans and a growth chamber that was designed to provide an 
aerosol residence time of approximately two seconds throughout the entire model (see 
Figure 7.1). Characteristic airway dimensions for the three upper airway models are 
provided in Table 7.1. Characteristic length scales in the NT region are consistent with 
nasal deposition studies by Storey-Bishoff et al. (2008) and Golshahi et al. (2011), and 
dimensions from the trachea were measured directly from CT scans. Measurements 
beyond the trachea are not reported as the diseased state of the CF airways may not 
provide a clear comparison between age groups. As expected, characteristic dimensions 
for older patients are generally larger than the younger patients, which will likely influence 
aerosol deposition in the upper airways. 
Upper Airway and Growth Chamber Geometries 
The NT region of the upper airway models were developed by segmentation of CT 
scans with the Mimics software suite (Materialise, Leuven, Belgium) from patients with 
healthy airways, as no nasal scans were available for patients diagnosed with CF. This 
approach was deemed acceptable as the lung disease attributed to CF and Pa infections 
predominantly affects the lower airways (Tiddens et al., 2010). Scans for the NT region 
of the 2-3-, 5-6-, and 9-10-year-old upper airway models were selected from our database 
of medically necessary CT scans, which were reviewed for quality and completeness 
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under an Institutional Review Board protocol. When selecting scans for the study, 
preference was given to scans that had a slice resolution of 1.0 mm or less and of patients 
that had heights consistent with average values for the chosen age ranges. For the 2-3-, 
5-6-, and 9-10-year-old models, the patient heights were 90 cm, 114 cm, and 144 cm 
respectively, which are within the 20th and 80th percentiles based on the WHO growth 
charts (WHO, 2006). The segmentation and CAD model development generally followed 
the same method as outlined by Bass et al. (2019), with the exception that the latest 
automated skin surfacing capabilities in SpaceClaim v19.3 were utilized, which reduces 
the manual effort required to convert STL surfaces to CAD data. 
The tracheobronchial (TB) regions of the upper airway model (trachea to B3) were 
also developed by segmentation of CT scans with Mimics, but the chosen scans were 
from patients with moderate CF lung damage as scored by the PRAGMA-CF system 
(Rosenow et al., 2015). The CF CT scans for all three age groups were provided and 
evaluated for PRAGMA-CF score by Erasmus University Medical Center. For the 2-3-, 5-
6-, and 9-10-year-old model, the patient heights were 100 cm, 122 cm, and 131 cm 
respectively, which are also within the 20th and 80th percentiles based on the WHO growth 
charts (WHO, 2006) and consistent with the NT scans. After segmentation and CAD 
model development of the diseased TB regions, the airway was coupled to the NT region 
of the healthy patient to form the upper airway geometry (NT-B3). The two regions were 
coupled along the trachea at a point where there was less than a 1.0 mm deviation 
between the cross-section profiles of the NT and TB regions and preserved the expected 
tracheal length. A 10 mm coupling region along the length of the trachea (5 mm either 
side of the coupling point) was then created to define the transition between the NT and 
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TB regions. Due to the selection of a coupling point where there is minimal difference 
between two regions and a relatively short coupling section, the effect of artificially joining 
the healthy NT and diseased TB regions was assumed to be negligible. This assumption 
will be tested by identifying any abnormal deposition patterns in the coupling region from 
the CFD results. 
The cylindrical growth chamber was designed with insight from preliminary CFD 
work to provide minimal aerosol loss (<5% deposition) and a residence time of 
approximately two seconds, which is consistent with the typical particle transport through 
the lungs. The resulting chamber size for all age groups was a diameter of 101.6 mm (4”) 
and length of 155.0 mm. For the in vitro model, the chamber was constructed from a 
section of clear cast acrylic pipe, sourced from ePlastics (San Diego, CA), and a 
prototyped lid, base, and outlet pipe. 
Experimental Materials and Powder Formulation 
Albuterol sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena, 
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France). 
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ). 
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis, 
MO).  
Multiple batches of a spray-dried AS EEG powder formulation were produced 
based on the optimized method described by Son et al. (Son, Longest, & Hindle, 2013; 
Son, Longest, Tian, et al., 2013) using a Büchi Nano spray dryer B-90 (Büchi Laboratory-
Techniques, Flawil, Switzerland). The AS EEG powder formulation contained a 
30:48:20:2% w/w ratio of AS, mannitol, L-leucine, and Poloxamer 188. The AS EEG 
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powder was used as a surrogate test aerosol in place of tobramycin. It is expected that 
tobramycin powder formulations with the same hygroscopic properties as AS EEG will 
perform comparably in regard to targeted lung delivery. 
Experimental Methods 
The in vitro tests of the 5-6-year-old model were conducted under room (22.0°C 
and 33.5% RH) and humid airway (37.0°C and 99.0% RH) conditions, with the humid 
conditions controlled in an environment cabinet. In addition, for the humid airway 
conditions, the model walls were pre-wetted by running humid air (40.0°C and 99.0% RH) 
through the model before actuating the device in the humid airway experiments. Cooling 
of the 40°C saturated air in contact with the interior model walls resulted in water vapor 
condensing onto the walls forming a thin liquid layer. All experimental model components 
were developed by utilizing the CAD modelling capabilities in SolidWorks 2019 (Dassault 
Systèmes, Paris, France) and most parts were then rapid prototyped. The exceptions to 
prototyped parts were the acrylic growth chamber cylinder, as mentioned previously, and 
the face of the NT region, which was made from cast silicone to create a soft nose. The 
soft nose was required to accommodate the existing cannula design (which was 
developed to fit a different NT model) and to provide an air-tight seal around the cannula 
prongs. The material from which the soft nose is made is also more consistent with the 
flexible soft tissue of the human nose than rigid 3D printer plastic. The casting process 
used to make the soft nose was relatively simple, with the cast components developed in 
SolidWorks 2019 such that the void represents the anterior region of the NT model. The 
cast was then filled with Dragon SkinTM 20 silicone (Smooth-On, Lower Macungie, PA), 
left to cure following the product instructions, removed from the cast, and then fixed into 
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the NT model with epoxy. As an additional precaution against air leaks in the model, all 
connections between model components included O-rings to ensure air-tight sealing. 
The delivery system chosen for experimental testing was the best-case device and 
nasal cannula combination from Farkas et al. (2020). Details of the pediatric air-jet DPI 
(see Figure 7.2a) and patient interfaces (see Figure 7.2b) have been discussed 
extensively in our previous publications related to the development of this delivery system 
(Bass, Farkas, et al., 2019; Bass & Longest, 2020; Farkas et al., 2020; Farkas et al., 
2019). The chosen air-jet DPI operates at an approximate flow rate of 10 LPM (from a 
positive pressure gas source) and actuation time of 4.5 s (for an inhalation volume of 750 
mL for a 5-6-year-old) with inlet and outlet airflow passage (i.e. capillary) diameters of 
1.40 mm and 2.39 mm, respectively. The design parameters and operating conditions for 
the air-jet DPI have previously been shown to give the best aerosolization performance 
and high-efficiency N2L aerosol transmission (Farkas et al., 2020). The chosen nasal 
cannula utilizes a 3D rod array to attenuate the high-velocity, highly turbulent air jet that 
leaves the DPI outlet orifice, which has previously been shown to reduce interface and 
NT losses (Bass & Longest, 2020). 
The device actuation and experimental testing in the present study generally 
follows the methods presented by our previous in vitro development performance 
evaluation of the pediatric air-jet DPI and patient interfaces (Bass, Farkas, et al., 2019; 
Farkas et al., 2020). Briefly, the aerosolization chamber is loaded with 10 mg of AS EEG 
powder and actuated with a 6 kPa positive-pressure air source, using a compressed air 
line and solenoid valve device, which efficiently aerosolizes the powder. Characterization 
of the aerosol that leaves the growth chamber was performed using a Next-Generation 
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Impactor (NGI) and AS drug masses were assayed with high-performance liquid 
chromatography (HPLC). Preliminary experimental tests of the growth chamber model 
showed that device actuation time was not sufficient to clear all the aerosol from the 
growth chamber to the NGI, which lead to low recovered doses as powder remained 
dispersed in the cylinder and was not assayed. Therefore, a second solenoid valve was 
utilized that switched between pulling air from the chamber to ambient air, which was 
controlled by a separate timer from the device actuation and ran for 8 s longer than device 
actuation. In summary, the testing process was as follows: (i) switch the device solenoid 
valve to deliver compressed air to the DPI at 10 LPM (see Label 1 in Figure 7.1) and at 
the same time switch the NGI solenoid valve to pull air through the growth chamber at 45 
LPM (see Label 2 in Figure 7.1) allowing make-up air at 35 LPM to be drawn through the 
top of the growth chamber via one-way valves (see Label 3 in Figure 7.1); (ii) after 4.5 s, 
the device solenoid valve closes and device actuation stops while the NGI solenoid valve 
stays open for a total of 12 s, drawing all the aerosol from the chamber and delivering it 
to the NGI. Using this approach, all recovered doses from experimental runs were greater 
than 90% (average of 96.5%). The device emitted dose (ED) was defined as the 
difference between the loaded AS dose and the mass of AS retained in the DPI after 
actuation, divided by the loaded dose, and expressed as a percentage. The delivery 
system ED was defined with a similar method, with the combined mass of AS retained in 
the device and nasal cannula divided by loaded dose. The aerosol MMAD was identified 
with linear interpolation of a cumulative percentage drug mass vs. cut-off diameter plot 
from the NGI. The cut-off diameters of each NGI stage were calculated using the formula 




Computational Domain and Spatial Discretization 
The computational domain for the 5-6-year-old upper airway and growth chamber 
replicates the experimental model as closely as possible, with numerical extensions 
added as needed to ensure fully-developed flow enters the model inlets. As the CFD 
model in this study neglects the device and patient interface, the inlet to the computational 
domain begins 5 mm downstream of the nostrils, which is consistent with insertion of the 
cannula prongs into the soft nose of the in vitro model. The inlet boundary is the elliptical 
cross-section of the cannula prongs, with the surface between the nostrils and prongs 
defined as walls to represent the air-tight seal between the cannula and soft nose. All 
other inlet, outlet, and fluid-side wall boundaries are consistent between the 
computational domain and in vitro model. The CFD model geometry was generated by 
combining the flow path in the upper airway with the internal volume of the growth 
chamber, and the solid parts of the TB region were subtracted from the air-side volume 
to include the thickness of the model components in the chamber region. For CFD 
evaluation of all three age groups, a similar approach was used to generate the 2-3- and 
9-10-year-old models, using the same size growth chambers, with all geometries created 
in SpaceClaim v19.3. Figure 7.3a shows the full geometry, including the upper airway 
and growth chamber, for the 5-6-year-old CFD model, with Figure 7.3b-d showing only 
the upper airway geometry for the 2-3-, 5-6-, and 9-10-year-old CFD models, respectively. 
The cannula prong inlets on all three models were dimensioned to have similar areas, 
and hence provide similar inlet velocities given a flow rate of 5 LPM, but the major and 
minor radii of the elliptical prongs differed slightly to accommodate the different nostril 
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shapes. For the 2-3- and 9-10-year old models, the major and minor radii were 2.5 and 
4.5 mm respectively, which gave an average inlet velocity of approximately 2.36 m/s. For 
the 5-6-year-old model, the major and minor radii were 2.25 and 5.25 mm respectively, 
which gave an average inlet velocity of 2.25 m/s. As there is only a 0.1 m/s absolute 
difference in inlet velocity between the models (5.0% relative difference) the effect of 
changing cannula prongs on NT deposition is expected to be negligible and is a necessary 
modification to accommodate differing nostril dimensions. Also note that the angular 
rotation of prongs was different among all three models to fit the specific characteristics 
of each patient. The effect of these alterations to the cannula design on patient interface 
deposition is not known at this time. 
Spatial discretization of the computational domain was performed by utilizing the 
meshing capabilities available in FLUENT v19.3 (ANSYS Inc., Canonsburg, PA). An 
unstructured mesh approach, as opposed to structured hexahedral cells, was used to 
accurately resolve the complexity of the nasal passage surfaces and the transition from 
the upper airway to growth chamber regions. Instead of traditional tetrahedral-type cells, 
polyhedral cells were used to discretize the computational domain, which our group has 
previously shown to be more computationally efficient and equally as accurate for 
modeling particle transport through the upper airways (Bass, Boc, et al., 2019). Our 
previous model development work has also identified that the near-wall (NW) mesh 
resolution is critical to obtaining a successful experimental validation of the CFD model 
(Bass & Longest, 2018b). The CFD models in the present study follow our current best 
practices for polyhedral meshes of the respiratory airways (Bass, Boc, et al., 2019; Bass 
& Longest, 2018b) with a wall y+ value of approximately one, five prismatic NW cell layers, 
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and a layer-to-layer growth ratio of 1.2. As a final step, cell nodes were smoothed in 
FLUENT v19.3 until the orthogonal quality metric was greater than 0.15, which ensures 
a high-quality spatial discretization of the computational domain. 
Mesh independence of the 5-6-year-old CFD model was established using the 
Roache method for mesh refinement studies (Roache, 1994) by comparing the volume-
average velocity magnitude (𝑣𝑚𝑎𝑔) and turbulent kinetic energy (𝑘) between three meshes 
with increasingly higher degrees of spatial resolution. The three meshes had total cell 
counts of 1.17, 1.98, and 4.06 million cells, which resulted in normalized grid spacing 
ratios of 1.51, 1.27, and 1.00 respectively. Comparing the 1.98 and 4.06 million cell 
meshes, the grid convergence index was less than 1% for both volume-average 𝑣𝑚𝑎𝑔 and 
𝑘. Using Richardson Extrapolation (Richardson & Gaunt, 1927) to estimate the exact 
solution of the field quantities and comparing these values to the 1.98 million cell case, 
the relative error in 𝑣𝑚𝑎𝑔 and 𝑘 was 0.07% and 0.45%. Therefore, the 1.98 million cell 
case was chosen for evaluation of the 5-6-year-old model, and its degree of spatial 
discretization was subsequently applied to the 2-3- and 9-10-year old models. 
Furthermore, the 1.98 million cell count is consistent with the previous growth chamber 
study by Longest et al. (2012) which used a total of 1.49 million cells. 
Numerical Models and Solver Settings 
The Reynolds number at each nostril inlet, given a flow rate of 5 LPM and hydraulic 
diameter of 6.1 mm (from the elliptical inlet boundary), was approximately 1,000, which 
suggests laminar flow conditions. However, changes in cross-section throughout the 
entire domain are known to change local flow conditions and induce turbulence in the 
respiratory airways (Bass, Boc, et al., 2019). As such, the low-Reynolds number (LRN) 
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k-ω turbulence model was implemented to model the transitional-to-turbulent flow regime. 
The LRN k-ω model includes an eddy viscosity damping coefficient that allows it to 
provide an accurate representation of the flow field in regions of both low and high levels 
of turbulence. As this study evaluated EEG aerosol growth, both water vapor and air are 
modeled as components of the continuous phase in the computational domain to account 
for varying degrees of relative humidity, which required the addition of multi-species and 
energy transport equations to the standard mass, turbulence, and continuity equations. 
As the gas phase is composed of both air and water vapor, and temperature is not a 
constant variable, the incompressible ideal gas law was used to model the fluid density. 
Preliminary work on model development showed a jet formed as the flow passed 
through the constriction of the glottis in the larynx (laryngeal jet), and this jet exhibits 
transient behavior by oscillating back and forth through the trachea. The laryngeal jet 
phenomenon is consistent with previous observations by Xi et al. (2008) and has a 
significant effect on aerosol transport and deposition in the TB region. To capture this 
phenomenon accurately and achieve a converged solution, a transient formulation of the 
flow and turbulence transport equations was implemented in the CFD models. A time step 
of 0.005 s was sufficient to reach convergence within at most 100 iteration per time step 
and accurately modelled the oscillatory behavior of the laryngeal jet. A negligible 
difference in flow field and particle deposition results was also observed when decreasing 
the time step to 0.002 and 0.001 s, so using a time step of 0.005 s was deemed sufficient 
for all CFD models. The flow field was initialized with quiescent conditions and a water 
vapor mass fraction that was consistent with either room or humid airway conditions. 
Monitoring plots of volume-average 𝑣𝑚𝑎𝑔 and 𝑘  against flow time showed that the 
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transient start-up plateaued after approximately 0.5 s, so a total simulation time of 1.0 s 
was used for all CFD models. As an alternative and more computationally efficient method 
of tracking particles simultaneously with the flow field solution, particle trajectories were 
calculated at a single representative time step, as opposed to tracking particles 
throughout the full simulation duration. To ensure particle deposition and residence time 
was not vastly different between time steps, trajectories were calculated in the 5-6-year-
old model every 0.25 s, with the maximum absolute deviation from the mean deposition 
fraction (DF) being 0.4% and the maximum absolute deviation from the mean residence 
time being 0.3 s. 
FLUENT v19.3 (ANSYS Inc., Canonsburg, PA) was used to obtain solutions for all 
flow and turbulence equations, and all settings for modeling particle transport in the 
respiratory airways followed our previously defined best practices (Bass, Boc, et al., 2019; 
Bass & Longest, 2018b). The spatial discretization of the flow and turbulence transport 
equations were second-order accurate, the gradient discretization used the Green-Gauss 
Node-based method, and the SIMPLEC pressure-velocity coupling scheme was used. 
Further details on the mass, momentum, and turbulence transport equations are available 
in our previous publications (Longest et al., 2007; Longest et al., 2006). All inlet 
boundaries used mass flow inlet conditions, with the nostril inlets (see Label 1 in Figure 
7.1) each assigned a mass flow that gave a volumetric flow rate of 5 LPM (based on the 
10 LPM device flow rate). The two one-way valve inlets (see Label 2 in Figure 7.1) were 
each assigned a mass flow rate that gave a volumetric flow rate of 17.5 LPM, which 
totaled a flow rate of 45 LPM through the model outlet to match the NGI operating 
conditions (see Label 3 in Figure 7.1). Considering the water vapor entering the domain 
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under humid airway conditions, the water vapor mass fraction at the one-way valve inlets 
was consistent with the 99% RH at 37°C in the environmental chamber. As the device 
was actuated with compressed air from a wall outlet, the water vapor mass fraction at the 
nostril inlets was consistent with the 10% RH that is expected from dry wall air. All wall 
boundaries in the CFD model use the no slip shear condition, the effects of surface 
roughness on the flow field and particle trajectories were neglected, and the deposit-on-
touch particle boundary condition was used to model deposition. As the walls of the in 
vitro model were pre-wetted to be representative of upper airway conditions, the water 
vapor mass fraction on all model walls was 99% RH at a wall temperature of 37°C. 
Particle Transport and Growth 
The discrete phase model (DPM) available in FLUENT v19.3 was used to calculate 
the particle trajectories and deposition through the domain, with the Runge-Kutta scheme 
selected to integrate the particle equations of motion. All DPM settings followed our 
previously defined best practices and modeling recommendations (Bass, Boc, et al., 
2019; Bass & Longest, 2018b; Longest & Xi, 2007; Walenga & Longest, 2016), which 
have been validated against experimental deposition data in the upper airways. NW 
corrections, implemented via FLUENT user-defined functions (UDFs), were applied to 
correct the over-prediction of micro-particle deposition that is often observed with the LRN 
k-ω model. These NW corrections have been discussed in detail in our previous studies 
(Bass, Boc, et al., 2019; Bass & Longest, 2018b; Longest & Xi, 2007) and provide an 
accurate match between CFD and experimental deposition data. The effect of two-way 
coupling between the flow field and particles, which is where the particle trajectories and 
growth influence the continuous phase and vice versa, was evaluated as a possible 
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improvement to matching numerical and experimental growth results. This is in contrast 
to one-way coupling where only the flow field influences the particle trajectories and 
growth. For two-way coupling, changes to water vapor mass fractions in the continuous 
phase, based on mass transfer in and out of the discrete phase, is implemented via a 
UDF and was previously described by Longest and Hindle (2011). Preliminary work 
showed that a monodisperse aerosol, as opposed to using a polydisperse size 
distribution, was capable of providing the expected aerosol growth and minimized 
computational expense. When evaluating two-way particle tracking, reducing processing 
times is an important consideration due to the additional computational requirements. The 
initial particle diameter entering the nostrils is based on the 1.53 µm MMAD for the best-
case device and nasal cannula combination from Farkas et al. (2020). To ensure particle 
convergence, a total of 10,000 particles were introduced to the domain, with 5,000 
particles at each nostril inlet. 
The current study implemented an enhancement to the NW correction UDFs 
regarding the threshold, below which, the damping of the wall-normal velocity is applied 
to model particle-wall hydrodynamic interactions. Previous versions of the NW correction 
UDFs used a critical wall-normal distance between the particle and wall (called the NW 
limit), and the wall-normal velocity was damped in the region below this value, with CFD 
models using a typical NW limit value of 1-2 µm (Bass, Boc, et al., 2019; Bass & Longest, 
2018b). A drawback to this approach in the current study is that there is a vast difference 
between the average velocity in the upper airways and growth chamber, so a single NW 
limit value was not able to achieve adequate model validation for both regions. Therefore, 
a local Stokes number was implemented to define the criterion for damping the wall-
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where: 𝑣𝑝 is the particle velocity magnitude, 𝜌𝑝 is the particle density, 𝑑𝑝 is the particle 
diameter, 𝐶𝑐 is the Cunningham slip correction factor, 𝜇𝑓 is the fluid viscosity, and ℎ𝑝 is 
the wall-normal distance between the particle and wall. With this implementation of the 
NW correction UDFs, a critical Stk𝑙 of 15 was used to determine whether the wall-normal 
velocity is damped (as opposed to the NW limit), which gave the best validation with 
experimental deposition data throughout the model geometry. 
As a dry particle absorbs water from the humid airways it becomes a droplet, with 
this condensation (as well as evaporation) of water implemented in FLUENT v19.3 via a 
UDF. Longest and Xi (2008) originally reported the heat and mass transfer model for 
multicomponent hygroscopic aerosols in the respiratory airways that was used in the 
current study. These aerosol growth UDFs have been successfully validated against 
experimental data in a simplified coiled tube geometry (Longest & Hindle, 2012), adult 
growth chamber models (Longest et al., 2015; Longest, Tian, Li, et al., 2012), and for 
noninvasive ventilation high flow therapy (Golshahi et al., 2013). The mass flux between 
the droplet and humid ambient air is dependent on the mass fraction of water vapor on 






where: 𝑆 is the water activity coefficient, 𝑃𝑣,𝑠 is the water vapor saturation pressure, 𝜌𝑓 is 
the fluid density, 𝑅𝑣 is water vapor gas constant, and 𝑇𝑑 is the droplet temperature. In 
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Equation (7.3.2), the water vapor saturation pressure (𝑃𝑣,𝑠) is a function of the droplet 
temperature, which is calculated in the growth UDFs with the Antoine equation and 
includes the influence of the Kelvin effect, as follows: 
 
𝑃𝑣,𝑠 = exp (
23.196 − 3816.44
𝑇𝑑 − 46.13




where: 𝜎𝑑 is the droplet surface tension, 𝑑𝑑 is the droplet diameter, and 𝜌𝑑 is the droplet 
density. In Equation (7.3.3), the droplet surface tension is a function of the droplet 
temperature, which is given by: 
 𝜎𝑑 = 0.0761 − 1.55𝐸-4(𝑇𝑑 − 273) (7.3.4) 
In Equation (7.3.2), the water activity coefficient (𝑆) is given by: 
 
𝑆 = (1 +





where: 𝑖 represents the component van’t Hoff factors, 𝜒 represents the component mole 
fraction, and the subscripts 𝐴𝑆, 𝑀𝑁, and 𝐿 are the Albuterol Sulfate, Mannitol, and l-
Leucine formulation components, respectively. The growth UDFs calculate the mass flux 
(Δ𝑚𝑤) to or from the droplet from condensation and evaporation as:  
 Δ𝑚𝑤 = 𝜌𝑓ℎ𝑚(𝑌𝑣,𝑠 − 𝑌𝑣,𝑓) (7.3.6) 
where: ℎ𝑚 is the mass transfer coefficient and 𝑌𝑣,𝑓 is the mass fraction of water vapor in 






where: Sh is the Sherwood number and 𝐷 is the mass diffusivity. Further details on the 
specifics of the particle growth UDFs with regard to growth chamber models were 
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described by Longest et al. (2012), and the material and hygroscopic properties for the 
drug and the excipients were presented by Longest and Hindle (2011). 
7.4 Results 
Experimental Aerosol Deposition and Growth 
Table 7.2 summarizes the aerosol deposition and growth results from experimental 
testing of the 5-6-year-old model under room (22.0°C and 33.5% RH) and airway (37.0°C 
and 99.0% RH) conditions. The mean (standard deviation (SD)) delivery system ED 
(exiting the cannula and based on the device loaded dose) was 80.1% (3.6%) and 79.4% 
(2.8%) for room and airway conditions respectively, which is consistent with the previous 
experimental testing of the same device and nasal cannula combination by Farkas et al. 
(2020) (reported as 79.5% (2.6%)). N2L aerosol transmission was very good and 
provided high-efficiency delivery to the lower airways (B4+), with mean (SD) NT-B3 
deposition losses of 4.2% (0.9%) and 5.3% (2.3) for room and airway conditions, 
respectively. Comparing upper airway losses between the room and airway results shows 
EEG aerosol growth in the humid conditions does not affect impaction deposition in the 
NT and TB regions, and is hence capable of targeting the lower airways, as there is no 
statistical significance between the room and airway NT-B3 DFs (p-value = 0.25). In vitro 
losses in the growth chamber were below the acceptable limit (<5%) under both the room 
and airway conditions with mean (SD) DFs of 3.7% (2.1%) and 0.9% (0.6%), respectively. 
There was a significant increase in growth chamber losses under room conditions 
compared to the humid experimental test (p-value = 0.03), which may be attributed to 
increased static charge on the cast acrylic cylinder when humidity is relatively low. 
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The aerosol MMAD at the growth chamber outlet under room conditions is 
significantly larger (p-value = 0.002) than the aerosol size at the cannula prong outlet 
reported by Farkas et al. (2020), with mean (SD) MMADs of 1.70 (0.05) µm and 1.53 
(0.03) µm respectively. This result is consistent with observations from the growth 
chamber study from Longest et al. (2012). At this time, it is unclear whether a small 
amount of hygroscopic growth occurs in the in vitro model under room conditions, or 
whether deposition associated with Brownian diffusion and turbulent dispersion increases 
the aerosol MMAD at the growth chamber outlet. Comparing aerosol growth between the 
room and airway conditions, the MMAD increased from 1.70 µm to 3.49 µm (with an 
absolute difference of 1.49 µm MMAD or growth ratio of 1.9) due to humidity in the 
respiratory airways, which is expected to provide targeted drug delivery to the lower 
airways. 
CFD Model Validation 
The validation of CFD-predicted aerosol deposition and growth with experimental 
data is illustrated in Figure 7.4. Figure 7.4a shows deposition results in the computational 
domain under room conditions, with DFs based on the ED from the delivery system (as 
opposed to loaded dose), due to the fact that the CFD model does not include the device 
or patient interface. Numerical deposition predictions in the NT-B3 model and growth 
chamber regions match the in vitro data well and are within the experimental SD, which 
indicates successful validation of the particle tracking models. CFD predictions of 
depositional losses in the growth chamber are somewhat lower than the experimental 
results, but as mentioned previously, it is suspected that static charge on the acrylic 
cylinder walls increased losses in this region. The CFD models do not include the effect 
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of static charge on wall boundaries, and hence this behavior was not accounted for in the 
numerical deposition results. As stated in the Methods, a 10 mm coupling region between 
the healthy NT and CF-diseased TB regions was required in the model geometry. 
Deposition patterns in the trachea, where the coupling region is located, do not show any 
signs of abnormal deposition, which suggests the steps taken to connect the NT and TB 
regions do not adversely affect interpretation of the results. Due to the relatively small 
amount of hygroscopic particle growth that occurs under room conditions, aerosol 
MMADs are not compared between experiments and CFD results in Figure 7.4a. 
Figure 7.4b compares aerosol deposition and growth between experimental and 
numerical data under humid airway conditions, with one-way coupling between the 
continuous and discrete phase. As with the results from room conditions, CFD-prediction 
of DFs in the NT-B3 model and growth chamber regions are well validated against in vitro 
data and fall within the experimental SDs. A small decrease in airway model deposition 
fraction was observed for humid airway conditions, which is surprising considering that 
aerosol size increase should increase deposition by impaction. However, this small 
decrease can be attributed to the random nature of both the turbulent dispersion model 
and anisotropic NW turbulence corrections, and may also stem from small variations in 
the flow fields for each case. That said, both CFD models are well validated and fall within 
the experimental SDs for aerosol deposition, so the CFD predictions are considered an 
accurate representation of particle transport. There was also no statistical significance 
between NT-B3 losses when comparing experimental results under room and airway 
conditions, so the DF increase that was observed during in vitro testing cannot be 
attributed only to the presence of humidity. Looking at losses in the growth chamber, static 
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charge on the cylinder walls is expected to be lower under humid conditions, and this 
supports the decrease in deposition losses in this region that is seen in Figure 7.4b. The 
CFD-predicted deposition on the growth chamber walls also shows a closer match to 
experimental results in Figure 7.4b, which reinforces the suggestion that growth chamber 
losses under room conditions were due to static charge on the cylinder walls. The CFD-
predicted MMAD at the growth chamber outlet compares well to the in vitro data, which 
indicates successful validation of the one-way coupled particle transport models and 
evaporation/condensation UDFs. 
Comparisons between the one-way and two-way coupled particle tracking 
methods for aerosol deposition and growth are provided in Table 7.3. This shows there 
is little difference between the two methods in the current study, with a maximum absolute 
difference between two-way and one-way particle tracking for NT-B3 DF, Chamber DF, 
and outlet MMAD of 0.1%, 0.7%, and 0.06 µm respectively. For two-way coupling, results 
are presented for both 10 and 20 coupled cycles between the continuous and discrete 
phase, which shows that doubling the number of coupled cycles does not influence 
aerosol deposition and growth. Two-way coupled particle tracking consumes water vapor 
(and reduces the RH) from the continuous phase as the particles grow under humid 
conditions, but the relatively large volume of the growth chamber region means a large 
amount of humid air is available, which is the most likely reason why there is little apparent 
difference between one-way and two-way coupled particle tracking in the current study. 
When considering particle paths through narrow airway bifurcations with less volume, the 
effect of using with one-way or two-coupled particle tracking may be more pronounced. 
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As the CFD model is well validated against experimental results using one-way particle 
tracking (see Figure 7.4), this method is used throughout the remainder of this study. 
Flow Field Characteristics 
Figure 7.5 shows plots of velocity magnitude and relative humidity to illustrate the 
flow field characteristics in the computational domain. Figure 7.5a presents a contour plot 
of velocity magnitude on a plane that cuts through the left nostril, nasal passage, trachea, 
and growth chamber. The figure demonstrates the wide range of velocity magnitudes in 
the CFD model; for example, the velocity magnitudes at Point A and B were 8.55 m/s and 
0.16 m/s respectively. This justifies the implementation of a local Stokes number to 
determine the upper limit of the NW region, below which, wall-normal velocity is damped 
to model particle-wall hydrodynamic interactions. The inset in Figure 7.5a shows a close-
up view of flow through the larynx and clearly illustrates the laryngeal jet phenomena. 
Similarly, Figure 7.5c shows the three-dimensional nature of the laryngeal jet with an iso-
surface of 7.0 m/s velocity magnitude through the trachea. 
Figure 7.5b shows contours of relative humidity on the same plane as Figure 7.5a, 
with the inset providing a close-up view of the nostrils and anterior nose. This illustrates 
the introduction of the dry actuation air (at 10% RH) to the computational domain, which 
is delivered from the cannula prong outlets in the experimental model. By the time the 
flow reaches the nasopharynx region, observations from the CFD model show the dry air 
has mixed with the humid air and RH values are greater than approximately 90%. 
Conditions in the growth chamber are close to 99% RH, which facilitates aerosol growth 
and provides an accurate representation of the respiratory airways. Figure 7.5d shows an 
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iso-surface of 80% RH in the nasal passage and further illustrates mixing of dry and humid 
air in the anterior region of the nose. 
Residence Time and Maximum Particle Growth 
Figure 7.6 plots the particle diameter (as MMAD) vs. residence time for the 5-6-
year-old CFD model. The points represent the diameter and time for each individual 
particle that was tracked through the domain, at the time that they either deposited or 
exited the mixing chamber, up to a maximum time of 5.0 s. The red dotted line shows a 
logistic best-fit curve that represents the average particle diameter vs. residence time 




0.75 + exp (−4.5𝑡)
 (7.4.1) 
where: 𝑑𝑝 is the particle diameter and 𝑡 is the particle residence time. This shows that the 
MMAD begins to plateau around 1.2 s and levels off completely by a residence time of 
2.0 s. As 𝑡 → ∞ in Equation (7.4.1), the particle diameter (𝑑𝑝) approaches an MMAD of 
3.56 µm. From this, the 𝑡90 is defined as the residence time used in Equation (7.4.1) that 
gives an MMAD that is 90% of 3.56 µm, which for this case is 0.55 s. Therefore, a 
residence time of approximately 2.0 s is more than sufficient to maximize aerosol growth 
and target drug delivery in the lower airways. 
Comparison of Deposition and Growth between Age Groups 
CFD predicted particle trajectories (colored by MMAD) and regional DFs are 
presented in Figure 7.7. All three models show that the particle MMADs were less than 
approximately 2.5 µm when the aerosol leaves the upper airways (NT-B3) and enters the 
growth chamber. This suggests the hygroscopic properties of the powder formulation are 
capable of targeting drug delivery to the lower airways (B4+). This claim was further 
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supported with CFD predictions of relatively low aerosol deposition in the NT-B3 region 
for all age groups. The MMADs at the outlet of the growth chamber for the 2-3- (Figure 
7.7a) and 9-10-year-old (Figure 7.7c) models were 3.40 µm and 3.47 µm respectively, 
which is consistent with the 3.38 µm MMAD from the 5-6-year-old model (Figure 7.4b and 
Figure 7.7b). As stated above, a residence time of approximately 0.55 s was required to 
reach 90% of the average final particle size for the 5-6-year-old model. Similar 
expectations can be applied to the 2-3- and 9-10-year-old age groups, based on the 
consistency in CFD predictions of aerosol growth between all three models. The relatively 
large increase in aerosol size (absolute increase of 1.49 µm MMAD or a growth ratio of 
1.9) suggests the EEG powder formulation is capable of targeting the lower airways. The 
larger particle diameters in the lower airways are expected to reduce exhalation losses 
with an increase in particle momentum and impaction, and improve lung retention with an 
increase in sedimentation deposition (if a breath hold maneuver is employed). 
As mentioned previously, the delivery system and powder formulation provide 
high-efficiency N2L transmission in the 5-6-year-old model with a NT-B3 DF of 4.8%, as 
shown by both Figure 7.4b and Figure 7.7b. For the 2-3-year-old model in Figure 7.7a, 
the NT-B3 losses are higher than the 5-6-year-old with a CFD-predicted DF of 10.9%. 
This increase in upper airway losses can be attributed to the smaller airway dimensions 
in the younger patient (see Table 7.1), which leads to an increase in impaction deposition. 
For the 9-10-year-old model in Figure 7.7c, the NT-B3 losses are also higher than the 5-
6-year-old with a CFD-predicted DF of 7.0%. In this case, the increased losses are most 
likely due to the increase in length of the upper airways, which leads to longer residence 
times and more hygroscopic growth in the NT-B3 region. Looking at the particle 
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trajectories in Figure 7.7c, the MMADs in the 9-10-year-old model are approximately 2.5 
µm around the glottis, whereas the MMADs in a similar region for the 2-3- and 5-6-year-
old models is less than approximately 1.75 µm. The increased particle size in the upper 
airways for the 9-10-year-old caused more impaction losses and accounts for the small 
increase in NT-B3 DFs. Despite the 2-3- and 9-10-year-old models having slightly higher 
deposition in the NT-B3 region than the 5-6-year-old model, upper airway losses were 
relatively low for all three cases and expected drug delivery to the lower airways (B4+) 
was high. Upper airway losses may be improved by designing air-jet DPIs specifically for 
the 2-3 and 9-10-year-old age groups. 
7.5 Discussion 
This study meets the objective by using a concurrent numerical and experimental 
approach to demonstrate EEG powder formulations are capable of targeting the lower 
airways (B4+) with N2L transmission through the diseased airways of pediatric patients 
with CF. Upper airway losses (NT-B3) for the 2-3-, 5-6-, and 9-10-year-old age groups 
were 10.9%, 4.8%, and 7.0%, respectively. Furthermore, the experimental results in 
Table 7.2 show upper airway penetration fractions of approximately 70%, which is a vast 
improvement to lung doses in pediatric patients compared to commercial devices. For 
example, Below et al. (2013) reported that the Novolizer and Easyhaler provide a lung 
dose (with respect to nominal dose) of 5% and 22%, respectively, on the tracheal filter of 
a 4-5-year-old in vitro model. For the Cyclohaler, HandiHaler, and Spinhaler, Linder et al. 
(2014) reported lung delivery efficiencies of 9% to 11%. The validated CFD models 
showed the aerosol MMAD is expected to grow to at least 3.3 µm in the lower airways 
after a residence time of approximately two seconds. As aerosol MMADs greater than 2.5 
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µm are expected to be retained in the lungs (Longest et al., 2015), this demonstrates EEG 
powder formulations are capable of maximizing lung dose in the diseased airways. Both 
N2L transmission and lung retention may be improved further by designing devices and 
powder formulations that are specific to each age group. Results in Figure 7.7 showed 
differences in NT-B3 losses between the three models, which are attributed to differences 
in airway dimensions between patients at different ages (see Table 7.1).  
As a secondary outcome of this study, a locally-defined Stokes number (see 
Equation (2.3.1)) was implemented for the first time to define the NW region where wall-
normal velocities are damped to model particle-wall hydrodynamic interactions. This 
approach led to successful validation of the CFD model by matching experimental particle 
deposition data in both the upper airways and growth chamber regions. The 
implementation of particle condensation and growth, as described by Equations (7.3.2) 
to (7.3.7), was also successfully validated by matching the experimental characterization 
of the aerosol MMAD at the growth chamber outlet. 
A primary limitation of the current study for evaluating tobramycin delivery to CF-
diseased airways is the use of AS EEG powder as a surrogate test aerosol. At this time, 
the hygroscopic properties of tobramycin, particularly the van’t Hoff factor, have not been 
experimentally determined, and as such tobramycin EEG powder formulations cannot be 
evaluated with CFD models. Despite this limitation to the current study, inferences on the 
ability for the delivery system to provide highly-efficient N2L transmission are still valid, 
providing future tobramycin EEG powder formulation have similar hygroscopic 
capabilities as the AS EEG aerosol. Other limitations include the use of a growth chamber 
as a representation of particle growth in the lung pathways, modifications to the cannula 
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prongs specific to each patient, and a lack of evaluation regarding interpatient variability. 
The growth chamber was designed to provide a residence time of two seconds, which is 
consistent with transport through the airways, but particle trajectories through lung 
bifurcations are vastly different and may have an influence on aerosol growth. As such, 
evaluation of EEG aerosol transport and growth through complete airways of CF-
diseased lungs is required, which may be modelled using the stochastic individual 
pathway methodology (Longest et al., 2015; Longest & Hindle, 2009a; Longest et al., 
2007; Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Longest 
& Vinchurkar, 2007b; Tian et al., 2011; Walenga & Longest, 2016). Modifying the cannula 
prong dimensions and angular rotation for the 2-3- and 9-10-year-old age groups may 
influence upstream losses in the patient interface. If device development of age-specific 
devices is conducted, the effect of modifying the cannula design can be tested at the 
same time. Finally, the current study evaluated a single upper airway model for each of 
the three age groups, but interpatient variability is known to be significant for nasal 
deposition of aerosols (Garcia, Tewksbury, Wong, & Kimbell, 2009; Golshahi, Noga, & 
Finlay, 2012; Golshahi et al., 2011; Storey-Bishoff et al., 2008) and should be taken into 
consideration. 
Future work should intend to address the limitations of the current study that are 
outlined above, including the evaluation of cannula modifications and expectations for 
interpatient variability. The most important consideration for future work is to identify the 
hygroscopic properties of tobramycin and conduct CFD-based evaluation of tobramycin 
EEG aerosol transport through complete airway models. Identification of optimal powder 
formulations is required to maximize lung delivery and retention, which can be tested by 
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changing the fractions and types of hygroscopic excipients. Two-way coupled particle 
tracking should also be reconsidered in complete airway models, as the reduced volume 
of airway bifurcations compared to the growth chamber may cause a greater decrease in 
RH values in the continuous phase as the particles absorb moisture. Also, the effect of 
two-way coupled particle tracking is expected increase in significance as the aerosol 
grows beyond 3 µm (Longest & Hindle, 2010, 2012), which is true for the current powder 
formulation. Beyond numerical and in vitro testing of the air-jet DPI and 3D rod array 
interface, in vivo evaluation of tobramycin delivery to the lower airways is required. 
Additional validation of the locally-defined Stokes number and its implementation in the 
NW correction UDFs is required to determine whether it is a worthwhile enhancement for 
a variety of geometries and applications. Finally, future experimental work that uses 
growth chamber models should endeavor to minimize static charge on the cast acrylic 
cylinder to reduce chamber losses and provide better comparisons between the in vitro 
and CFD results. 
In conclusion, three growth chamber models were developed that represent the 
diseased upper airways of pediatric patients diagnosed with CF in the age ranges of 2-3, 
5-6, and 9-10 years old. The CFD models successfully validated aerosol deposition and 
growth through the computational domain against experimental data via the 
implementation of NW corrections and aerosol condensation and growth models. Results 
show that the chosen air-jet DPI and nasal cannula delivery system was capable of 
providing highly-efficient N2L aerosol delivery to the lower airways (B4+), with NT-B3 
losses of 10.9%, 4.8%, and 7.0% for the 2-3-, 5-6-, and 9-10-year-old models 
respectively. Lung retention of the delivered aerosol is also expected to be high, as the 
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aerosol grows to an MMAD of approximately 3.4 µm in all three cases after a residence 






Figure 7.1: Schematic of the experimental model showing the device (Air-jet DPI), 
patient interface (Nasal Cannula), in vitro model (Upper Airway), and two-second 
residence time chamber (Growth Chamber). Air flow in and out of the model is labelled 
(1) 10 LPM actuation air into the device, (2) 35 LPM make-up air through two one-way 




Figure 7.2: Overview of flow pathways for the best-case nose-to-lung delivery system 
from Farkas et al. (2020) showing (a) the air-jet dry powder inhaler with inlet and outlet 
flow passages and powder aerosolization chamber and (b) the 3D rod array nasal 
cannula. Note that the air-jet DPI and cannula interface are included in the in vitro portion 




Figure 7.3: Summary of computational domains showing (a) the full CFD model of the 
nose-throat, tracheobronchial region, and growth chamber for the 5-6-year-old child, (b) 
the nose-throat to B3 (NT-B3) for the 2-3-year-old child, (c) the NT-B3 for the 5-6-year-




Figure 7.4: Validation of the numerical models showing (a) comparison of deposition 
fractions (DF) in the airway and chamber regions between the CFD and in vitro 
experimental (Exp.) results under room (i.e. no particle growth) conditions (22.0 °C and 
33.5% RH) and (b) comparison of regional DF and particle mass-median aerodynamic 
diameter (MMAD) at the model outlet between the CFD and experimental results under 
upper airway conditions (37°C and 99%RH). Note that DFs here are given based on 





Figure 7.5: Summary of flow field characteristics in the 5-6-year-old model showing (a) 
contours of velocity magnitude (Vel. Mag.) with a close-up view of the laryngeal jet, (b) 
contours of relative humidity (RH) with a close-up view of the dry wall air (used to actuate 
the device) entering the in vitro model, (c) iso-surface of 7 m/s velocity magnitude 





Figure 7.6: Plot of particle diameter vs. residence time, with each individual point 
representing the values for a single particle at the time it deposited or exited the 
computational domain. The red dashed line shows the best-fit curve and the dotted line 
marks the average chamber residence time, which shows a two-second residence time 




Figure 7.7: Examples of CFD-predicted particle trajectories and growth through the 
domain for the (a) 2-3-year-old, (b) 5-6-year-old, and (c) 9-10-year-old models, with 
annotations of nose-throat to Bifurcation 3 deposition fraction (DFNT-B3), growth chamber 




Table 7.1:  Characteristic dimensions for the 2-3-, 5-6-, and 9-10-year-old upper airway 
models. 
Dimension 2-3-year-old 5-6-year-old 9-10-year-old 
𝑉 [mm3] 18,411 24,186 41,323 
𝐴𝑠 [mm
2] 13,742 16,202 23,060 
𝑉/𝐴𝑠 [mm] 1.34 1.49 1.79 
𝐿𝐶𝑃 [mm] 124.4 126.4 128.5 
√𝑉/𝐿𝐶𝑃 [mm] 12.2 13.8 17.9 
𝐷ℎ,𝐺 [mm] 5.7 6.7 6.8 
𝐿𝑇 [mm] 64.6 75.3 97.7 
𝑉: NT-B3 volume 
𝐴𝑠: NT-B3 surface area 
𝐿𝐶𝑃: Central path length from nostrils to glottis 
𝐷ℎ,𝐺: Hydraulic diameter of the glottis 





Table 7.2:  Summary of aerosol deposition and growth from experimental testing under 
room and humid airway conditions. Deposition fractions are defined based on device 




(22.0°C and 33.5% RH) 
Airway Conditions 
(37.0°C and 99.0% RH) 
Aerosol Deposition 
Device DF [%] 13.3 (2.1) 13.8 (3.1) 
Cannula DF [%] 6.6 (1.5) 6.9 (0.5) 
System ED [%] 80.1 (3.6) 79.4 (2.8) 
NT-B3 DF [%] 4.2 (0.9) 5.3 (2.3) 
Chamber DF [%] 3.7 (2.1) 0.9 (0.6) 
Model PF [%] 70.6 (5.0) 70.1 (1.4) 
Aerosol Growth 
MMAD [µm] 1.70 (0.05) 3.19 (0.30) 
RH: Relative humidity 
DF: Deposition fraction 
ED: Emitted dose 
NT-B3: Nose-throat to Bifurcation 3 
PF:  Penetration fraction 





Table 7.3:  Comparison of aerosol deposition and growth between the one-way and 
two-way coupled particle tracking methods. Deposition fractions are based on delivery 
system emitted dose. 






NT-B3 DF [%] 4.8 4.7 4.8 
Chamber DF [%] 1.7 1.2 1.0 
Aerosol Growth 
MMAD [µm] 3.38 3.39 3.32 
NT-B3: Nose-throat to Bifurcation 3 
DF:  Deposition fraction 





Chapter 8: Extend and Develop CFD Lung Models to Predict Regional 
Lung Deposition and Tobramycin ASL Concentrations in Healthy 
and CF Complete-airway Lung Models 
8.1 Objective 
The objective of this study was to develop a high-efficiency aerosol delivery 
strategy for nose-to-lung (N2L) administration of tobramycin antibiotics to children with 
Cystic Fibrosis (CF) using a complete-airway computational fluid dynamics (CFD) model. 
The basis of the strategy is excipient enhanced growth (EEG) delivery where a small 
particle aerosol is initially formed and increases in size through the respiratory airways. 
Ideal conditions for antibiotic aerosol delivery included: (i) airway surface liquid (ASL) 
concentrations of tobramycin greater than the minimum inhibitory concentration (MIC) of 
512 mg/L; (ii) uniform drug delivery throughout the tracheobronchial (TB) airways; and 
(iii) high concentrations of tobramycin in the small TB airways (which often have 
occlusions and trapped air). Specifically, this study aimed to: (i) determine tobramycin 
concentration in the ASL for N2L aerosol delivery in a 5-6-year-old complete airway model 
for static and EEG aerosol administration; (ii) determine the effect of CF-diseased airways 
on aerosol delivery for static and EEG aerosols; and (iii) determine the extent to which 
EEG powder formulations can overcome the challenges associated with the delivery of 
aerosols to partially occluded airways. 
8.2 Introduction 
Bacterial lung infections in patients that are diagnosed with CF can be treated by 
oral prophylactic antibiotics (Elborn, 2016; Hoiby, 2011), but administration of inhaled 
tobramycin is the preferred method as it treats Pseudomonas aeruginosa (Pa) infections 
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directly in the airways (Proesmans, Vermeulen, Boulanger, Verhaegen, & De Boeck, 
2013; Ratjen, Munck, Kho, Angyalosi, & Grp, 2010; Taccetti et al., 2012). Pa is the most 
predominant bacteria found in the lungs of CF patients (Elborn, 2016), and early treatment 
in pediatric patients can prevent the development of chronic infections during childhood 
(Hoiby, 2011). In a series of publications, our group has developed a high-efficiency 
delivery system (Bass, Farkas, et al., 2019; Bass & Longest, 2020; Farkas et al., 2020; 
Farkas et al., 2019) for N2L administration of tobramycin EEG powder formulations to 
children. Most recently, the best-case air-jet dry powder inhaler (DPI) and nasal cannula 
system from Farkas et al. (2020) demonstrated excellent aerosolization and delivery 
performance, with a 1.53 µm mass-median aerodynamic diameter (MMAD) and 79.5% 
emitted dose (ED) from the cannula prong outlets. This delivery system is operated at a 
flow rate of approximately 10 LPM, which combined with an inhalation volume of 750 mL, 
gives an actuation time of approximately 4.5 s. The small aerosol size and hygroscopic 
growth of the powder formulation is expected to maximize nasal transmission and target 
delivery to the lower airways. Concurrent numerical and experimental evaluation in a 
growth chamber model of a 5-6-year-old CF patient (Chapter 7) showed low upper airway 
losses (6.6%) and an outlet MMAD of 3.19 µm after a residence time of approximately 
2.0 s.  
This study builds upon the previous work in this series by evaluating EEG aerosol 
transport and delivery in an anatomically-accurate, complete-airway, CFD model. The 
growth chamber model provides a good representation of typical aerosol residence times 
through the lungs, but particle trajectories through airway bifurcations are expected to be 
very different. Our group has developed and used stochastic individual pathway (SIP) 
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models for a number of studies on pharmaceutical aerosol delivery in the complete-airway 
CFD models. This method has been successfully validated against both in vitro (Longest, 
Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al., 2011) and 
in vivo (Longest et al., 2015; Tian et al., 2015; Walenga & Longest, 2016) data sets. The 
current study advances SIP modeling capabilities by applying the method to pediatric 
patients and including the effects of CF-related airway disease on airway anatomy. 
Previous work has also used albuterol sulphate (AS) EEG powder formulations as 
a surrogate test aerosol, as the hygroscopic properties of tobramycin were not 
established. The water activity characteristics for tobramycin were identified by 
supplemental work for this study, following a similar method as Longest and Hindle 
(2011), which allowed for CFD-based evaluation of tobramycin EEG powder formulations 
through complete-airway models. The EEG method uses an initially small aerosol size, 
with the particles growing in size and becoming droplets due to hygroscopic excipients 
that absorb moisture from the humid airways. The chosen hygroscopic excipient in this 
case was mannitol, which has the added benefit of improving transport though the ASL 
(Geller & Rubin, 2009). This study provides a proof of concept for the administration of 
tobramycin EEG aerosol to the diseased airways of pediatric CF patients. EEG delivery 
strategies are capable of navigating the natural filtration of the extrathoracic (ET) region 
and targeting delivery to specific airways. Lung retention can also be improved, with the 
larger final particle size increasing sedimentation (breath-hold) and impaction (exhalation) 
deposition in the lower airways. These advantages are well suited to the challenges 
associated with treating bacterial infection in diseased airways, as antibiotics require 





The SIP methodology for complete airway modeling has been utilized in numerous 
studies by our group and has shown successful validation against both in vitro (Longest, 
Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 2012; Tian et al., 2011) and 
in vivo (Longest et al., 2015; Walenga & Longest, 2016) data. The current study follows 
the most recent methodology and best practices for SIP models from Tian et al. (2015) 
who validated pharmaceutical aerosol deposition against in vivo, 2D gamma scintigraphy 
results. Briefly, the airways of the lungs are split into three regions that are modeled 
individually with CFD: (i) the upper airways consisting of the nose-throat to Bifurcation 3 
(NT-B3); (ii) the middle airways (B4-B7); and (iii) the lower airways (B8-B15). Alveolar 
models are also available for evaluation of aerosol transport beyond B15 (Khajeh-
Hosseini-Dalasm & Longest, 2015). Separating the airways into distinct regions allows 
for the application of the required CFD models to account for differences in flow conditions 
throughout the lungs. The upper airway geometry is extracted from computed tomography 
(CT) scans to ensure that it is anatomically accurate and specific to the chosen patient 
population (e.g. adults, pediatrics, and disease states). The small diameters of the middle 
and lower airways make it difficult to extract them from CT scans, so idealized, physically 
realistic bifurcation units are used for the geometry from B4-B15 (Heistracher & Hofmann, 
1995). Previous work has shown that following pathways through the lower-left lobe 
provides a representative average of deposition in the entire lung (Longest, Tian, 
Delvadia, et al., 2012), so the same approach is applied in the current study as a basis 
for comparison between aerosol delivery strategies. However, future studies are planned 
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that intend to compare lobar differences between healthy and CF-diseased airways. The 
current study assumes a breath-hold maneuver is performed by the patient after aerosol 
administration, and as such all particles that leave B15 are assumed to deposit in the 
alveoli by sedimentation deposition. Therefore, a numerical alveolar-level aerosol 
transport and deposition model was not required. 
The SIP models in previous work have focused on aerosol transport through adult 
airways. As the current study is specific to healthy and CF-diseased pediatric airways, 
modifications to the models must be made to account for the differences in airway 
dimensions and disease characteristics. For the upper airways, the NT-B3 region is 
extracted from CT scans of a healthy and a CF-diagnosed 5-6-year-old child. For the B4-
B7 and B8-B15 regions, the SIP geometries must first be scaled to appropriate 
dimensions. The scale factor was selected such that the B4 inlet diameter matched the 
hydraulic diameter of the B3 outlets into the lower-left lobe from the upper airway CT 
scans. A hydraulic diameter was used as the CT scan geometry had non-circular outlets. 
For the healthy and CF-diseased airways the measured diameters were 4.4 mm and 3.8 
mm, respectively, which is consistent with the 4.4 mm diameter from the ICRP model 
(1994) and the 4.6 mm diameter (standard error of 0.37 mm) from Phalen et al. (1985) of 
an average 5-year-old. It is also expected that the diseased airways would generally have 
smaller diameters due to mucus accumulation and inflammation (de Jong et al., 2004), 
as well as CF patients generally being underdeveloped compared to their peers (Stalvey 
et al., 2017). This approach to scaling the SIP geometries was previously validated 
against well-known algebraic and empirical correlations for an infant complete airway 
model (Bass & Longest, 2018a). Due to the absence of relevant in vitro and in vivo data, 
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the current study also validates the 5-6-year-old SIP models against the ICRP (1994), 
Rudolf (1990), and Finlay (2001) algebraic correlations of deposition fraction. Specifically, 
the Finlay correlation combines an analytical approximation for sedimentation (Heyder & 
Gebhart, 1977) and an empirical impaction probability (Chan & Lippmann, 1980). To 
account for hygroscopic growth in the correlations, the particle size in distal regions of 
each model is taken as the average particle size from upstream outlets of the CFD results. 
For example, the particle size entering the B4 region in the correlations is taken as the 
average MMAD of the aerosol that leaves the upper airway CFD model (NT-B3). 
As a disease and in combination with bacterial infections, CF is associated with 
several types of damage to the airways, including inflammation (airway narrowing), 
bronchiectasis (airway widening), and mucus accumulation (airway obstructions) (de 
Jong et al., 2004). Instances of these forms of airway damage were observed in CF-
diagnosed patients at very early ages (Tiddens et al., 2010), with examples from CT scans 
of a 5-6-year-old patient shown in Figure 8.1a. Label A in Figure 8.1a shows an example 
of axisymmetric mucus plugging on a daughter branch of a bifurcation, Label B shows an 
example of asymmetric mucus accumulation in the bifurcation, and Label C shows an 
example of bronchiectasis. To provide an accurate representation of the diseased 
airways, modifications were added to the B4-B7 and B8-15 SIP regions to account for 
CF-related airway damage. Figure 8.1b shows axisymmetric mucus plugging on the 
daughter branch of B4, Figure 8.1c shows asymmetric mucus accumulation in the 
bifurcation region of B5, Figure 8.1d shows axisymmetric bronchiectasis on the daughter 
branch of B6, and Figure 8.1e shows asymmetric mucus accumulation on the daughter 
branch of B7 (not shown in CT scan example). These four forms of lung damage were 
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selected as they were both representative of observations in CF-diseased airways and 
could be added to the structured block meshing of the SIP models. More complex forms 
of airway damage would require an unstructured meshing approach for the SIP 
bifurcations, which has not currently been validated. Measurements from CT scans of a 
patient with moderate CF disease, as scored by PRAGMA-CF (Rosenow et al., 2015), 
showed an average 30% change in cross section (narrowing or widening) in areas of 
airway damage, up to an approximate maximum of 60% to 70%. As such, these same 
localized percent reductions or increases in airway dimensions were included in the 
diseased SIP models (as shown in Figure 8.1b-e) to be consistent with observations from 
the CT scans. 
In summary, four SIP models were evaluated in the current study as a basis for 
comparison between healthy patients and varying degrees of CF disease states, namely: 
the (i) Healthy; (ii) CF Scaled; (iii) CF Moderate; and (iv) CF Severe models. For the 
Healthy model, the upper airways (NT-B3) were extracted from separate head and chest 
CT scans taken from a single patient on the same day. The CT scans were medically 
necessary, yet unrelated to airway disease, and confirmed to be free of airway 
abnormalities by a pediatric otolaryngologist. The B4-B7 and B8-B15 regions of the 
Healthy model were scaled versions (to a B4 inlet diameter of 4.4 mm) of the adult SIP 
geometries through the lower-left lobe, as described above. For the three CF models, the 
upper airways used the same nose-throat (NT) region as the Healthy model, as CT scans 
of the nasal cavity for CF patients are typically not conducted to minimize radiation 
exposure. The trachea to B3 region was extracted from CT scans of a patient with 
moderate CF disease, which were provided by Erasmus Medical Centre (Dr. Harm 
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Tiddens), and coupled to the healthy NT region. This CF upper airway geometry is the 
same as the 5-6-year-old model used in the growth chamber study (Chapter 7). For the 
B4-B7 and B8-B15 regions, three examples of each region were developed to account 
for varying degrees of disease state. The CF Scaled model uses scaled versions (to a B4 
inlet diameter of 3.8 mm) of the adult SIP geometries through the lower-left lobe. The CF 
Moderate model starts with the CF Scaled geometry and adds one form of airway damage 
(from Figure 8.1b-e) to each bifurcation with a 30% change in cross section. Forms of 
airway damage added to each bifurcation were randomly selected. Similarly, the CF 
Severe model also starts with the CF Scaled geometry, but adds one instance of 
axisymmetric mucus plugging (Figure 8.1b), asymmetric mucus accumulation (Figure 
8.1c), and axisymmetric bronchiectasis (Figure 8.1d) to each bifurcation (resulting in three 
forms of damage per bifurcation) with a 60% change in cross section. Comparisons 
between the Healthy and CF models are given in Figure 8.2, with Figure 8.2a showing 
the NT-B3, B4-B7, and B8-B15 regions for the Healthy model, and Figure 8.2b showing 
the same three regions for the CF Moderate model. Comparing between the three CF 
models, Figure 8.3a and b show the B4-B7 and B8-B15 regions for the CF Scaled model, 
Figure 8.3c and d show the same two regions of the CF Moderate model, and Figure 8.3e 
and f show the extreme case in the CF Severe model. 
One final consideration for applying SIP models to CF-diseased pediatric airways 
is lobar ventilation and its influence on flow distribution at each of the outlets in the upper 
airway CFD models. For the original SIP models, lobar ventilation fractions were sourced 
from Horsfield et al. (1971), Asgharian and Price (2006), and Yin et al. (2010), which were 
measured from healthy adults. However, lobar differences in disease severity is known 
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to exist in the lungs of CF patients (Bos et al., 2017; Bos et al., 2015), which affects lobar 
ventilation fractions. In the current study, lobar ventilation fractions were measured 
directly from inhalation and exhalation CT scans of a 5-6-year-old with moderate CF 
disease (the same patient as the upper airway models). Lung lobes were semi-
automatically segmented from the inhalation and exhalation scans using the Chest 
Imaging Platform module (Estepar et al., 2015) available in the open-source 3D Slicer CT 
segmentation software (Kikinis, Pieper, & Vosburgh, 2014). The ratio of inhalation to 
exhalation volume for each lobe was then used to determine the lobar ventilation fractions 
specific to the selected patient. Figure 2.1 shows the segmentation of each lung lobe at 
inhalation and exhalation, and Table 7.1 summarizes the ventilation fractions for the 
healthy (based on the adult SIP models) and diseased models. 
CFD Models 
Computational Domain and Spatial Discretization 
The geometry for the computational domain of both the Healthy and CF upper 
airway models was generated with a similar method to the growth chamber study 
(Chapter 7). Briefly, CT scans of the nasal cavity and tracheobronchial airways were 
segmented with the Mimics software suite (Materialise, Leuven, Belgium). The triangular 
STL surfaces of the NT-B3 regions were then converted to CAD surfaces by utilizing the 
automated skin surfacing capabilities in SpaceClaim v19.3 (ANSYS Inc., Canonsburg, 
PA), and prepared for mesh generation. Spatial discretization of the computational 
domain was performed with the polyhedral meshing capabilities available in FLUENT 
v19.3 (ANSYS Inc., Canonsburg, PA) to accurately resolve the complexity of the nasal 
cavity geometry. The spatial resolution of the mesh matched the grid independent, 
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validated results from the growth chamber study (Chapter 7). The near-wall mesh 
resolution follows our best practices of five prismatic layers and an area-averaged wall y+ 
value of approximately one (Bass, Boc, et al., 2019; Bass & Longest, 2018b). Numerical 
extensions were added to each of the upper airway B3 outlets to prevent reversed flow 
and aid in convergence of the transport equations. As the physically realistic bifurcations 
of the B4-B7 and B8-B15 regions lend themselves to blocked topologies, a structured 
hexahedral mesh can be applied to resolve the spatial discretization, which improves 
solution convergence, model accuracy, and computation times. The spatial resolution of 
the B4-B7 and B8-B15 regions matches the models used in the in vivo validations 
described by Tian et al. (2015). When adding examples of airway damage to the middle 
and lower airways for the CF Moderate and CF Severe models, care was taken to 
maintain the blocking structure and spatial resolution of the SIP models. 
Numerical Models and Solver Settings 
The numerical models and solver settings for the upper airway flow fields generally 
followed the SIP best practices outlined by Tian et al. (2015). Despite an inlet Reynolds 
number of approximately 1,000 (flow rate of 5 LPM and hydraulic diameter of 6.1 mm), 
low-Reynolds number (LRN) k-ω turbulence was used to model the transitional-to-
turbulent flow regime, as the glottis in the laryngeal region is known to induce turbulence 
(Bass, Boc, et al., 2019; Xi et al., 2008; J. X. Xi et al., 2012). A transient form of the 
transport equations was also employed to model the oscillatory behavior of the laryngeal 
jet (Xi et al., 2008), which is also consistent with the SIP modeling recommendations 
presented by Tian et al. (2015). Plots of deposition fraction vs. flow time were monitored 
and aerosol deposition was observed to plateau at approximately 0.5 s, so flow solutions 
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were terminated after 1.0 s flow time instead of modeling the full 4.5 s actuation time. In 
contrast to the upper airways, the CFD set-up for the middle and lower airways employs 
laminar flow models and a steady-state formulation of the transport equations. 
Observations from CFD models have previously shown that turbulent flow can extend 
from the laryngeal jet through B4 (Xi et al., 2008), but validation work in the SIP models 
have shown the best match to in vivo data with laminar conditions in the B4-B7 and B8-
B15 regions (Longest et al., 2015; Tian et al., 2015; Walenga & Longest, 2016). For 
context, in the Healthy model, the Reynolds number is approximately 500 at the B4 inlet 
and approximately 100 at the B8 inlet. 
Beyond considerations specific to SIP models, the remaining solver settings 
followed our previously defined best practices for respiratory aerosol transport (Bass, 
Boc, et al., 2019; Bass & Longest, 2018b). FLUENT v19.3 (ANSYS Inc., Canonsburg, 
PA) was used to obtain solutions for all flow and turbulence equation. The spatial 
discretization of the flow and turbulence transport equations were second-order accurate, 
the gradient discretization used the Green-Gauss Node-based method, and the SIMPLEC 
pressure-velocity coupling scheme was used. As the current study evaluates hygroscopic 
aerosol growth, the continuous phase in the flow field was composed of air and water 
vapor to model the relative humidity (RH) of the fluid. The multi-species and energy 
models were activated, and the incompressible ideal gas law was used to model fluid 
density. 
In this study, the pediatric air-jet DPI was operated in nose-to-lung aerosol delivery 
mode, in which the nasal cannula interface is inserted into the nostrils forming an airtight 
seal. The simulation began at the nostril interface. As the device was operated at a flow 
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rate of 10 LPM, the mass flow inlet boundary condition was applied at the nostrils with a 
mass flow rate selected that provided a volumetric flow rate of 5 LPM through each nostril. 
The water vapor mass fraction at the nostril inlets was consistent with the 10% RH that is 
expected from dry wall air, which is passed through the air-jet DPI and nasal cannula, 
and the temperature was set to ambient conditions (20°C). The outlet boundaries in the 
upper airway models were set to the outflow condition at approximately the lobar bronchi, 
where a fraction of the total outlet mass flow rate is applied to each boundary, with the 
fractions defined for the Healthy and CF models as shown in Table 7.1. Downstream of 
the upper airways, in the B4-B7 and B8-B15 regions, the inlet boundaries used velocity 
inlet boundary conditions with a parabolic spatial profile (due to laminar flow) that matched 
the volume flow rate from the upstream bifurcation outlet. The water vapor mass fractions 
at the inlet to the middle and lower airways were taken as the area-weighted average 
value from the upstream outlet, which was close to 99% RH in all cases as the dry wall 
air had completely mixed with the humid airway by the end of the upper airways. Outlet 
boundaries used outflow fractions that assume 50% of the flow goes through each 
bifurcation outlet, which is consistent with the assumptions from Tian et al. (2015). The 
wall boundaries in all models used the no-slip shear condition, and effects of surface 
roughness were neglected as airway surfaces are expected to be smooth at the 
microscopic level. In addition, the water vapor mass fraction on all wall boundaries was 
set to 99% RH as the airway surfaces are expected to be moist. 
Particle Transport and Growth 
The discrete phase model (DPM) available in FLUENT v19.3 was used to calculate 
the particle trajectories and deposition through the domain, with all DPM settings following 
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our previously defined best practices and modeling recommendations (Bass, Boc, et al., 
2019; Bass & Longest, 2018b). In the upper airways, where the k-ω turbulence model is 
applied, near-wall corrections were implemented (Longest & Xi, 2007) to account for the 
over-prediction of aerosol deposition associated with the k-ω model. As the middle and 
lower airways were modeled with laminar flow conditions the near-wall corrections were 
not applicable and not required. At the inlet to the upper airway models, particles were 
introduced in to the domain with a monodisperse size distribution, which is an acceptable 
assumption based on findings from Tian et al. (2015). Using a polydisperse size 
distribution would provide a more accurate representation of the aerosol, but would be 
more computationally expensive in the transient model. In the B4-B7 and B8-B15 regions, 
the particles were introduced with a polydisperse distribution that matched the aerosol 
size at the upstream outlet and accounted for variability in particle growth through the 
upper airways. To ensure particle convergence, a total of 90,000 particles were 
introduced into each SIP region, which is consistent with the recommendations from Tian 
et al. (2015). 
The growth of the EEG aerosol is implemented in the CFD models with the 
evaporation and condensation UDF that was described in Chapter 7 and originally 
presented by Longest and Xi (2008). Previous work has utilized AS EEG powder 
formulation as a surrogate test aerosol for tobramycin, as the hygroscopic properties for 
tobramycin were not available. In the current study, the hygroscopic properties for 
tobramycin were established by the VCU School of Pharmacy, which allowed for 
tobramycin EEG formulations and its growth characteristics to be modeled with CFD for 
the first time. The material and hydroscopic properties for tobramycin used in this study 
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were a molecular weight of 467.5 g/mol, density of 990.0 kg/m3, saturated mole fraction 
of 0.037, and van’t Hoff factor of 2.46. The true density was measured by gas pycnometer 
AccuPyc II 1340 (Micromeritics) and the water activity (saturated mole fraction and van’t 
Hoff factor) was measured with a method consistent with Longest and Hindle (2011). The 
chosen tobramycin EEG powder formulation in this study contained a 60:20:20% w/w 
ratio of tobramycin, mannitol, and L-leucine, which resulted in a particle density of 1117.2 
kg/m3. 
In summary, four initial aerosol cases were modeled to demonstrate a comparison 
between delivery strategies and provide a proof of concept for tobramycin EEG aerosol 
administration to CF-diseased airways, namely: (i) Base EEG; (ii) Min Static; (iii) Max 
Static; and (iv) Optimal EEG. The Base EEG case includes aerosol growth based on the 
tobramycin EEG powder formulation stated above, and an initial monodisperse geometric 
particle diameter of 1.45 µm, which is consistent with the 1.53 µm aerosol MMAD from 
the chosen delivery system (Farkas et al., 2020). The Min Static case does not include 
aerosol growth and uses an initial geometric particle diameter of 1.45 µm (ρ = 1117.2 
kg/m3) to evaluate how hygroscopic growth influences drug delivery by drawing 
comparisons with the Base EEG case. Similarly, the Max Static case also does not 
include hygroscopic growth, but uses an initial geometric particle diameter of 3.31 µm 
(3.50 µm MMAD) to evaluate how a small or large aerosol size penetrates the upper 
airways. The three initial aerosol cases stated above all assumed a nominal value of 75 
mg of tobramycin entered the upper airways, which was used to determine ASL 
concentrations throughout the airways. Based on the current fraction of tobramycin 
loaded into EEG particles, this would require a 125 mg mass of delivered powder. In 
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contrast, the Optimal EEG case uses a monodisperse aerosol with a geometric particle 
diameter of 1.45 µm that represents 50 mg of tobramycin, and a second monodisperse 
aerosol with a geometric particle diameter of 1.80 µm (aerodynamic diameter of 1.91 µm) 
that represents 25 mg of tobramycin, which both included hygroscopic growth. This case 
demonstrates how delivery strategies can be optimized to achieve regional deposition 
targets, such as the uniform distribution and lower thresholds associated with inhaled 
antibiotics. If a polydisperse aerosol were employed, the Optimal EEG case could be 
described as a bi-modal distribution, with the first peak (smaller aerosol) used to target 
distal airways and the second peak (larger aerosol) used to target intermediate regions. 
The selection of the Optimal EEG tobramycin mass distribution and particle sizes was 
based on analysis of the CFD results, but is included here for clarity in the Methods 
section. 
ASL Volumes 
To determine whether the delivered tobramycin provided uniform concentrations 
and was above the MIC, regional ASL volumes in the lung bifurcations and alveoli were 
required. The airway surface area was measured from the SIP models and combined with 
estimations of ASL thickness to determine the regional ASL volume, which can be used 
with the deposited mass and bifurcation counts to establish regional tobramycin 
concentrations (mg/L). The method for calculating regional tobramycin concentration in 











where: 𝑐𝑅 is the concentration in region R, DF𝑖 is the CFD-predicted DF in the bifurcation, 
𝑚𝑖𝑛 is the mass that enters region R, and 𝑉𝑖 is the ASL volume in the bifurcation. Previous 
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studies of aerosol delivery to CF-diseased airways have assumed a uniform ASL 
thickness throughout the airways (Bos et al., 2017; Bos et al., 2015), with minimum 
(Tarran et al., 2005) and maximum (Tarran, Button, & Boucher, 2006) thicknesses of 3 
µm and 7 µm, and also evaluated an average thickness of 5 µm. These uniform ASL 
thicknesses were specific to CF-disease lungs, but the literature shows that ASL 
thickness varies between bifurcation levels (Hasan & Lange, 2007; ICRP, 1994; Patton, 
1996).  
In the extrathoracic (ET), bronchial (BB), and bronchiolar (bb) regions, the ICRP 
model (1994) reports the thickness of the mucus and cilia layers (which combined give 
the ASL thickness) as 15 µm, 11 µm, and 6 µm, respectively. More recently, Hasan and 
Lange (2007) presented a mass conservation model for estimating ASL thickness (ℎ𝐴𝑆𝐿,𝑘) 
based on mucus production and clearance rates: 
 











− ℎ𝐶,𝑘 (8.3.3) 
 ℎ𝐴𝑆𝐿,𝑘 = ℎ𝐶,𝑘 + ℎ𝑀,𝑘 (8.3.4) 
where: 𝑘 is the generation number, ℎ𝑀 is the mucus layer thickness, 𝑟𝑘 is the radius of 
the airway up to the mucus layer, 𝑝𝑖  is the mucus production rate, 𝑣𝑘  is the mucus 
clearance rate, 𝑑𝑘 is the generation diameter, and ℎ𝐶,𝑘 is the height of the cilia layer. The 
cilia height was determined from experimental measurements by Serafini and Michaelson 
(1977) and the bifurcation-level mucus production distribution was sourced from material 
measured from rhesus monkeys by Plopper et al. (1989). Mucus clearance rates are 
known to have both interpatient and intrapatient (from day-to-day) variability (Hasan & 
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Lange, 2007; Lange, Hancock, Samuel, & Finlay, 2001). Typical fast and slow clearance 
rates in the trachea for healthy nonsmoking adults (Wanner, Salathe, & O'Riordan, 1996) 
are 15 mm/min and 5 mm/min, respectively, with Yeates et al. (1976) reporting no 
difference in clearance rates for CF-diseased lungs. Clearance rates in distal lung regions 
are scaled from the tracheal value and data sourced from Stahlhofen (1980). For mucus 
production, Finlay et al. (2000) reported a pediatric (4-years-old) rate of 2.8 mL/day based 
on body-weight scaling from adult values, with Oberwaldner et al. (Oberwaldner, Evans, 
& Zach, 1986; Oberwaldner, Theissl, Rucker, & Zach, 1991) reporting that production 
rates can be up to four times higher in CF-diseased airways. In the alveolar-interstitial 
region (AI), the ASL is predominantly surfactant with Weibel (1963) and Macklin (1955) 
reporting thicknesses of 0.068 µm and 0.2 µm, respectively. This was combined with the 
AI surface area from the ICRP model (1994), scaled to pediatric dimensions, and gave 
the ASL volume distal to B15. 
In summary, three ASL volume cases were evaluated in the current study to 
provide a range of tobramycin concentration predictions, namely: the (i) ICRP ASL, (ii) 
Min ASL, and (iii) Max ASL volumes. In the ET, BB, and bb regions, the ICRP ASL volume 
is simply based on the regional thicknesses reported by the ICRP model (1994). The Min 
ASL volume in the NT-B15 regions is based on the mass conservation model (Hasan & 
Lange, 2007) and uses fast clearance (trachea: 15 mm/min) and low mucus production 
(2.8 mL/day for a healthy pediatric) as input to the model, which provides the minimum 
estimation of ASL volume. Similarly, the Max ASL volume also uses the mass 
conservation model, but uses slow clearance (trachea: 5 mm/min) and increased mucus 
production (11.2 mL/day, or four times higher than a healthy pediatric), which provides 
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the maximum estimation of ASL volume. In the upper airway CFD models, distinctions 
are not made between bifurcation levels, so an area-average ASL thickness from B1-B3 
is combined with its surface area to determine the ASL volume in this region. As the mass 
conservation model only includes bifurcation-level mucus production distribution from B1 
through B14, the ASL thickness for B15 was assumed to be the same as B14. The results 
present regional tobramycin concentrations as an ensemble of multiple bifurcations, so 
the effect of this assumption is assumed to be negligible. Similarly, the mass conservation 
model does not include the ET region, so the thickness for the Min and Mas ASL cases 
were scaled from the ICRP model based on total ASL volumes. In the AI region, the Min 
ASL volume uses the 0.068 µm thickness from Weibel (1963), the Max ASL volume uses 
the 0.2 µm thickness from Macklin (1955), and the ICRP ASL volume uses the average 
of these two values (0.134 µm). For the three cases detailed above, Table 8.2 
summarizes the bifurcation-level ASL thicknesses and volumes, and Table 8.3 
summarizes the regional total ASL volumes used in calculation of tobramycin 
concentrations. 
8.4 Results 
CFD Model Validation and Upper Airway Deposition  
Figure 8.5 shows regional deposition fractions and patterns in the upper airways 
(NT-B3) for the Healthy (Figure 8.5a) and CF Moderate (Figure 8.5b) models. The total 
DF shown in Figure 8.5b is compared against the in vitro data from the 5-6-year-old 
growth chamber model (Chapter 7). Note that both the CFD and experimental results in 
Figure 8.5 use an AS EEG powder formulation, but validate aerosol deposition, not 
growth. The initial AS EEG aerosol size from the growth chamber study was a geometric 
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diameter of 1.29 µm (1.53 µm MMAD with ρ = 1399.7 kg/m3), which is consistent with the 
MMAD of the tobramycin EEG aerosol that is evaluated in subsequent sections, and little 
aerosol growth is expected in the ET region. This demonstrates validation of the upper 
airway CFD model as the numerical prediction of aerosol deposition is within the standard 
deviation of experimental replicates. Surprisingly, total and regional deposition fractions 
in the Healthy model are higher than the CF Moderate model (absolute difference of 
2.4%), though the difference between the two models is relatively small considering the 
experimental standard deviation (2.6%). The variation in deposition between the two 
models can be attributed to interpatient variability. Inspection of the TB anatomy in Figure 
8.5 shows that the B1 branching angle is noticeably larger in the Healthy geometry, which 
would suggest an increase in impaction deposition, and there is clearly more deposition 
on the carinal ridge in the first bifurcation. CF-related airway damage would presumably 
lead to increased deposition losses in the CF Moderate model, but disease is known to 
be more predominant in the lower airways (Tiddens et al., 2010), so differences in the 
upper airways are expected to be small. 
Table 8.4 compares regional deposition in the bronchial (Trachea to B8) and 
bronchiolar (B9-B15) regions between the Healthy SIP models and the ICRP (1994), 
Rudolf (1990), and Finlay (2001) models. The aerosol size entering the bronchial region 
(from the outlet of B3) was an MMAD of 1.67 µm, and the size entering the bronchiolar 
region (from the outlet of B7) was an MMAD of 2.23 µm. The CFD results compare well 
with the ICRP and Rudolf correlations, with the algebraic Finlay model suggesting slightly 
higher deposition in these regions. These results are consistent with conclusions from 
Bass and Longest (2018a), which used a similar method for validating the numerical SIP 
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model results. It is noted that aerosol growth was accounted for in the correlations by 
using the average aerosol size in distal regions from upstream regions. This validation of 
the SIP models ensures that CFD-predictions of deposited drug mass provide accurate 
regional ASL concentrations. 
Particle Trajectories and Aerosol Growth 
Figure 8.6 illustrates particle trajectories and growth through the three regions of 
the Healthy (Figure 8.6a) and CF Moderate (Figure 8.6b) models for the Base EEG 
aerosol case. Note that particle trajectories extend beyond the computation domain due 
to the addition of numerical extensions. In both models, the particle MMAD leaving the 
upper airways is less than approximately 2.0 µm, which provides good N2L aerosol 
transmission. In distal regions (B4-B15) of the healthy and CF-diseased lungs, the 
tobramycin EEG powder formulation grows larger than 2.5 µm due to hygroscopic 
absorption of moisture from the humid airways. This aerosol size increase would lead to 
increased sedimentation deposition (with a breath hold) and impaction deposition (upon 
exhalation), and helps to target lung regions where CF-related bacterial infections are 
more predominant. The growth characteristics of the tobramycin EEG powder formulation 
in the current study (60:20:20% w/w ratio of tobramycin:mannitol:L-leucine) is consistent 
with the AS EEG powder that has been used as a surrogate test aerosol in Chapter 7 and 
previous publications (Bass, Farkas, et al., 2019; Bass & Longest, 2020; Farkas et al., 
2020; Farkas et al., 2019). 
Airway Surface Liquid Concentrations 
Table 8.5 summarizes CFD-predicted regional deposition fractions (similar to 
Figure 8.5), which were combined with the assumed 75 mg of tobramycin (leaving the 
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nasal cannula) and ASL volumes (see Table 8.2) to determine regional drug 
concentrations. Figure 8.7 plots the tobramycin concentrations in the ASL for all four SIP 
models and the ICRP (Figure 8.7a), Min (Figure 8.7b), and Max (Figure 8.7c) ASL 
volumes for the Base EEG aerosol. The solid and dashed lines on these plots indicate 
the MIC (512 mg/L) and double the MIC for reference. Table 8.6 summarizes regional 
tobramycin concentrations relative to the MIC for the Base EEG aerosol and compares 
between all SIP models and ASL volumes. This shows that the Base EEG delivery 
strategy, with 75 mg of tobramycin emitted from the delivery system, is consistently 
capable of delivering tobramycin ASL concentrations that are well above the MIC for all 
SIP models and ASL volumes considered. The worst-case regional delivery is the B4-B7 
region of the Healthy SIP model with Max ASL volume that had a CFD-predicted 
concentration of 2.5 x MIC. Recall that the dimensions of the Healthy SIP model were 
larger than all CF-diseased models, due to different scaling factors, which decreases the 
Stokes number and suggest less impaction deposition. This justifies the lower tobramycin 
ASL concentrations that the CFD models predicted in the Healthy SIP model, as less drug 
mass is deposited. In the CF SIP models, the worst-case regional delivery is the B4-B7 
region of the CF Scaled model with Max ASL volumes that had a CFD-predicted 
concentration of 2.9 X MIC. Interestingly, the models with increased states of disease 
progression (CF Moderate and CF Severe) had higher concentrations, as the forms of 
lung damage added to the geometry increased potential impaction deposition sites. 
Though the minimum delivered concentrations are above the MIC targets of this study, 




Figure 8.8 and Table 8.7 present the tobramycin concentrations for all SIP models 
and ASL volumes considered for the Min Static aerosol. As with the Base EEG case, the 
small aerosol size of the Min Static aerosol is capable of penetrating the upper airways 
beyond B3. However, as there is no hygroscopic growth, the aerosol is also able to 
navigate the filtration of the lower airways and shows relatively low levels of deposition in 
the B4-B7 and B8-B15 regions. Therefore, delivered tobramycin concentrations in the 
ASL for the lower airways is low for all cases considered. Minimum concentrations were 
predicted to be only just above the MIC for the B8-B15 region of the Healthy SIP model 
with Max ASL volume (1.0 x MIC), with similar results for the B8-B15 regions of the CF 
SIP models with Max ASL volume (1.2-1.6 x MIC). Figure 8.9 and Table 8.8 present the 
tobramycin concentrations for all SIP models and ASL volumes considered for the Max 
Static aerosol. In this case, concentrations are consistently high and well above the MIC 
due to a large amount of deposited drug mass from the larger aerosol size (minimum 
concentrations of 3.1 and 4.8 x MIC for the Healthy and CF SIP models, respectively). 
However, as there is poor N2L transmission due to the increased particle size, CFD 
predictions show up to a 10-fold difference in regional concentrations (4.8-45.9 x MIC in 
the NT and B4-B7 regions of CF Scaled with Max ASL) and exhibit poor dose uniformity 
throughout the airways. 
Figure 8.10 and Table 8.9 present the tobramycin concentrations for all SIP models 
and ASL volumes considered for the Optimal EEG aerosol. Recall that the Optimal EEG 
aerosol used 50 mg of 1.45 µm and 25 mg of 1.80 µm particles (geometric particle 
diameters). For the three CF SIP models, the Optimal EEG case reduced variability in 
regional concentrations and is consistently well above the MIC (minimum of 5.8 x MIC in 
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the B4-B7 region of CF Scaled with Max ASL). Table 8.10 compares the ratios of 
maximum to minimum concentrations in all SIP models, ASL volumes, and aerosol cases. 
For the CF-diseased models with EEG aerosols, variability (expressed as the ratio of 
maximum to minimum ASL concentration) is reduced from a range of 2.4- to 5.2-fold 
(Base EEG) to a range of 1.7- to 4.3-fold (Optimal EEG). For the Healthy SIP model, 
variability in tobramycin concentration is also reduced with the Optimal EEG aerosol, but 
it is not as low as the CF-diseased models. As the delivery system is intended to 
administer antibiotics to pediatric patients with CF, the variability in the Healthy model is 
not considered a negative outcome. However, this does raise questions on interpatient 
variability and its influence on establishing an optimal delivery strategy.  
8.5 Discussion 
This study meets the objective by providing a proof of concept for tobramycin EEG 
aerosol administration to treat bacterial lung infections in pediatric patients diagnosed 
with CF. Validated CFD predictions demonstrated that the EEG delivery strategy was 
consistently capable of delivering tobramycin to the ASL that was above the MIC for all 
cases considered, with the minimum CF-diseased concentration being 2.8 and 5.8 x MIC 
for the Base and Optimal EEG aerosol, respectively. The Optimal EEG aerosol was 
capable of reducing regional concentration variability to an approximate four-fold 
difference between maximum and minimum CFD-predicted values. Furthermore, the 
validated numerical models predicted high tobramycin ASL concentrations in the lower 
airways (B8-B15), where bacterial infections are more predominant (Tiddens et al., 2010), 
with a minimum concentration of 7.5 x MIC in the CF Moderate SIP model with Max ASL 
volume. This study assumed a nominal value of 75 mg of tobramycin entering the upper 
344 
 
airways from the delivery system, which combined with the 79.5% device ED (Farkas et 
al., 2020) and 60% mass fraction in the EEG formulation, suggests a loaded dose of 
approximately 160 mg of powder. This is high considering the device is designed to hold 
100 mg of powder (Farkas et al., 2020), but the high-efficiency delivery of tobramycin to 
the ASL means that less powder would still ensure concentrations above the MIC. For 
example, a loaded dose of 100 mg of powder (60 mg of the drug) leads to 47.7 mg of 
tobramycin entering the upper airway, which gives a worst-case ASL concentration of 3.7 
x MIC for the Optimal EEG aerosol. Alternatively, different EEG powder formulations that 
increase the mass fraction of drug relative to excipients may be considered, as the water 
activity characteristics show that tobramycin has good hygroscopic properties.  
As a secondary outcome, this study directly compared a range of static and EEG 
aerosol delivery strategies and demonstrates the advantages of powder formulations that 
utilize hygroscopic growth. The Min Static aerosol was capable of navigating the filtration 
of the ET region, but the small aerosol size in the lower airways lead to low tobramycin 
ASL concentrations. This becomes more of an issue when considering drug delivery and 
lung retention during a breath-hold or upon patient exhalation. The Max Static aerosol 
provided high regional ASL concentrations, but variability between regions was poor due 
to increased upper airway losses. Only the EEG aerosol cases were able to provide good 
N2L transmission, and meet the MIC and regional variability targets that are associated 
with the administration of inhaled antibiotics. This study also compared the delivery of 
inhaled tobramycin between healthy patients and varying degrees of CF disease states. 
The smaller dimensions of the CF-diseased airways and addition of various forms of lung 
damage increase the likelihood of impaction deposition throughout the SIP models, which 
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leads to an increase in predictions of tobramycin concentrations from the numerical 
models. This is promising for treatment methods with inhaled antibiotics, as the regions 
with increased lung damage are also likely to have the most bacterial infections, which is 
where the drug is required. The increase in CFD-predicted tobramycin delivery in the CF 
models is most apparent in the middle airways (B4-B7) due to the increased flow 
velocities in this region compared to the lower airways (B8-B15). 
Interpatient variability in delivered tobramycin concentrations was apparent when 
drawing comparisons between the Healthy and CF models. Differences in upper airway 
anatomy lead to differences in CFD-predicted losses in the NT-B3 region, which in turn 
affected the amount of drug that was delivered to the middle and lower airways. 
Interpatient variability has been well established for infant, pediatric, and adult populations 
in the ET region (Garcia et al., 2009; Golshahi et al., 2012; Golshahi et al., 2011; Storey-
Bishoff et al., 2008), and it is reasonable to expect the same in regard to deposition in 
distal diseased (Bos et al., 2015) airways. Establishing an ideal EEG delivery strategy 
that is applicable to the entire patient population is difficult, as an optimal aerosol for one 
patient may not meet delivery targets for others. One approach may be to define low, 
medium and high deposition models for the ET region and distal airways that are 
representative of the chosen patient population, which is similar to the method described 
by Rani et al. (2020). Predictions of delivered tobramycin concentrations are also 
inherently dependent on the estimations of regional ASL volumes, which also exhibit 
interpatient and intrapatient variability (Hasan & Lange, 2007; Lange et al., 2001). 
Regarding MIC targets, results should focus on predicted aerosol delivery to ASL 
thicknesses that provide estimations of maximum ASL volumes, as the concentration 
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exhibits the worst-case scenario. The mass conservation model (Hasan & Lange, 2007) 
gives increased fidelity over the ICRP model (ICRP, 1994) as it provides bifurcation-level 
estimations of ASL thickness in the airways. However, as with all models, it is only as 
accurate as the assumptions and inputs allow. The cilia thickness was estimated from 
data measured from adults (Serafini & Michaelson, 1977) and the bifurcation-level mucus 
production distribution from rhesus monkeys (Plopper et al., 1989), both of which may 
need to be redefined for pediatric patients with CF. Furthermore, lobar and regional 
variability in mucus production, especially for diseased airways, has a direct effect on 
CFD predictions of regional variability in delivered tobramycin concentrations. Finally, the 
ASL volumes in this study do not account for the mucus accumulation and plugging that 
is typically observed in CF-diseased airways. Measurements from CT scans showed up 
a to 70% reduction in airway cross sections, equating to mucus accumulations that are 
approximately 1 mm thick, which is three orders of magnitude larger than the calculated 
ASL thicknesses. The sites of mucus accumulations are expected to be highly infected 
with bacteria, so adequate delivery of tobramycin is important in these regions. 
Beyond the variability in deposition predictions and ASL volumes, limitations in the 
current study primarily include assumptions made in the numerical models and validation 
of the CFD predictions. In the middle and lower airway SIP geometries, a parabolic 
velocity profile was applied at the inlet that matched the upstream outlet volumetric flow 
rate. This assumption was made as the non-circular shape and polyhedral mesh topology 
in the upper airways does not permit one-to-one matching of cell centroids and velocities 
between regions, which is recommended by the in vivo validation of Tian et al. (2015). 
The parabolic profile assumption is reasonable, given the laminar flow conditions, but the 
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curvature of airway bifurcations is known to skew the velocity profile at the outlet (Longest 
& Oldham, 2008). An improved approach would be to map the non-circular spatial 
distribution to the circular SIP model inlet and use inverse-distance weighted interpolation 
between the velocities at the polyhedral and hexahedral face centroids. The CFD models 
also assumed that the MMAD of the tobramycin EEG aerosol that is emitted from the 
delivery system was the same as the experimental data from Farkas et al. (2020), which 
used an AS EEG powder formulation as a surrogate test aerosol. As the particle density 
differs between the tobramycin and AS EEG powder formulations (1117.2 kg/m3 and 
1339.72 kg/m3, respectively), it is reasonable to expect different MMADs for the same 
device, if the physical particle diameter is the same between the two from the spray drying 
process. The differences in powder dispersion characteristics between tobramycin and 
AS EEG formulations are also not established, which may also affect the aerosol size 
leaving the DPI. Finally, the outlet ventilation fractions in the upper airway models were 
based on lobar volumes extracted from inhalation and exhalation CT scans, and assumed 
that all lobes inflated at the same rate. However, in CF-diseased lungs, it is known that 
that the inflation of each lobe is time dependent (L. J. Smith et al., 2018). That is, the 
inflation of a particular lobe may be delayed in relation to the onset of inhalation, and the 
rate of inflation for each lobe varies. This can influence how much tobramycin is delivered 
to each lung lobe based on the timing of inflation and aerosol delivery. For example, for 
a 4.5 s device actuation time, aerosol may hypothetically only be emitted from the delivery 
system for approximately 2.0 s. If one of the lung lobes only begins inflating after a 1.0 s 
delay, it would receive much less of the inhaled antibiotic than the other four lobes. 
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With regard to CFD model validation, the current study matched deposition in the 
upper airway CF model with the experimental data (both with the same AS powder 
formulation) from the growth chamber study (Chapter 7). The healthy B4-B7 and B8-B15 
SIP models were validated against algebraic and empirical correlations (W. H. Finlay, 
2001; ICRP, 1994; Rudolf et al., 1990). Ideally, the predictions of aerosol deposition in all 
CFD models would be validated directly against in vitro or in vivo data. Ethical concerns 
limit the availability of in vivo datasets for pediatric patients with CF, especially with radio-
labelling, due to the amount of medically necessary CT scans that CF patients may 
require during their life. SIP models have been validated against in vitro data by a number 
of previous studies (Longest, Tian, Delvadia, et al., 2012; Longest, Tian, Walenga, et al., 
2012; Tian et al., 2011), and similar methods could be applied to the CF SIP models that 
were developed by the current study. The difficulty with experimental testing of diseased 
pediatric models is whether current 3D printing capabilities can accurately produce 
physical models with small airway dimensions. Similarly, the current study does not 
directly validate the CFD-predicted growth of the tobramycin EEG powder formation 
against experimental data. Previous work (Chapter 7) successfully validated the particle 
condensation and evaporation models for AS EEG powder formulations, and the 
tobramycin hygroscopic properties were experimentally determined based on the same 
methods (Longest & Hindle, 2011), so the numerical results are expected to be accurate. 
However, the CFD models for tobramycin EEG growth should also be validated against 




As this is the first study of its kind to evaluate tobramycin EEG powder formulations 
in SIP models of CF-diseased airways, the scope for future work is extensive. As 
mentioned in the Methods section, the current study followed pathways through the lower-
left lobe as this has previously been shown to be representative of the ensemble average 
deposition in the entire lung (Longest, Tian, Delvadia, et al., 2012). Future studies are 
planned that will compare lobar and regional variability in aerosol deposition, which is 
known to be an issue in CF-diseased lungs (Bos et al., 2017; Bos et al., 2015), as some 
lobes are generally more damaged than others. Future work also intends to expand the 
range of pediatric populations considered by evaluating both a 2-3- and 9-10-year-old 
model. Establishing whether the CF-diseased SIP models provide an accurate 
representation of aerosol transport and deposition in the diseased airways is also 
required. One approach may be to extract anatomically accurate, diseased bifurcations 
from CT scans and compare them to the CF Moderate and Severe bifurcations. 
Adjustments can then be made to the SIP models to improve the match to diseased 
airway results. Previous work (Bos et al., 2017; Bos et al., 2015) has shown that CF 
diseased airways can be extracted from CT scans up to approximately B6, so 
assumptions would still need to be made about the lower airways. This approach would 
also need to establish how unstructured meshes, required for modeling the complex 
geometry of diseased airways from CT scans, compare with structured hexahedral 
meshes in airway bifurcations. 
Beyond expanding and improving the computational domain, the detail and 
potential accuracy of the numerical models can also be explored in future work. The use 
of polydisperse aerosols, as opposed to the monodisperse aerosol in this study, provides 
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a more realistic representation of the aerosol that enters the domain and may influence 
drug delivery to the lower airways. Two-way coupling between the continuous (fluid) and 
discrete (particles) phase is also a more accurate, yet computationally expensive, method 
of modeling aerosol growth, which has previously provided a better match to experimental 
data (Longest & Hindle, 2012). Laminar flow was assumed in the middle and lower 
airways based on the in vivo SIP model validation by Tian et al. (2015), but the k-ω model 
may be considered in future work as constrictions in the diseased airway may induce 
turbulence. In stenosed tubes, which are similar to the CF-diseased airway constrictions, 
previous work has shown that a 50-75% area reduction at Reynolds numbers of 400-
1100 can induce turbulent flow (Ahmed & Giddens, 1983a, 1983b; Ghalichi et al., 1998). 
Alveolar models (Khajeh-Hosseini-Dalasm & Longest, 2015) may also be used to 
establish the breath-hold duration required to maximize sedimentation deposition. The 
current delivery system requires an actuation time of approximately 4.5 s, so an extended 
breath-hold period may not be feasible, but if the powder empties early in the delivery 
cycle, it also may not be necessary. Related to actuation time, device flow rates may be 
considered as part of delivery strategy optimization, in addition to bi-modal size 
distributions, to target regions of the lungs and reduce regional variability. However, 
compromises will need to be made, as the aerosolization performance of the air-jet DPI 
is also influenced by the flow rate through the device (Bass, Farkas, et al., 2019). 
In conclusion, this study provides a proof of concept for high-efficiency EEG 
aerosol administration to treat bacterial infection in CF-diseased airways and meet the 
dosing requirements of inhaled tobramycin antibiotics. This is the first such study to apply 
numerical models for the evaluation of tobramycin EEG powder formulations in complete-
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airway, diseased, pediatric SIP models. An optimal EEG aerosol was identified that met 
the delivery targets associated with tobramycin administration, with ASL concentrations 
above the MIC, minimal regional variability, and high concentrations in the lower airways. 
Comparisons were made between static and EEG particles that demonstrated the 
advantages of administering aerosols that utilize hygroscopic growth. Furthermore, 
comparisons were made between models that represent healthy patients and varying 
degrees of CF disease states. Future work is planned that intends to expand upon this 






Figure 8.1: Examples of CF-related lung damage in (a) CT scans, with Label A showing 
axisymmetric mucus plugging on a daughter branch, Label B showing asymmetric mucus 
plugging in the bifurcation region, and Label C showing localized widening of a daughter 
branch (bronchiectasis); and examples of lung damage implemented in the SIP geometry 
with (b) axisymmetric mucus plugging, (c) asymmetric mucus accumulation in the 
bifurcation region, (d) axisymmetric bronchiectasis, and (d) asymmetric mucus 




Figure 8.2: Overview of CFD SIP model geometries showing the (a) Healthy and (b) CF 




Figure 8.3: Overview of the lower airway SIP geometries for the three CF-diseased 
models showing the (a) CF Scaled B4-B7, (b) CF Scaled B8-B15, (c) CF Moderate B4-





Figure 8.4: Comparison of extracted lobes from CT scans at (a) inhalation and (b) 
exhalation. Lobes are colored as: green – left upper; blue – left lower; red – right upper; 




Figure 8.5: Deposition patterns in the NT-B3 region for the (a) Healthy and (b) CF 
Moderate models. Note that validation of the CF-diseased model is compared against the 





Figure 8.6: Particle trajectories and growth through the CFD regions, with the Base 




Figure 8.7: Regional tobramycin concentrations in the airway surface liquid (ASL) 
between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the Base EEG 




Figure 8.8: Regional tobramycin concentrations in the airway surface liquid (ASL) 
between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the Min Static 




Figure 8.9: Regional tobramycin concentrations in the airway surface liquid (ASL) 
between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the Max Static 




Figure 8.10: Regional tobramycin concentrations in the airway surface liquid 
(ASL) between the Healthy, CF Scaled, CF Moderate, and CF Severe models for the 




Table 8.1: Comparison of lobar ventilation fractions between healthy and CF-diseased 
lungs. 
Lobe Healthya CF Diseased 
Left Upper 14% 16% 
Left Lower 7% 7% 
Right Upper 33% 28% 
Right Middle 15% 21% 
Right Lower 31% 28% 
a:  Ventilation fractions consistent with the 





Table 8.2: Summary of bifurcation-level surface area, airway surface liquid thickness, 
and volume for the ICRP, Min, and Max ASL volumes. Values are given for a single 
bifurcation, that is, not summed over the number of a given bifurcation found in the lungs. 
















B4 1.47 11.00 1.62 10.19 1.50 76.67 11.27 
B5 1.43 11.00 1.57 9.60 1.37 72.80 10.40 
B6 0.99 11.00 1.09 8.20 0.82 58.42 5.81 
B7 0.81 11.00 0.90 6.74 0.55 42.84 3.49 
B8 0.47 11.00 0.51 5.85 0.27 33.82 1.58 
B9 0.42 6.00 0.25 5.31 0.22 28.94 1.22 
B10 0.23 6.00 0.14 4.95 0.11 26.15 0.59 
B11 0.20 6.00 0.12 4.67 0.10 24.05 0.49 
B12 0.15 6.00 0.092 4.39 0.067 21.74 0.33 
B13 0.040 6.00 0.024 4.23 0.017 20.66 0.084 
B14 0.025 6.00 0.015 3.44 0.0083 10.13 0.025 
B15 0.016 6.00 0.010 3.44 0.0053 10.13 0.016 
As: Surface area 
h: Airway surface liquid thickness 
V: Airway surface liquid volume 





Table 8.3: Summary of regional airway surface liquid volumes for the ICRP, Min, and 
Max ASL volumes. Values for each region include summation over the number of a given 








NT 0.19 0.10 0.29 
B1-B3 0.03 0.04 0.27 
B4-B7 0.13 0.10 0.67 
B8-B15 0.89 0.61 2.81 
Alv 6.41 3.25 9.56 
Total 7.65 4.09 13.60 
VICRP: ICRP ASL Volume 
VMin: Min ASL Volume 
VMax: Max ASL Volume 
NT: Nose-throat region 
BX: Bifurcation number X 





Table 8.4: Comparison of regional deposition in the Healthy SIP model to algebraic 
and empirical correlations. 
Region CFD SIP MMAD [µm] ICRPa Rudolfb Finlayc 
BB (T-B8) 2.25% 1.67 2.17% 1.58% 5.12% 
Bb (B9-B15) 4.74% 2.23 3.56% 5.91% 10.86% 
a:  Sourced from (ICRP, 1994) 
b: Sourced from (Rudolf et al., 1990) 
c:  Sourced from (W. H. Finlay, 2001) 
 
BB: Bronchial region 

















NT 4.6 3.8 3.8 3.8 
1-3 2.7 1.5 1.5 1.5 
4-7 1.2 1.4 3.3 4.6 
8-15 6.6 13.4 9.6 12.4 
Min Static 
NT 4.6 3.9 3.9 3.9 
1-3 2.6 1.4 1.4 1.4 
4-7 0.9 1.1 2.7 3.7 
8-15 2.2 3.3 2.4 3.1 
Max Static 
NT 8.6 9.1 9.1 9.1 
1-3 5.2 2.4 2.4 2.4 
4-7 1.7 2.5 5.8 7.1 
8-15 9.8 11.8 12.6 13.7 
Optimal EEG 
NT 5.0 4.0 4.0 4.0 
1-3 3.1 1.5 1.5 1.5 
4-7 1.4 2.8 3.4 4.1 





Table 8.6: Summary of regional tobramycin concentrations in the airway surface liquid 
(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all 
ASL volumes, and the Base EEG case. 
Region 
Healthy 
[x MIC mg/L] 
CF Scaled 
[x MIC mg/L] 
CF Moderate 
[x MIC mg/L] 
CF Severe 
[x MIC mg/L] 
ICRP ASL Volume 
NT 35.5 29.2 29.2 29.2 
1-3 131.7 74.4 74.4 74.4 
4-7 12.8 14.7 35.0 49.5 
8-15 9.9 20.6 14.4 18.4 
Alveolar 19.5 18.5 18.9 18.1 
Min ASL Volume 
NT 67.5 55.5 55.5 55.5 
1-3 98.8 55.8 55.8 55.8 
4-7 16.6 19.1 45.5 64.4 
8-15 14.4 30.1 21.0 26.8 
Alveolar 38.5 36.5 37.3 35.7 
Max ASL Volume 
NT 23.3 19.1 19.1 19.1 
1-3 14.6 8.3 8.3 8.3 
4-7 2.5 2.9 6.8 9.6 
8-15 3.1 6.5 4.6 5.8 





Table 8.7: Summary of regional tobramycin concentrations in the airway surface liquid 
(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all 
ASL volumes, and the Min Static case. 
Region 
Healthy 
[x MIC mg/L] 
CF Scaled 
[x MIC mg/L] 
CF Moderate 
[x MIC mg/L] 
CF Severe 
[x MIC mg/L] 
ICRP ASL Volume 
NT 35.7 30.4 30.4 30.4 
1-3 129.0 70.6 70.6 70.6 
4-7 9.9 11.2 28.7 39.2 
8-15 3.3 5.1 3.7 4.7 
Alveolar 20.5 20.7 20.5 20.2 
Min ASL Volume 
NT 67.8 57.8 57.8 57.8 
1-3 96.8 53.0 53.0 53.0 
4-7 12.9 14.6 37.3 51.0 
8-15 4.8 7.4 5.4 6.9 
Alveolar 40.4 40.8 40.4 39.8 
Max ASL Volume 
NT 23.4 19.9 19.9 19.9 
1-3 14.3 7.8 7.8 7.8 
4-7 1.9 2.2 5.6 7.6 
8-15 1.0 1.6 1.2 1.5 





Table 8.8: Summary of regional tobramycin concentrations in the airway surface liquid 
(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all 
ASL volumes, and the Max Static case. 
Region 
Healthy 
[x MIC mg/L] 
CF Scaled 
[x MIC mg/L] 
CF Moderate 
[x MIC mg/L] 
CF Severe 
[x MIC mg/L] 
ICRP ASL Volume 
NT 66.6 70.0 70.0 70.0 
1-3 255.4 115.6 115.6 115.6 
4-7 16.1 24.6 57.4 71.2 
8-15 13.6 16.8 17.3 18.5 
Alveolar 17.4 17.4 16.7 16.2 
Min ASL Volume 
NT 126.5 133.0 133.0 133.0 
1-3 191.6 86.7 86.7 86.7 
4-7 20.9 32.0 74.6 92.6 
8-15 19.8 24.5 25.2 27.0 
Alveolar 34.3 34.3 32.9 32.0 
Max ASL Volume 
NT 43.6 45.9 45.9 45.9 
1-3 28.4 12.8 12.8 12.8 
4-7 3.1 4.8 11.1 13.8 
8-15 4.3 5.3 5.5 5.9 





Table 8.9: Summary of regional tobramycin concentrations in the airway surface liquid 
(ASL), compared to the minimum inhibitory concentration (MIC), for all SIP models, all 
ASL volumes, and the Optimal EEG case. 
Region 
Healthy 
[x MIC mg/L] 
CF Scaled 
[x MIC mg/L] 
CF Moderate 
[x MIC mg/L] 
CF Severe 
[x MIC mg/L] 
ICRP ASL Volume 
NT 38.3 30.6 30.6 30.6 
1-3 152.8 74.0 74.0 74.0 
4-7 14.2 30.0 36.1 43.2 
8-15 18.0 27.6 23.6 26.3 
Alveolar 18.2 17.1 17.6 17.1 
Min ASL Volume 
NT 72.8 58.1 58.1 58.1 
1-3 114.6 55.5 55.5 55.5 
4-7 18.5 39.0 46.9 56.2 
8-15 26.3 40.3 34.4 38.4 
Alveolar 35.9 33.7 34.7 33.7 
Max ASL Volume 
NT 25.1 20.0 20.0 20.0 
1-3 17.0 8.2 8.2 8.2 
4-7 2.8 5.8 7.0 8.4 
8-15 5.7 8.7 7.5 8.3 





Table 8.10: Ratios of maximum to minimum regional concentration, demonstrating 











ICRP ASL Volume 13.3 39.1 18.8 10.8 
Min ASL Volume 6.8 20.1 9.7 6.2 
Max ASL Volume 9.4 22.4 14.0 9.1 
CF Scaled 
ICRP ASL Volume 5.1 13.8 6.9 4.3 
Min ASL Volume 2.9 7.8 5.4 1.7 
Max ASL Volume 6.7 12.3 9.6 3.4 
CF Moderate 
ICRP ASL Volume 5.2 19.1 6.9 4.2 
Min ASL Volume 2.7 10.7 5.3 1.7 
Max ASL Volume 4.2 17.0 8.4 2.9 
CF Severe 
ICRP ASL Volume 4.1 15.0 7.1 4.3 
Min ASL Volume 2.4 8.4 4.9 1.7 





Chapter 9: Conclusions and Future Work 
9.1 Objective 1: Accurate CFD Simulations of Aerosol Delivery in Infants and 
Children 
The packed bed lung model study (Chapter 2) sought a complete-airway in vitro 
model with aerosol deposition characteristics similar to in vivo conditions in an infant, 
which meets the requirements of Task 1.1. This study concluded that in vitro packed bed 
lung models are capable of matching total aerosol deposition in the lungs of an infant. 
However, comparisons between sphere layers and bifurcation regions of a CFD SIP 
model showed a marked difference in regional deposition patterns and particle residence 
times. This means that packed bed models are not well suited for comparisons with 
regional in vivo data, where gamma scintigraphy characterizes deposition in central and 
peripheral regions. The fundamental issue was that the geometry of the voids in a packed 
bed model are too far removed from lung bifurcations, such that particle trajectories and 
deposition patterns were very different. The positive outcome from this study was that the 
CFD-based infant SIP model matched algebraic and empirical correlations with regard to 
deposition profiles across the micro-particle size range. 
The 90° bend study (Chapter 3) established recommended meshing and solution 
guidelines for modeling aerosol transport and deposition with the LRN k-ω model, which 
meets the requirements of Task 1.2. This study demonstrated the successful validation 
of the numerical models against experimental data across a range of Reynolds numbers 
and micro-particle sizes. The primary benefit of these recommendations is an increase in 
model accuracy and consistency, as well as streamlining the CFD mesh and model 
development process. Furthermore, the results from the two-equation k-ω model, with 
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near-wall corrections, provided comparable accuracy to the more complex LES model. 
LES models are more computationally expensive, so utilizing the more efficient k-ω model 
has benefits when running transient studies or more advance particle tracking methods. 
The 6-month-old nose-to-lung study (Chapter 4) validated the CFD meshing and 
solution guidelines in a nasal cavity model, which meets the requirements of Task 1.3. 
The nasal cavity model had more complex geometry features and flow field conditions 
than the characteristic 90° bend, which extended the applicability of the aforementioned 
CFD recommendations. Numerical results compared well with experimental data for nasal 
administration of EEG aerosols to infants. As a secondary outcome, this study also 
demonstrated the capabilities of EEG aerosols for navigating the natural filtration of the 
extrathoracic airways in infant patients, which maximizes available lung dose. 
Furthermore, evaluation of the CFD results identified deposition hotspots in the nasal 
cannula and nostril regions, which should be the focus of further effort to reduce 
depositional losses. A final outcome of this study was an anatomically-accurate infant 
nose-to-lung model, extracted from CT scans, which will be useful for future studies on 
pharmaceutical aerosol delivery to infants. 
9.2 Objective 2: Quantitative Analysis and Design of High Efficiency Pediatric 
DPIs 
The tobramycin DPI study (Chapter 5) detailed the optimization process for 
improving the aerosolization performance of a positive-pressure pediatric DPI, which 
meets the requirements of Task 2.1. This study developed dispersion parameters and 
correlations that were predictive of the aerosol MMAD and emitted dose from the DPI 
outlets. A priori validation of the best-case design candidates was successful, whereby 
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experimental results confirmed the performance improvements from CFD predictions, 
with no subsequent changes to the numerical models. Furthermore, results showed how 
changes to design parameters affected turbulent kinetic energy and flow rate (by changes 
to flow resistance), which were key factors in the dispersion parameter correlations. The 
best-case design candidates improved aerosolization performance over the initial device 
by reducing aerosol MMAD from 1.69 µm to 1.55 µm and increasing emitted dose from 
86.0% to 92.3%, while maintaining a constant pressure drop across the device. 
The patient interface study (Chapter 6) presented design improvements to 
pediatric mouthpieces and nasal cannulas that minimized delivery system and 
extrathoracic losses, thus maximizing available lung dose, which meets the requirements 
of Task 2.2. The aerosolization performance of the air-jet DPI (from Task 2.1) requires 
small diameter capillaries, which lead to a highly-turbulent, high velocity jet entering the 
patient interface and extrathoracic region. This jet increases aerosol loss in these regions 
through turbulent dispersion and inertial impaction, so a design was sought that was 
capable of effectively diffusing the air jet. This study followed several design iterations, 
which concluded that the addition of a 3D rod array and widening the geometry near the 
device outlet capillary gave the best reduction in losses. Three mouthpiece design 
concepts were presented with CFD predictions of a three-fold reduction in total interface 
and extrathoracic loss over the original design (from 16.7% to 5.1%). The nasal cannula 
design concepts were not as efficient, as the design concepts were not as effective at 
reducing losses in the nose-throat region. However, a 25% reduction in device flow rate 
(from 13.3 to 9.9 LPM) reduced delivery system and extrathoracic losses from 24.1% to 
16.3%. This reduction in device flow rate is not expected to have a negative impaction on 
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the DPI aerosolization performance (Bass, Farkas, et al., 2019). Furthermore, this study 
presented correlations that were predictive of extrathoracic deposition based on the 
maximum value of the velocity profile that leaves the patient interface. This showed that 
for a constant flow rate, the downstream deposition was vastly different if the velocity had 
a high peak velocity (jet-like profile) compared with a low peak velocity (blunt turbulent 
profile). This has implications for extrathoracic loss correlations that utilize the impaction 
parameter (𝑄𝑑𝑎), as this traditional metric does not capture the characteristics of the 
velocity profile that enters the mouth-throat or nose-throat regions. 
9.3 Objective 3: CFD Predictions of EEG Aerosol Antibiotic Delivery to Children 
with Cystic Fibrosis 
The growth chamber study (Chapter 7) developed three experimental and CFD 
models (2-3-, 5-6-, and 9-10-year-olds) for evaluating upper airway deposition and EEG 
aerosol size increase through the lungs of CF pediatric patients, which meets the 
requirements of Task 3.1 and 3.2. This study demonstrated concurrent numerical and 
experimental analysis of EEG aerosol delivery, with good validation of the CFD results 
against in vitro deposition and growth data. Results showed administration of EEG 
aerosols with the best-case delivery system gave low upper airway losses, with 
approximately 11%, 5%, and 7% deposition for the 2-3-, 5-6-, and 9-10-year-old models, 
respectively, at a constant device actuation flow rate of 10 LPM. This is a marked 
improvement over evaluation of commercial devices and delivery strategies in the 
literature, with the best available case being 22% lung dose (78% loss) from the Easyhaler 
(Below et al., 2013). The growth chamber was designed to provide a particle residence 
time of approximately 2.0 s, which is consistent with typical particle trajectories through 
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the lungs, resulting in final aerosol MMAD of approximately 3.3 µm due to hygroscopic 
growth. The larger aerosol size in distal regions of the lungs is expected to maximize lung 
retention of the delivered drug via increased sedimentation (during a breath-hold 
maneuver) and impaction (upon exhalation) deposition. This study also presented an 
enhancement to the near-wall corrections by implementing a local particle Stokes number 
to determine when particle-wall hydrodynamic interactions are modeled. The new method 
provided a non-dimensional approach and allowed the near-wall corrections to work 
independently of local flow conditions. 
The CF SIP study (Chapter 8) developed complete-airway CFD models of 
diseased pediatric patients to predict regional tobramycin concentrations delivered to the 
airway surface liquid, which meets the requirements of Task 3.3. This study provided a 
proof of concept for EEG aerosol administration to treat bacterial infections in the 
diseased airways of CF patients. Treatment of infection with antibiotics requires the drug 
dose to be above a minimum lower threshold and a uniform distribution through all lung 
regions. For both EEG aerosol cases considered, the delivered tobramycin concentration 
within the airway surface liquid was consistently above the minimum inhibitory 
concentration (MIC), which is 512 mg/L, within all lung regions. For the CF-diseased 
models, the minimum predicted concentration in all lung regions was 2.9 x MIC for the 
base EEG aerosol and 5.8 x MIC for the optimal case. The optimal case also reduced 
regional variability to an approximate four-fold difference between maximum and 
minimum concentrations. Furthermore, the CFD models predicted high tobramycin 
concentrations in the lower airways, where CF-related airway damage is most 
predominant, with a minimum value of 7.5 x MIC in the B8-B15 region. As a secondary 
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outcome, this study also compared the advantages of EEG powder formulations 
compared to static aerosols (no hygroscopic growth) in regard to nasal transmission and 
targeted drug delivery. Finally, this study evaluated delivery to airways with varying 
degrees of disease state and considered the influence of interpatient variability on optimal 
delivery strategies. 
9.4 Contributions to Science 
From the studies detailed in this dissertation, the contributions to the fields of CFD 
methods development, respiratory device design, and aerosol delivery strategy 
development are summarized below. 
Task 1.1: Evaluate Deposition Realism of In Vitro Packed-Bed Breathing Infant 
Lung Model (BIL) 
• Thorough assessment of packed bed lung models and their use for in vitro 
evaluation of pharmaceutical aerosol delivery, showing they are representative 
of total, but not regional, deposition fractions 
• Complete-airway CFD SIP model of microparticle particle tracking and 
deposition in a neonate 
Task 1.2: Recommendations for Simulation of Microparticle Transport and 
Deposition Using Two-Equation Turbulence Models 
• A set of CFD meshing and solution guidelines for modeling microparticle 
trajectories through respiratory airways, which were validated against 
experimental data in a characteristic 90° bend geometry 
• Enhancement to near-wall corrections that interpolate flow quantities at the 
particle location, from nodal values, with an inverse-distance weighted method 
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• Established that the k-ω turbulence model, with near-wall corrections, is 
capable of matching in vitro data with comparable accuracy to the more 
computationally-expensive LES model 
Task 1.3: Validating CFD Predictions of N2L Aerosol Delivery in a 6-Month-Old 
Infant Airway Model 
• Experimental and CFD models for nasal administration of pharmaceutical 
aerosols to a 6-month-old infant 
• Further validation of k-ω turbulence and the aforementioned guidelines in the 
complex flow field of the nasal cavity 
Task 2.1: CFD Optimization of an Inline DPI for EEG Tobramycin Formulations 
• Pediatric air-jet DPI designs that maximize aerosolization performance by 
optimization of inlet and outlet capillary diameters 
• Dispersion parameters that are predictive of the device aerosol size and 
emitted dose from CFD flow field quantities 
Task 2.2: Develop DPI Patient Interfaces for Improved Aerosol Delivery to 
Children 
• Patient interface design concepts that minimize delivery system and 
extrathoracic losses by utilizing a 3D rod array for flow intensity attenuation 
• Deposition correlations that are predictive of extrathoracic losses from 
characteristics of the flow field at the interface outlet 
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Task 3.1: Develop In Vitro Upper Airway Geometries of CF Patients in Age Ranges 
of 2-3, 5-6, And 9-10 Years 
• Three rapid-prototyped growth chamber models for the given age ranges and 
moderate disease state that will be utilized in future tobramycin EEG aerosol 
studies 
Task 3.2: Develop CFD Models of Upper Airway Geometries for Pediatric Patients 
and Evaluate Delivery Efficiency and Aerosol Growth with Comparisons to In 
Vitro Experiments 
• Concurrent numerical and experimental evaluation of hygroscopic aerosol 
growth through CF-diseased pediatric upper airways 
• Enhancement to near-wall corrections that implement a localized particle 
Stokes number as a non-dimensional method of identifying when particle-wall 
hydrodynamic interactions take effect 
Task 3.3: Extend and Develop CFD Lung Models to Predict Regional Lung 
Deposition and Tobramycin ASL Concentrations in Healthy and CF Complete-
Airway Lung Models 
• Proof of concept for administration of tobramycin EEG aerosols to treat 
bacterial infections in pediatric CF patients 
• Development of complete-airway pediatric SIP models that include forms of 
airway damage that are associated with CF and bacterial infection 
9.5 Future Work 
Considering CFD methods development for respiratory drug delivery, future work 
should focus on exploring new meshing technologies and modeling capabilities as they 
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become available in commercial software. Polyhedral cell topologies are a relatively 
recent advancement in volume discretization methods, which have been shown to provide 
computationally-efficient, accurate, and validated results (Bass, Boc, et al., 2019; Bass & 
Longest, 2020). Unstructured meshing approaches, such as polyhedral cells, are 
invaluable when developing the computational domain for complex geometries, as the 
surface and volume discretization can conform to irregular surfaces. Considering 
diseased airways where structured meshes may not be feasible, polyhedral cells will be 
useful for resolving flow fields and particle trajectories in the complex domain. 
Commercial CFD software is also regularly updated, and advancements in modeling and 
solver capabilities may be implemented to reduce the computational overhead and 
increase the solution and post-processing detail. For example, physical details of the 
secondary breakup mechanism in air-jet DPIs and through 3D rod arrays is not well 
understood at this time. Discrete element methods or other advanced Lagrangian tracking 
models may be able to provide more insight into this phenomenon. For diseased airways, 
the complete-airway SIP models can be developed further to provide a more realistic and 
validated representation of aerosol transport in the airways of pediatric CF patients. 
Further enhancements can also be made to the near-wall corrections to make them 
suitable to a wider range of applications and reduce the amount of parameter tuning that 
is required to match in vitro and in vivo data sets. 
For delivery system improvements, future work should explore the influence of 
more design factors on DPI aerosolization performance. This dissertation evaluated 
changes to the inlet and outlet capillary diameters, but the size and shape of the 
aerosolization chamber can be optimized, as well as flow orifice positioning and actuation 
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flow rates. Similar optimization studies can be conducted on the 3D rod array patient 
interfaces that explore the effects of rod array configuration and placement on delivery 
system and extrathoracic losses. Other design changes may be required to maximize 
system performance in different pediatric age ranges, such as younger (2-3-year-old) and 
older (9-10-year-old) patients. Furthermore, it would be interesting to test the aerosol 
dispersion parameters and extrathoracic loss correlations on a wider range of air-jet DPI 
design concepts and different patient populations. Finally, as mentioned above, greater 
insight in to the secondary break-up mechanisms, as the powder is aerosolized and 
passes through the rod array, is required. 
Regarding delivery strategy development, future work should expand the 
assessment of EEG aerosols in complete-airway CFD models by evaluating lobar 
variability in delivered tobramycin and consider the 2-3- and 9-10-year-old age groups. 
Interpatient variability and its effect on establishing optimized delivery strategies should 
be considered, as well as the use of different cannula sizes (to meet the needs of the 
entire patient population) and how they influence delivery system and extrathoracic 
losses. Direct validation of the numerical models for aerosol deposition and growth of 
tobramycin EEG powder formulations is required. In addition, the optimal EEG delivery 
strategy can be explored further by testing the influence of powder formulation (mass 
fractions of drug and excipients), bi-modal aerosol size distributions, and delivery flow 
rates. Finally, advanced CFD modeling capabilities can be implemented, such as 
polydisperse aerosols and two-way coupled tracking, to improve the accuracy and detail 
in results obtained from numerical models. 
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